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Rheumatoid	   arthritis	   (RA)	   is	   a	   chronic	   inflammatory	   disease	   of	   autoimmune	  
origin	  affecting	  approximately	  1%	  of	  adult	  population	  worldwide.	  The	  clinical	  course	  
of	   RA	   is	   highly	   variable,	   ranging	   from	   self-­‐limiting	   to	   severe	   disease,	   with	  
considerable	  individual	  and	  socio-­‐economic	  implications.	  	  
It	  is	  now	  well	  acknowledged	  that	  early	  diagnosis	  and	  treatment	  equates	  to	  better	  
long-­‐term	  outcomes.	  
However,	   despite	   major	   therapeutic	   advances	   in	   recent	   decades,	   the	  
management	   of	   RA	   remains	   challenging	   as	   a	   significant	   proportion	   of	   patients	  
presents	  with	  active	  disease	  despite	  maximization	  of	   therapy.	   It	   is	  also	  difficult	   to	  
predict	  which	  patients	  will	  respond	  adequately	  to	  various	  treatment	  regimens.	  The	  
identification	  of	  biomarkers	  of	  clinical	  outcome	  capable	  of	  stratifying	  patients	   into	  
accurate	  prognostic	  categories	  and	  guide	  pharmacological	  intervention	  is	  therefore	  
urgently	  needed.	  	  
Notably,	   along	   with	   clinical	   variability,	   RA	   is	   characterised	   by	   high	   biological	  
heterogeneity	  at	  the	  tissue	   level.	  The	  cellular	   infiltrate	  of	  the	  RA	  synovium	  can	  be	  
distinguished	   into	   at	   least	   three	   main	   patterns	   according	   to	   the	   degree	   and	  
organisation	   of	   the	   immune	   cells:	   the	   ‘Lymphoid’	   pattern	   characterised	   by	  
predominant	   B	   and	   T	   lymphocytes	   which	   tend	   to	   cluster	   in	   discrete	   aggregates	  
resembling	   ectopic	   lymphoid	   structures;	   the	   ‘Myeloid’	   pattern	   characterised	   by	  
absence	   of	   lymphocytic	   aggregates	   but	   significant	   expression	   of	   sublining	  
macrophages;	   the	   ‘Pauci-­‐immune’	   pattern,	   that	   hardly	   shows	   any	   infiltrating	  




The	  hypothesis	  of	   this	   thesis	  was	   to	  determine	  whether	   these	  distinct	   synovial	  
pathotypes	  may	  define	  specific	  disease	  subsets	  and	  predict	  response	  to	  therapy	  in	  
patients	  with	  RA.	  	  
Specifically,	  this	  work	  aims	  at:	  	  
1.	   evaluating	   whether	   the	   synovial	   pathotype	   associates	   with	   the	   presence	   of	  
specific	  clinical,	  serological,	  radiological	  and	  ultrasonographic	  findings	  in	  an	  early	  RA	  
cohort	  (<	  1	  year	  onset);	  
2.	   exploring	   the	   potential	   role	   of	   the	   synovial	   pathotype	   as	   a	   predictor	   of	  
response	   to	   conventional	   synthetic	   disease-­‐modifying	   antirheumatic	   drugs	  
(csDMARD)	  after	  6	  months	  in	  an	  early	  RA	  cohort;	  	  
3.	   exploring	   the	   potential	   role	   of	   the	   synovial	   pathotype	   as	   a	   predictor	   of	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LIST	  OF	  ABBREVIATIONS	  
ACPA	   	   anti-­‐citrullinated	  protein	  antibodies	  
ACR	   	   American	  College	  of	  Rheumatology	  
ADAMTS	   A-­‐disintegrin	   and	   metalloproteinase	   with	   thrombospondin-­‐1-­‐like	  	  
domains	  
ADCC	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  antibody-­‐dependent	  cell-­‐mediated	  cytotoxicity	  
AID	   	   Activation-­‐Induced	  Cytidine	  Deaminase	  	  
AMPD1	   adenosine	  monophosphate	  deaminase1	  
Anti-­‐CCP1	   anti-­‐cyclic	  citrullinated	  proteins	  antibodies	  1	  	  
Anti-­‐CCP2	   anti-­‐cyclic	  citrullinated	  proteins	  antibodies	  2	  
AP	   	   antero-­‐posterior	  
APC	   	   antigen	  presenting	  cells	  	  
APF	   	   antibody	  perinuclear	  factor	  	  
APRIL	   	   proliferation-­‐inducing	  ligand	  	  
ARAMIS	   Arthritis	  Rheumatism	  and	  Aging	  Medical	  Information	  System	  	  
ASPIRE	  	   ‘Active-­‐Controlled	  Study	  of	  Patients	  Receiving	  Infliximab	  for	  the	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Treatment	  of	  Rheumatoid	  Arthritis	  of	  Early	  Onset’	  	  
ATTRACT	  	   ‘Infliximab	  Versus	  Placebo	  in	  Rheumatoid	  Arthritis	  Patients	  Receiving	  	  	  	  	  	  	  
Concomitant	  Methotrexate:	  a	  Randomised	  Phase	  III	  Trial’	  	  
BAFF	   	   B	  cell	  activating	  factor	  	  
bDMARD	   biologic	  Disease-­‐Modifying	  Antirheumatic	  Drugs	  	  
BeSt	   	   ‘Behandel	  Strategieën’	  	  
BLyS	   	   B	  lymphocyte	  stimulator	  
CAMERA	   ‘Computer	  Assisted	  Management	  for	  Early	  Rheumatoid	  Arthritis’	  	  
CC	   	   CC-­‐chemokine	  
CCL19	   	   CC-­‐chemokine	  ligand	  19	  	  
CCL21	   	   CC-­‐chemokine	  ligand	  21	  	  
CDC	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  complement-­‐dependent	  cytotoxicity	  
CD40L	   	   CD40	  ligand	  
CI	   	   confidence	  intervals	  




CLIP-­‐Cert	   ‘Clinical	   responsiveness	   to	   anti-­‐TNFα	   therapy	   and	   modulation	   of	  
synovial	  lymphoid	  structures	  and	  B	  cell	  function	  in	  RA-­‐	  An	  exploratory	  
open	  label	  prospective	  study	  in	  RA’	  
COBRA	  	   ‘Combinatie	  therapie	  Bij	  Reumatoide	  Artritis’	  	  
COMET	   ‘Comparison	  of	  Methotrexate	  Monotherapy	  with	  a	  Combination	  of	  	  
Methotrexate	   and	   Etanercept	   in	   Active,	   Early,	   Moderate	   to	   Severe	  
Rheumatoid	  Arthritis’	  	  
COX-­‐2	   	   cyclo-­‐oxygenase	  2	  	  
CRP	   	   C-­‐reactive	  protein	  	  
csDMARD	   conventional	  synthetic	  Disease-­‐Modifying	  Antirheumatic	  Drugs	  
CSF	   	   granulocyte–macrophage	  colony-­‐stimulating	  factor	  	  
CTLA4	   	   cytotoxic	  T	  lymphocyte	  associated	  antigen	  4	  	  
CV	   	   cardiovascular	  	  
CXC	   	   CXC-­‐chemokine	  	  
CXCL13	   CXC-­‐chemokine	  ligand	  13	  	  
CZP	   	   Certolizumab	  pegol	  
DAMPs	   damage	  associated	  molecular	  patterns	  	  
DAS28	  	   28	  joint	  count-­‐Disease	  Activity	  Score	  	  
DC	   	   dendritic	  cells	  	  
DIA	   	   digital	  image	  analysis	  	  
DIPs	   	   distal	  interphalangeal	  joints	  	  
Dkk-­‐1	   	   dickkopf-­‐1	  	  
DMARD	   Disease-­‐Modifying	  Antirheumatic	  Drugs	  
DNA	   	   deoxyribonucleic	  acid	  	  
EAC	   	   early	  arthritis	  clinic	  
EAM	   	   extra-­‐articular	  manifestations	  	  
EBV	   	   Epstein-­‐Barr	  virus	  	  
ELN	   	   ectopic	  lymphoid	  neogenesis	  	  
ELS	   	   ectopic	  lymphoid-­‐like	  structures	  	  
ESR	   	   erythrocyte	  sedimentation	  rate	  	  
EULAR	  	   European	  League	  Against	  Rheumatism	  




Fc	   	   crystallized	  fragment	  	  
FcR-­‐γ	   	   crystallized	  fragment	  receptor	  γ	  
FcεRI	   	   high-­‐affinity	  IgE	  receptor	  
FDC	   	   follicular	  dendritic	  cells	  	  
FLS	   	   fibroblast-­‐like	  synoviocytes	  	  
FOXP3	  	   forkhead	  box	  P3	  	  
FRAX	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Fracture	  Risk	  Assessment	  Tool	  
G0,1,2,	  3	   grade	  0,1,2,3	  
GATA3	  	   GATA	  binding	  protein	  3	  	  
GC	   	   germinal	  centres	  
GI	   	   gastrointestinal	  	  
GM-­‐CSF	   granulocyte	  monocyte-­‐colony	  stimulating	  factor	  	  
GM-­‐FGF	   fibroblast	  growth	  factor	  
H&E	   	   haematoxylin	  and	  eosin	  	  
HA	   	   hyaluronic	  acid	  
HAQ	   	   Health	  Assessment	  Questionnaire	  	  
HBV	   	   hepatitis	  B	  	  
HCQ	   	   Hydroxychloroquine	  	  
HCV	   	   hepatitis	  C	  	  	  
HEV	   	   high	  endothelial	  venules	  	  
HIFs	   	   hypoxia-­‐inducible	  factors	  	  
HIV	   	   Human	  Immunodeficiency	  Virus	  	  
HLA	   	   human	  leukocyte	  antigen	  	  
HSPs	   	   heat	  shock	  proteins	  
ICC	   	   intra-­‐class	  correlation	  coefficients	  	  
IFNα	   	   interferon	  α	  	  
IFNβ	   	   interferon	  β	  	  
IFNγ	   	   interferon	  γ	  
IgA	   	   immunoglobulin	  A	  
IgE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  immunoglobulin	  E	  
IgG	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  immunoglobulin	  G	  




IGRA	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Interferon-­‐Gamma	  Release	  Assay	  
IL-­‐1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  interleukine-­‐1	  
IL-­‐1Ra	   	   interleukine-­‐1	  receptor	  antagonist	  
IL-­‐2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  interleukine-­‐2	  
IL-­‐4	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  interleukine-­‐4	  
IL-­‐5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  interleukine-­‐5	  
IL-­‐6	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  interleukine-­‐6	  
IL-­‐6R	   	   interleukine-­‐6	  receptor	  
IL-­‐7	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  interleukine-­‐7	  
IL-­‐10	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  interleukine-­‐10	  
IL-­‐17	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  interleukine-­‐17	  
IL-­‐18	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  interleukine-­‐18	  
IL-­‐22	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  interleukine-­‐22	  
IL-­‐23	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  interleukine-­‐23	  
IL-­‐32	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  interleukine-­‐32	  
IL-­‐33	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  interleukine-­‐33	  
IQR	   	   interquartile	  range	  
JE	   	   joint	  erosions	  score	  	  
JSN	   	   joint	  space	  narrowing	  	  
kDa	   	   kiloDalton	  	  
LEF	   	   Leflunomide	  	  
LTα	   	   lymphotoxin	  α	  
LTβ	   	   lymphotoxin	  β	  	  
M-­‐CSF	   	   macrophage	  colony	  stimulating	  factor	  	  
MALT	   	   mucosa	  associated	  lymphoid	  tissue	  
MAP	   	   mitogen-­‐activated	  proteins	  
MC	   	   manual	  cell	  counting	  	  
MCPs	   	   metacarpophalangeal	  joints	  
MHC	   	   major	  histocompatibility	  complex	  	  
mi-­‐RNA	   micro-­‐ribonucleic	  acid	  	  
MICE	   	   multivariate	  imputation	  by	  chained	  equations	  




MMP-­‐1	   matrix	  metalloproteinase-­‐1	  (MMP-­‐1)	  
MMPs	   	   matrix	  metalloproteinases	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1.1	  	  	  DEFINITION	  OF	  RHEUMATOID	  ARTHRITS	  
Rheumatoid	   arthritis	   (RA)	   is	   a	   chronic	   autoimmune	   inflammatory	   disease	   of	  
unknown	  origin,	  primarily	  affecting	  the	  synovial	  joints	  however	  characterised	  by	  a	  
broad	   spectrum	   of	   extra-­‐articular	   manifestations.	   The	   clinical	   course	   of	   RA	   is	  
variable,	   ranging	   from	  mild	  to	  severe	  disease,	  which	  can	  potentially	   lead	  to	   joint	  
damage,	   chronic	   disability	   and	   early	   mortality.	   This	   translates	   to	   considerable	  
costs	  at	  the	  individual,	  societal	  and	  economic	  level.	  1	  
	  
1.2	  	  	  EPIDEMIOLOGY	  
RA	  affects	  approximately	  1%	  of	  the	  adult	  population	  worldwide.	  2	  
The	  prevalence	  varies	  geographically	  and	  among	  population	  groups,	  suggesting	  
a	   role	   for	   genetic	   background	   and	   environmental	   exposure.	   However,	  
epidemiology	   studies	   on	   RA	   are	   affected	   by	   methodological	   issues,	   partially	  
because	  the	  methods	  of	  case	  identification	  and	  case	  recording	  have	  changed	  over	  
time.	   In	   1987	   the	   revised	   American	   College	   of	   Rheumatology	   (ACR)	   criteria	  
replaced	   the	   previous	   existing	   criteria	   (1958	   New	   York	   classification	   criteria).	   3	  
More	   recently,	   the	  American	  College	  of	  Rheumatology/European	  League	  Against	  
Rheumatism	   (ACR/EULAR)	   2010	   criteria	   have	   been	   introduced.	   4	   Also,	   the	   small	  
number	  of	  studies	  for	  most	  areas	  of	  the	  world	  and	  the	  lack	  of	  incidence	  studies	  for	  
developing	  countries	  must	  be	  taken	  into	  account.	  
A	  trend	  towards	  higher	  prevalence	  and	  incidence	  in	  northern	  Europe	  and	  North	  
America	  compared	  to	  developing	  countries	  has	  been	  observed,	  to	  an	  extent	  that	  
RA	   is	   virtually	   undetectable	   in	   rural	   areas	   of	   Africa	   and	   China.	   Interestingly,	  




societies	  present	  with	  an	   increased	  risk	  compared	   to	   their	  counterparts	  who	  did	  
not	  migrate,	  stressing	  the	  importance	  of	  environmental	  factors.	  The	  disease	  is	  also	  
less	  common	  in	  southern	  compared	  to	  northern	  Europe.	  5	  
In	   certain	   human	   groups,	   where	   specific	   genes	   may	   have	   segregated	   due	   to	  
geographical	   and	   social	   isolation,	   the	  prevalence	  may	  differ	   consistently.	  Among	  
Native	   Americans	   and	   Alaskans,	   for	   example,	   rates	   of	   up	   to	   5.3-­‐6%	   have	   been	  
reported.	  3	  	  
The	  prevalence	  of	  RA	  is	  estimated	  to	  be	  around	  0.8%	  in	  the	  United	  Kingdom.	  6	  
The	   peak	   age	   of	   onset	   is	   the	   5th	   to	   6th	   decade,	   and	   the	   prevalence	   increases	  
with	  age.	  The	  disease	  is	  more	  common	  in	  women,	  with	  a	  male	  to	  female	  ratio	  of	  
1:3,	   suggesting	   the	   importance	   of	   genetic	   and	   possibly	   a	   role	   for	   hormonal	  
influence	  in	  disease	  pathogenesis.	  3	  
A	  general	  trend	  for	  a	  decrease	  in	  both	  incidence	  and	  prevalence	  of	  the	  disease	  
over	  the	  past	  few	  decades	  has	  been	  registered	  worldwide.	  5	  
	  
1.3	  	  	  AETIOLOGY	  
Significant	   advances	   in	   understanding	   the	   pathogenesis	   of	   the	   disease	   have	  
been	  made	  in	  recent	  years,	  leading	  to	  the	  discovery	  of	  new	  potential	  targets	  and	  
effective	   therapies,	   and	   ultimately	   to	   a	   significant	   improvement	   in	   clinical	  
outcome.	  	  
Unfortunately,	   despite	   such	   remarkable	   progresses,	   the	   aetiology	   of	   RA	  
remains	   unknown.	   The	   current	   paradigm	   is	   that	   the	   disease	   is	   the	   result	   of	   a	  
complex	   interplay	   between	   genetic	   and	   environmental	   factors,	   most	   of	   which	  




1.3.1	  	  	  Genetics	  
The	  disease	  is	  known	  to	  cluster	  in	  families.	  The	  individual	  risk	  of	  developing	  RA	  
is	  between	  2	  and	  4	  fold	  higher	  when	  a	  first-­‐degree	  relative	  is	  affected.	  7	  
Genes	  may	   have	   a	   substantial	   contribution	   to	   RA,	   and	   it	   has	   been	   estimated	  
that	  up	   to	  60%	  of	   risk	   is	  attributable	   to	  genetic	   factors.	  Twins	  studies	  show	  that	  
concordance	   rates	   for	   RA	   are	   higher	   in	   monozygotic	   (15-­‐30%)	   as	   opposed	   to	  
dizygotic	  twins	  (5%)	  and	  higher	  in	  dizygotic	  twins	  than	  general	  population.	  8	  	  
Over	  30	  genetic	   regions	  have	  been	   identified	   in	  association	  with	  RA,	  however	  
each	   single	   allele	   provides	   only	   modest	   contribution	   to	   the	   global	   genetic	  
susceptibility.	   Taken	   together,	   currently	   known	   genetic	   risk	   factors	   for	   RA	   only	  
explain	  ~16%	  of	   the	   susceptibility	  on	  an	   individual	  basis.	  Overall,	   if	  on	  one	  hand	  
this	  data	  supports	   the	  genetic	  component	  of	  RA,	  on	   the	  other	  hand	   implies	   that	  
genes	   alone	   are	   insufficient	   to	   explain	   the	   disease	   pathogenesis,	   suggesting	   a	  
concomitant	  role	  for	  environmental	  factors.	  
Class	   II	   human	   leukocyte	   antigen	   (HLA)	   and	   non-­‐HLA	   genes	   have	   been	  
implicated	  in	  susceptibility	  to	  RA.	  A	  potential	  association	  between	  HLA	  alleles	  and	  
RA	  was	  first	  reported	  in	  1969.	  9	  Subsequent	  studies	  showed	  that	  the	  region	  HLA-­‐
DR	  may	  account	  for	  up	  to	  one	  third	  on	  the	  genetic	  risk	   in	  RA	  10,	  although	  recent	  
data	   suggested	   that	   this	   figure	  may	   represent	   an	   overestimation.	   Specifically,	   it	  
has	  been	  observed	  an	  association	  with	  HLA-­‐DRB1	  alleles,	  which	  are	  located	  on	  the	  
short	  arm	  of	  chromosome	  6	  (6p21.3).	  HLA-­‐DRB1	  alleles	  share	  a	  common	  motif	  -­‐a	  
sequence	  of	   amino	   acids	   in	   the	   third	   hypervariable	   region	  of	   the	  β	   chain	   of	   the	  
HLA-­‐DR,	   known	   as	   the	   shared	   epitope	   (SE).	   This	   sequence	   occurs	   within	   the	  




which	   influences	   the	   antigen	   presentation	   to	   T	   cells,	   suggesting	   a	   possible	  
alteration	  in	  T-­‐cell	  repertoire	  selection,	  antigen	  presentation	  and	  antigen	  affinity,	  
ultimately	  resulting	  in	  a	  dysregulation	  of	  the	  innate	  immune	  system	  and	  antigen-­‐
driven	  T	  and	  B	  cell	  activation.	  10	  
HLA-­‐DRB1	   is	   associated	   with	   the	   development	   of	   certain	   autoantibodies	  
specifically	   found	   in	   RA,	   anti-­‐citrullinated	   protein	   antibodies	   (ACPA).	   11	   The	  
contribution	  of	  HLA	  alleles	  to	  the	  genetic	  variance	  has	  been	  estimated	  at	  40	  %	  for	  
ACPA	  seropositive	  and	  only	  2	  %	  for	  ACPA	  negative	  patients,	  suggesting	  that	  ACPA-­‐
positive	  and	  ACPA-­‐negative	  RA	  maybe	  genetically	  distinct	  subsets.	  12	  	  
Some	   HLA-­‐DR4	   subtypes,	   such	   as	   Dw10	   and	   Dw13,	   have	   been	   negatively	  
associated	  with	  RA.	  13	  
Among	  the	  non-­‐HLA	  associated	  genes,	  a	  well-­‐known	  association	  is	  with	  PTPN22	  
(protein	  tyrosine	  phosphatase	  N22),	  a	  gene	  encoding	  for	  an	   intracellular	  enzyme	  
which	  negatively	   regulates	   T	   cell	   activation.	   14	   Such	  association	  has	  been	  mostly	  
observed	  in	  ACPA	  seropositive	  patients.15	  
Potential	  associations	  have	  been	  observed	  with	  other	  non-­‐HLA	  genes	  involved	  
in	   several	   immune-­‐regulatory	   process,	   including:	   nuclear	   factor	   kB	   (NF-­‐kB)	  
dependent	   signalling16,	   proteins	   regulating	   T	   cell	   activation	   such	   as	   cytotoxic	   T	  
lymphocyte	   associated	   antigen	   4	   (CTLA4)17,	   enzymes	   involved	   in	   protein	  
citrullination	   like	  peptidyl	  deiminase	   type	  4	   (PADI4)18,	   signal	   transducers	   such	  as	  
signal	   transducer	  and	  activator	  of	   transcription	  4	   (STAT4)19,	  proteins	  regulating	  T	  
cell	  receptor	  and	  TNF	  receptor	  signalling	  such	  as	  TNF	  receptor	  associated	  factor	  5-­‐	  
C1	   (TRAF5-­‐C1)20,	   macrophage	   inhibitory	   factor	   (MIF)21.	   Nonetheless,	   the	  




emerged	   from	   limited	   studies	   only,	   with	   inconsistent	   results	   obtained	   across	  
different	  populations.	  	  
	  
1.3.2	  	  	  Epigenetics	  	  
Epigenetics	   is	   emerging	   as	   a	   key	   pathogenic	   mechanism	   in	  several	   human	  
diseases,	   including	   cancer	   and	  autoimmunity,	  with	  prospects	   for	   future	   targeted	  
therapies. 
Epigenetics	   defines	   stable	   although	   potentially	   reversible	   changes	   in	   gene	  
expression	   which	   does	   not	   involve	   changes	   in	   the	   nucleotide	   sequence,	   but	   is	  
rather	   the	   result	   of	   intra-­‐cellular	  biochemical	   signals	   that	   can	  activate	  or	   silence	  
genes.	  The	  transcription	  of	  deoxyribonucleic	  acid	  (DNA)	  is	  ultimately	  regulated	  by	  
sophisticated	   extra-­‐genetic	  mechanisms.	   This	   regulatory	   system	   is	   not	   fixed	   but	  
extremely	   dynamic	   and	   influenced	   by	   environmental	   factors.	   	   Epigenetic	  
mechanisms	  include	  DNA	  methylation,	  post-­‐translational	  histone	  modification	  and	  
micro-­‐ribonucleic	   acid	   (mi-­‐RNA).	   22	   These	   pathways	   are	   suspected	   of	   being	  
involved	   in	  typical	   immune	  alterations	  observed	   in	  RA,	  such	  as	  the	  generation	  of	  
auto-­‐reactive	   T	   and/or	   B	   cell	   clones	   or	   the	   stromal	   cells	   activation	   within	   the	  
inflamed	  synovium.	  23	  As	  an	  example,	  it	  has	  been	  observed that	  the	  expression	  of	  
miRNA-­‐203	   is	   up-­‐regulated	   in	   RA	   synovial	   fibroblasts,	   and	   this	   overexpression	   is	  
associated	  with	  the	  secretion	  of	  mediators	  of	  local	  inflammation	  and	  damage	  such	  
as	   interleukine-­‐6	   (IL-­‐6)	   and	   matrix	   metalloproteinase-­‐1	   (MMP-­‐1).	   24	   This	   is	   an	  
intriguing	  and	  expanding	   field	  of	   research,	  as	  epigenetics	  may	   represent	   the	  key	  
link	   between	   genetic	   susceptibility	   and	   exposure	   to	   environmental	   factors	  




1.3.3	  	  	  Environmental	  factors 
1.3.3.1	  	  	  Infectious	  agents	  
A	   number	   of	   infectious	   agents	   have	   been	   suggested	   as	   putative	   pathogenic	  
triggers	  for	  RA,	  including	  Epstein-­‐Barr	  virus	  (EBV)25,	  Human	  retrovirus26,	  Parvovirus	  
B1927,	  Mycoplasma28	  and	  many	  others.	   Several	   immunological	  mechanisms	  have	  
been	   hypothesised,	   and	   more	   than	   one	   could	   be	   involved	   simultaneously:	  
molecular	   mimicry	   (structural	   similarities	   between	   microbial	   and	   self-­‐antigens	  
causing	   immune	   cross-­‐reactivity),	   bystander	   activation,	   polyspecific	   B	   cell	  
activation,	   accumulation	   of	   infectious	   agent-­‐specific	   CD8+	   T-­‐cells	   in	   sites	   of	  
inflammation,	  and	  epigenetic	  dysregulation.	  29	  
RA	   is	  known	  to	  be	  associated	  with	  an	   increased	  EBV	  viral	   load	   in	   the	  synovial	  
fluid,	  peripheral	  blood	  and	  synovial	  tissue,	  as	  well	  as	  with	  high	  titres	  of	  anti	  EBV-­‐
antibodies	  and	   cross-­‐reactive	   circulating	  antibodies	   to	   viral	   antigens.	   30,31	  Recent	  
data	   also	   suggests	   that	   persistency	   of	   auto-­‐reactive	   plasma	   cells	   to	   EBV	   in	   the	  
synovial	  lymphoid	  structures	  of	  RA	  patients	  is	  associated	  with	  local	  differentiation	  
of	   ACPA-­‐reactive	   B	   cells,	   raising	   the	   hypothesis	   that	   EBV	   infection	   may	   play	   a	  
direct	  role	  in	  the	  production	  of	  these	  autoantibodies.32	  
A	   role	   in	   the	   pathogenesis	   of	   RA	   has	   also	   been	   recently	   postulated	   for	  
Porphyromonas	   gingivalis,	   a	   pathogen	   responsible	   for	   chronic	   periodontitis.	   RA	  
and	   periodontitis	   are	   known	   to	   be	   associated	   at	   an	   epidemiological	   level,	   as	  
patients	   with	   chronic	   periodontitis	   have	   two-­‐fold	   risk	   of	   developing	   RA	   and	  
viceversa.	   33	   Interestingly,	   this	   organism	   produces	   a	   specific	   bacterial	  
enzyme,	  P.	  gingivalis	  peptidyl-­‐arginine	   deaminase	   (PPAD),	   which	   is	   capable	   of	  




However,	   to	   date	   the	   specific	   contribution	   of	   a	   single	   infectious	   agent	   in	   the	  
pathogenesis	  of	  the	  disease	  remains	  elusive.	  
1.3.3.2	  	  	  Smoking	  
The	  relationship	  between	  smoking	  and	  autoimmunity	  is	  widely	  known.	  Smoking	  
has	  the	  capacity	  to	  induce	  epigenetic	  changes	  through	  the	  release	  of	  free	  radicals	  
and	  other	   toxins,	   causing	  dysregulation	  of	   the	   immune	   system	  at	   various	   levels.	  
Tobacco	  smoke	  can	  has	  also	  promote	  macrophage	  and	  dendritic	  cell	  activity	  and	  
release	  of	  several	  pro-­‐inflammatory	  cytokines.35	  
Specifically,	   smoking	   is	  a	  well	  established	  environmental	   risk	   factor	   for	  RA,	  as	  
emerged	  from	  several	  epidemiological	  studies	  and	  case-­‐control	  cohorts.	  36-­‐38	  This	  
risk	  appears	   to	  be	  dose-­‐dependent	  and	  can	  persist	  up	   to	  20	  years	  after	  smoking	  
cessation.38	  
A	  strong	  association	  between	  cigarette	  smoking	  and	  RA	  is	  observed	  within	  the	  
context	   of	   HLA-­‐DRB1	   SE	   and	   presence	   of	   ACPA	   autoantibodies.	   	   39	   It	   has	   been	  
estimated	  that	  the	  combination	  of	  the	  SE	  and	  smoking	  habit	  increases	  the	  relative	  
risk	  of	  developing	  RA	  by	  21	   fold	   in	  ACPA	  seropositive	  patients.	   40	  To	  explain	   this	  
association,	   a	   comprehensive	   immunopathological	   model	   has	   been	   proposed	   1:	  
smoking	  may	  induce	  post-­‐translational	  modifications	  of	  proteins	  expressed	  in	  the	  
lungs	  via	  an	  up-­‐regulation	  of	  certain	  enzymes	  such	  as	  peptidyl-­‐arginine	  deiminase	  
(PAD)	   expressed	   by	   macrophages,	   resulting	   in	   an	   accumulation	   of	   citrullinated	  
peptides.	  In	  genetically	  susceptible	  people	  (e.g.	  individuals	  carrying	  the	  HLA–DR	  SE	  
alleles,	  to	  which	  these	  post-­‐translational	  modified	  epitopes	  can	  bind)	  this	  may	  lead	  
to	   the	   persistent	   activation	   of	   the	   adaptive	   immune	   response	   and	   subsequent	  




entirely	   understood,	   and	   possibly	   after	   the	   intervention	   of	   a	   “second	   hit”,	   the	  
immune	   response	   can	   localise	   to	   other	   organs,	   particularly	   the	   synovium,	  
perpetuating	   autoimmunity	   and	   inflammation	   in	   situ	   that	   may	   ultimately	   result	  
into	  the	  development	  of	  chronic	  arthritis.40	  
Several	  studies	  have	  reported	  a	   familial	  association	   in	  the	  expression	  of	  ACPA	  
antibodies,	  although	  whether	  such	  expression	  is	  related	  to	  shared	  genetic	  and/or	  
shared	  environmental	   factors	  has	  not	  yet	  been	  addressed.	   41-­‐44	  A	   recent	  analysis	  
from	  the	  National	  Swedish	  Twin	  Register	  reported	  that	  environment,	  lifestyle	  and	  
stochastic	   factors	   including	   smoking	   may	   be	   more	   relevant	   than	   genetics	   in	  
inducing	   the	  development	  of	  ACPAs,	  however	   genetic	   factors,	   and	  especially	   SE,	  
may	   have	   an	   important	   role	   in	   determining	  which	   ACPA-­‐positive	   individuals	  will	  
subsequently	  develop	  RA.	  45	  
It	  has	  been	  postulated	  that	  smoking	  status	  can	  also	  influence	  the	  clinical	  course	  
of	   RA:	   several	   studies	   report	   that	   smokers	   tend	   to	   have	   a	  worse	   outcome,	  with	  
greater	   radiological	   progression	   and	   loss	   of	   function	   46,47,	   as	   well	   as	   a	   poorer	  
response	  to	  therapy.48	   	  Whether	  such	  an	  association	  is	  direct	  or	   indirect	  -­‐namely	  
mediated	   by	   the	   contribution	   of	   smoking	   in	   development	   of	   ACPA	   antibodies	  
which	  mark	  a	  more	  aggressive	  disease	  course-­‐	  is	  unknown.	  	  
1.3.3.3	  	  	  Hormonal	  and	  reproductive	  factors	  
Sex	   hormones,	   especially	   estrogens,	   have	   been	   proposed	   as	   having	   a	   role	   in	  
susceptibility	  to	  RA.	  49	  This	  association	  is	  supported	  by	  several	  findings.	  	  
First,	  the	  previously	  mentioned	  3	  times	  higher	  prevalence	  in	  women	  compared	  




Second,	   pregnancy	   has	   a	   significant	   impact	   on	   the	   incidence	   of	   RA	   and	   its	  
clinical	   course.	   Pregnancy	   is	   associated	  with	   a	   reduction	   in	   disease	   incidence	   of	  
about	  70%	  and	  overall	  with	  beneficial	  effects	  on	  disease	  activity	  and	  achievement	  
of	  clinical	  remission.	  50	  This	  could	  be	  directly	  related	  to	  hormonal	  changes	  but	  also	  
to	  maternal-­‐fetal	  disparity	  in	  HLA	  class	  II	  alloantigens.	  51	  Conversely,	  an	  increased	  
incidence	   of	   the	   disease	   and	   high	   rates	   of	   flares	   has	   been	   reported	   in	   the	  
immediate	   post-­‐partum	   and	   during	   the	   breastfeeding	   period,	   which	   has	   been	  
partially	  attributed	  to	  the	  pro-­‐inflammatory	  effects	  of	  prolactin.	  52	  
There	   is	  no	  strong	  evidence	  supporting	   the	   influence	  of	  exogenous	  hormones	  
such	   us	   oral	   contraceptives	   or	   hormone	   replacement	   therapy	   53,	   although	   a	  
modest	   protective	   effect	   for	   oral	   contraceptives	   has	   been	   observed	   in	   small	  
studies.	  54	  
	  
1.4	  	  	  IMMUNOPATHOLOGY	  
Immunopathology	   of	   RA	   is	   characterised	   by	   a	   complex	   interplay	   between	  
adaptive	  and	   innate	   immune	  system,	  along	  with	  responses	  mediated	  by	  synovial	  
resident	   cells.	   Indeed,	   the	   demarcation	   between	   these	   immunological	  
compartments	   is	   a	   simplistic	   and	   artificial	   schematisation	   as	   in	   real	   life	   they	  
crosstalk	  and	  integrate	  to	  form	  an	  inextricable	  network.	  
The	   currently	   accepted	   immunopathological	   model	   is	   that,	   in	   genetically	  
susceptible	  individuals,	  environmental	  factors	  can	  induce	  citrullination	  of	  proteins	  
and	  consequently	  cause	  a	  breach	  of	  peripheral	  immune	  tolerance	  to	  self-­‐antigens,	  
leading	  to	  inflammation	  and	  autoimmunity.	  Thereafter,	  the	  immune	  response	  can	  




understood.	  Local	  micro-­‐vascular,	  micro-­‐environmental	  and	  biomechanical	  factors	  











Figure	  1.1	  :	  Multistep	  progression	  to	  the	  development	  of	  rheumatoid	  arthritis	  
Environment–gene	   interactions	   promote	   loss	   of	   tolerance	   to	   self-­‐proteins	   that	   contain	   a	  
citrulline	   residue,	   which	   is	   generated	   by	   post-­‐translational	   modifications.	   This	   anti-­‐citrulline	  
response	   can	   be	   detected	   in	   T-­‐cell	   and	   B-­‐cell	   compartments	   and	   is	   probably	   initiated	   in	  
secondary	   lymphoid	   tissues	   or	   bone	   marrow.	   Thereafter,	   localisation	   of	   the	   inflammatory	  
response	   occurs	   in	   the	   joint	   by	   poorly	   understood	  mechanisms	   that	   probably	   involve	  micro-­‐
vascular,	   neurological,	   biomechanical,	   or	   other	   tissue-­‐specific	   pathways.	   Synovitis	   is	   initiated	  
and	  perpetuated	  by	  positive	   feedback	   loops	  and	   in	  turn	  promotes	  systemic	   inflammation	  and	  
potential	  extra-­‐articular	  manifestations.	  
Abbreviations:	  ACPA	  =	  anti–citrullinated	  protein	  antibody;	  RF=	  rheumatoid	  factor.	  	  
From	  1	  ,	  with	  permission.	  
	  




However,	  as	  RA	  is	  a	  heterogeneous	  condition	  characterised	  by	  a	  wide	  range	  of	  
clinical	   expressivity,	   different	   pathological	   pathways	   could	   be	   predominant	   in	  
different	  subsets	  of	  the	  disease.	  
	  
1.4.1	  	  	  The	  adaptive	  immune	  system	  response	  
The	   adaptive	   immune	   response	   allows	   for	   generation	   of	   effector	   cells	   with	  
specificity	   toward	   a	   particular	   pathogen	   or	   antigen.	   It	   involves	   mechanisms	   of	  
cellular	  and	  humoral	  immunity	  mediated	  by	  T	  and	  B	  lymphocytes.	  
T	   cells	   include	   two	  main	   subtypes:	   CD4+	   T	   helper	   (Th)	   and	   CD8+	   T	   cytotoxic	  
cells.	   RA	   has	   been	   long	   considered	   the	   prototype	  of	   a	   classic	   CD4+	   Th	   cells	  
mediated	   disease.	   CD4+	   Th	   cells	   are	   activated	   by	   antigens	   presented	   by	  
professional	   antigen	   presenting	   cells	   (APC)	   -­‐macrophages,	   dendritic	   cells	   and	   B	  
cells-­‐	  through	  a	  MHC	  class	  II	  restricted	  mechanism.	  Once	  bound	  to	  the	  MHC	  class	  II	  
complex	   expressed	   by	   the	   APC,	   the	   antigen	   is	   recognised	   by	   a	   specific	   T	   cell	  
receptor	   (TCR).	   T	   cell	   activation	   requires	   a	   complementary	   co-­‐stimulatory	   signal	  
between	   CD28	   expressed	   on	   the	   T	   cells	   surface	   and	   CD80/86	   (B7-­‐1	   and	   B7-­‐2	  
molecules)	   expressed	   on	   APC.	   Once	   activated,	   CD4+	   Th	   cells	   secrete	   a	   series	   of	  
cytokines	  to	  “help”	  the	  activation	  and	  function	  of	  adaptive	  and	  innate	  immunity.	  	  
Two	  specific	  CD4+	  Th	  cells	  subsets	  exist:	  type	  1	  Th	  cell	  (Th1),	  characterised	  by	  
the	   expression	   of	   T-­‐box	   transcription	   factor 21	   (TBX21)	   and	   the	   predominant	  
secretion	  of	   interferon	  gamma	   (INFγ),	   and	   type	  2	  Th	   cell	   (Th2),	   characterised	  by	  
the	   expression	   of	   trans-­‐acting	   T-­‐cell-­‐specific	   transcription	   factor	   GATA3	   (GATA	  
protein	  binding	  3)	  and	   the	  predominant	   secretion	  of	   the	  signature	  cytokine	   IL-­‐4.	  




properties:	  Th1	  are	  primary	  linked	  to	  cellular	  immune	  responses	  effected	  by	  CD8+	  
T	   cells,	   while	   Th2	   promote	   humoral	   immune	   responses	   effected	   by	   B	   cells.	   The	  
immunopathological	  profile	  of	  RA	  is	  characterised	  by	  a	  marked	  shift	  toward	  a	  Th1	  
immunopathological	  pattern.	  55	  	  
However,	   new	   evidence	   from	   recent	   years	   has	   added	   further	   levels	   of	  
complexity	   to	   the	   knowledge	   of	   the	   adaptive	   immune	   system	   response,	  
challenging	   the	   classic	   paradigma	   based	   on	   imbalanced	   Th1/Th2	   profile.	   In	  
particular,	  a	  new	  subtype	  of	  CD4+	  Th	  cells	  has	  been	  identified	  in	  the	  last	  decade,	  
named	  type	  17	  Th	  cell	  (Th17).	  
Th17	  selectively	  express	  the	  transcription	  factor	  RORC2	  (retinoic	  acid	  receptor-­‐
related	   orphan	   receptor	   C2)	   56,	   and	   are	   crucial	   in	   adaptive	   defence	   against	  
extracellular	  pathogens,	  as	  well	  as	   in	  several	  critical	  pathogenetic	  mechanisms	  of	  
inflammation	   and	   autoimmunity.	   These	   cells	   require	   specific	   cytokines	   for	   their	  
proliferation	  and	  function,	  including	  IL-­‐1,	  IL-­‐6,	  IL-­‐23	  and	  transforming	  grow	  factor	  
β	  (TGFβ),	  that	  are	  abundantly	  present	  in	  the	  RA	  synovium.	  In	  turn,	  Th17	  secrete	  a	  
series	  of	   inflammatory	  cytokines	  such	  as	  tumor	  necrosis	   factor	  α	  (TNFα),	   IL-­‐6,	   IL-­‐
21,	  IL-­‐22	  and	  IL-­‐17,	  which	  amplify	  the	  synovial	  inflammation	  and	  mediate	  cartilage	  
damage	  and	  bone	  resorption.	  57	  
Furthermore,	   it	   has	   been	   discovered	   that,	   other	   than	   classic	   CD4+	   and	   CD8+	  
patterns,	  T	  cells	  can	  differentiate	  into	  a	  third	  lineage,	  CD4+	  CD25+	  regulatory	  T	  cells	  
(Treg).	   Treg	   are	   characterised	   by	   the	   expression	   of	   the	   transcription	   factor	  
forkhead	  box	  P3	   (FOXP3),	  and	  have	  a	  primary	   role	   in	  maintaining	   immunological	  




population,	   a	   series	   of	   autoimmune	   disorders	   could	   be	   induced.	   Conversely,	  
immune-­‐tolerance	  is	  restored	  by	  transferring	  adaptive	  Treg.58	  
Treg	   counter-­‐regulate	   the	   pro-­‐inflammatory	   function	   of	   Th17	   and	   vice	   versa.	  
Th17	  and	  Treg	  are	  therefore	  in	  a	  dynamic	  balance	  depending	  on	  the	  local	  cytokine	  
milieu,	   including	   levels	  of	   IL-­‐2,	   IL-­‐6	  and	  TGF-­‐β.	  When	  such	  balance	   is	  altered,	  the	  
maintenance	   of	   immune	   homeostasis	   is	   compromised,	   and	   pathogenetic	  
mechanisms	  leading	  to	  malignancy	  and	  autoimmunity	  can	  occur.59	  
B	   lymphocytes	   are	   the	   main	   effector	   cells	   of	   the	   humoral	   immune	   system.	  
Following	   lymphopoiesis	   in	   the	   bone	  marrow,	   naive	   B	   cells	   transit	   to	   secondary	  
lymphoid	   organs	   (lymph	   nodes,	   spleen	   and	  mucosa	   associated	   lymphoid	   tissue,	  
MALT)	   for	   final	   maturation.	   Of	   most	   importance,	   the	   inflamed	   synovium	   can	  
become	  a	  site	  for	  formation	  of	  tertiary	   lymphoid	  organs,	  where	  ectopic	  germinal	  
centres	  can	  develop	  and	  function.	  	  
In	  peripheral	  lymphoid	  organs,	  B	  cell	  maturation	  and	  activation	  is	  supported	  by	  
local	  cytokines	  and	  co-­‐stimulatory	  molecules	  derived	  from	  resident	  mesenchymal	  
cells,	  especially	  follicular	  dendritic	  cells	  (FDC).	  A	  key	  step	  in	  the	  maturation	  process	  
is	   somatic	   hypermutation	   in	   the	   variable	   regions	   of	   heavy	   and	   light	   chain	  
immunoglobulins	   and	   class	   switching.	   Eventually,	   some	   follicular	   B	   cells	   will	  
differentiate	   to	   plasma	   cells	   and	   secrete	   autoantibodies	   on	   antigen	   exposure,	  
while	  others	  will	  return	  to	  a	  quiescent	  stage	  as	  memory	  B	  cells.	  	  
As	  B	   cells	   are	   classic	   effectors	  of	  humoral	   immune	   response,	   the	  presence	  of	  
autoantibodies	  such	  as	  rheumatoid	  factor	  (RF)	  and	  ACPA	  has	  long	  suggested	  a	  key	  
role	  for	  B	  cell-­‐mediated	  immunity	  in	  the	  pathogenesis	  of	  RA.	  However	  the	  role	  of	  




APC	   and	   mediators	   of	   T	   cell	   activation,	   as	   well	   as	   active	   producers	   of	   pro-­‐
inflammatory	   cytokines,	   chemokines,	   adhesion	   molecules	   and	   pro-­‐angiogenetic	  
factors	  that	  orchestrate	  and	  amplify	  the	  immune	  response.	  60	  	  
A	  population	  of	  regulatory	  B	  cells	  (Breg)	  has	  also	  been	  recognised,	  which	  seems	  
to	  represent	  a	  source	  of	  inhibitory	  cytokines	  such	  as	  IL-­‐10	  and	  TGFβ.	  However,	  the	  
characterisation	  of	  the	  role	  of	  Breg	  in	  autoimmune	  diseases	  is	  still	  underway.	  61	  
The	   pivotal	   role	   of	   B	   cells	   in	   the	   pathogenesis	   of	   RA	   is	   supported	   by	   the	  
therapeutic	  efficacy	  of	  the	  B	  cell	  depleting	  agent	  Rituximab.	  62	  
	  
1.4.2	  	  	  The	  innate	  immune	  system	  response	  
The	   innate	   immune	   response,	   although	   not	   specific,	   represents	   the	   first-­‐line	  
immunological	   response	   against	   biological,	   chemical	   or	   physical	   insults.	  
Macrophages,	  neutrophils,	  dendritic	  cells	  (DC),	  eosinophils,	  natural	  killer	  cells	  (NK)	  
and	  mast	  cells	  are	  the	  main	  effectors	  of	  innate	  immunity.	  63	  
Macrophages	  are	  supposed	  to	  have	  a	  primary	  role	   in	   the	  pathogenesis	  of	  RA.	  
They	   are	   highly	   expressed	   in	   the	   inflamed	   synovium	   and	   show	   a	   state	   of	  
activation.	   Macrophages	   act	   as	   powerful	   APC	   and	   are	   able	   to	   release	   a	   high	  
number	  of	  pro-­‐inflammatory	  cytokines	  and	  mediators	  of	  structural	  damage:	  TNFα,	  
IL-­‐1,	   IL-­‐4,	   IL-­‐6,	   IL-­‐10,	   IL-­‐15,	   IL-­‐18,	   IL-­‐32,	  granulocyte	  monocyte-­‐colony	   stimulating	  
factor	   (GM-­‐CSF),	   interferon-­‐α	   and	   interferon-­‐β	   (IFNα/β),	   platelet-­‐derived	   growth	  
factor	   (PDGF),	   vascular	   endothelial	   growth	   factor	   (VEGF)	   and	   several	   others.	   1	  
Indirect	   evidence	   supporting	   their	   pathogenetic	   role	   in	   RA	   is	   the	   consistent	  





DC	  function	  as	  efficient	  APC	  that	  activate	  the	  expansion	  of	  clonal	  CD4+	  T	  cells	  in	  
the	  lymph	  nodes,	  therefore	  they	  have	  a	  central	  role	  in	  the	  modulation	  of	  immune	  
tolerance.	  In	  RA	  patients,	  a	  high	  degree	  infiltration	  of	  DC	  in	  the	  synovium	  has	  been	  
observed,	   suggesting	   in-­‐situ	   perpetuation	   of	   auto-­‐antigen	   presentation.	   They	  
contribute	   to	   the	  maturation	  and	  differentiation	  of	  B-­‐cells	  as	  well,	   and	  display	  a	  
high	  level	  of	  pro-­‐inflammatory	  cytokines	  expression.	  65	  
The	  role	  of	  neutrophils	  in	  the	  pathogenesis	  of	  RA	  has	  been	  recently	  highlighted.	  
Neutrophils	  are	  abundantly	  expressed	  in	  the	  synovial	  fluid	  of	  RA	  patients,	  and	  may	  
show	  several	  alterations	  in	  phenotype	  and	  function.	  	  Neutrophil	  activation	  causes	  
granular	   release	   of	   mediators	   of	   cartilage	   damage,	   along	   with	   up-­‐regulation	   of	  
pro-­‐inflammatory	  pathways	  such	  as	  NF-­‐kB.	  66,67	  
A	   role	   in	  RA	   immunopathogenesis	  has	  been	  proposed	   for	  mast	  cells	   in	   recent	  
years.	  These	  cells,	  classically	  involved	  in	  Th2-­‐mediated	  inflammation	  and	  allergies,	  
participate	   in	   other	   forms	   of	   immunity	   as	   well.	   Their	   number	   is	   significantly	  
expanded	  in	  RA	  synovium,	  where	  they	  actively	  promote	  the	  release	  of	  vasoactive	  
mediators	  such	  as	  histamine	  and	  leukotrienes,	  cytokines	  	  (TNFα,	  IL-­‐4,	   IL-­‐5	  and	  IL-­‐
6),	   adhesion	   molecules,	   chemokines	   and	   degradation	   enzymes,	   resulting	   in	   the	  
amplification	  of	  chronic	  inflammation	  and	  ultimately	  organ	  damage.	  68	  It	  has	  been	  
recently	  demonstrated	  that	  mast	  cells	  are	  a	  source	  of	  IL-­‐17,	  a	  cytokine	  that	  has	  an	  
important	  role	  in	  RA	  immunopathogenesis.	  69	  
Effector	  mechanisms	  of	  innate	  immunity	  are	  activated	  following	  the	  recognition	  
of	   exogenous	   or	   endogenous	   stimuli	   by	   specific	   receptors	   called	   pattern	  
recognition	   receptors	   (PRRs).	   These	   receptors	   represent	   innate	   sensors	   able	   to	  




components	   -­‐pathogen	   associated	   molecular	   patterns	   (PAMPs)-­‐	   or	   endogenous	  
products	   of	   cell	   damage	   -­‐damage	   associated	   molecular	   patterns	   (DAMPs)-­‐	   like	  
nucleic	   acids,	   heat	   shock	   proteins	   (HSPs),	   hyaluronic	   acid	   (HA),	   oligosaccharides,	  
heparan	   sulfate,	   glycoprotein	   gp96,	   fibronectin,	   fibrinogen,	   surfactant	  protein	  A,	  
fatty	  acids.	  63,70	  
Among	  PRRs,	  an	  increasing	  interest	  has	  emerged	  for	  toll	  like	  receptors	  (TLRs)	  in	  
the	   recent	  years.	  TLRs	   form	  a	   family	  of	   trans-­‐membrane	   receptors	  expressed	  on	  
the	   cell	   surface	   and	   endosome	   of	   macrophages,	   fibroblasts,	   mast	   cells,	   DC,	  
epithelial	  and	  endothelial	  cells.	  To	  date,	  10	  TLRs	  subtypes	  have	  been	  identified	  in	  
humans	  (TLR	  1	  to	  10).	  It	  has	  been	  proposed	  that	  dysregulated	  TLR	  signalling	  may	  
provide	  a	  pathway	  to	  autoimmunity.	  Indeed	  accumulating	  evidence	  suggests	  that	  
DAMPs	   could	  be	   implicated	   in	   the	  auto-­‐antigen	   recognition	  and	  perpetuation	  of	  
non-­‐infectious	  inflammation.	  70	  TLR	  signalling	  is	  dysregulated	  in	  animal	  models	  of	  
arthritis.	   71	   An	   overexpression	   and	   enhanced	   function	   of	   TLRs	   2,	   3,	   4	   and	   7	   has	  
been	  observed	   in	  the	  RA	  synovium,	  which	   is	  associated	  with	  the	  production	  of	  a	  
number	  of	  pro-­‐inflammatory	  cytokines	  and	  metalloproteinases.72-­‐74	  
	  
1.4.3	  	  	  Role	  of	  resident	  cells	  	  
Resident	   joint	   cells	   such	   as	   fibroblast-­‐like	   synoviocytes	   (FLS),	   chondrocytes,	  
osteoblasts	  and	  osteoclasts	  contribute	  to	  maintenance	  of	  extracellular	  matrix	  and	  
joint	   homeostasis	   in	   the	   normal	   synovium.	   In	   RA,	   they	   tend	   to	   acquire	   a	  
transformed,	   aggressive	   phenotype,	   becoming	   active	   participants	   in	   the	   chronic	  




The	  central	  role	  of	  FLS	  in	  the	  pathogenesis	  of	  RA	  has	  clearly	  emerged	  over	  the	  
last	  decade.	  Far	  from	  being	  inert	  structural	  cells,	  they	  contribute	  to	  initiation	  and	  
amplification	   of	   the	   immune	   response,	   directly	   promoting	   activation	   of	   effector	  
cells.	  75,76	  
The	   transformation	   of	   FLS	   toward	   a	   pathogenic	   phenotype	   involves	   the	  
activation	   of	   pivotal	   downstream	   signalling	   cascades	   such	   as	   the	   mitogen-­‐
activated	   proteins	   (MAP)	   kinase	   system	   and	   the	   transcription	   factor	   NF-­‐kB,	  
promoted	  by	  cytokine-­‐dependent	  (especially	  TNFα,	   IL-­‐1,	   IL-­‐6	  and	  IFNγ)	  as	  well	  as	  
cytokine-­‐independent	  pathways.	   77	  As	  a	   result,	  FLS	  acquire	  somatic	  mutations	  of	  
proto-­‐oncogenes	  and	  tumor	  suppressor	  genes	  which	  are	  similar	  to	  those	  observed	  
in	  neoplastic	  transformation.	  	  Basically	  they	  turn	  from	  local	  homeostatic	  cells	  into	  
hyperplastic	  and	  dysfunctional	  cells	  which	  become	  capable	  of	  activating	   immune	  
pathways	  and	  promoting	  inflammatory	  responses.	  75,78	  
Once	  acquired	  such	  pathogenic	  features,	  FLS	  become	  critical	  in	  the	  organization	  
of	   the	   inflamed	   synovium	   architecture.	   They	   actively	   promote	   a	   cell-­‐to-­‐cell	  
interaction	  with	  leukocyte	  and	  mesenchymal	  cells,	  enhancing	  their	  activation	  and	  
function.	   This	   cross	   talk	   requires	   the	   presence	   of	   special	   adhesion	   molecules,	  
particularly	  cadherin-­‐11,	  a	  trans	  membrane	  glycoprotein	  that	  facilitates	  cell-­‐to-­‐cell	  
surface	  adhesion.	  The	   importance	  of	  cadherin-­‐11	  has	  been	  highlighted	   in	  murine	  
models	  of	  arthritis,	  where	  the	  absence	  of	  this	  protein	  resulted	  in	  a	  hypoplastic	  and	  
less	   inflamed	   synovium.	   79	   Several	   ongoing	   studies	   are	   aimed	   at	   identifying	  
markers	  of	  FLS	  activation,	  and	  cadherin-­‐11	  seems	  an	  attractive	  candidate	  due	  to	  




Transformed	   FLS	   release	   a	   variety	   of	   pro-­‐inflammatory	   cytokines,	   growth	  
factors,	   adhesion	   molecules	   and	   angiogenic	   factors.	   They	   are	   a	   key	   source	   of	  
mediators	  that	  promote	  recruitment,	  differentiation	  and	  activation	  of	  Th1	  cells,	  as	  
well	  as	  cytokines	  (IL-­‐6,	  IL-­‐23,	  IL-­‐15	  and	  TGFβ)	  able	  to	  influence	  the	  expansion	  and	  
differentiation	  of	  Th17	  cells.	  In	  turn,	  T-­‐cells	  can	  induce	  the	  activation	  of	  FLS	  trough	  
direct	   cell-­‐to	   cell	   interactions	   or	   via	   the	   release	   of	  mediators	   such	   us	   IL-­‐17	   and	  
IFNγ,	  generating	  an	  intricate	  loop	  that	  contributes	  to	  amplify	  and	  perpetuate	  the	  
inflammatory	  cascade	  in	  a	  bi-­‐directional	  fashion.	  75,76,80	  
FLS	  are	  also	  involved	  in	  the	  enhancement	  of	  B-­‐cell	  function:	  they	  sustain	  IL-­‐15-­‐	  
dependent	  B-­‐cell	  survival,	  and	  promote	  immunoglobulin	  class-­‐switching	  via	  B	  cell	  
activating	  factor	  (BAFF,	  also	  known	  as	  B	  lymphocyte	  stimulator,	  BLyS).	  81 	  They	  are	  
also	  critical	  in	  the	  organization	  and	  function	  of	  synovial	  germinal	  centres.	  
There	   is	   evidence	   that	   FLS	   are	   effectors	   of	   innate	   immunity	   as	   well.	   They	  
express	  TLRs	  (predominantly	  TLR	  2,	  3	  and	  4)	  81	  and	  other	  receptors	  involved	  in	  the	  
activation	   of	   innate	   immunity	   responses	   such	   as	   nucleotide-­‐binding	  
oligomerization	   domain-­‐like	   receptor	   (NLR)	   and	   protease-­‐activator	   receptor	   2	  
(PAR2).	  In-­‐vitro	  studies	  demonstrated	  that	  they	  may	  act	  as	  professional	  APCs	  after	  
acquiring	  the	  capacity	  of	  processing	  and	  presenting	  antigens	  to	  T	  cells	  via	  an	  MHC	  
class	  II-­‐restricted	  mechanism.	  82	  	  
FLS	   also	   promote	   angiogenesis	   through	   the	   production	   of	   VEGF	   and	   PDGF.	   76	  
Ultimately,	   activated	   FLS	   release	   matrix	   degrading	   enzymes	   such	   as	  MMP-­‐1,	   A-­‐
disintegrin	  and	  metalloprotease	  with	   thrombospondin-­‐1-­‐like	  domains	   (ADAMTS),	  




are	   a	   source	   of	   the	   receptor	   activator	   of	   nuclear	   factor	   κ-­‐B	   ligand	   (RANKL)	   and	  
other	  molecules	  directly	  involved	  in	  bone	  erosions	  such	  as	  dickkopf-­‐1	  (DKK-­‐1).	  79	  
In	  summary,	  FLS	  represent	  a	  complex	  and	  intricate	   link	  between	  adaptive	  and	  
innate	   response,	   which	   orchestrate	   immunopathological	   pathways	   leading	   from	  
synovial	  inflammation	  to	  tissue	  damage.	  In	  consideration	  of	  their	  multipotent	  pro-­‐
inflammatory	  properties,	  FLS	  are	  becoming	  an	  attractive	  target	  for	  new	  classes	  of	  
drugs	  in	  RA.	  	  
	  Figure	   1.2	   summarises	   the	   main	   pathways	   and	   mediators	   involved	   in	   the	  
complex	   interplay	   between	   immune	   response,	   adaptive	   response	   and	   synovial	  










Figure	   1.2	   :	   Interplay	   between	   adaptive	   immunity,	   innate	   immunity	   and	   resident	   cells	   in	  
rheumatoid	  arthritis	  
In	  the	  synovial	  membrane	  adaptive	  and	  innate	  immune	  pathways	  integrate	  with	  resident	  cells	  
to	  promote	  and	  perpetuate	  inflammation,	  tissue	  remodelling	  and	  damage.	  
Abbreviations:	   ACPA=	   anti-­‐citrullinated	   protein	   antibodies;	   ADAMTS=	   A-­‐disintegrin	   and	  
metalloproteinase	   with	   thrombospondin-­‐1–like	   domains;	   CC=	   CC	   chemokine;	   CD40L=	   CD40	  
ligand;	   CXC=	   CXC	   chemokine;	   CSF=	   granulocyte–macrophage	   colony-­‐stimulating	   factor;	  
DAMPs=	   damage-­‐associated	  molecular	   patterns;	   Dkk-­‐1=	   dickkopf-­‐1;	   FcεRI=	   high-­‐affinity	   IgE	  
receptor;	  FcR-­‐γ=	  Fc	  receptor	  γ;	  GM-­‐FGF=	  fibroblast	  growth	  factor;	  HA=	  hyaluronic	  acid;	  HSPs=	  
heat-­‐shock	   proteins;	   IFN	   α/β=interferon	   α/β;	   MMPs=	   matrix	   metalloproteinases;	   NLR=	  
nucleotide-­‐binding	   oligomerization	   domain–like	   receptor;	   PAMPs=	   pathogen-­‐associated	  
molecular	   patterns;	   PAR2=	   protease-­‐activated	   receptor	   2;	   PDGF=	   platelet-­‐derived	   growth	  
factor;	  RANKL=	  receptor	  activator	  of	  nuclear	  factor	  κB	   ligand;	  RF=	  rheumatoid	  factor,	  TGFβ=	  
transforming	  growth	  factor	  β;	  Th0=	  type	  0	  helper	  T	  cell;	  Th1=	  type	  1	  T	  helper	  cell;	  Th2=	  type	  2	  
T	  helper	  cell;	  Th17=	  type	  17	  T	  helper	  cell;	  TLR=	  toll	  like	  receptor;	  TNFα=	  tumor	  necrosis	  factor	  
α;	  VEGF=	  vascular	  endothelial	  growth	  factor.	  	  





1.4.4	  	  Autoantibodies	  
A	  number	  of	  autoantibodies	  can	  be	  detected	  in	  the	  serum	  of	  RA	  patients.	  
These	  antibodies	  are	  directed	  against	  different	  auto-­‐antigens	  such	  as	  circulating	  
immunoglobulins	  (e.g.	  RF),	  circulating	  proteins	  (anti-­‐fibrinogen,	  anti-­‐plasminogen,	  
anti-­‐fibrin),	   enzymes	   (anti-­‐calpastatin,	   anti-­‐enolase,	   anti-­‐aldolase,	   anti-­‐glucose	   6	  
phosphate	   isomerase),	   components	   of	   cartilage	   (anti-­‐collagen	   II,	   IX	   and	   XI),	  
citrullinated	  antigens	  (anti-­‐cyclic	  citrullinated	  proteins	  antibodies,	  anti-­‐fibrin,	  anti-­‐
vimentin,	  anti-­‐filaggrin	  and	  several	  others,	   forming	  the	  class	  of	  ACPA	  antibodies)	  
or	  nuclear	  components	  such	  as	  ribonucleoprotein	  (RNPs)	  and	  HSPs.	  83	  
Autoantibodies	   carry	   out	   their	   pathogenic	   activity	   via	   formation	   of	   immune	  
complexes,	  activation	  of	  complement	  and	  recruitment	  of	   inflammatory	  cells,	  and	  
enhancement	  of	  local	  damage	  via	  Fc	  receptor	  γ	  (FcR-­‐γ).	  
Murine	   models	   have	   shown	   that	   some	   autoantibodies	   may	   have	   a	   direct	  
pathogenic	   role	   in	   experimental	   autoimmune	   arthritis.	   ACPA,	   in	   particular,	  were	  
capable	  of	  contributing	  to	  cartilage	  damage	  in	  the	  collagen	  induced	  arthritis	  (CIA)	  
mouse	  model.84	  Little	  evidence	  exists	  to	  support	  a	  pathogenic	  role	  in	  humans.	  	  
It	  is	  possible	  that,	  among	  the	  several	  autoantibodies	  identified	  in	  RA,	  some	  may	  
represent	  only	  an	  epiphenomenon	  of	  chronic	  inflammation	  and	  not	  be	  relevant	  to	  
disease	  pathogenesis	  whilst	  others	  contribute	  substantially.	  
Indeed,	   RF	   and	  ACPA	   are	   valuable	   hallmarks	   of	   RA,	   defining	   clinically	   distinct	  
subsets	  of	  disease,	  with	  important	  diagnostic	  and	  prognostic	  implications.	  	  
RF	  was	  first	  described	  by	  Waaler	  in	  1939.	  85	  RF	  is	  an	  antibody	  directed	  against	  
the	   crystallized	   fragment	   (Fc)	   of	   immunoglobulin	   G	   (IgG),	   which	   may	   exist	   in	  




immunoglobulin	   A	   (IgA),	   and	   IgG.	   IgM-­‐RF	   is	   the	   isotype	   routinely	   measured	   in	  
clinical	  assay.	  It	  shows	  good	  sensitivity	  but	  low	  specificity	  for	  RA,	  as	  it	   is	  found	  in	  
several	   other	   autoimmune	   diseases,	   infectious	   diseases	   like	   hepatitis	   B	   (HBV),	  
hepatitis	   C	   (HCV)	   and	   tuberculosis	   (TB)	   and	   in	   up	   to	   10%	  of	   healthy	   individuals.	  
Testing	   for	   IgG-­‐RF	   and	   IgA-­‐RF	   in	   conjunction	   with	   IgM-­‐RF	   has	   been	   shown	   to	  
improve	  diagnostic	  performance.	  60,86	  
The	  first	  ACPA	  antibody	  described	  in	  RA	  patients	  was	  in	  1964	  by	  Nienhuis,	  who	  
named	  it	  antibody	  perinuclear	  factor	  (APF):	  this	  was	  an	  antibody	  directed	  against	  
the	  perinuclear	  keratohyaline	  granules	  of	  epithelial	  cells	  from	  healthy	  human	  oral	  
mucosa.	   87	   Subsequently,	   a	   large	   variety	   of	   autoantibodies	   against	   citrullinated	  
proteins	   were	   discovered.	   Citrullination	   is	   the	   post-­‐translational	   modification	   of	  
the	   amino	   acid	   arginine	   to	   citrulline	   by	   PAD	   enzyme,	  which	  may	   be	   induced	   by	  
environmental	  factors	  in	  genetically	  predisposed	  individuals.	  This	  is	  thought	  to	  be	  
the	   ‘primum	   movens’	   of	   breach	   of	   immune	   tolerance	   in	   RA,	   as	   previously	  
discussed.	  Citrullinated	  proteins	  are	  found	  in	  the	  RA	  synovium,	  and	  ACPA	  could	  be	  
produced	  locally.	  88	  
The	   original	   assay	   developed	   for	   the	   detection	   of	   ACPA,	   known	   as	   the	   anti-­‐
cyclic	   citrullinated	   proteins	   antibodies	   1	   (anti-­‐CCP1)	   test,	   showed	   limited	  
diagnostic	  performance,	  and	  was	  followed	  by	  a	  second	  generation	  assay,	  the	  anti-­‐
cyclic	  citrullinated	  proteins	  antibodies	  2	  (anti-­‐CCP2)	  test,	  that	  was	  generated	  from	  
an	   expanded	   library	   of	   citrullinated	   proteins.	   This	   second	   test	   was	   able	   to	  
recognise	   additional	   citrulline	   epitopes,	   resulting	   in	   sensitivity	   and	   specificity	  




significantly	   higher	   compared	   to	   RF.	   90	   A	   third	   anti-­‐CCP	   generation	   essay	   is	  
available	  since	  2005,	  however	  its	  practical	  use	  remains	  limited.	  91	  
Intriguing,	  studies	  from	  blood	  donors	  show	  that	  the	  presence	  of	  RF	  and	  ACPA	  
has	   been	   found	   in	   almost	   50%	  of	   RA	   patients	   several	   years	   before	   the	   onset	   of	  
symptoms,	  suggesting	  the	  existence	  of	  an	  immunological	  pre-­‐clinical	  phase	  of	  the	  
disease.92	  Magnetic	  resonance	  imaging	  (MRI)	  and	  biopsy	  studies	  from	  the	  joints	  of	  
individuals	   who	   were	   seropositive	   for	   RF	   and	   ACPA	   but	   had	   subsequently	   not	  
developed	   any	   clinical	   manifestation	   of	   arthritis,	   showed	   a	   relatively	   normal	  
synovium,	   with	   minor	   infiltration	   of	   T	   cells.	   93	   Such	   observations	   support	   the	  
hypothesis	   that	   systemic	   autoimmunity	   precedes	   the	   development	   of	   synovitis,	  
implying	   that	   a	   breach	   in	   immune	   tolerance	  with	   development	   of	   auto-­‐reactive	  
lymphocytes	   may	   start	   in	   other	   anatomical	   sites	   than	   the	   joints.	   In	   some	  
individuals	   this	   response	   is	   then	   initiated	   and	   maintained	   within	   the	   joints	  
themselves,	  where	  additional	  self-­‐antigens	  could	  be	  localised.	  
Finally,	  although	  not	  diagnostic,	  RF	  and	  ACPA	  have	  a	  positive	  predictive	  value	  
(PPV)	  for	  the	  development	  of	  RA	  in	  early	  inflammatory	  arthritis	  94-­‐97	  and	  may	  help	  
to	   identify	   patients	   that	  may	  benefit	   from	  early	   intervention.	   The	  PPV	  has	   been	  
estimated	  at	  4%	  for	  RF	  seropositive	  and	  16%	  for	  ACPA.	  98	  	  
The	  presence	  of	   these	  antibodies	  has	  also	  prognostic	   value	   in	  RA	  patients,	   as	  
they	  are	  important	  predictors	  of	  structural	  damage	  and	  clinical	  outcome,	  and	  this	  
is	  especially	  relevant	  for	  ACPA.	  99-­‐101	  
Collectively,	   these	   evidences	   suggest	   that	   RF	   and	   especially	   ACPA	  may	   play	   a	  
key	   pathogenetic	   role	   in	   initiating	   and	   perpetuating	   RA,	   imprinting	   the	   severity	  





1.4.5	  	  	  Cytokines	  and	  intracellular	  signalling	  pathways	  
Cytokines	  play	  a	  critical	  role	  in	  the	  pathogenesis	  of	  RA.	  	  Particularly	  TNFα,	  IL-­‐6	  
and	   IL-­‐1	   have	  major	   pathogenic	   relevance	   and	   represent	   the	   targets	   of	   current	  
cytokine-­‐blocking	  armamentarium.	  	  
TNFα	  was	  the	  first	  cytokine	  to	  be	  recognised	  as	  a	  potential	  therapeutic	  target	  in	  
RA.	   Indeed	   the	   pivotal	   role	   of	   this	   cytokine	   in	   RA	   pathophysiology	   is	   strongly	  
supported	  by	  the	  clinical	  benefits	  upon	  its	  inhibition.	  	  
TNFα	   is	   produced	   by	   activated	   macrophages	   and	   T	   cells	   and	   exerts	   biologic	  
functions	   after	   binding	   to	   its	   receptors:	   p55	   (TNF	   receptor	   I,	   TNF-­‐RI),	   which	   is	  
expressed	   in	   several	   human	   cells,	   and	  p75	   (TNF	   receptor	   II,	   TNF-­‐RII),	   specifically	  
expressed	   in	   immune	   system	   cells.	   Increased	   levels	   of	   TNFα	   can	   be	   detected	   in	  
serum,	   synovial	   fluid	   and	   synovial	   tissue	   of	   RA	   patients.	   102,103	   TNFα	   is	   a	  
multifunctional	   cytokine	   with	   pro-­‐inflammatory	   effects	   on	   various	   cells:	  
leukocytes,	  macrophages,	  synoviocytes,	  chondrocytes,	  and	  osteoclasts.	  TNFα	  has	  a	  
key	  role	  in	  the	  induction	  of	  other	  pro-­‐inflammatory	  mediators,	  including	  cytokines,	  
chemokines,	   adhesion	   molecules,	   angiogenic	   factors,	   resulting	   in	   the	  
enhancement	  of	   leukocytes	  and	  monocyte	  recruitment	  and	  function,	  FLS	  survival	  
and	   activation,	   release	   of	   cartilage	   degradation	   enzymes	   and	   activation	   of	  
RANK/RANKL	   system.	   These	   pathways	   ultimately	   lead	   to	   the	   amplification	   and	  
perpetuation	   of	   the	   inflammatory	   cascade,	   cartilage	   degradation	   and	   bone	  
erosion.	  104	  	  
IL-­‐6	   is	   a	   pro-­‐inflammatory	   cytokine	   promoting	   local	   leukocyte	   activation,	  




effects,	  it	  has	  a	  pivotal	  role	  in	  inducing	  systemic	  inflammation	  such	  as	  the	  release	  
of	   acute	   phase	   reactants,	   anaemia,	   fever,	   fatigue	   and	   dysregulation	   of	   lipid	  
metabolism.	  The	  IL-­‐6	  receptor	  (IL-­‐6R)	  is	  composed	  of	  2	  subunits:	  the	  80	  kiloDalton	  
(kDa)	  portion,	  which	  represents	  the	  IL-­‐6-­‐binding	  portion,	  and	  the	  130	  kDa,	  which	  
represents	  the	  signal-­‐transducing	  portion.	  Two	  forms	  of	  IL-­‐6R	  exist:	  the	  membrane	  
and	   the	   soluble	   form,	   which	   represent	   the	   pharmacological	   targets	   of	   the	  
monoclonal	  antibody	  Tocilizumab.	  Tocilizumab	  inhibits	  the	  biological	  activity	  of	  IL-­‐
6	  by	  competitively	  binding	  to	  IL-­‐6R.	  105,106	  
IL-­‐1	  is	  a	  key	  pro-­‐inflammatory	  cytokine	  overexpressed	  in	  RA.	  Its	  biologic	  effects	  
are	   counter-­‐balanced	  by	   a	  natural	   receptor	   antagonist	   (IL-­‐1	   receptor	   antagonist,	  
IL-­‐1Ra).	   In	   the	   RA	   synovium,	   IL-­‐1	   promotes	   the	   activation	   of	   leukocytes,	  
endothelial	   cells,	   resident	   mesenchimal	   cells,	   osteoclasts	   and	   chondrocytes.	   107	  	  
Despite	  the	  primary	  pro-­‐inflammatory	  role	  of	  this	  cytokine,	  the	  clinical	  benefits	  of	  
anti-­‐IL-­‐1	   monoclonal	   antibody	   Anakinra	   have	   been	   proved	   of	   modest	   entity	   in	  
comparison	  to	  TNFα	  and	  IL-­‐6R	  blocking	  agents.	  108	  
Within	  the	  IL-­‐17	  family,	  which	  includes	  several	  members	  from	  IL-­‐17A	  to	  IL-­‐17F,	  
IL-­‐17A	  has	  recently	  emerged	  has	  a	  major	  contributor	  to	  the	  immune-­‐pathogenesis	  
of	   RA.	   109	   	   Il-­‐17A	   is	   in	   fact	   the	   archetypal	   IL-­‐17	   cytokine,	   and	   in	   this	   thesis	   I	  will	  
refer	  to	  IL-­‐17A	  as	  IL-­‐17.	  The	  major	  source	  of	  this	  cytokine	  is	  CD4+	  Th17	  cells,	  and	  in	  
minor	   entity	   CD8+	   cells,	   NK,	   monocytes,	   neutrophils	   and	   mast	   cells.	   IL-­‐17	  
synergizes	  with	   other	   cytokines,	   especially	   TNFα,	   IL-­‐1	   and	   IFNγ,	   to	   promote	   the	  
activation	  of	  leukocytes,	  monocytes	  and	  resident	  mesenchimal	  cells,	  the	  synthesis	  
of	   inflammatory	   mediators,	   the	   release	   of	   degradation	   enzymes	   and	   the	  




cascade	   has	   been	   activated,	   several	   positive	   feedback-­‐loop	   mechanisms	  
contribute	   to	   increase	   the	   synthesis	  of	   IL-­‐17	   further.	   The	   synovial	   levels	  of	   IL-­‐17	  
correlate	  with	   disease	   activity	   and	   severity.110,111	   Il-­‐17	   has	   became	   an	   attractive	  
therapeutic	   target	   in	   several	   autoimmune	   conditions,	   and	   the	   IL-­‐17	   blocker	  
monoclonal	   antibody	   Secukinumab	   has	   been	   recently	   licensed	   for	   use	   in	   plaque	  
psoriasis	   and	   psoriatic	   arthritis.	   112	   Trials	   for	   the	   use	   of	   Secukinumab	   in	   RA	   are	  
currently	  ongoing,	  however	  preliminary	  results	  are	  not	  encouraging.	  113	  	  
The	  differentiation	  of	  Th17	  cells	  and	  the	  synthesis	  of	  IL-­‐17	  is	  dependent	  on	  IL-­‐
23,	  another	  cytokine	  highly	  expressed	   in	   the	  synovial	   fluid	  and	  synovial	   tissue	  of	  
RA	   patients.	   Blocking	   the	   IL-­‐23/Th17	   axis	   is	   therefore	   an	   additional	   attractive	  
therapeutic	  target.	  114	  
A	   major	   role	   is	   also	   played	   by	   cytokines	   and	   chemokines	   predominantly	  
involved	   in	   the	   tropism	   of	   B	   lymphocytes	   and	   in	   the	   organisation	   of	   germinal	  
centres.	   Within	   the	   inflamed	   synovium,	   high	   levels	   of	   BAFF	   are	   secreted	   by	  
macrophages,	   DC,	   neutrophils	   and	   FLS.	   A	   BAFF	   homologue,	   the	   proliferation-­‐
inducing	   ligand	   (APRIL),	   is	   released	   by	   macrophages,	   DC	   and	   T	   cells.	   These	  
cytokines	  are	  responsible	  for	  B-­‐cell	  differentiation	  and	  activation,	  antibodies	  class	  
switch	  recombination,	  and	  B-­‐cell	  dependent	  T-­‐cell	  activation	  	  115-­‐117	  
CXC-­‐chemokine	   ligand	   13	   (CXCL13),	   CC-­‐chemokine	   ligand	   21(CCL21)	   and	  
lymphotoxin	  β	  (LTβ),	  which	  are	  mediators	  critically	  involved	  in	  the	  formation	  and	  
function	   of	   synovial	   germinal	   centres,	   are	   also	   abundantly	   expressed	  within	   the	  




Several	  other	  cytokines	  play	  an	  active	  role	  in	  RA	  synovitis:	  IL-­‐15,	  IL-­‐18,	  IL-­‐32,	  IL-­‐
33,	  GM-­‐CSF,	  macrophage	  migration	  inhibitory	  factor	  (MIF)	  and	  many	  others,	  some	  
of	  which	  are	  currently	  undergoing	  testing	  as	  potential	  therapeutic	  targets.118-­‐120	  	  
	  
1.5	  	  	  CLINICAL	  FEATURES	  
RA	   is	   characterised	   by	   persistent	   synovitis,	   systemic	   inflammation,	  
autoantibody	   production,	   cartilage	   and	   bone	   destruction,	   leading	   to	   chronic	  
disability	   and	   reduced	   life	   expectancy.	   2	   However	   the	   disease	   shows	   a	   wide	  
spectrum	  of	   clinical	  phenotypes:	   some	  patients	  have	  a	  mild,	  non-­‐erosive	  course,	  
whereas	  others	  present	  with	  severe,	  rapidly	  erosive	  and	  disabling	  disease.121	  
	  
1.5.1	  	  	  Clinical	  presentation	  
The	   typical	   onset	   of	   RA	   is	   characterised	   by	   progressive,	   symmetrical	   joint	  
tenderness	   and	   swelling	   in	   the	   metacarpophalangeal	   (MCPs),	   proximal	  
interphalangeal	  (PIPs)	  and	  metatarsophalangeal	  (MTPs)	   joints.	  An	  involvement	  of	  
the	  wrists	  is	  also	  very	  common	  in	  the	  early	  phase	  of	  the	  disease,	  meanwhile	  large	  
joints	   such	   as	   knees,	   elbows,	   shoulders,	   ankles	   and	   hips	   are	   less	   frequently	  
involved.	   Although	   any	   joint	   can	   virtually	   be	   affected,	   the	   distal	   interphalangeal	  
joints	   (DIPs),	   the	   thoracolumbar	   spine	   and	   the	   sacroiliac	   joints	   are	   normally	  
spared.	   Peri-­‐articular	   structures,	   especially	   tendons	   and	   bursae,	   are	   frequently	  
involved.	   	   Morning	   stiffness	   lasting	   over	   30	   minutes	   with	   impaired	   articular	  
function,	  followed	  by	  progressive	  improvement	  during	  the	  day,	  is	  a	  typical	  feature	  
of	   RA.	   Fatigue	   is	   often	   present.	   More	   severe	   systemic	   symptoms	   like	   fever,	  




There	   is	   no	   laboratory	   test	   that	   can	   confirm	   or	   rule	   out	   the	   diagnosis	   of	   RA,	  
however	   abnormal	   values	   reflecting	   systemic	   inflammation	   and	   activation	   of	  
humoral	  immunity	  are	  usually	  detected	  serologically:	  raised	  inflammatory	  markers	  
such	   as	   erythrocyte	   sedimentation	   rate	   (ESR)	   and	   C-­‐reactive	   protein	   (CRP),	  
normocytic	   normochromic	   anaemia,	   thrombocytosis,	   seropositivity	   for	   RF	   and	  
ACPA	  122,123	  
An	   atypical	   onset	   occur	   in	   about	   25%	   of	   cases,	   including	   monoarticular	  
involvement	   of	   a	   single	   large	   joint	   (knee,	   shoulder,	   ankle),	   predominant	   peri-­‐
articular	   involvement	   (tenosynovitis,	   bursitis),	   systemic	   manifestations	   without	  
joint	  symptoms,	  palindromic	  onset	  (recurrent	  episodes	  of	  oligoarthritis	  lasting	  1-­‐2	  
days	   and	   spontaneously	   remitting	   with	   no	   residual	   radiologic	   damage).	  
Polymyalgia	   rheumatica-­‐like	   onset	   (involvement	   of	   the	   proximal	   muscles	   of	   the	  
shoulder	   and	   pelvic	   girdle	  with	   associated	   raised	   inflammatory	  markers)	   can	   be	  
observed	  in	  the	  elderly.	  122	  	  
	  
1.5.2	  	  	  Extra-­‐articular	  manifestations	  
Extra-­‐articular	  manifestations	  (EAM)	  of	  RA	  can	  affect	  various	  organs.	  However	  
it	   may	   be	   difficult	   distinguish	   them	   from	   the	   comorbidities	   and	   the	   long-­‐term	  
complications	  associated	  with	  RA.	  	  
A	   specific	   definition	   for	   EAM	  does	  not	   exist.	   Some	  diagnostic	   criteria	   (Malmo	  
criteria)	  were	  proposed	  in	  2004	  but	  they	  are	  not	  universally	  accepted.	  124	  Partially	  





In	   clinical	   practice,	   the	   prevalence	   of	   extra-­‐articular	   features	   is	   observed	   in	  
about	   1%	   of	   patients	   or	   less.	   However,	   skin	  manifestations	   such	   as	   rheumatoid	  
nodules	  can	  be	  detected	  in	  up	  to	  30%	  of	  patients	  over	  the	  course	  of	  the	  disease.	  
Anaemia,	   secondary	   Sjogren’s	   Syndrome	   and	   pulmonary	   complications	   are	   also	  
relatively	  common,	  ranging	  from	  6	  to	  10%.	  125	  
The	  prevalence	  of	  EAM	  correlates	  with	  the	  duration	  of	  disease,	  although	  they	  
can	  virtually	  occur	  at	  any	  stage,	  including	  the	  early	  phases	  of	  RA.	  126	  	  
There	   are	   no	   specific	   predictors	   for	   development	   of	   EAM,	   but	   they	   are	  more	  
frequently	   associated	   with	   male	   gender,	   smoking,	   high	   levels	   of	   inflammatory	  
markers,	  presence	  of	  autoantibodies	  and	  the	  HLA	  SE.	  125	  
The	   presence	   of	   EAM	   is	   related	   to	   worse	   outcome,	   including	   higher	   disease	  
activity,	  erosions	  and	  disability,	  and	  overall	  increased	  mortality.127	  A	  higher	  risk	  of	  
cardiovascular	  events	  has	  also	  been	  observed.	  128	  
EAM	  of	  RA	   includes	  a	  wide	   range	  of	   cutaneous,	  pulmonary,	   cardiac,	   vascular,	  
ocular,	  neurological,	  haematological	  and	  renal	  features.	  	  
Among	  the	  cutaneous	  manifestations,	  rheumatoid	  nodules	  are	  the	  commonest.	  
129	   These	   nodules	   are	   solitary	   or	   multiple	   subcutaneous	   granulomatous	   lesions	  
that	  preferentially	   localise	   in	  areas	  of	  repetitive	  mechanical	  pressure	  such	  as	  the	  
elbows,	  the	  extensor	  surfaces	  of	  the	  forearm,	  the	  hands	  and	  the	  feet.	  Nodules	  can	  
also	  occur	   in	   internal	  organs,	  especially	   lungs,	  pleura,	  pericardium,	  meninges.	   130	  
Accelerated	   nodulosis	   has	   been	   observed	   during	  Methotrexate	   therapy	   131,	   and	  
recently	  an	  association	  with	  other	  therapies	  including	  Leflunomide	  and	  anti-­‐TNFα	  
agents	  has	  been	  reported.	  132	  Other	  typical	  skin	  manifestations	  include	  cutaneous	  




Pulmonary	   involvement	   is	   common,	   occurring	   in	   5-­‐10%	   of	   RA	   patients,	   and	  
represent	  a	  major	  cause	  of	  morbidity	  and	  mortality:	  pleural	  effusions,	   interstitial	  
lung	  disease,	  pulmonary	  fibrosis,	  pulmonary	  nodules,	  bronchiolitis	  obliterans	  and	  
pulmonary	  hypertension	  have	  been	  observed.	  134	  
All	   cardiac	  structures	  can	  be	   involved	   in	  RA,	   therefore	  a	  vast	   range	  of	  cardiac	  
complications	  has	  been	  described:	  pericarditis,	  myocarditis,	  endocarditis,	  valvular	  
disease,	   arrhythmias,	   coronary	   arteritis,	   aortitis,	   ischaemic	   heart	   disease.	   135	  
Pericarditis	   is	   the	   commonest	   cardiac	   EAM:	   symptomatic	   pericarditis	   has	   been	  
observed	   in	   about	   1%–4%	   of	   patients,	   however	   subclinical	   pericarditis	   can	   be	  
detected	  on	  echocardiogram	  or	  autopsy	  in	  up	  to	  30%–50%	  of	  patients.	  136	  
Ophthalmic	   manifestations	   include	   keratoconjuntivitis	   sicca	   (secondary	  
Sjögren's),	   episcleritis,	   scleritis,	   keratitis	   and	   retinopathy.	   Ocular	   involvement	  
occurs	   in	   up	   to	   27%	   of	   patients,	   with	   secondary	   Sjögren	   and	   scleritis	   being	   the	  
commonest	   manifestations	   observed.	   137	   Necrotizing	   scleritis	   and	   peripheral	  
ulcerative	   keratitis	   (also	   known	   as	   ‘corneal	   melt’)	   are	   the	   most	  
severe	  ocular	  manifestations	  associated	  with	  RA,	  which	  could	  lead	  to	  visual	  loss	  if	  
not	  promptly	  identified	  and	  treated.	  138	  
Neurological	  manifestations	  of	  RA	  can	   involve	  both	  the	  central	  and	  peripheral	  
system.	   Peripheral	   nervous	   system	   involvement	   can	   be	   secondary	   to	   vasculitis,	  
nerve	   entrapment,	   amyloid	   deposition.	   Mononeuritis	   multiplex,	   mediated	   by	  
vasculitis	  of	  vasa	  nervorum	  secondary	  to	  immune	  complex	  deposition,	  is	  the	  most	  
frequent	  peripheral	  manifestation.	  Carpal	   tunnel	   syndrome	   is	   relatively	   common	  
and	  is	  associated	  with	  compression	  of	  the	  median	  nerve	  at	  the	  wrist	  level,	  mainly	  




standing	  disease	  is	  cervical	  myelopathy	  secondary	  to	  atlanto-­‐axial	  subluxation,	  as	  
the	   result	   of	   local	   synovitis	   and	   bone	   deformities.	   140	   Isolated	   vasculitis	   of	   the	  
central	  nervous	  system	  and	  aseptic	  granulomatous	  meningoencephalitis	  have	  also	  
been	  reported,	  although	  rarely.	  141,142	  
Renal	   involvement	   is	  not	   frequent,	  mostly	   represented	  by	  glomerulonephritis,	  
interstitial	  nephritis	  and	  nephrotic	  syndrome	  as	  the	  result	  of	  amyloid	  deposits	   in	  
long-­‐standing	  disease.	  143	  
Hematological	  EAM	  are	  very	  common,	  especially	  chronic	  anaemia,	  neutropenia,	  
lymphopenia	   and	   thrombocytopenia.	   144	   Mild	   to	   moderate	   anaemia	   and	  
thrombocytosis	   are	   often	   observed	   during	   acute	   flares	   of	   RA.	   Finally,	   Felty’s	  
syndrome	   is	   a	   rare	   condition	   characterised	   by	   polyarthritis,	   neutropenia	   and	  
splenomegaly,	  observed	  in	  less	  than	  1%	  of	  RA	  patients.	  145	  
	  
1.5.3	  	  	  Natural	  history	  of	  rheumatoid	  arthritis:	  disability,	  comorbidities,	  mortality	  
Structural	   joint	   damage	   is	   observed	   in	   15-­‐30%	   of	   patients	   with	   early	   RA.	   146	  
Joint	   destruction	   can	   evolve	   rapidly:	   radiographic	   evidence	   is	   present	   in	   almost	  
50%	  of	  patients	  within	  the	  first	  year	  147	  and	  in	  more	  than	  80%	  of	  patients	  within	  
the	   first	   2	   years	   148.	   MRI	   can	   identify	   synovial	   hypertrophy,	   bone	   oedema,	   and	  
early	  erosive	  changes	  as	  early	  as	  4	  months	  after	  symptoms	  onset.	  149-­‐151	  
The	  grade	  of	  disability	  parallels	  the	  progression	  of	  the	  joint	  damage	  over	  time.	  
152	  However,	   loss	  of	   independence	  and	   loss	  of	  ability	   to	  work	   can	  occur	  early:	   it	  
has	  been	  estimated	  that	  20-­‐30%	  of	  patients	  become	  permanently	  disabled	  and	  are	  




demanding	   job	   and	   lower	   social	   status	   are	   risk	   factors	   for	   premature	   loss	   of	  
performance	  at	  work.	  	  153	  	  
Disability	   accounts	   for	   a	   significant	   proportion	   of	   the	   substantial	   cost	   of	   RA,	  
both	   at	   the	   individual	   and	   societal	   level:	   absence	   from	   work,	   work	   restrictions	  
resulting	  in	  reduced	  income,	  job	  loss,	  need	  for	  health	  care,	  entitlement	  for	  socio-­‐
economic	   benefits	   and	   disability	   pensions	   have	   a	   high	   impact	   on	   the	   indirect	  
financial	  costs	  of	  the	  disease.154,155	  
RA	   is	   associated	   with	   comorbidities	   that	   may	   result	   in	   worse	   long-­‐term	  
outcome	   and	   reduced	   life	   expectancy,	   with	   additional	   individual	   and	   societal	  
costs.	   156,157	   A	   recent	   study	   showed	   that	   a	   persistent	   inflammatory	   status	   was	  
associated	  with	  the	  onset	  of	  at	  least	  one	  new	  co-­‐morbidity	  during	  5	  years	  follow-­‐
up	   period	   in	   patients	   with	   early	   RA.	   158	   The	   more	   relevant	   co-­‐morbidities	   are	  
osteoporosis,	   cardiovascular	   (CV)	   diseases,	   malignancies,	   infections,	  
gastrointestinal	  (GI)	  diseases.	  
Two	   forms	  of	  osteoporosis	  occur	   in	  RA:	  periarticular	  osteoporosis	   around	   the	  
inflamed	  joints,	  and	  generalized	  osteoporosis	  affecting	  the	  axial	  and	  appendicular	  
skeleton.	   Periarticular	   demineralization	   represents	   a	   prominent	   feature	   of	   early	  
RA,	   and	   one	   of	   its	   radiographic	   hallmarks	   along	   with	   erosions	   and	   joint	   space	  
narrowing.	   Local	   bone	   tissue	   remodelling	   is	   the	   result	   of	   reciprocal	   interactions	  
between	  osteoclasts,	   osteoblasts	   and	   immune	   system	   cells.	   In	   fact	   the	   inflamed	  
synovium	   is	  a	  source	  of	  a	  number	  of	  cytokines	  and	   inflammatory	  mediators	   that	  
can	   induce	   the	   recruitment,	   differentiation	   and	   activation	   of	   osteoclasts.	  
Osteoclastogenesis	   requires	   the	   presence	   of	   RANKL	   and	   the	   permissive	   factor	  




stromal	   cells.	   RANKL	   binds	   to	   its	   receptor	   RANK	   expressed	   on	   the	   surface	   of	  
osteoclast	   precursor	   cells	   and	   stimulates	   their	   differentiation	   into	   mature,	  
functional	  cells.	  	  Raised	  levels	  of	  TNFα,	  IL-­‐1,	  IL-­‐6,	  IL-­‐7,	  IL-­‐17	  in	  the	  synovium	  lead	  to	  
increased	  expression	  of	  RANKL	  and	  M-­‐CSF,	  and	  in	  turn	  to	  pathological,	  accelerated	  
loss	  of	  bone	  mass.	  159	  Moreover,	  RA	  synovium	  is	  a	  source	  of	  DKK-­‐1,	  a	  physiological	  
inhibitor	   of	   bone	   formation	   that	   works	   inactivating	   the	  Wnt-­‐signalling	   pathway.	  
160	  In	  addition,	  the	  rheumatoid	  synovium	  is	  enriched	  with	  cells	  of	   the	  monocyte/	  
macrophage	   lineage	   that,	   under	   the	   influence	   of	   appropriate	   stimuli,	   can	  
differentiate	  into	  pre-­‐osteclasts	  and	  ultimately	  into	  functional	  osteoclasts.	  159	  	  
Generalized	   osteoporosis	   in	   RA	   has	   a	   multifactorial	   aetiology.	   It	   is	   related	  
partially	   to	   factors	   intrinsic	   to	   the	  disease	   -­‐primarily	   the	  over-­‐expression	  of	  pro-­‐
inflammatory	   cytokines	   and	   the	   activation	   of	   pathways	   of	   bone	   resorption-­‐	   but	  
also	   to	   co-­‐factors	   including	   reduced	   mobility	   and	   use	   of	   corticosteroids.161	  
Importantly,	   a	   significant	   amount	   of	   bone	  mass	   is	   lost	   in	   the	   early	   phase	  of	   the	  
disease,	  and	  the	  entity	  of	  bone	   loss	  and	  associated	  risk	  of	  osteoporotic	  fractures	  
correlates	  with	   the	  disease	  activity.	   	   162,163	  RA	  has	  been	   incorporated	  as	  a	  major	  
determinant	   of	   global	   fracture	   risk	   in	   the	   FRAX	   (Fracture	   Risk	   Assessment	   Tool)	  
algorithm	  developed	  by	   the	  University	  of	  Sheffield	   in	  association	  with	   the	  World	  
Health	   Organisation	   (https://www.shef.ac.uk/FRAX/tool.jsp).	   A	   study	   that	  
included	   over	   30.000	   RA	   patients	   from	   the	   British	   General	   Practice	   Research	  
Database,	  revealed	  that	  the	  relative	  risk	  (RR)	  for	  a	  hip	  fracture	  was	  2.0	  and	  for	  a	  
vertebral	  fracture	  2.4.	  164	  	  
Patients	   with	   RA	   have	   a	   reduced	   life	   expectancy	   compared	   to	   the	   general	  




hearth	   disease	   and	   ischaemic	   stroke	   represent	   the	   major	   contributors	   to	   this	  
excess	  mortality.	  165-­‐167	  It	  has	  been	  estimated	  that	  the	  increased	  CV	  risk	  observed	  
in	   RA	   is	   comparable	   to	   that	   associated	  with	   type	   2	   diabetes.	   168	   169	   	   These	   high	  
rates	  of	  CV	  morbidity	  and	  mortality	  cannot	  be	  entirely	  explained	  by	  traditional	  CV	  
risk	   factors.	   RA	   is	   characterised	   by	   endothelial	   dysfunction,	   lipid	   metabolism	  
alterations	   and	   accelerated	   atherosclerosis,	   and	   systemic	   inflammation	   and	  
immune	  dysregulation	  have	  a	  key	  role	  in	  determining	  this	  pro-­‐atherogenic	  status.	  
Indeed	  the	  concept	  that	   inflammation	   is	  a	  key	  component	  of	  atherosclerosis	  has	  
been	   explored	   by	   a	   number	   of	   studies	   170-­‐174	   supporting	   the	   concept	   that	  
atherogenesis	   is	   an	   inflammatory-­‐driven	   disorder.	   It	   is	   also	   acknowledged	   that	  
sustained	   systemic	   inflammation	   represents	   an	   independent	   predictor	   of	   CV	  
events	  in	  the	  general	  population.	  175,	  176	  	  	  
Patients	   with	   RA	   have	   twice	   the	   risk	   of	   developing	   congestive	   heart	   failure	  
compared	   to	   the	   general	   population	   177,	   and	   mortality	   from	   congestive	   hearth	  
failure	  is	  higher	  in	  RA	  in	  comparison	  with	  non-­‐RA	  individuals.	  178	  
Malignancies	  represent	  the	  second	  commonest	  cause	  of	  death	  in	  patients	  with	  
RA.	   A	   meta-­‐analysis	   by	   Smitten	   et	   al	   showed	   a	   two-­‐fold	   increased	   risk	   of	  
lymphoproliferative	   disorders,	   especially	   Hodgkin’s	   lymphoma,	  as	   well	   as	   lung	  
cancer	  and	  melanoma.	  179,180	  When	  evaluating	  neoplastic	  risk	  in	  the	  RA	  population,	  
it	   is	  difficult	   to	  discriminate	  between	  the	   intrinsic	  effects	  of	  RA	  and	  confounding	  
factors	  such	  as	   immunosuppressive	  drug	  exposure	   181;	  however,	   recent	  evidence	  
suggests	   that	   persistent	   immune	   system	   activation	   rather	   than	   treatment	   is	   a	  




Infections	  are	  an	  important	  cause	  of	  morbidity	  and	  mortality	  in	  RA:	  pulmonary	  
infections,	   urinary	   tract	   infections,	   sepsis,	   osteomyelitis,	   cellulitis	   and	   septic	  
arthritis	  are	  the	  most	  frequently	  observed.	  183,184	  This	  increased	  risk	  is,	  at	  least	  in	  
part,	   related	   to	   intensive	   and	   prolonged	   immunosuppressive	   therapy.	  
Furthermore,	  RA	  per	  se	  is	  characterised	  by	  intrinsic	  dysregulation	  of	  the	  immune	  
system	  that	  may	  predispose	   to	   infections.	  This	   is	  also	  suggested	  by	   the	   fact	   that	  
the	  infective	  risk	  is	  higher	  in	  patients	  with	  more	  active	  disease.	  185	  
Finally,	  RA	  has	  long	  been	  strongly	  associated	  with	  GI	  events,	  particularly	  in	  the	  
upper	  tract,	  ranging	  from	  minor	  manifestations	  like	  dyspepsia	  and	  nausea	  to	  more	  
severe	   organic	   conditions	   such	   as	   esophagitis,	   gastritis,	   duodenitis,	   gastric	   and	  
duodenal	  ulceration	  and	  perforation.	  185	  RA	  showed	  a	  50%	  increased	  risk	  of	  death	  
related	  to	  GI	  events	  from	  the	  Arthritis	  Rheumatism	  and	  Aging	  Medical	  Information	  
System	   (ARAMIS).	   186	   A	   large	   epidemiological	   study	   conducted	   on	   hospitalized	  
patients	  found	  that	  RA	  subjects	  presented	  a	  5	  fold	  higher	  mortality	  from	  GI	  causes	  
than	  the	  non-­‐RA	  subjects.	   187	   	  This	   increased	  risk	  has	  been	  historically	   related	  to	  
use	   of	   non-­‐steroidal	   anti-­‐inflammatory	   drugs	   (NSAIDs).	   Indeed,	   a	   progressive	  
decline	  in	  the	  incidence	  of	  GI	  complications	  in	  RA	  patients	  -­‐	  estimated	  about	  0.5%	  
per	  year	  by	  2000	  -­‐	  has	  been	  observed	  in	  coincidence	  with	  a	  reduced	  use	  of	  NSAIDs	  
after	   the	   introduction	   of	   biologic	   disease-­‐modifying	   anti-­‐rheumatic	   drugs	  
(bDMARD),	   the	   development	   of	   cyclooxygenase	   2	   (COX-­‐2)	   inhibitors	   and	   the	  
increasing	  use	  of	  proton-­‐pump	  inhibitors.	  185	  GI	  complications	  intrinsically	  related	  
to	   the	   pathogenesis	   of	   the	   disease,	   such	   as	   vasculitis	   and	   amyloid	   infiltration	  of	  





Persistently	   active	   disease,	   presence	   of	   comorbidities	   and	   extra-­‐articular	  
features	  are	  the	  most	  important	  factor	  risks	  associated	  with	  reduced	  survival	  in	  RA	  
patients	  compared	  to	  the	  general	  population.157	  Advances	  in	  the	  treatment	  of	  RA	  
in	   recent	   years,	   such	   as	  early	   intervention,	   target	   to	   treat	   strategy	   and	  
introduction	  of	  biologic	  drugs	  have	  significantly	  modified	  the	  natural	  history	  of	  the	  
disease	  and	  improved	  outcome	  and	  quality	  of	  life.	  189	  Also,	  patients	  who	  respond	  
to	  methotrexate	  have	  only	  a	  slightly	  increased	  mortality	  risk	  compared	  to	  general	  
population,	  meanwhile	  the	  non	  responders	  present	  a	  4	  fold	  increased	  risk.190	  
Nonetheless,	   data	   from	   a	   population-­‐based	   incidence	   cohort	   of	   RA	   patients	  
from	   the	   Mayo	   Clinic,	   Rochester,	   Minnesota,	   published	   by	   Gonzalez	   and	  
colleagues	  in	  2007,	  disappointingly	  showed	  that	  the	  mortality	  rate	  for	  RA	  patients	  
has	   remained	   unchanged	   over	   the	   past	   four	   decades,	   and	   the	   survival	   gap	  
between	  general	  population	  and	  RA	  population	  has	  even	  widened.	   191	  However,	  
the	  authors	  highlight	  that	  their	  findings	  cannot	  be	  extrapolated	  to	  RA	  patient	  after	  
2000,	   when	   the	   use	   of	   bDMARD	   and	  more	   intensive	   treatment	   strategies	   were	  
introduced.	  	  
	  
1.6	   	   	   RATIONALE	   FOR	   EARLY	   DETECTION	   AND	   TREATMENT	   OF	  
RHEUMATOID	  ARTHRITIS	  
1.6.	  1	  	  	  Advantage	  of	  early	  diagnosis	  and	  treatment:	  the	  ‘window	  of	  opportunity’	  
Early	   identification	   and	   treatment	   of	   RA	   represent	   an	   effective	   chance	   to	  
improve	  outcome,	  with	  a	  considerable	  reduction	  of	  individual	  and	  socio-­‐economic	  
costs.	  Several	  studies	  have	  showed	  that	  prolonged	  symptom	  duration	  and	  delayed	  




achieving	  clinical	  remission.	  192	  Even	  a	  relatively	  short	  delay	  in	  starting	  treatment	  
may	  have	  a	  negative	   impact	  on	  disease	  progression.	   193	   Importantly,	   the	  clinical,	  
radiological	  and	  functional	  benefits	  obtained	  treating	  the	  disease	  earlier	  appears	  
to	  be	  sustained	  over	  time.	  	  
Indeed,	   the	   early	   phase	   represents	   a	   unique	   ‘window	   of	   opportunity’	   for	  
effective	   treatment.	   194	   Van	   der	  Heijde	   and	   colleagues	   randomised	   238	   patients	  
with	   RA	   for	   less	   than	   the	   12	  months	   to	   receiving	   either	  NSAIDs	   or	   conventional	  
syntetic	  disease-­‐modifying	  antirheumatic	  drugs	  (csDMARD);	  after	  12	  months,	  the	  
group	   that	   had	   received	   csDMARD	   experienced	   more	   significant	   clinical	  
improvement	   compared	   to	   the	   NSAIDs	   group.	   195	   Stenger	   and	   colleagues	  
compared	   the	   effect	   of	   aggressive	   versus	   step-­‐up	   treatment	   on	   radiographic	  
progression	  in	  228	  patients:	  after	  2	  years	  follow-­‐up,	  the	  radiographic	  progression	  
was	   significantly	   lower	   in	   the	   group	   treated	   aggressively	   at	   onset.	   196	   A	   recent	  
meta-­‐analysis	  of	  12	  studies	  found	  that,	  in	  patients	  with	  a	  diagnosis	  of	  RA	  standing	  
less	   than	   two	  years,	   a	  nine	  month	  delay	   in	   starting	   treatment	   resulted	   in	  a	  33%	  
more	  severe	  radiological	  damage.	  197	  A	  meta-­‐analysis	  of	  14	  randomised	  controlled 
trials	   (RCTs)	   found	   that	   shorter	   disease	   duration	  was	   the	   strongest	   predictor	   of	  
clinical	   response	   to	   csDMARD	   therapy, with	   the	   best	   response	   observed	   in	  
patients	  presenting	  with	  less	  than	  one	  year	  symptoms.	  198 Recently,	  the	  PROMPT	  
(PRObable	   rheumatoid	   arthritis:	   Methotrexate	   versus	   Placebo	   Treatment)	   study	  
compared	   early	   treatment	   versus	   placebo	   in	   patients	   with	   inflammatory	  
polyarthritis	   not	   fulfilling	   classification	   criteria	   for	   RA,	   showing	   that	   a	   lower	  




To	   avoid	   missing	   the	   window	   of	   opportunity,	   a	   critical	   point	   is	   the	   early	  
recognition	   of	   symptoms	   by	   primary	   care	   physicians	   and	   the	   rapid	   referral	   to	  
rheumatology	   centres,	   as	  well	   as	   the	   institution	  or	  pathways	   for	   rapid	   access	   to	  
them.	  A	  survey	  from	  2009	  and	  2010	  showed	  that	  the	  median	  delay	  from	  symptom	  
onset	   to	   patients	   seeing	   a	   rheumatologist	   across	   10	   European	   centres	   was	   24	  
weeks,	  meaning	  that	  a	  significant	  proportion	  of	  patients	  were	  falling	  outside	  the	  
therapeutic	  window	  of	  opportunity.	  200	  The	  establishment	  of	  early	  arthritis	  clinics	  
(EACs)	  has	  significantly	   improved	  this	  shortfall.	  The	  aim	  of	  EACs	   is	   to	  allow	  rapid	  
referral,	   quick	   assessment	   and	   prompt	   start	   of	   treatment	   for	   patients	   with	  
suspected	   inflammatory	   arthritis.	   The	   time	   between	   symptoms	   onset	   and	   first	  
rheumatological	   evaluation	   is	   on	   average	   three	   months	   shorter	   within	   EACs	  
compared	   with	   standard	   clinics,	   and	   this	   translates	   into	   an	   immediate	   and	  
sustained	  better	   clinical	  outcome	  with	   cost	   saving	  over	   the	   long	   run	   (e.g.	  higher	  
rate	  of	   patients	   achieving	   remission,	   less	   requiring	  biologic	   drugs,	   less	   sustained	  
disability).	  201	  
Another	   aspect	   of	   critical	   importance	   is	   whether	   the	   advantage	   of	   earlier	  
intervention	   is	   indefinite	   or	   there	   is	   a	   certain	   point	   when	   the	   window	   of	  
opportunity	  closes.	  It	  looks	  like	  the	  relationships	  between	  symptom	  duration	  and	  
favourable	  outcome	  is	  not	   linear	  and	  that	  a	  time	  limit	   is	  reached	  after	  which	  the	  
benefit	  of	  starting	  treatment	  earlier	  is	  missed.	  Data	  from	  the	  Leiden	  cohort	  shows	  
that	  the	  window	  of	  opportunity	  seems	  to	  start	  closing	  at	  14.9	  weeks.	  Overall	  the	  
Leiden	  experience	  suggest	  that	  there	  is	  a	  period,	  within	  approximately	  the	  first	  6	  




csDMARD	   treatment	   must	   be	   started	   in	   order	   to	   achieve	   better	   long-­‐term	  
outcomes.	  202	  	  
	  
1.6.2	  	  	  Defining	  early	  rheumatoid	  arthritis:	  how	  early	  is	  early? 
Since	  timing	  is	  crucial	  for	  optimizing	  outcome,	  defining	  early	  RA	  is	  not	  a	  purely	  
semantic	  matter,	  but	  has	  got	  important	  practical	  implications.	  	  
A	  major	   issue	  for	  the	  definition	  of	  early	  RA	   is	  the	  heterogeneous	  definition	  of	  
disease	   ‘onset’,	  which	   in	   some	   studies	   refers	   to	   the	   time	  of	   initial	   symptoms,	   in	  
others	  to	  the	  time	  patients	  seek	  medical	  attention,	  or	  to	  when	  a	  formal	  diagnosis	  
is	  made.	  Another	  critical	   issue	   is	   that	   recognizing	   the	  earliest	   symptoms	  of	  RA	   is	  
challenging	   for	   patients,	   as	   some	  early	   symptoms	   such	   as	  morning	   stiffness	   and	  
fatigue	  are	  poorly	  defined	  and	  may	  remain	  underestimated	   for	  several	  weeks	  or	  
months.	  203	  	  
NICE	   (National	   Institute	   for	   Health	   and	   Care	   Excellence)	   recommend	   that	  
patients	   with	   suspected	   inflammatory	   arthritis	   should	   be	   referred	   urgently	   for	  
assessment	   if	   symptoms	  have	  been	  present	   for	  more	   than	   six	  weeks	  and	  any	  of	  
the	  following	  apply:	  
-­‐ swelling	  of	  two	  or	  more	  joints	  is	  present;	  
-­‐ the	  small	  joints	  of	  the	  hands	  or	  feet	  are	  affected;	  
-­‐ there	  is	  a	  positive	  MCP	  or	  MTP	  joints	  squeeze	  test	  (pain	  produced	  by	  gentle	  
pressure	  across	  the	  MCP	  or	  MTP	  joints).	  
Other	  features	  that	  should	  raise	  suspicion	  of	  inflammatory	  arthritis	  include:	  
-­‐ early	  morning	  joint	  stiffness	  for	  more	  than	  30	  minutes;	  




As	   mentioned	   in	   the	   previous	   paragraph,	   the	   establishment	   of	   EACs	   has	  
represented	  a	  fundamental	  strategy	  to	  ensure	  rapid	  referral	  and	  rapid	  assessment	  
of	  patients	  with	  suspected	  early	  inflammatory	  arthritis.	  
Currently,	   the	   accepted	   definition	   of	   early	   RA	   is	   a	   disease	   not	   exceeding	   12	  
months	  duration.	  204,205	  However	  the	  notion	  of	  ‘early’	  is	  becoming	  earlier.	  A	  study	  
comparing	   clinical	   and	   radiological	   outcomes	   in	   two	   groups	   of	   patients	   who	  
received	   csDMARD	   treatment	   within	   either	   12	   weeks	   or	   12	   months	   after	  
symptoms	  onset,	  showed	  that	  the	  earlier	  group	  performed	  significantly	  better.	  206	  	  
Similar	   findings	   have	   been	   confirmed	   in	   other	   studies	   207,208,	   highlighting	   the	  
importance	   of	   timing	   as	   a	   major	   determinant	   of	   therapeutic	   success.	   There	   is	  
accumulating	   evidence	   that	   the	   first	   12	   weeks	   from	   onset	   represent	   a	   distinct	  
pathological	  phase,	  which	  has	  led	  to	  the	  concept	  of	  ‘very	  early’	  RA.	  	  
The	   question	   is	   whether	   unique	   pathological	   processes	   operate	   during	   the	  
earliest	  stages.	  Raza	  et	  al	  found	  that	  the	  synovial	  fluid	  of	  patients	  with	  RA	  within	  
the	  first	  12	  weeks	  is	  characterised	  by	  marked	  absence	  of	  IFN-­‐γ	  and	  predominance	  
of	  IL-­‐4	  and	  IL-­‐13,	  IL-­‐2,	  IL-­‐15,	  IL-­‐17,	  fibroblast	  growth	  factor	  and	  epidermal	  growth	  
factor,	   defining	   a	   transient	   Th2	   response	   that	   subsequently	   shifts	   towards	   a	  
persistent	  Th1	  response.	   209	  McInnes	  et	  al	   recently	  postulated	  the	  existence	  of	  a	  
predominant	   cytokine	   pattern	   in	   different	   phases	   of	   the	   disease,	   namely	   a	   pre-­‐
clinical/early	  transient	  pattern	  (IL-­‐6,	  IL-­‐21,	  IL-­‐23,	  IL-­‐17	  predominant),	  followed	  by	  a	  
pattern	  reflecting	  transition	  to	  chronicity	  (TNFα,	  IL-­‐6	  predominant)	  and	  ultimately	  
a	   permanent	   pattern	   reflecting	   persistence	   of	   immune	   activation	   and	   damage,	  




However,	  as	  data	  on	  synovial	  pathology	  within	  the	  first	  months	  after	  the	  onset	  
of	   symptoms	   is	   scarce,	   currently	   the	   concept	   of	   	   ‘early	   arthritis’	   represents	   a	  
purely	  clinical	  definition	  rather	  a	  pathobiological	  entity.	  	  
The	   question	   remains	   whether	   the	   existence	   of	   a	   window	   of	   opportunity	   is	  
based	  on	  underlying	   specific	   immune	  pathobiology	   in	   the	   first	  weeks	  or	  months	  
from	  disease	   onset.	  Herein	   I	  will	   explore	   if	   there	   are	   any	   specific	   characteristics	  
that	  makes	  early	  RA	  a	  distinct	  pathobiological	  as	  well	   as	   clinical	  entity,	   and	  how	  
histological	  and	  clinical	  characteristics	  are	  mutually	  related	  in	  this	  crucial	  phase	  of	  
the	  disease.	  	  
 
1.6.3	  	  	  From	  1987	  to	  2010	  classification	  criteria	  for	  rheumatoid	  arthritis	  
Delays	   in	   the	   recognition	   and	   treatment	   of	   RA	  may	   be	   related	   to	   the	   lack	   of	  
established	  criteria	  to	  make	  a	  definite	  diagnosis.	  In	  fact,	  diagnostic	  criteria	  for	  RA	  
do	  not	  exist	  and	  diagnosis	  is	  based	  on	  physician	  discretion/expert	  opinion.	  
Classification	   criteria	   have	   been	   developed	   in	   order	   to	   minimize	  
misclassification	   and	  make	   cohorts	   homogeneous	   in	   clinical	   and	   epidemiological	  
studies.	   The	   set	   of	   classification	   criteria	   developed	   in	   1987	   by	   the	   American	  


























Table	  1.1:	   The	  1987	  American	  College	  of	  Rheumatology	   revised	   criteria	   for	  
rheumatoid	  arthritis	  
1.	  Morning	  stiffness	  
2.	  Arthritis	  in	  3	  or	  more	  joints	  
3.	  Arthritis	  of	  hand	  joints	  
4.	  Symmetrical	  arthritis	  
5.	  Rheumatoid	  nodules	  
6.	  Rheumatoid	  factor	  
7.	  Radiographic	  changes	  (erosions)	  
Four	   out	   of	   the	   seven	   criteria	  must	   be	   satisfied,	   with	   the	   1-­‐4	   criteria	   to	   be	  









These	  criteria	  perform	  poorly	  in	  early	  RA.	  211	  This	  is	  not	  surprising,	  considering	  
that	  they	  were	  derived	  from	  patients	  with	  over	  7	  years	  disease	  duration.	  At	  least	  
two	   of	   the	   seven	   criteria	   -­‐presence	   of	   rheumatoid	   nodules	   and	   erosions-­‐	   are	  
typically	   observed	   in	   longstanding	   rather	   than	   early	   disease.	   When	   applied	   to	  
patients	  with	  <	  1	  year	  disease	  duration,	  sensitivity	  decreased	  to	  81%	  compared	  to	  
91%	  observed	  in	  patients	  with	  longer	  disease	  duration.	  129	  
The	   need	   to	   identify	   patients	   at	   an	   early	   phase	   led	   to	   development	   of	   new	  
classification	   criteria	   proposed	   by	   ACR	   and	   EULAR	   in	   2010	   (Table	   1.2).4	   These	  
criteria	   have	   been	   constructed	   through	   two	   phases,	   as	   a	   combination	   of	   data-­‐
driven	   and	   expert-­‐driven	   approaches:	   in	   the	   first	   phase,	   Methotrexate	   (the	  
commonest	  csDMARD	  used	  for	  the	  treatment	  of	  RA)	  prescription	  during	  the	  first	  
year	  after	  diagnosis	  was	  chosen	  as	  an	   indication	  of	  RA;	   in	   the	  second	  phase,	   the	  

















Table	  1.2:	  The	  2010	  ACR/EULAR	  classification	  criteria	  for	  rheumatoid	  arthritis	  
The	  criteria	  apply	  to	  patients	  with:	  1)	  evidence	  of	  clinical	  synovitis	  (at	  least	  one	  swollen	  joint)	  2)	  
synovitis	  not	  better	  explained	  by	  another	  disease.	  Rheumatoid	  arthritis	  is	  defined	  by	  a	  total	  score	  
≥	   6.	   Joint	   involvement	   refers	   to	   any	   swollen	   or	   tender	   joint	   on	   examination,	   which	   may	   be	  
confirmed	  by	   imaging	  evidence	  of	   synovitis.	  Distal	   interphalangeal	   joints,	   first	   carpometacarpal	  
joints,	  and	   first	  metatarsophalangeal	   joints	  are	  excluded	   from	  assessment.	   Large	   joints	   refer	   to	  
shoulders,	  elbows,	  hips,	  knees,	  and	  ankles.	  Small	  joints	  refer	  to	  the	  metacarpophalangeal	  joints,	  
proximal	   interphalangeal	   joints,	   second	   through	   fifth	   metatarsophalangeal	   joints,	   thumb	  
interphalangeal	   joints,	  and	  wrists.	  Negative	  refers	  to	  international	  units	  (IU)	  values	  that	  are	  less	  
than	  or	  equal	  to	  the	  upper	  limit	  of	  normal	  (ULN)	  for	  the	  laboratory	  and	  assay;	  low-­‐positive	  refers	  
to	  IU	  values	  that	  are	  higher	  than	  the	  ULN	  but	  three	  of	  less	  times	  the	  ULN	  for	  the	  laboratory	  and	  
assay;	  high-­‐positive	  refers	  to	  IU	  values	  that	  are	  more	  than	  3	  times	  the	  ULN	  for	  the	  laboratory	  and	  
assay.	  Where	  antibody	  titre	   is	  only	  available	  as	  positive	  or	  negative,	  a	  positive	  result	  should	  be	  
scored	  as	  low	  positive.	  Normal/abnormal	  is	  determined	  by	  local	  laboratory	  standards.	  	  
Abbreviations:	   RF=	   rheumatoid	   factor;	   anti-­‐CCP=	   anti-­‐citrullinated	   protein	   antibody,	   ESR=	  
erythrocyte	  sedimentation	  rate;	  CRP=	  C-­‐reactive	  protein.	  4	  
Joint	  involvement	   Score	  
1	  large	  joint	  
2-­‐10	  large	  joints	  
1-­‐3	  small	  joints	  
4-­‐10	  small	  joints	  






Serology	   	  
RF	  (-­‐)	  and	  anti-­‐CCP	  (-­‐)	  
Low	  RF	  (+)	  or	  anti-­‐CCP	  (+)	  




Acute	  phase	  reactants	  	   	  
Normal	  ESR	  and	  CRP	  
Abnormal	  ESR	  or	  CRP	  
0	  
1	  









Major	  differences	  between	  the	  new	  and	  the	  old	  set	  criteria	  are:	  	  the	  removal	  of	  
rheumatoid	  nodules;	   the	  removal	  of	  erosions	  (highly	  specific	   for	  the	  diagnosis	  of	  
RA	  but	  not	  helpful	  when	  aiming	  to	   identify	  the	  disease	  at	  an	  early	  stage	  146);	  the	  
removal	   of	   morning	   stiffness	   due	   to	   its	   lack	   of	   specificity;	   a	   higher	   importance	  
attributed	   to	   laboratory	   tests,	   including	   incorporation	   of	   raised	   inflammatory	  
markers	  and	  presence	  of	  anti-­‐CCP	  antibodies	  and	  RF	  antibodies.	  Seropositivity	   is	  
not	   just	   counted	   as	   a	   dichotomic	   parameter,	   as	   the	   autoantibody	   titre	   is	   also	  
considered,	  with	  higher	  levels	  resulting	  in	  higher	  scores.	  	  
Overall,	   the	   2010	   ACR/EULAR	   criteria	   allow	   more	   rapid	   identification	   of	   RA	  
patients	  compared	  to	  the	  1987	  criteria.	  However,	  due	  to	   lower	  specificity,	   issues	  
related	   to	   potential	   misclassification	   and	   over-­‐diagnosis	   have	   been	   raised.	   212	  
Importantly,	   despite	   improving	   ability	   to	   identify	   more	   patients	   at	   an	   earlier	  
phase,	   they	   have	   limited	   discriminative	   value	   to	   differentiate	   potentially	  
destructive	   from	   non-­‐erosive,	   mild	   disease.	   212,213	   In	   particular,	   it	   has	   been	  
observed	  that	  the	  discriminative	  power	  for	  development	  of	  erosions	  in	  10	  years	  is	  
only	   slightly	   better	   than	   the	   1987	   ACR	   criteria.	   214	   Therefore,	   extra	   efforts	   are	  
needed	   to	   identify	   accurate	   clinical	   and	   molecular	   biomarkers	   to	   predict	   the	  
clinical	  course	  of	  early	  inflammatory	  arthritis.	  
	  
1.7	  	  	  THERAPEUTIC	  STRATEGIES	  FOR	  RHEUMATOID	  ARTHRITIS	  	  
1.7.1	  	  	  Aims	  of	  treatment	  
The	   aims	   of	   the	   treatment	   of	   RA	   have	   been	   identified	   as:	   symptom	   control,	  
prevention	   of	   joint	   damage,	   improvement	   of	   quality	   of	   life	   and	  maintenance	   of	  




The	   ultimate	   goal	   should	   be	   the	   achievement	   of	   sustained	   clinical	   remission,	  
which	  has	  been	  defined	  as	  “absence	  of	  articular	  and	  extra-­‐articular	  inflammation	  
and	  disease	  activity”.216	  With	   the	   introduction	  of	  new	  drugs	  and	  optimisation	  of	  
therapeutic	   strategies,	   this	   is	  now	  a	   realistic	   goal	   and	   should	  be	  aimed	   for	  most	  
patients,	  particularly	  for	  those	  identified	  at	  an	  early	  stage.	  	  
However,	   no	   universally	   accepted	   definition	   of	   remission	   currently	   exists	   and	  
remission	   criteria	   vary	   from	   study	   to	   study,	   making	   it	   difficult	   to	   compare	  
remission	   rates	   across	   different	   cohorts.217,218	   In	   particular,	   it	   is	   not	   clear	   if	  
remission	  should	   incorporate	  absence	  of	  clinical	   signs	  of	   synovitis,	  or	  absence	  of	  
surrogate	  markers	  of	  disease	  activity	  such	  as	  inflammatory	  markers	  or	  radiological	  
progression.	   It	   has	   been	   observed	   that	   patients	   could	   develop	   radiographic	  
erosions	   in	  the	  hands	  and	  feet	  over	  2	  to	  5	  years	  after	  achievement	  of	  persistent	  
clinical	   remission,	   suggesting	   that	   clinical	   definition	   of	   remission	   may	   not	   be	  
stringent	  enough	  to	  ensure	  absence	  of	  disease	  progression	  over	  time.219	  	  
Indeed,	  a	  high	  proportion	  of	  patients	  considered	  to	  be	  in	  clinical	  remission	  -­‐no	  
matter	  how	  stringent	  these	  criteria	  are-­‐	  shows	  evidence	  of	  residual	  inflammatory	  
activity	  by	  using	  sensitive	  imaging	  technique	  such	  as	  ultrasound	  (US)	  or	  MRI,	  and	  
this	   sub-­‐clinical	   synovitis	   correlates	   with	   ongoing	   structural	   damage.	   	   220,221	  
Therefore,	   the	  question	   arises	  whether	   a	  modern	  definition	  of	   remission	   should	  
incorporate	  the	  notion	  of	  imaging	  remission	  as	  well.	  222	  
Finally,	   the	   very	   ultimate	   goal	   should	   be	   drug-­‐free	   remission,	  which	   refers	   to	  
achievement	   of	   a	   sustained	   state	   of	   remission	   with	   medications	   no	   longer	  
required.	   	   From	  the	  analysis	  of	   several	   studies,	   it	  has	  been	  observed	   that	  only	  a	  




Among	  them,	  up	  to	  45%	  will	   require	  a	   re-­‐introduction	  of	  medications	  over	   time,	  
and	   regaining	   a	   satisfactory	   control	   of	   the	  disease	  may	  be	  more	  difficult	   at	   that	  
point.	  219	  
Importantly,	   in	   order	   to	   optimise	   therapeutic	   strategies	   and	   evaluate	  
achievement	  of	  therapeutic	  goals,	  baseline	  status	  and	  progresses	  over	  time	  must	  
be	  objectively	  measurable,	   and	   the	  measurements	   reproducible.	  Disease	  activity	  
should	  be	  formally	  assessed	  and	  documented	  at	  onset	  and,	  once	  commenced	  on	  
treatment,	   close	   monitoring	   of	   patients	   and	   regular	   assessment	   of	   response	   is	  
crucial.	  
	  
1.7.2	  	  	  The	  Treat	  to	  Target	  strategy	  
Treat	  to	  Target	  (T2T)	  is	  generally	  defined	  as	  a	  treatment	  strategy	  tailored	  to	  the	  
individual	  patient,	   in	  which	  the	  achievement	  of	  an	  objective	  outcome	  measure	  is	  
used	   as	   a	   goal	   (the	   “target”)	   to	   monitor	   therapeutic	   response	   and	   guide	  
adjustment	  of	  therapy.	  	  
T2T	  that	  was	  originally	  introduced	  in	  the	  field	  of	  diabetes	  care,	  to	  design	  clinical	  
trials	   focusing	   on	   a	   standardized	   and	   objective	   therapeutic	   target	   (the	   level	   of	  
glycosylated	   haemoglobin).	   Subsequently,	   this	   concept	   spread	   to	   other	   areas	   of	  
medicine,	  such	  as	  hypertension	  and	  lipid	  metabolism.	  	  
Over	  the	  past	  10-­‐15	  years,	  T2T	  has	  been	  adopted	  in	  the	  management	  of	  RA	  as	  
well.	   223	   In	   2010,	   ten	   recommendations	   were	   published	   as	   the	   result	   of	   the	  





1.	  The	  primary	  target	  for	  treatment	  of	  rheumatoid	  arthritis	  should	  be	  a	  state	  
of	  clinical	  remission	  
2.	  Clinical	  remission	  is	  defined	  as	  the	  absence	  of	  signs	  and	  symptoms	  of	  significant	  
inflammatory	  disease	  activity	  
3.	   While	   remission	   should	   be	   a	   clear	   target,	   based	   on	   available	   evidence	   low	  
disease	  activity	  may	  be	  an	  acceptable	   alternative	   therapeutic	   goal,	   particularly	   in	  
established	  long-­‐standing	  disease	  
4.	  Until	  the	  desired	  treatment	  target	  is	  reached,	  drug	  therapy	  should	  be	  adjusted	  at	  
least	  every	  3	  months	  
5.	   Measures	   of	   disease	   activity	   must	   be	   obtained	   and	   documented	   regularly,	   as	  
frequently	   as	   monthly	   for	   patients	   with	   high/moderate	   disease	   activity	   or	   less	  
frequently	  (such	  as	  every	  3–6	  months)	  for	  patients	  in	  sustained	  low	  disease	  activity	  
or	  remission	  
6.	  The	  use	  of	  validated	  composite	  measures	  of	  disease	  activity,	  which	  include	  joint	  
assessments,	  is	  needed	  in	  routine	  clinical	  practice	  to	  guide	  treatment	  decisions	  
7.	   Structural	   changes	   and	   functional	   impairment	   should	   be	   considered	   when	  
making	   clinical	   decisions,	   in	   addition	   to	   assessing	   composite	  measures	  of	   disease	  
activity	  
8.	   The	   desired	   treatment	   target	   should	   be	  maintained	   throughout	   the	   remaining	  
course	  of	  the	  disease	  
9.	   The	   choice	  of	   the	   (composite)	  measure	  of	  disease	  activity	   and	   the	   level	  of	   the	  
target	  value	  may	  be	  influenced	  by	  consideration	  of	  co-­‐morbidities,	  patient	  factors,	  
and	  drug-­‐related	  risks	  
10.	  The	  patient	  has	   to	  be	  appropriately	   informed	  about	   the	  treatment	  target	  and	  
the	   strategy	   planned	   to	   reach	   this	   target	   under	   the	   supervision	   of	   the	  
rheumatologist	  
	  
Table	  1.3:	  Ten	  recommendations	  on	  treating	  rheumatoid	  arthritis	  to	  target	  	  
From	  224,	  with	  permission. 
	  




Several	   RCTs	   and	   cohort	   studies	   have	   provided	   evidence	   that	   a	   T2T	   strategy	  
ensures	  achievement	  of	  superior	  outcome	  compared	  to	  standard	  care.	  223	  
The	  modality	  of	  monitoring	  the	  disease	  activity	  must	  be	  reliable	  and	  sensitive	  
to	   change,	   reproducible	   and	   feasible	   for	   use	   in	   clinical	   practice.	   Several	   points	  
remain	  elusive,	  and	  particularly	  what	   is	   the	  best	   target	   to	   set:	   should	  we	  aim	  at	  
low	   disease	   activity	   or	   clinical	   remission?	   should	   imaging	   remission	   be	   formally	  
pursued?	  225	  and	  again:	  what	  is	  the	  ideal	  frequency	  of	  monitoring	  for	  achievement	  
of	   target?	   should	   the	   frequency	   of	   evaluation	   depend	   on	   the	   level	   of	   disease	  
activity,	   so	   patients	   with	   more	   active	   disease	   may	   require	   more	   frequent	  
assessments?	  should	  the	  set	  target	  take	   into	  account	  the	  stage	  of	  the	  disease	  as	  
well	  (e.g.,	  it	  will	  it	  be	  less	  realistic	  to	  pursue	  formal	  remission	  in	  patients	  with	  long	  
standing	  disease	  compared	  to	  whom	  with	  early	  disease)?	  
Given	  the	  discrepancy	  between	  achievement	  of	  clinical	  remission	  and	  presence	  
of	  ongoing	  active	  synovitis	  detected	  by	  US,	  and	  considering	  the	  evidence	  that	  this	  
residual	   activity	   has	   a	   significant	   impact	   on	   future	   structural	   and	   functional	  
outcomes	  220,226,	  the	  concept	  that	  targeting	  therapy	  to	  imaging	  measures	  may	  be	  
superior	  than	  targeting	  to	  clinical	  measures	  only	  has	  recently	  emerged.	  227	  On	  the	  
basis	   of	   this	   assumption	   an	   international	   network	   of	   ultrasonographers	   and	  
rheumatologists	   have	   instituted	   the	   Targeted	   Ultrasound	   Initiative	   (TUI)	   group.	  
One	  of	  the	  initiatives	  undertaken	  is	  a	  multicentre	  study,	  the	  Targeted	  Ultrasound	  
in	   Rheumatoid	   Arthritis	   (TURA)	   study,	   in	   which	   patients	   with	   RA	   will	   be	  
randomised	   to	   target	   therapy	   aiming	   to	   the	   achievement	   of	   either	   both	   clinical	  
remission	   and	   US	   remission	   or	   clinical	   remission	   only,	   to	   assess	   whether	   the	  




Very	  recently	  the	  results	  of	  the	  TaSER	  (Targeting	  ultrasound	  remission	  in	  early	  
rheumatoid	  arthritis)	  study	  have	  been	  published,	  where	  111	  newly	  diagnosed	  RA	  
patients	   (<	   1year	   symptom	   duration)	   were	   randomised	   to	   csDMARD	   step-­‐up	  
strategy	  aiming	   to	  either	   low	  disease	  activity	  or	  US	   remission	   (defined	  as	  power	  
doppler	  joint	  count	  ≤	  1).	  The	  study	  showed	  that	  the	  group	  aiming	  at	  US	  remission	  
required	   greater	   intensity	   of	   csDMARD	   therapy,	   in	   keeping	  with	   the	   assumption	  
that	  US	   remission	   is	  more	   stringent	   remission.	  However	   this	  was	   not	   associated	  
with	  superior	  clinical,	   functional	  or	  health-­‐related	  quality	  of	   life	  outcomes	  at	   the	  
end	  of	  the	  18	  months	  follow-­‐up	  period.	  228	  The	  authors	  postulate	  that	  one	  of	  the	  
reasons	  could	  be	  the	  fact	  that	  both	  populations	  had	  an	  excellent	  overall	  response,	  
and	  this	  may	  have	  limited	  the	  power	  of	  the	  study	  to	  detect	  small	  size	  inter-­‐group	  
differences.	  Another	  possible	  explanation	  could	  be	  that	  the	  follow-­‐up	  period	  was	  
too	   short	   to	   detect	   differences,	   which	   could	   have	   emerged	   over	   much	   longer	  
follow-­‐up	  periods.	  	  
The	   ARCTIC	   trial,	   where	   122	   patients	   with	   early	   RA	   were	   randomised	   to	   an	  
ultrasound	  tight	  control	  strategy	  targeting	  clinical	  and	  imaging	  remission	  and	  116	  
were	   randomised	   to	   a	   conventional	   tight	   control	   strategy	   targeting	   clinical	  
remission,	   also	   failed	   to	   show	   the	   added	   value	   of	   US	   to	   clinical	   driven	   T2T	  
treatment	  strategy.	  229	  
Despite	   the	   several	   theoretical	   and	   practical	   issues	   implicated,	   the	   T2T	  
represents	  an	  undisputed	  revolutionary	  concept	  in	  its	  linear	  goal-­‐driven	  approach:	  
setting	   a	   specific	   target,	   monitoring	   changes	   using	   a	   standardized	   outcome	  





1.7.3	  	  	  A	  paradigm	  change:	  from	  “pyramid	  model”	  to	  “tight	  control”	  approach	  
For	  years,	  the	  management	  	  of	  	  RA	  	  has	  	  been	  based	  on	  a	  stepped-­‐up	  approach	  
(the	  so	  called	   	  “pyramid	  model”),	  meaning	   	   	  an	   	   	   initially	   	   	  soft	   	   	  pharmacological	  
regime	  followed	  by	  progressive	  escalation	  of	  treatment	  to	  achieve	  disease	  control.	  	  
NSAIDs	   and	   steroids	   were	   the	   initial	   drugs	   administered	   to	   control	   joint	  
symptoms,	  while	  csDMARD	  were	  usually	  added	  later	  in	  the	  course	  of	  the	  disease.	  
This	   approach	  was	  based	  on	   the	  assumptions	   that	  NSAIDs	  have	  a	   relatively	   safe	  
profile,	   meanwhile	   csDMARD	   were	   considered	   extremely	   toxic	   drugs,	   and	   RA	  
regarded	  as	  an	  overall	  benign,	  non	  life-­‐threatening	  disease.	  	  230	  
Over	  the	  last	  decade,	  after	  these	  postulations	  have	  been	  proved	  incorrect	  and	  
new	  concepts	  such	  as	  the	  importance	  of	  early	  identification	  and	  treatment	  of	  RA	  
have	  emerged,	  a	  dramatic	  paradigm	  change	  has	  occurred.	  This	  translates	  into	  the	  
so-­‐called	  “inverted	  pyramid”	  approach	  (meaning	  aggressive	  therapy	  to	  start	  with,	  
followed	   by	   gradual	   tapering	   once	   the	   therapeutic	   target	   has	   been	   achieved)	   in	  
order	  to	  get	  early	  control	  of	  inflammation	  and	  prevent	  rapid	  disease	  progression.	  
Importantly,	   the	   modern	   management	   of	   RA	   implies	   not	   only	   early	   intensive	  
treatment	  but	  also	  a	  closer	  monitoring	  of	  patients,	  allowing	  prompt	  escalation	  of	  
therapy	   whenever	   the	   therapeutic	   targets	   are	   missed.	   This	   strategy	   is	   defined	  
“tight	  control”.	  231	  	  
Evidence	  of	   improved	  outcomes	  with	   the	  adoption	  of	   a	   tight	   control	   strategy	  
has	  been	  provided	  by	  several	  studies,	  such	  as	  the	  Behandel	  Strategieën	  (BeSt)232,	  
the	  Computer	  Assisted	  Management	   for	  Early	  Rheumatoid	  Arthritis	   (CAMERA)233	  




TICORA,	   in	   particular,	   is	   a	   randomised	   controlled	   trial	   specifically	   designed	   to	  
compare	   the	   superiority	   of	   an	   intensive	   treatment	   group	   versus	   a	   standard	  
treatment	   group	   in	  patients	  with	  RA	  and	  disease	  duration	  up	   to	   five	   years.	  One	  
year	  after	  commencement	  of	  treatment,	  remission	  rates	  were	  significantly	  higher	  
in	   the	   intensive	   therapy	   group	   versus	   the	   standard	   care	   group	   (65%	   vs	   16%).	  
Similarly,	   radiographic	   progression,	   physical	   function	   and	   quality	   of	   life	   were	  
superior	   in	  the	  tight	  control	  group,	  at	  no	  additional	  costs.	   Importantly,	  when	  the	  
intensively	   treated	   group	   was	   switched	   to	   standard	   care	   after	   18	   months,	   the	  
initial	  benefits	  were	  lost.234	  
These	   studies	  deliver	   an	   important	  message	   to	   clinicians:	  optimal	   therapeutic	  
strategy	  and	  intensity	  of	  treatment	  is	  not	  less	  important	  than	  the	  effectiveness	  of	  
the	  drug	  armamentarium	  to	  increase	  the	  chances	  of	  success	  in	  RA	  management.	  	  
A	   fundamental	   question	   remains	   unanswered	   though:	   whether	   an	   intensive	  
treatment	   strategy	   is	   necessary	   for	   all	   patients	   with	   early	   RA,	   or	   whether	   for	  
patients	   at	   lower	   risk	   of	   disease	   progression	   the	   pursuit	   of	   stringent	   treatment	  
targets	  results	  in	  no	  net	  gain	  but	  actually	  in	  exposure	  to	  unnecessary	  risk	  related	  
to	  potential	   treatment	   toxicity.	  Answering	   this	  question	  will	  be	  difficult	  until	  our	  
ability	  to	  stratify	  patients	  according	  to	  prognostic	  categories	  remains	  limited.225	  
	  
1.7.4	  	  	  An	  overview	  of	  current	  therapeutic	  options	  
	  1.7.4.1	  	  	  Symptomatic	  drugs	  
NSAIDs	   and	   COX-­‐2	   inhibitors	   are	   effective	   in	   relieving	   the	   symptoms	   of	   RA,	  
especially	   joint	   pain	   and	   stiffness.	   A	   limitation	   in	   the	   use	   of	   these	   drugs	   is	  




further	   by	   their	   unfavourable	   safety	   profile.	   NSAIDs	   use	   has	   been	   historically	  
associated	  with	  GI	  events	   in	  RA	  patients.	  While	   the	  addition	  of	  gastro-­‐protective	  
agents	  or	  the	  use	  of	  COX-­‐2	  selective	  drugs	  have	  significantly	  reduced	  the	  rate	  of	  GI	  
complications,	   both	   NSAIDs	   and	   COX-­‐2	   inhibitors	   have	   been	   associated	   with	  
increased	   cardiovascular	   risk,	   especially	   fluid	   retention,	   exacerbation	   of	  
hypertension,	   renal	   impairment	   and	   thrombotic	   events.	   Therefore,	   their	   use	  
should	   be	   limited	   to	   the	   shortest	   treatment	   duration	   possible	   and	   after	  
gastrointestinal,	   cardiac	   and	   renal	   risk	   have	   been	   carefully	   evaluated	   at	   the	  
individual	  level.148,235	  	  
1.7.4.2	  	  	  Glucocorticoids	  
Despite	  major	   treatment	  advances	  over	   the	   last	   two	  decades,	  particularly	   the	  
introduction	  of	  biologic	  agents,	  steroids	  remain	  a	  milestone	  in	  the	  treatment	  of	  RA	  
after	  65	  years	  of	  use.	  236 
Systemic	   glucocorticoids,	   and	   especially	   oral	   prednisolone	   (PRED),	   are	   widely	  
used	   for	   the	   short-­‐term	   relief	   of	   signs	   and	   symptoms	   of	   RA.	   They	   have	   an	  
important	  role	  in	  establishing	  control	  of	  synovitis	  particularly	  in	  the	  early	  phase	  of	  
the	   disease	   and	   as	   a	   “bridging	   therapy”	   until	   csDMARD	   reach	   maximum	  
therapeutic	   effect.	   Systemic	   or	   intra-­‐articular	   steroids	   are	   also	   helpful	   in	   the	  
management	  of	  rheumatoid	  flares.	  	  
A	  Task	   Force	   instituted	  by	  EULAR	  with	   the	  aim	  of	  updating	  guidelines	   for	   the	  
management	   of	   RA,	   recommends	   that	   low-­‐dose	   glucocorticoids	   should	   be	  
considered	   as	   part	   of	   the	   initial	   treatment	   strategy	   in	   combination	  with	   one	   or	  
more	  csDMARD.	  237	  There	  is	  in	  fact	  data	  supporting	  that	  the	  use	  of	  steroids,	  either	  




Bij	  Reumatoide	  Artritis)	  regimen	  238)	  or	  at	  very	  low	  doses	  over	  two	  years	  239,	  may	  
have	   a	   disease-­‐modifying	   effect,	   showing	   a	   beneficial	   role	   in	   retarding	  
radiographic	   progression.	   240-­‐243	   It	   has	   been	   observed	   that	   the	   long-­‐term	   use	   of	  
low	   dose	   of	   steroids,	   especially	   when	   administered	   early	   in	   the	   course	   of	   the	  
disease,	  may	  slow	  by	  at	  least	  50%	  the	  magnitude	  of	  radiographic	  progression.	  244	  
Additionally,	   long-­‐term	   follow-­‐up	   studies	   show	   that	   treatment	   regimens	   which	  
include	   steroids	   in	   the	  early	  phase	  may	  have	  a	   sustained	  positive	   impact	  on	   the	  
disease	  course	  after	  their	  discontinuation.	  238,245-­‐248	  	  
The	   main	   limitation	   in	   steroid	   use	   is	   related	   to	   side	   effects	   depending	   on	  
cumulative	   dose	   -­‐hypertension,	   obesity,	   osteoporosis,	   diabetes,	   avascular	  
osteonecrosis,	   cataracts,	   glaucoma-­‐	   and	   therefore	   long-­‐term	   use	   should	   be	  
avoided.	   148,215	   It	   is	   important	   that	  adequate	  monitoring	  of	  potential	   side	  effects	  
and	   specific	   preventive	   measures	   are	   in	   place249-­‐251.	   The	   EULAR	   Task	   Force	  
recommends	  limiting	  steroid	  use	  to	  a	  maximum	  of	  6	  months,	  ideally	  tapering	  the	  
dose	  at	  earlier	  time	  points.	  237	  
1.7.4.3	  	  	  Conventional	  synthetic	  Disease-­‐Modifying	  Antirheumatic	  Drugs	  
Early	   initiation	   of	   therapy	  with	   csDMARD,	   ideally	  within	   one	  month	   from	   the	  
diagnosis,	  is	  crucial	  for	  optimal	  management	  of	  RA.	  	  
By	  definition	  csDMARD	  are	  able	  not	  only	  to	  control	  signs	  and	  symptoms	  of	  RA,	  
but	  also	  to	  retard	  the	  progression	  of	  the	  disease.	  235	  The	  potential	  risks	  associated	  
with	  csDMARD	  therapy	  are	  acceptable	  with	  long-­‐term	  use,	  and	  overall	  preferable	  
to	  those	  related	  to	  persistently	  active,	  untreated	  RA.	  252	  
Unless	   contraindicated,	   the	   current	   EULAR	   recommendation	   is	   that	  




with	  early	  RA.	  148,237	  MTX	  indeed	  remains	  the	  “anchor”	  drug	  in	  the	  treatment	  of	  RA	  
253,	  used	  in	  monotherapy	  or	  in	  combination	  with	  other	  csDMARD	  or	  bDMARD.	  	  
MTX	  monotherapy,	  with	  or	  without	   steroids,	   can	   lead	   to	   achievement	  of	   low	  
disease	  activity	  in	  about	  25–50%	  of	  patients	  with	  early	  RA	  within	  6–12	  months.	  254-­‐
256	   Notably,	   some	   RCTs	   have	   shown	   that	   MTX	   monotherapy	   is	   comparable	   to	  
bDMARDs	  in	  RA	  when	  commenced	  in	  the	  early	  phase	  of	  the	  disease.	  257,258	  	  
Potential	   side	   effects	   of	   MTX	   include	   liver	   toxicity,	   skin	   nodulosis,	   acute	  
interstitial	   pneumonitis	   (that	   could	   be	   potentially	   fatal),	   lung	   fibrosis,	   cytopenia,	  
mouth	  ulcers,	  alopecia,	  nausea,	   vomiting,	  general	   sickness,	  and	   increased	   risk	  of	  
infections.	  	  However,	  an	  acceptable	  long-­‐term	  safety	  profile	  for	  this	  drug	  has	  been	  
demonstrated.	  259	  Important	  aspects	  of	  the	  use	  of	  MTX	  include	  dose	  optimisation	  
and	   route	   of	   administration	   (oral,	   intramuscular	   or	   subcut)	   260,	   concomitant	  
optimal	  use	  of	  folic	  acid	  261,	  and	  recognition	  that	  the	  maximum	  therapeutic	  effect	  
is	   obtained	   for	   each	   dose	   level	   after	   an	   average	   of	   4–6	   weeks	   255,257.	   In	   this	  
respect,	   it	   is	   recommended	   that	  MTX	   should	   be	  maintained	   at	   a	   sufficient	   dose	  
and	   for	   sufficient	   time	   (at	   least	  8	  weeks)	  before	  progressing	   to	  potentially	  more	  
intensive	  therapies.	  237	  
There	  is	  good	  evidence	  for	  a	  disease	  modifying	  effect	  for	  Sulfasalazine	  (SSZ)	  and	  
Leflunomide	  (LEF)	  as	  possible	  alternative	  to	  MTX,	  meanwhile	  the	  evidence	  is	  lower	  
for	   Hydroxychloroquine	   (HCQ),	   Cyclosporine,	   Azathioprine,	   Penicillamin	   and	   oral	  
gold.	  215	  	  
Due	  to	  its	  favourable	  safety	  profile	  and	  ability	  to	  improve	  symptoms	  and	  some	  
objective	  measures	  of	  inflammation,	  HCQ	  is	  commonly	  used	  for	  the	  management	  




with	  MTX.	   SSZ	   is	   also	   frequently	   used	   in	   early	   or	   established	   RA,	   particularly	   in	  
association	  with	  MTX	  in	  those	  forms	  of	  RA	  perceived	  as	  more	  severe	  and	  likely	  to	  
evolve	  toward	  persistent	  or	  erosive	  disease.	  LEF	   is	  considered	  a	  good	  alternative	  
to	   MTX,	   with	   a	   comparable	   safety	   profile.	   215,235	   Of	   note,	   SSZ	   and	   HCQ	   are	  
compatible	  with	  conceiving	  and	  pregnancy,	  while	  MTX	  and	  LEF	  are	  associated	  with	  	  
teratogenicity	  and	  require	  concomitant	  contraceptive	  measures/discontinuation	  if	  
conception	  is	  desired.	  262	  
Whether	   csDMARD	   combination	   therapy	   is	   superior	   to	   monotherapy,	   and	  
especially	   whether	   the	   combination	   of	   MTX	   with	   other	   csDMARD	   in	   the	   early	  
phase	   of	   the	   disease	   is	   superior	   to	   MTX	   alone,	   is	   debated.	   In	   clinical	   practice,	  
csDMARD	   combination	   therapy	   is	   very	   common,	   although	   data	   are	   conflicting.	  
Some	  RCTs	  showed	  that	  combination	  of	  MTX	  with	  SSZ	  was	  not	  superior	  to	  single	  
drug	  treatment.	  263,264	  Nonetheless,	  reports	  from	  RCTs	  in	  early	  RA	  such	  as	  COBRA	  
238,265	   and	   FIN-­‐RACo	   266,	   demonstrated	   clinical	   and	   radiological	   superiority	   of	  
combination	  therapy	  compared	  to	  step-­‐up	  approach.	  	  
A	  milestone	  study	  from	  O’Dell	  suggested	  that	  “triple	  therapy”	  –combination	  of	  
MTX,	   SSZ	   and	   HCQ–	   is	   superior	   to	   MTX	   plus	   SSZ	   or	   MTX	   plus	   HCQ	   to	   achieve	  
clinical	  remission	  in	  established	  RA,	  at	  no	  cost	  of	  more	  side	  effects.	  267	  In	  a	  recent	  
review	  of	  current	  therapeutic	  strategies	  for	  early	  RA,	  Sethi	  and	  O’Dell	  found	  that	  
MTX	  monotherapy	  is	  normally	  able	  to	  achieve	  therapeutic	  target	  in	  over	  one-­‐third	  
of	   patients;	  when	  MTX	   on	   its	   own	   fails	   this	   target,	   triple	   csDMARD	   therapy	  will	  
result	   in	   control	   of	   another	   one-­‐third	  of	   the	  patients;	   the	   remainder	  of	   patients	  




1.7.4.4	  	  	  Biologic	  Disease-­‐Modifying	  Antirheumatic	  Drugs	  
In	  the	  last	  decade,	  there	  have	  been	  significant	  improvements	  in	  the	  treatment	  
of	  RA.	  One	  of	  the	  most	  important	  advances	  has	  been	  the	  development	  of	  biologic	  
DMARD	   (bDMARD	   or	   biologics),	   genetically	   engineered	   proteins	   derived	   from	  
either	  murine	   or	   human	   genes.	   These	   drugs	   differ	   from	   traditional	  medications	  
used	   in	   the	   treatment	   of	   RA	   as	   they	   target	   specific	   components	   of	   the	   immune	  
system	   that	   play	   a	   key	   role	   in	   activating	   and	   perpetuating	   the	   inflammatory	  
cascade.	  	  
Biologic	  drugs	  are	  used	  in	  patients	  with	  moderate	  and	  severe	  RA	  that	  have	  not	  
responded	   adequately	   to	   initial	   treatment	   with	   csDMARD	   (about	   30–40%	   of	  
patients).	  269	  	  
The	   first	  bDMARD	  approved	   for	   the	   treatment	  of	  RA	  were	   inhibitors	  of	  TNFα,	  
which	   were	   first	   launched	   in	   1998	   270.	   Currently	   five	   anti-­‐TNFα	   are	   licensed	   for	  
clinical	   use	   in	   RA:	   Infliximab,	   Etanercept,	   Adalimumab,	   Certolizumab	   pegol	   and	  
Golimumab.	  	  
Infliximab	   is	   a	   chimeric	   (human	   and	   murine)	   IgG1	   anti–TNFα	   antibody	  
administered	  intravenously,	  which	  binds	  with	  high	  affinity	  to	  both	  the	  soluble	  and	  
the	   membrane	   TNFα	   and	   inhibits	   the	   interaction	   between	   the	   cytokine	   and	   its	  
receptor.	  270	  Etanercept	  is	  a	  fusion	  protein	  consisting	  of	  the	  extracellular	  region	  of	  
two	  human	  p75	  TNFα	  receptors	  coupled	  to	  the	  Fc	  portion	  of	  a	  monoclonal	  human	  
antibody,	   administered	   subcutaneously.	   Unlike	   other	   TNFα	   inhibitors,	   Enbrel	  
targets	   TNFβ	   (lymphotoxin)	   as	   well;	   another	   important	   pharmacological	  
difference,	  which	   derives	   from	   its	   biomechanical	   structure,	   is	   that	   Etanercept	   is	  




Adalimumab	   is	   a	   recombinant,	   fully	   humanized	  monoclonal	   anti–TNFα	   antibody	  
given	  subcutaneously.	   270	  Certolizumab	  pegol	   is	  a	  pegylated	  anti-­‐TNFα	  consisting	  
of	   a	   fragment	   antigen-­‐binding	   (Fab)	   attached	   to	   a	   40	   kilo-­‐Dalton	   polyethylene	  
glycol	   (PEG)	   moiety.	   It	   is	   administered	   subcutaneously	   every	   two	   weeks.	   The	  
attachment	   of	   PEG	   to	   the	   Fab	  modifies	   the	   half-­‐life	   and	  may	   contribute	   to	   the	  
preferential	  distribution	  of	  the	  drug	  to	   inflamed	  tissues.	  Moreover,	  Certolizumab	  
lacks	  the	  Fc	  region	  and	  so	  it	  does	  not	  induce	  complement	  or	  antibody-­‐dependent	  
cell-­‐mediated	  cytotoxicity	  which	  has	  been	  observed	  in	  vitro	  with	  other	  anti-­‐TNFαs.	  
272	  Finally,	  Golimumab	  is	  the	   last	  approved	  human	  monoclonal	  antibody	  to	  TNFα	  
and	  is	  administered	  subcutaneously	  at	  monthly	  intervals.	  273	  
Across	  a	  large	  number	  of	  trials	  and	  registries,	  the	  efficacy	  and	  safety	  profile	  of	  
the	   five	   currently	   available	  anti-­‐TNFα	  drugs	   is	   comparable	   274,	   however	  head-­‐to-­‐
head	   studies	   are	   scarce.	   In	   most	   of	   the	   RCTs,	   these	   agents	   were	   studied	   in	  
comparison	  or	  in	  combination	  with	  MTX.	  	  
At	   present,	   the	   combination	   of	   MTX	   with	   TNFα	   blockers	   appears	   to	   provide	  
good	   therapeutic	   effect,	   both	   in	   terms	   of	   clinical	   efficacy	   and	   prevention	   of	  
radiological	  progression.	  This	  has	  emerged	  from	  several	  trials,	  such	  as	  the	  ‘Active-­‐
Controlled	  Study	  of	  Patients	  Receiving	  Infliximab	  for	  the	  Treatment	  of	  Rheumatoid	  
Arthritis	   of	   Early	   Onset’	   (ASPIRE)	   275,	   the	   ‘Trial	   of	   Etanercept	   and	  Methotrexate	  
with	   Radiographic	   Patients	   Outcome’	   (TEMPO)	   258,	   the	   ‘Efficacy	   and	   Safety	   of	  
Adalimumab	   and	   Methotrexate	   versus	   Methotrexate	   Monotherapy	   in	   Subjects	  
with	   Early	   Rheumatoid	   Arthritis’	   (PREMIER)	   257	   and	   the	   ‘Comparison	   of	  
Methotrexate	  Monotherapy	  with	  a	  Combination	  of	  Methotrexate	  and	  Etanercept	  




Unfortunately,	   approximately	   30–40%	   of	   patients	   on	   anti-­‐TNFα	   continue	   to	  
have	  active	  disease.	  Among	  them,	  some	  do	  not	  respond	  from	  the	  very	  beginning	  
(primary	   failure),	   while	   other	   show	   an	   initial	   response	   but	   will	   loose	   it	  
subsequently	  (secondary	  failure).	  269	  
Access	  to	  anti-­‐TNFα	  agents	  vary	  largely	  across	  countries	  depending	  on	  national	  
and	   local	   regulatory	   bodies.	   In	   some	   countries	   the	   standards	   for	   initiation	   of	  
treatment	  are	  relatively	  liberal,	  in	  others	  the	  fulfilment	  of	  strict	  criteria	  is	  required.	  
In	  the	  UK	  eligibility	  criteria	  are	  relatively	  stringent,	  as	  patients	  must	  present	  with	  
high	   disease	   activity	   (DAS28	   >	   5.1)	   after	   failure	   of	   intensive	   therapy	   with	   a	  
combination	  of	  csDMARD	  (www.nice.org.uk/guidance/ta375).	  
There	   is	   growing	  body	  of	   evidence	   suggesting	   a	   significant	   benefit	   from	  early	  
initiation	   of	   TNFα	   inhibitors	   in	   DMARD-­‐naïve	   RA	   patients.	   Several	   studies	   have	  
shown	   higher	   proportion	   of	   patients	   achieving	   remission	   and	   less	   radiographic	  
progression	  in	  patients	  on	  MTX	  plus	  anti-­‐TNFα	  compared	  to	  MTX	  alone.	  254,257,275-­‐
279	  Similarly,	  a	  sub-­‐analysis	  of	  the	  BeSt	  study	  showed	  a	  better	  outcome	  of	  patients	  
receiving	  early	  compared	  to	  delayed	  Infliximab	  plus	  MTX	  combination	  therapy.	  280	  
A	   study	   by	   Quinn	   et	   al	   suggested	   a	   role	   for	   intensive	   induction	   therapy	   with	  
biologics	  in	  DMARD-­‐naïve	  RA,	  followed	  by	  maintenance	  with	  csDMARD.	  281	  
A	   number	   of	   other	   biologic	   agents	   aimed	   at	   targets	   other	   than	   TNFα	   are	  
available	  for	  treatment	  of	  patients	  with	  RA:	  Rituximab,	  a	  chimeric	  human/murine	  
monoclonal	  antibody	  targeting	  the	  CD20	  antigen	  expressed	  on	  mature-­‐B	  and	  pre-­‐
B	   cells;	   Tocilizumab,	   a	   humanized	   anti-­‐IL6R;	   Abatacept,	   a	   recombinant	   fusion	  




of	   human	   IgG1,	   which	   inhibits	   the	   co-­‐stimulatory	   signal	   required	   for	   APC	  
dependent	  T	  cell	  activation.	  282	  
1.7.4.5	  	  	  Targeted	  synthetic	  Disease-­‐Modifying	  Antirheumatic	  Drugs	  
Targeted	  synthetic	  DMARD	  (tsDMARD)	  represent	  an	  emerging	  class	  of	  drugs	  for	  
RA,	   that	   modulates	   a	   specific	   target	   implicated	   in	   the	   inflammatory	   cascade.	  	  
Examples	   include	   janus	   kinase	   (JAK)	   inhibitors,	   like	   tofacitinib	   or	   baricitinib.	  
Cytokines,	   on	   binding	   to	   cell-­‐surface	   receptors,	   exert	   their	   function	   by	   inducing	  
intracellular	   signalling	   that	   activate	   intracellular	   pathways.	   The	   non-­‐receptor	  
tyrosine	   kinase	   family	   JAK	   has	   an	   essential	   role	   in	   transducing	   cytokine-­‐induced	  
signals	  that	  influence	  normal	  and	  pathological	  intracellular	  pathways	  and	  immune	  
cell	  functions,	  including	  pathogenic	  mechanisms	  involved	  in	  RA.	  283	  
Tofacitinib	   was	   the	   first	   approved	   tsDMARD	   for	   treatment	   of	   moderate	   to	  
severe	  RA.	   It	   is	  an	  orally	  administered	  small	  molecule	   inhibitor	  which	  modulates	  
the	   inflammatory	   process	   by	   selectively	   targeting	   the	   JAK3	   pathway	   cascade.	  
Tofacitinib	   is	   indicated	   for	   the	   treatment	   of	   patients	   with	   RA	  who	   have	   had	   an	  
inadequate	  response	  to	  MTX	  and/or	  other	  DMARD.	  284	  	  
Baricitinib	   is	   a	   JAK1/2	   inhibitor	   now	   approved	   for	   use	   in	   Europe.	   In	   phase	   3	  
clinical	   trials	   it	   appears	   to	   have	   similar	   therapeutic	   efficacy	   as	   bDMARD	   and	  
Tofacitinib	  in	  patients	  with	  moderate	  to	  severe	  RA.	  285	  
The	  current	  approach	  to	  the	  treatment	  of	  early	  RA	  is	  schematised	  in	  the	  algorithm	  

























	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  Figure	  1.3:	  Therapeutic	  algorithm	  for	  the	  treatment	  of	  early	  rheumatoid	  arthritis	  	  
	  	  *Unfavourable	  prognostic	  factors:	  high	  disease	  activity,	  RF/ACPA	  positive,	  early	  joint	  damage.	  
	  	  	  Abbreviations:	   csDMARD=	   conventional	   synthetic	   Disease-­‐Modifying	   Drugs;	   MTX=	  
Methotrexate;	   RA=	   rheumatoid	   arthritis;	   tsDMARD=	   targeted	   synthetic	   Disease-­‐Modifying	  
Drugs.	  
	  	  	  Adapted	  from	  237	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1.8	   	   	   SYNOVIAL	   TISSUE	   EXTRACTION	  AND	  ANALYSIS:	   STATE	  OF	   THE	  
ART	  
1.8.1	  	  	  Recent	  progresses	  in	  synovial	  tissue	  acquisition	  	  
The	   inflamed	   synovium	   is	   the	   pathological	   hallmark	   of	   RA.	   Exploring	   the	  
characteristics	   of	   the	   joint	   tissue	   is	   pivotal	   in	   enhancing	   our	   understanding	   of	  
disease	   pathogenesis	   and	   in	   developing	   future	   targeted	   therapies.	   Therefore,	  
advancement	  in	  biopsy	  techniques	  harvesting	  sufficient	  quantity	  and	  good	  quality	  
tissue	  is	  essential.	  	  
A	   number	   of	   approaches	   have	   been	   attempted	   in	   order	   to	   facilitate	   the	  
acquisition	  of	  tissue	  samples	  from	  large	  and	  small	  joints.	  	  
Historically,	   synovial	   biopsies	   have	   been	   performed	   by	   using	   a	   blind	   needle	  
approach	  (Parker–Pearson	  or	  Williamson–Holt	  needle).	   286	  Because	  of	  the	   lack	  of	  
direct	   visualization	  making	   it	   difficult	   to	   biopsy	   small	   joints,	   this	   technique	   was	  
restricted	  to	  large	  joints,	  mainly	  knees.	  This	  represented	  a	  significant	  limitation	  in	  
early	   arthritis	   studies	   where	   small	   joints	   and	   particularly	   hands	   and	   wrists	   are	  
predominantly	   involved.	   287	   Large	   joint	   involvement	   in	   the	   early	   phase	   of	   the	  
disease	   identifies	   a	   subset	   of	   patients	   with	   worse	   prognosis,	   therefore	   studies	  
based	   exclusively	   on	   tissue	   from	   knees	   or	   other	   large	   joints	   would	   inevitably	  
introduce	  a	  methodological	  bias.	   288	  Another	  disadvantage	  of	   this	   technique	  was	  
the	   difficulty	   to	   obtain	   adequate	   tissue	   samples	   from	   joints	   that	   had	   became	  
quiescent	  following	  effective	  therapy.	  	  
Due	  to	  such	   limitations,	   this	  methodology	  had	  been	  progressively	  replaced	  by	  




quantity	   and	   quality	   tissue	   under	   direct	   visualization.	   During	   arthroscopy,	   the	  
operator	   is	  able	  to	  visualize	  the	  synovium	  macroscopically,	  so	   it	   is	  relatively	  easy	  
to	  obtain	  adequate	  amounts	  of	  synovial	  tissue	  even	  when	  the	  volume	  of	  the	  tissue	  
has	   reduced	   after	   successful	   treatment.	   To	   date,	   arthroscopy	   remains	   the	   gold	  
standard	  for	  synovial	  tissue	  extraction.	  289	  However,	  arthroscopic	  biopsies	  present	  
several	  issues,	  including	  technical	  complexity	  requiring	  specific	  training,	  high	  costs,	  
pain	   or	   discomfort	   during	   the	   procedure	   reported	   by	   up	   to	   35%	   of	   patients,	   290	  
minor	  complications	  such	  as	  vasovagal	  reactions	  and	  post-­‐procedure	  joint	  swelling	  
observed	  in	  5–10%	  of	  cases,	  more	  severe	  complications	  like	  haemarthrosis	  (0.9%),	  
deep	  vein	  thrombosis	  (0.2%)	  and	  biopsy	  site	  infection	  (0.1%).	  291	  	  
More	   recently,	  advances	   in	   the	  use	  of	  musculoskeletal	  US	  by	   rheumatologists	  
has	   led	   to	   the	   development	   of	   US-­‐guided	   synovial	   biopsies,	   allowing	   the	  
acquisition	  of	  synovial	  tissue	  using	  a	  minimally	  invasive,	  easy	  to	  perform	  and	  well	  
tolerated	  technique.	  US-­‐guided	  synovial	  biopsies	  offer	  undoubted	  advantages:	  US	  
assessment	  may	  facilitate	  selection	  of	  the	  best	  joint	  suitable	  for	  biopsy;	  US	  images	  
guide	   the	   operator	   during	   the	   procedure,	   facilitating	   site	   visualization	   with	  
minimal	   invasiveness;	   the	   technique	   requires	   less	   intensive	   training	   and	   after	  
purchase	   of	   an	   US	   machine	   minimal	   investment	   in	   equipment;	   it	   can	   be	   easily	  
performed	   in	   a	   standard	   rheumatology	   setting;	   it	   allows	   easy	   approach	  of	   small	  
joints	  as	  equally	  as	  large	  joints,	  therefore	  it	  is	  ideal	  to	  be	  utilized	  in	  early	  arthritis	  
studies.	  	  
Previous	  studies	  described	  US-­‐guided	  synovial	  biopsy	  performed	  using	  a	  portal	  
and	  forceps	  technique.	  292,293	  This	  method	  consists	  in	  inserting	  a	  flexible	  wire	  into	  




Hartmann's	  forceps	  used	  for	  the	  tissue	  extraction.	  This	  method	  has	  been	  validated	  
in	  a	  small	  case	  series	  of	  nine	  patients	  with	  long	  standing	  RA.	  292	  
However	  in	  a	  recent	  survey	  of	  93	  US-­‐guided	  synovial	  biopsies	  performed	  in	  the	  
Rheumatology	  Department	  at	  Barts	  and	  The	  London	  Hospital,	  successful	  biopsies	  
of	  large	  and	  small	  joints	  have	  been	  obtained	  through	  minimally	  invasive	  US	  guided	  
technique	  using	  a	  14-­‐16G	  Quick-­‐Core	  (Cook	  Medical)	  needle.	  287	  Of	  the	  93	  biopsy	  
procedures,	   57	  were	   performed	   prior	   to	   csDMARD	   therapy	   and	   36	  were	   repeat	  
biopsies	   after	   6	   months	   of	   treatment	   in	   patients	   recruited	   as	   part	   of	   the	  
‘Pathobiology	  of	  Early	  Arthritis	  Cohort’	  (PEAC)	  study.	  Five	  joint	  sites	  were	  biopsied	  
(knee,	   elbow,	  wrist,	  metacarpal	   phalangeal	   and	  proximal	   interphalangeal	   joints).	  
Up	  to	  12-­‐15	  biopsy	  samples	  from	  any	  joint	  site	  were	  retrieved	  per	  procedure.	  86	  
(92.5%)	   biopsy	   procedures	   yielded	   high-­‐quality	   tissue	   suitable	   for	  
histopathological	  characterisation	  (the	  rate	  of	  success	  for	  renal	  and	  liver	  biopsies	  
routinely	   performed	   for	   diagnostic	   purposes	   is	   83-­‐97%	   294,295	   and	   81-­‐97%	   296	  
respectively).	   Notably,	   tissue	   quality	   was	   preserved	   in	   subsequent	   biopsies	  
following	   therapeutic	   intervention	   as	   shown	   by	   the	   36	   patients	   who	   received	   a	  
second	  synovial	  biopsy.	  This	  is	  important	  in	  the	  context	  of	  using	  such	  a	  technique	  
to	  monitor	  changes	  in	  synovial	  biomarkers	  of	  response	  to	  therapy.	  
This	  data	  also	  demonstrated	   that	   the	  procedure	   is	   safe	  and	  well	   tolerated	  by	  
patients.	  No	  significant	  complications	  were	   reported.	  No	  significant	  difference	   in	  
the	  assessment	  of	  joint	  pain,	  swelling	  and	  stiffness	  on	  a	  visual	  analogue	  scale	  pre-­‐	  
and	  post-­‐biopsy	  was	  detected	  (Figure	  1.4).	  287	  Notably,	  biopsies	  of	  small-­‐sized	  and	  
medium-­‐sized	  joints	  (MCPs,	  PIPs	  and	  wrists)	  were	  better	  tolerated	  than	  large	  sized	  




investigating	   pathobiology	   of	   early	   arthritis	  where	   involvement	   of	   small	   joints	   is	  
predominant.	  	  
The	  majority	  of	  patients	  were	  agreeable	  to	  undergo	  a	  repeat	  procedure	  (Figure	  
1.4).	  This	  is	  of	  great	  importance	  in	  the	  context	  of	  using	  serial	  synovial	  biopsies	  to	  

















Figure	  1.4	  :	  US-­‐guided	  biopsy	  is	  a	  safe	  and	  tolerated	  procedure	  
Patients	   completed	   a	   visual	   analogue	   score	   assessment	   of	   joint	   pain,	   stiffness	   and	  
swelling	  prior	   to	  and	  after	   the	  procedure.	  No	  significant	  difference	   in	  any	  of	   the	   three	  
parameters	  pre-­‐	  and	  post-­‐procedure	  was	  reported	  (A).	  
After	  the	  biopsy,	  patients	  were	  asked	  how	  agreeable	  there	  were	  to	  having	  a	  subsequent	  
one	  at	  a	  later	  time-­‐point:	  very	  likely,	  somewhat	  likely,	  not	  sure,	  somewhat	  unlikely,	  very	  
unlikely.	  Results	  expressed	  as	  percentages	  of	  total	  patients	  (B).	  
Abbreviations:	  NS=	  not	  sure;	  SL=	  somewhat	   likely;	  SU=	  somewhat	  unlikely;	  VAS=	  visual	  
analogue	  scale;	  VL=	  very	  likely;	  VU=	  very	  unlikely.	  







1.8.2	  	  	  Methodological	  issues	  related	  to	  synovial	  tissue	  extraction	  and	  analysis	  
In	  order	   to	  make	   synovial	  pathobiological	  analysis	  a	   reliable	  and	   reproducible	  
tool,	  a	  number	  of	  critical	  issues	  need	  to	  be	  addressed,	  and	  specifically:	  i.	  is	  a	  single	  
joint	  truly	  representative	  of	  the	  other	   inflamed	  joints?	   ii.	  does	  a	  single	   joint	  area	  
faithfully	   reflect	   the	   inflammation	   in	   the	   whole	   joint?,	   iii.	   how	   many	   biopsy	  
specimens	  from	  the	  same	  joint	  are	  necessary	  to	  be	  analysed	  to	  ensure	  an	  accurate	  
representation	  of	  the	  whole	   joint?,	   iv.	  how	  many	  sections	  from	  a	  single	  biopsy	  ?	  
and	  ,	  v.	  what	  is	  the	  minimum	  tissue	  area/sample	  size	  required	  for	  analysis?	  297	  	  
To	  address	  whether	   the	   cellular	   infiltrate	  of	   a	   single	   joint	   is	   representative	  of	  	  
other	   inflamed	   joints,	   a	   study	   from	   Kraan	   and	   colleagues	   compared	   the	  
characteristics	  of	  the	  cellular	  infiltrate	  in	  paired	  biopsies	  of	  large	  joints	  (knees)	  and	  
small	   joints	   (wrists	   or	   MCPs)	   of	   nine	   patients	   with	   RA,	   showing	   no	   significant	  
differences	   in	   any	   of	   the	   cellular	   and	   molecular	   biomarkers.	   298	   	   This	   provides	  
proof	  of	  concept	  that	  the	  cellular	  infiltration	  of	  a	  single	  joint	  is	  truly	  representative	  
of	  the	  systemic	  disease	  process.	  However	  potential	   limitations	  of	  the	  study	  were	  
the	   small	   sample	   size	   and	   the	   fact	   that	   patients	  were	   at	   different	   disease	   time-­‐
points	   ranging	   from	   early	   to	   long-­‐standing	   disease	   and	   had	   heterogeneous	  
treatment	  exposure.	  
Another	  crucial	  issue	  is	  to	  establish	  the	  minimum	  amount	  of	  tissue	  required	  for	  
analysis.	  Based	  on	  multiple	  analysis	  of	  variance,	  it	  was	  established	  that	  a	  minimum	  
of	   six	   to	   eight	   tissue	   samples	   is	   required	   in	   order	   to	   avoid	   overestimation	   or	  
underestimation	   of	   the	   inflammatory	   infiltrate	   and	   provide	   a	   reliable	  
representation	   of	   cellular/molecular	   components	   of	   the	   whole	   joint.	   289	   This	  




from	  knee	  joints	  from	  3	  patients	  with	  RA	  299.	  Another	  study	  on	  US-­‐guided	  biopsies	  
of	  hand	   joints	  of	  nine	  patients	  with	  RA,	  demonstrated	   that	   the	  analysis	  of	   a	  2.5	  
mm2	   tissue	   section	  provides	   a	   reliable	   estimate	  of	   synovial	  macrophages	   (CD68-­‐
positive	   cells),	   T	   cells	   (CD3-­‐positive	   cells)	   and	  B	   cells	   (CD20-­‐positive	   cells)	   count,	  
within	  10%	  variability	  of	  the	  total	  sample	  mean.	  292	  
Recently	  published	  data	  aiming	  to	  determine	  the	  degree	  of	  variation	  of	  synovial	  
cellular	  infiltration	  of	  CD3,	  CD20	  and	  CD68	  between	  single	  joint	  biopsies	  obtained	  
from	  different	  patients	  as	  well	  as	  between	  and	  within	  biopsy	  specimens	  from	  the	  
same	   joint,	   in	   order	   to	   standardize	   the	   minimum	   quantity	   of	   synovial	   tissue	  
necessary	   to	   obtain	   a	   representative	   picture	   of	   the	   immunohistochemical	  
environment	   by	   using	   US-­‐guided	   needle	   synovial	   biopsy	   of	   small	   joints.300	   The	  
results	  showed	  a	  significant	  variation	  in	  the	  degree	  of	  cellular	  infiltration	  between	  
patients	  and	  between	  biopsy	  specimens	  extracted	  from	  the	  same	  patient,	  but	  no	  
significant	  variation	  within	  multiple	  sections	  from	  the	  same	  biopsy	  specimen.	  The	  
authors	   concluded	   that,	   rather	   than	   examination	   of	   multiple	   sections	   from	   the	  
same	   specimen,	   analysis	   of	   multiple	   biopsy	   specimens	   is	   required.	   They	  
demonstrated	  that	  the	  examination	  of	  a	  minimum	  of	  4	  biopsy	  specimens	  gives	  an	  
accurate	   representative	   assessment	   of	   CD3,	   CD20	   and	   CD68	   cellular	   infiltrate.	  
Finally,	   they	  aimed	   to	  determine	  whether	  pre-­‐biopsy	  US	  assessment	  of	   synovitis	  
was	   useful	   to	   predict	   synovial	   tissue	   yields,	   reporting	   that	   joints	   with	   greater	  
synovial	   thickening	   yielded	   better	   tissue	   in	   terms	   of	   both	   quantity	   and	   quality,	  
meanwhile	   the	   presence	   of	   Doppler	   signal	   did	   not	   predict	   the	   success	   of	   the	  
procedure.	  These	  observations	  remark	  that	  US	  assessment	  represents	  a	  powerful	  




1.8.3	  	  	  The	  characteristics	  of	  the	  normal	  synovium	  
To	   investigate	   the	   synovial	   tissue	  pathobiology,	  an	  essential	  prerequisite	   is	   to	  
understand	  the	  microarchitecture	  of	  the	  normal,	  uninflamed	  synovium.	  
Synovial	   tissue	   lines	   the	   surface	   of	   diarthrodial	   joints,	   tendon	   sheaths	   and	  
bursae.	  It	  consists	  of	  two	  anatomically	  and	  functionally	  distinct	  compartments:	  an	  
intimal	  layer	  of	  1-­‐2	  cells	  (intima)	  which	  is	  in	  contact	  with	  the	  articular	  cavity,	  and	  
an	   underlying	   tissue	   (subintima)	   containing	   blood	   vessels,	   fat	   cells,	   resident	  
fibroblasts	  and	  a	  small	  number	  of	  infiltrating	  cells	  (macrophages,	  lymphocytes	  and	  
plasma	  cells)	  surrounded	  by	  collagenous	  extracellular	  matrix.	  	  	  
The	  physiological	  functions	  of	  synovium	  are	  various,	  including	  to	  confer	  a	  non-­‐
adherent	   surface	   with	   viscoelastic	   properties	   allowing	   joint	   movement	   and	  
stretching,	  to	  provide	  lubrication	  of	  cartilage,	  to	  regulate	  the	  composition	  and	  the	  
volume	   of	   the	   synovial	   fluid	   and	   to	   ensure	   the	   nutrition	   of	   the	   articular	  
chondrocytes.	  80,301	  	  
Two	   types	   of	   cells	   compose	   the	   intimal	   layer:	   type	   A	   synoviocytes,	   deriving	  
from	   the	   macrophage	   lineage	   (macrophage-­‐like	   synoviocytes),	   and	   type	   B	  
synoviocytes,	   deriving	   from	   the	   fibroblast	   lineage	   (fibroblast-­‐like	   synoviocytes,	  
FLS).	  Type	  A	  synoviocytes	  are	  true	  macrophages	  derived	  from	  hematopoietic	  cells	  
and	  migrating	  into	  the	  synovium	  from	  the	  bone	  marrow	  via	  circulation,	  however	  it	  
is	  not	  clear	  whether	  their	  differentiation	  occurs	  in	  the	  bone	  marrow	  or	  in	  situ.	  The	  
intimal	   macrophages	   strongly	   express	   CD163	   and	   CD68	   but	   less	   CD14,	   while	  
subintimal	   macrophages	   mostly	   express	   CD14.	   The	   number	   of	   intimal	  




the	   predominant	   cell	   population	   in	   patients	   with	   inflammatory	   arthritides,	  
accounting	  up	  to	  80%	  of	  total	  number	  of	  cells.	  301	  
Type	  B	  synoviocytes	  are	  mesenchymal	  cells	  displaying	  classic	  characteristics	  of	  
fibroblasts	   including	  expression	  of	   type	   IV	  and	  V	  collagen,	  vimentin,	  vascular	  cell	  
adhesion	   molecule-­‐1	   (VCAM-­‐1),	   CD90	   and	   CD55.	   It	   is	   not	   clear	   whether	   they	  
migrate	   from	   the	   subintima	   or	   are	   a	   locally	   derived	   population.	   They	   secrete	  
hyaluronic	  acid	  and	  lubricin,	  which	  are	  critical	  proteins	  for	  lubrication	  of	  cartilage.	  
301	  Type	  B	  synoviocytes	  have	  some	  peculiar	  properties	  that	  distinguish	  them	  from	  
other	  fibroblast	  lineages,	  including	  sublining	  resident	  fibroblasts.	  They	  specifically	  
express	   cadherin-­‐11,	   an	   adhesion	   molecule	   that	   plays	   a	   key	   role	   in	   cell-­‐cell	  
adhesion	   in	  a	  variety	  of	  cell	   types	  and	   is	  up	  regulated	   in	  several	   forms	  of	  cancer	  
and	   other	   pathological	   conditions	   including	   inflammatory	   arthritis.	  Mice	  models	  
that	  are	  cadherin-­‐11	  deficient	  present	  a	   less	  structurally	  defined	  synovial	   intimal	  
lining	  and	  are	  refractory	  to	  the	  development	  of	  joint	  inflammation.	  	  
	  
1.8.4	  	  	  The	  characteristics	  of	  the	  rheumatoid	  synovium	  
There	   are	   no	   clear-­‐cut	   histological	   features	   that	   differentiate	   RA	   from	   other	  
forms	   of	   chronic	   inflammatory	   arthritis.	   302 Studies	   aiming	   at	   comparing	   the	  
characteristics	  of	  RA	  with	  psoriatic	  arthritis	  (PsA)	  synovium	  showed	  that,	  although	  
some	   aspects	   may	   be	   more	   typical	   of	  PsA	   -­‐less	   pronounced	   intimal	   lining	  
thickening,	   more	   pronounced	   vascularity,	   prevalence	   of	   innate	   over	   humoral	  
response-­‐	   they	   show	   more	   similarities	   than	   differences.	   	   303-­‐305	   However	   such	  




small	   groups	   of	   patients	   with	   longstanding	   disease	   and	   exposure	   to	   previous	  
treatment.	  	  
Macroscopically,	   RA	   synovium	   is	   characterised	   by	   hypertrophic	   and	  
oedematous	   tissue	  with	  prominent	   villi	   extending	   into	   the	  articular	   space,	   along	  
with	   profuse	   synovial	   fluid	   effusion.	  Microscopic	   analysis	   shows	   that	   the	   critical	  
component	  of	  the	  inflammatory	  process	  since	  early	  stage	  are	  cellular	   infiltration,	  
neoangiogenesis	   and	   hypervascularity.	   RA	   synovium	   is	   in	   fact	   characterised	   by	  
three	   major	   histopathological	   alterations:	   thickness	   of	   the	   intimal	   layer	   due	   to	  
infiltration	  of	  monocytes/macrophages	  and	  proliferation	  of	  FLS;	  heavily	  infiltrated	  
subintimal	   region	   by	   a	   diverse	   array	   of	   inflammatory	   cells	   -­‐predominantly	  
macrophages	  and	  CD4/CD8	  T	   lymphocytes,	  but	  also	  B	   lymphocytes,	  plasma	  cells,	  
neutrophils,	   NK,	   mast	   cells	   and	   DC-­‐	   and	   proliferation	   of	   resident	   synovial	  
fibroblasts;	  marked	  neoangiogenesis	   in	   the	   context	  of	   synovial	   tissue	  hypoxia	   as	  
the	  result	  of	  the	  production	  of	  pro-­‐angiogenetic	  factors	  such	  as	  VEGF	  and	  hypoxia-­‐
inducible	  factors	  (HIFs).	  302,306,307	  
According	  to	  the	  distribution	  of	  the	  immune	  cells	  within	  the	  synovial	  sublining,	  
the	  synovial	  infiltrate	  has	  been	  long	  distinct	  into	  two	  mutually	  exclusive	  patterns:	  
a	   diffusely	   distributed	   infiltrate,	   where	   lymphocytes	   are	   intermixed	   with	  
macrophages	  and	   resident	   fibroblasts	   (‘diffuse’	  pattern,	  Figure	  1.5),	  and	  a	  highly	  
organised	   infiltrate	   where	   T	   and	   B	   cells	   cluster	   into	   lymphocytic	   aggregates	  
(‘aggregate’	  pattern,	  Figure	  1.6).	   308	   In	  up	  to	  25%	  of	  patient	  these	  structures	  can	  
acquire	  a	  high	  degree	  of	  organization	  including	  the	  compartmentalization	  of	  T	  and	  
B	  cells	   in	  discrete	  domains,	   the	  differentiation	  of	  high	  endothelial	  venules	   (HEV),	  




formation	   of	   germinal	   centres	   (GC)	   with	   local	   immunoglobulin	   gene	   somatic	  
mutations.	   These	   highly	   organised	   structures	   resemble	   secondary	   lymphoid	  






























Figure	  1.5	  :	  Inflamed	  synovium	  characterised	  by	  ‘diffuse’	  synovitis	  
Cellularity	   is	   slightly	   increased	   with	   diffuse	   and	   perivascular	   inflammatory	  
infiltrate	  visible	  in	  the	  stroma.	  	  
Picture	  from	  the	  Pathobiology	  of	  Early	  arthritis	  Biobank	  (PEAC)	  biobank.	  Courtesy	  
















Figure	  1.6	  :	  Inflamed	  synovium	  characterised	  by	  ‘aggregate’	  synovitis	  
Cellularity	   is	   moderately	   increased	   with	   two	   large	   follicle-­‐like	   lymphocytic	  
aggregates	  (black	  circles).	  
Picture	  from	  the	  Pathobiology	  of	  Early	  arthritis	  Biobank	  (PEAC)	  biobank.	  Courtesy	  







The	   immunophenotypic	   characterisation	   of	   these	   two	   main	   histo-­‐
morphological	  patterns	  demonstrates	  B	  cells	  principally	  in	  aggregate	  synovitis	  (30–
40%	  of	  patients)	  and	  CD68+	  macrophages	  principally	  in	  diffuse	  synovitis.	  However	  
recent	   reports	   have	   shown	   that	   the	   synovial	   infiltrate	   has	   a	   more	   continuous	  
spectrum	  than	  the	  mutually	  exclusive	  distinction	  between	  these	  two	  patterns.	  	  
Recently,	   a	   third	   pattern	   has	   been	   described,	   Pauci-­‐immune	   (PI),	   that	   shows	  
hardly	  any	   classic	   infiltrating	   immune-­‐cells	   and	  yet	   is	   found	   in	  active	  disease.	   297	  
This	  has	   led	  to	  a	  new	  histological	  classification	  based	  on	   immunophenotypic	  and	  
cellular	  characterisation	  rather	  then	  on	  mere	  architectural	  organisation:	  Lymphoid	  
(lymphocytes-­‐dominant	   with	   presence	   of	   synovial	   aggregates),	   Myeloid	  
(macrophages-­‐dominant	  with	  absence	  of	  aggregates)	  and	  PI	  (low/absent	  infiltrate	  
and	  predominance	  of	  stromal	  tissue).	  A	  representative	  example	   illustrative	  of	  RA	  
synovial	  membrane	  with	   these	   three	   histo-­‐morphological	   appearances	   is	   shown	  

































Figure	  1.7	  :	  Three	  distinct	  histomorphological	  patterns	  of	  rheumatoid	  synovitis	  	  
Microphotographs	   of	   prototypical	   examples	   of	   Lymphoid,	   Myeloid	   and	   Pauci-­‐immune	  
synovitis.	   Three	   mm	   sections	   of	   paraffin	   embedded	   RA	   synovial	   tissues	   were	   stained	   with	  
Haematoxylin	  and	  Eosin	  (H&E)	  and	  by	  Immunohistochemisty	  for	  B	  cells	  (CD20),	  T	  cells	  (CD3),	  
Macrophages	  (CD68)	  and	  Plasma	  cells	  (CD138).	  	  
From	  297,	  with	  permission.	  
	  
	   	  







Notably,	   these	   histo-­‐morphological	   patterns	   segregate	   with	   specific	  
transcriptomic	  signatures:	  the	  analysis	  of	  a	  cross-­‐sectional	  cohort	  of	  samples	  from	  
49	   RA	   patients,	   revealed	   transcriptomic	   clustering	   into	   Lymphoid,	   Myeloid	   and	  
two	  Fibroblast	   (F,F/A)	  prevalent	  patterns,	   together	  with	  a	  mixed	  pattern.	   297	  The	  
presence	  of	  these	  two	  fibroblasts	  patterns	  is	  in	  line	  with	  previous	  reports	  showing	  
the	  coexistence	  in	  the	  RA	  synovium	  of	  FLS	  showing	  a	  transforming-­‐growth-­‐factor-­‐b	  
/activin-­‐A	   inducible	   signature	  characteristic	  of	  myofibroblasts,	  and	  FLS	  displaying	  
principally	   an	   insulin-­‐like-­‐growth-­‐factor	   regulated	   genes	   signature.	   309	   The	  
transition	   from	   normal	   FLS	   to	   myofibroblasts-­‐like	   FLS	   is	   associated	   with	   the	  
expression	   of	   matrix	   degrading	   proteases	   310	   that	   might	   explain	   the	   aggressive	  
phenotype	  acquired	  by	  these	  cells	  in	  RA	  patients	  311.	  	  
The	   fact	   that	   the	  PI	  pattern	   -­‐	  not	   constituted	  by	   classic	   immune	  cell	   infiltrate	  
and	   still	   associated	  with	   active	   disease	   -­‐	   has	   been	   genetically	   identified	  with	   an	  
abundant	  fibroblastic	  expression	  is	  of	  great	  interest	  given	  the	  emerging	  evidence	  
of	  a	  key	  role	  of	  these	  cells	  in	  the	  pathogenesis	  of	  RA.	  76	  	  
Confirming	  the	  above	  findings,	  in	  a	  recent	  publication	  Dennis	  et	  al	  described	  3	  
main	  patterns	  emerging	  from	  genome-­‐wide	  analysis	  of	  synovial	  tissue:	  Lymphoid	  
(B	   cells	   and	   plasma	   cells	   dominated),	  Myeloid	   (macrophage	   dominated),	   Fibroid	  
(hyperplastic,	  pauci-­‐immune	  tissue)	  along	  with	  an	  overlapping	  ‘Low-­‐inflammatory’	  
pattern,	   indicating	   that	   synovial	   heterogeneity	   exists	   as	   a	   biological	   continuum	  
rather	   than	   fixed,	   mutually	   exclusively	   patterns.	   Notably,	   histological	   and	   flow	  
cytometry	   analysis	   were	   consistent	   with	   the	   dominant	   gene-­‐expression	   defined	  




synovial	   aggregates,	   the	  Myeloid	   characterised	   by	   a	   diffuse	   immune	   infiltration	  
and	  the	  Fibroid	  showed	  little	  infiltration	  and	  complete	  absence	  of	  aggregates.	  312	  
As	   the	  presence	  of	   ELS	   is	   observed	  only	   in	   a	  proportion	  of	   patients,	   a	   critical	  
issue	   is	  whether	   lymphoid	  aggregate	   formation	   represents	  either	  a	   fixed	  pattern	  
or	   the	   transient	   phase	   of	   a	   dynamic	   process	   potentially	   involving	   all	   patients	  
during	  the	  course	  of	  the	  disease.	  For	  example,	  one	  could	  speculate	  that	  the	  PI	  and	  
the	   Myeloid	   synovitis	   are	   simply	   the	   precursors	   of	   higher	   grade	   of	   tissue	  
organisation	   that	   may	   evolve	   toward	   the	   formation	   of	   lymphocytic	   aggregates.	  
Data	  emerging	  from	  the	  literature	  is	  conflicting.	  Weyond	  and	  colleagues	  observed,	  
from	  the	  analysis	  of	  several	  biopsy	  series	  collected	  years	  apart,	   that	  the	  synovial	  
pattern	   was	   consistent	   for	   each	   patient	   and	   remained	   stable	   over	   time.	   313	  
Conversely,	  a	  recent	  study	  by	  van	  de	  Sande	  based	  on	  the	  analysis	  of	  17	  repeated	  
biopsies	  six	  months	  apart,	  showed	  that	  the	  presence	  of	  lymphocytic	  aggregates	  is	  
a	   dynamic	   phenomenon	   that	   may	   vary	   over	   time.	   314	   Methodological	  
discrepancies,	   including	   the	   non-­‐homogeneous	   definitions	   of	   aggregates	   utilized	  
across	   the	  above	   studies,	   the	   confounding	   role	  of	   therapeutic	   interventions,	   the	  
inclusion	   of	   patients	   at	   different	   stages	   of	   disease	   may	   account	   for	   these	  
conflicting	  conclusions,	  highlighting	   that	   the	   lack	  of	  methodological	  uniformity	   is	  
the	  main	  caveat	  in	  this	  field	  of	  research.	  	  
	  
1.8.5	  Synovial	  ectopic	  lymphoid	  structures:	  immunological	  and	  clinical	  aspects	  
As	  previously	  mentioned,	  T	  and	  B	  lymphocytes	  may	  be	  found	  randomly	  sparse	  
within	  the	  synovium	  or	  clustered	  to	  form	  discrete	  perivascular	  aggregates	  (ectopic	  




synovial	   fibroblasts	  and	  DC.	  These	  aggregates	  can	  ultimately	  acquire	   the	   specific	  
morphological	  and	  functional	  characteristics	  of	  ectopic	  lymphoid	  structures.	  315,316	  	  
The	  presence	  of	  ELS	  is	  an	  intrinsic	  feature	  of	  chronic	  inflammation	  and	  has	  been	  
described	   in	   a	   large	   spectrum	  of	   autoimmune	  diseases	   other	   than	  RA,	   including	  
Sjogren’s	   syndrome,	   thyroiditis,	   myasthenia	   gravis,	   multiple	   sclerosis.	  
Furthermore,	   they	  are	  not	  restricted	  to	  autoimmunity	  but	  can	  be	   found	   in	  other	  
forms	   of	   chronic	   inflammation,	   fibrosis,	   granulomatosis,	   chronic	   infections	   (e.g.	  
hepatitis,	  gastritis,	  protozoa-­‐induced	  diseases)	  and	  cancer,	  indicating	  that	  this	  type	  
of	  immune	  response	  is	  not	  disease	  or	  organ	  specific	  and	  is	  not	  representative	  of	  a	  
unique	  pathological	  process.	  317	  
The	   genesis	   of	   ectopic	   lymphoid	   tissue	   is	   not	   fully	   understood.	   The	   main	  
hypothesis	  is	  that	  a	  non	  efficient	  removal	  of	  the	  antigenic	  stimuli	  -­‐derived	  	  either	  
from	   an	   extrinsic	   on	   an	   intrinsic	   source-­‐	   may	   result	   into	   a	   persistent	   antigenic	  
stimulation	   leading	   to	   the	   up-­‐regulation	   of	   specific	   chemokines	   and	   adhesion	  
molecules	  patterns,	  promoting	  the	  dysregulation	  of	  T	  cells-­‐	  B	  cells-­‐	  dendritic	  cells	  
interactions	   and	   determining	   the	   persistence	   of	   a	   chronically	   inflamed	  
environment.	  318	  
Several	  molecular	   pathways	   contribute	   to	   the	   formation	   of	   ectopic	   lymphoid	  
tissue.	   These	   include	   the	   aberrant	   in	   situ	   production	   of	   lymphoid	   chemokines	  
(CXCL13,	   CCL19	   and	  CCL21)	   and	   cytokines	   (LTα	   and	   LTβ)	   that	   are	   constitutively	  
involved	   in	   the	   homeostatic	   maintenance	   of	   lymphoid	   tissue.	   313,319	   Lymphoid	  
chemokines	   are	   instrumental	   in	   regulating	   trafficking	   of	   naive	   and	  memory	   T–B	  
lymphocytes	   within	   the	   ectopic	   lymphoid	   tissue.	   The	   molecular	   remodelling	  




and	   the	   luminal	   expression	   of	   peripheral	   node	   addressin	   (PNAd)	   to	   which	  
lymphocyte	   expressing	   L-­‐selectine	   can	   bind,	   is	   also	   critical	   to	   promote	   adhesion	  
and	  internal	  transmigration	  of	  lymphocytes.	  320	  
A	   close	   relationship	   exists	   between	   the	   degree	   of	   aggregation	   and	   the	  
acquisition	   of	   specific	   lymphoid	   tissue	   features.	   Indeed	   the	   size	   of	   lymphocyte	  
aggregates	   appears	   to	   translate	   to	   function,	   with	   bigger	   sizes	   corresponding	   to	  
higher	   lever	   of	   organisation	   and	   function.	   Histomorphometric	   analysis	   based	   on	  
the	  aggregate	  radial	  cell	  count	  has	  led	  to	  the	  development	  of	  a	  validated	  grading	  
system	   based	   on	   a	   1-­‐3	   scale	   dimensional	   grading:	   the	   grading	   is	   established	  
according	   to	   the	   radial	   lymphocyte	   count	   from	   the	   central	   blood	   vessel	   to	   the	  
point	  of	  highest	  cell	  infiltration	  within	  the	  selected	  tissue	  area,	  with	  grade	  1	  (G1=	  
two	  to	  five	  cells)	  defining	  small-­‐size,	  grade	  2	  (G2=	  six	  to	  ten	  cells)	  and	  grade	  3	  (G3>	  
10	   cells)	   defining	   large-­‐size	   lymphocytic	   aggregates.	   319,321	   The	   acquisition	   of	  
structural	   and	   functional	   features	   constitutively	   of	   secondary	   lymphoid	   tissue	  
organisation	   is	   observed	   in	   large	   aggregates	   only.	   322	   The	   presence	   of	   large-­‐size	  
aggregates	  is	  seen	  in	  approximately	  30%-­‐40%	  of	  RA	  patients.	  323,324	  	  
Much	  debate	  has	  emerged	  about	  the	  pathophysiological	  significance	  of	  ELS	   in	  
RA.	   The	   main	   question	   is	   whether	   they	   represent	   only	   a	   bystander	   of	   chronic	  
inflammation,	  or	  are	  truly	  implicated	  in	  disease	  pathogenesis.	  Indeed,	  evidence	  is	  
accumulating	   that	  ELS	  are	  not	   just	  an	  epiphenomenon	  of	   local	   inflammation	  but	  
play	  a	  key	  role	  in	  activating	  and	  perpetuating	  the	  immunological	  response	  in	  RA.	  	  
A	   direct	   functional	   role	   in	   inflammation	   and	   autoantibody	   production	   for	  
synovial	  ELS	  has	  come	  from	  a	  number	  of	  studies	  including	  one	  using	  the	  human	  RA	  




demonstrated	  that	  synovial	  graft	  ELS	  support	  the	  proliferation	  and	  differentiation	  
of	  B	  cells	  as	  well	  as	  the	  expression	  of	  Activation-­‐Induced	  Cytidine	  Deaminase	  (AID),	  
an	  enzyme	  which	  is	  critical	  for	  class	  switch	  recombination	  and	  affinity	  maturation	  
of	   antibodies,	   and	   this	   correlated	   with	   human	   ACPA	   titres	   (IgG)	   within	   serum	  
(Figure	  1.8).	  These	  events	  occurred	  in	  the	  absence	  of	  new	  immune	  cells	  infiltrating	  
the	   grafts	   (SCID	   are	   in	   fact	   immune	   deficient)	   indicating	   that	   ELS	   contribute	   to	  


































Figure	   1.8	   :	   Expression	   of	   Activation-­‐Induced	   Cytidine	   Deaminase	   (AID)	   enzyme,	  
which	   is	   critical	   for	   the	   processes	   of	   class	   switch	   recombination	   and	   affinity	  
maturation	  of	   antibodies,	   identifies	   large	  B	   cells	   aggregates	  within	   the	   rheumatoid	  
synovium	  	  
(A)	   Paraffin-­‐embedded	   sections	   from	   RA	   patients	   were	   stained	   for	   AID	  
(203magnification).	   AID+	   cells	   (arrows)	   were	   frequently	   and	   exclusively	   seen	   in	   RA	  
synovial	  tissue	  characterised	  by	  the	  presence	  of	  large	  aggregates.	  
(B)	   Paraffin	   sections	   were	   double	   stained	   for	   AID	   (brown)	   and	   CD3	   (red)	  
(603magnification),	  demonstrating	  the	  close	  relationship	  between	  AID+	  cells	   (arrows)	  
and	  T	  cells	  in	  the	  peripheral	  T	  cell	  areas	  of	  the	  lymphoid	  aggregates.	  
(C)	   Merged	   double	   staining	   for	   AID	   (red)	   and	   CD20	   (green)	   on	   frozen	   RA	   sections	  
confirmed	   that	  AID+	   cells	  were	   of	   B	   cell	   origin	   (double-­‐stained	   cells	   are	   identified	   in	  
yellow).	  
(D)	  Higher	  magnification	  of	  an	  example	  of	  an	  AID/CD20	  cell	  (603	  magnification	  of	  [C]).	  
(E	  and	  F)	  Scattered	  AID	  cells	  (E)	  with	  the	  appearance	  of	  interfollicular	  B	  cells	  (F)	  were	  
occasionally	  found	  away	  from	  the	  central	  focus	  of	  the	  aggregate.	  	  
Scale	  bars:	  200	  lm	  (A,	  C,	  E),	  50	  lm	  (B,	  F),	  15	  lm	  (D).	  	  
Abbreviations:	   AID=	   Activation-­‐Induced	   Cytidine	   Deaminase	   enzyme;	   CD3=	   T	   cells,	  
CD20=	  B	  cells;	  RA=	  rheumatoid	  arthritis.	  





Nonetheless,	   lymphoid	   aggregates	   are	   also	   found	   in	   seronegative	   types	   of	  
arthritis	   such	   as	   spondyloarthritis	   and	   PsA.	   Canete	  et	   al	   analysed	   27	   knee	  
arthroscopic	  samples	  from	  PsA	  patients	  specifically	  looking	  for	  T/B	  cell	  aggregates	  
and	  expression	  of	  chemokines	  associated	  to	  lymphoid	  neogenesis	  like	  CXCL13	  and	  
CCL21:	  they	  found	  that	  up	  to	  25	  of	  27	  synovia	  contained	  aggregates,	  of	  which	  up	  
to	  60%	  were	  large	  size	  aggregates.	  326	  	  
The	  presence	  of	  lymphoid	  aggregates	  in	  the	  synovium	  has	  been	  associated	  with	  
higher	   levels	  of	  pro-­‐inflammatory	  mediators	   involved	   in	   the	  pathogenesis	  of	  RA,	  
supporting	   a	   direct	   functional	   role	   for	   autoantibody	   and	   pro-­‐inflammatory	  
mediators	  production	  by	  such	  structures.	  Yanni	  et	  al	  reported	  significantly	  higher	  
levels	   of	   IL-­‐1,	   IL-­‐6,	   and	   IL-­‐2	   in	   synovial	   tissue	   with	   lymphoid	   aggregates	   when	  
compared	   to	   tissue	   with	   a	   diffuse	   infiltrate,	   suggesting	   that	   the	   presence	   of	  
ectopic	  lymphoid	  tissue	  could	  reflect	  a	  more	  aggressive	  disease	  process.	  327	  In	  line	  
with	  these	  findings,	  Klimiuk	  et	  al	  demonstrated	  the	  existence	  of	  a	  unique	  cytokine	  
profile	  in	  different	  variants	  of	  synovitis,	  with	  typically	  lower	  expression	  of	  IFNγ,	  IL-­‐
4,	   IL-­‐1	   and	   TNFα	   in	   diffuse	   synovitis.	   308	   Thurlings	   et	   al	   also	   observed	   a	   higher	  
expression	  of	  TNFα	  producing	  cells	  in	  the	  sublining	  of	  aggregates-­‐reach	  synovium,	  
along	  with	  increased	  levels	  of	  serum	  biomarkers	  of	  systemic	  inflammation.	  323	  
Finally,	   a	   direct	   contribution	   of	   synovial	   lymphoid	   aggregates	   to	   radiographic	  
progression	   has	   been	   hypothesised.	   Kotake	   et	   al	   detected	   higher	   expression	   of	  
RANKL	   from	   activated	   T	   cells	   within	   synovial	   aggregates,	   suggesting	   a	   possible	  
direct	  role	  in	  the	  induction	  of	  local	  osteoclastogenesis	  and	  bone	  destruction.	  328 In	  
keeping	   with	   these	   observations,	   Klimiuk	   et	   al	   reported	   a	   more	   advanced	  




no	  aggregates	  by	  analysing	  end-­‐stage	  joint	  replacement	  tissue	  samples.	  329 These	  
findings	   were	   not	   confirmed	   by	   two	   subsequent	   studies.	   323,330	   Most	   of	   these	  
observations	   derive	   from	   studies	   conducted	   in	   heterogeneous	   cohorts	   of	   long-­‐
standing/end-­‐stage	  disease,	  with	  a	  significant	  number	  of	  confounding	  factors.	  	  
	  
1.8.6	  	  	  Sensitivity	  to	  change	  of	  the	  synovium	  after	  therapeutic	  intervention	  
Finally,	  an	   important	  question	   is	  whether	  effective	   treatment	  of	  RA	   is	  able	   to	  
induce	  changes	  in	  the	  synovium	  in	  parallel	  with	  changes	  observed	  clinically.	  	  
The	   evaluation	   of	   serial	   synovial	   biopsies	   has	   demonstrated	   that	   successful	  
treatment	   of	   RA	   is	   effectively	   associated	   with	   ability	   to	   modulate	   synovial	  
inflammation,	   as	   assessed	   by	   decrease	   of	   cellular	   infiltrate	   and	   expression	   of	  
cytokines,	   chemokines	   and	   adhesion	   molecules.	   331	   In	   particular,	   a	   number	   of	  
studies	   have	   suggested	   that	   clinical	   response	   to	   treatment	   correlates	   with	   a	  
significant	  decrease	  in	  the	  number	  of	  synovial	  sublining	  macrophages	  (CD68sl).	  As	  
such	   CD68sl	   has	   been	   recommended	   as	   a	   valid	   biomarker	   of	   response	   to	  
treatment	   in	   clinical	   trials.	  A	   study	   from	  Haringman	  and	  colleagues	   collecting	  88	  
patients	   with	   established	   RA,	   showed	   that	   the	   mean	   change	   in	   disease	   activity	  
correlated	   well	   with	   the	   mean	   change	   in	   the	   number	   of	   CD68sl,	   and	   this	   was	  
independent	  of	  the	  therapeutic	  strategy.	  64	  This	  observation	  was	  consistent	  across	  
centres	  332,	  suggesting	  a	  realistic	  potential	  for	  synovial	  tissue	  analysis	  as	  a	  tool	  to	  
evaluate	   efficacy	   of	   anti-­‐rheumatic	   treatment.	   There	   is	   however	   limited	   data	  
examining	  synovial	  CD68sl	  response	  in	  treatment	  naïve	  early	  arthritis	  patients.	  	  
Given	  the	  growing	  evidence	  that	  ELS	  are	  functional	  and	  potentially	  involved	  in	  




treatment	  to	  disrupt/revert	  these	  structures.	  A	  study	  from	  Canete	  and	  colleagues	  
looked	  at	  24	  paired	  synovial	  biopsies	  performed	  prior	  and	  after	  TNFα	  inhibitors:	  of	  
the	   16	   patients	   who	   presented	   with	   lymphoid	   neogenesis	   in	   the	   first	   biopsy,	   7	  
remained	  stable	  meanwhile	  9	  turned	  into	  a	  lymphoid	  neogenesis	  negative	  status,	  
and	   this	   change	   correlated	   with	   clinical	   response.	   330	   Similarly,	   Klaasen	   and	  
colleagues	  observed	  a	  reduction	  in	  the	  number	  and	  size	  of	  lymphocyte	  aggregates	  
following	   effective	   anti-­‐TNFα	   therapy,	   although	   this	   did	   not	   reach	   statistic	  
significance	  possibly	  due	  to	  the	  small	  sample	  size.	  324	  	  
It	  has	  been	  observed	   that	   treatment	  with	  anti-­‐CD20	  depleting	  agents	   such	  as	  
Rituximab	   induces	   not	   only	   a	   decrease	   in	   synovial	   B-­‐cell	   density,	   but	   also	   a	  
disruption	  of	  the	  lymphoid	  architecture	  and	  a	  reduction	  of	  cytokine	  expression,	  T	  
cells,	  plasma	  cells,	  FCD	  and	  subintimal	  macrophages.	  These	  observations	  support	  a	  
direct	   homeostatic	   role	   for	   B	   cells	   in	   induction	   and	   maintenance	   of	   synovial	  
aggregates,	   and	   provide	   evidence	   that	   B	   lymphocytes	   play	   an	   active	   role	   in	  
orchestrating	  the	  synovial	  inflammatory	  network	  in	  situ.	  333,334	  
The	   ability	   to	   modulate	   the	   inflamed	   synovium	   does	   not	   seem	   to	   be	   drug-­‐
specific	   but	   has	   been	   observed	   in	   several	   studies	   comparing	   pre-­‐	   and	   post-­‐	  
treatment	   biopsy	   series	   following	   different	   therapeutic	   strategies	   including	  
Rituximab	   335,	   Tocilizumab336	   and	  Abatacept337.	   Conversely,	   the	   analysis	   of	   serial	  
synovial	   samples	   from	   RA	   patients	   who	   received	   either	   placebo	   or	   ineffective	  





1.9	  	  	  FROM	  DIAGNOSTIC	  TO	  PROGNOSTIC	  CATEGORIES:	  RE-­‐THINKING	  
THE	   DIAGNOSIS	   AND	   THE	   CLASSIFICATION	   OF	   RHEUMATOID	  
ARTHRITIS	  
At	   the	   time	   of	   first	   presentation	   to	   the	   EAC,	   about	   30%	   of	   patients	   with	  
inflammatory	  arthritis	  cannot	  be	  categorized	  into	  a	  definite	  diagnostic	  group	  and	  
are	  labelled	  as	  undifferentiated	  arthritis	  (UA).	  201	  	  
From	  the	  analysis	  of	  early	  arthritis	  registers,	  including	  the	  Leiden	  Early	  Arthritis	  
Clinic	   in	   the	   Netherlands	   and	   the	   Norfolk	   Arthritis	   Register	   in	   the	   UK,	   it	   has	  
emerged	  that	  up	  to	  40-­‐50%	  of	  UA	  patients	  have	  a	  self-­‐limiting	  course	  that	  usually	  
resolves	   within	   a	   few	   weeks	   or	   months;	   about	   one	   third	   will	   evolve	   toward	  
persistent	  inflammatory	  arthritis	   including	  RA	  or	  PsA;	  and	  the	  remaining	  will	  stay	  
undifferentiated	  or	  develop	  other	  rheumatologic	  conditions.	  339-­‐341	  	  
Unfortunately,	   the	   benign/self-­‐limiting	   forms	   of	   UA	   cannot	   easily	   be	  
distinguished	  from	  the	  ones	  that	  will	  progress	  toward	  chronic/erosive	  arthritis	  just	  
as	  those	  patients	  originally	  identified	  as	  having	  RA.	  This	  means	  that	  some	  patients	  
with	  an	  early	   inflammatory	  arthritis	  may	  not	  be	   identified	  and	  treated	  promptly;	  
the	   opposite	   scenario	   would	   be	   over-­‐estimating	   mild,	   self	   remitting	   forms	   of	  
arthritis,	   resulting	   in	   over-­‐treatment	   and	   exposure	   to	   risk	   of	   drug	   toxicity	  
unnecessarily.	  	  
It	   is	   thus	   important	   to	   determine	   clinical,	   serological	   and	   histopathological	  
markers	  of	  persistent	  disease	  and	  joint	  damage	  to	  allow	  the	  identification	  of	  those	  
patients	   in	   need	   of	   prompt	   aggressive	   treatment.	   Future	   challenge	   in	  




arthritis	   according	   to	   severity/prognostic	   categories	   rather	   than	  
diagnostic/classification	   criteria,	   in	   order	   to	   tailor	   treatment	   strategies	   at	   the	  
individual	  level.	  
	  
1.9.1	  	  	  Prediction	  models	  for	  the	  diagnosis	  of	  rheumatoid	  arthritis	  
Currently,	   the	  strongest	   independent	  predictor	  of	  disease	  progression	   in	  early	  
inflammatory	  arthritis	  is	  the	  presence	  of	  ACPA	  antibodies.	  99	  However,	  there	  is	  no	  
single	  predictor	  showing	  sufficient	  discriminative	  power,	  with	  data	  demonstrating	  
that	   the	   combination	   of	  more	   than	   one	   factor	   is	   the	   key	   to	   improve	   prognostic	  
value.	  	  
The	   first	   prediction	   model	   for	   RA	   was	   originally	   proposed	   by	   Visser	   and	  
colleagues	  in	  2002.	  95	  This	  model	  was	  derived	  from	  a	  cohort	  of	  524	  patients	  who	  
attended	   the	   Leiden	   Early	   Arthritis	   Clinic,	   and	   consisted	   of	   seven	   variables:	  
symptoms	  duration,	  morning	  stiffness	  for	  at	  least	  one	  hour,	  arthritis	  in	  3	  or	  more	  
joints,	   bilateral	   compression	   pain	   in	   the	   MTP	   joints,	   seropositivity	   for	   RF,	  
seropositivity	   for	   ACPA,	   and	   presence	   of	   erosions	   in	   hands	   or	   feet.	   It	   showed	  
excellent	  ability	  to	  discriminate	  between	  self-­‐	  limiting,	  persistent	  non-­‐erosive	  and	  
persistent	  erosive	  arthritis	  at	   two	  years	   follow-­‐up:	   the	  ROC	  area	  under	  curve	   for	  
discrimination	   between	   self-­‐limiting	   and	   persistent	   arthritis	   was	   0.84	   and	   for	  
discrimination	  between	  erosive	  and	  non-­‐erosive	  arthritis	  was	  0.91.	  In	  comparison,	  
the	   discriminative	   power	   of	   the	   1987	  ACR	   classification	   criteria	  was	   significantly	  
lower.	   Notably,	   ACPA	   independently	   and	   significantly	   contributed	   to	   the	  
performance	   of	   the	   model.	   95	   Two	   major	   limitations	   of	   this	   work	   have	   been	  




as	  many	  had	  received	  or	  were	  receiving	  MTX	  or	  other	  csDMARD.	  The	  decision	  to	  
start	  csDMARD	  therapy	  could	  have	  been	  influenced	  by	  the	  same	  clinical	  variables	  
that	  were	   included	   in	   the	  model,	   leading	   to	   circularity.	   Second,	   the	  definition	  of	  
early	  arthritis	   included	  disease	  duration	  up	   to	  2	  years,	  a	   time	   frame	   that	  cannot	  
longer	  be	  accepted	  in	  light	  of	  the	  recent	  concept	  of	  window	  of	  opportunity.	  
A	   subsequent	   prediction	   rule	   was	   developed	   by	   van	   der	   helm-­‐van	  Mil’s	   and	  
colleagues,	  96	  which	  was	  again	  derived	  from	  the	  Leiden	  cohort	  in	  the	  Netherlands.	  
This	  model	  aimed	  to	  determine	  the	  likelihood	  of	  a	  patient	  with	  early	  inflammatory	  
arthritis	   fulfilling	  1987	  criteria	   for	  RA	  within	   the	   first	  year	   from	  symptoms	  onset.	  
The	   tool	   consists	   of	   nine	   variables:	   age,	   gender,	   distribution	   of	   involved	   joints,	  
severity	  of	  morning	  stiffness,	  number	  of	   tender	   joints,	  number	  of	   swollen	   joints,	  
CRP,	   seropositivity	   for	   RF	   and	   ACPA.	   In	   the	   derivation	   cohort,	   patients	   with	   ≤6	  
points	  had	  an	  absolute	  chance	  of	  not	  developing	  RA	  of	  91%,	  meanwhile	  patients	  
with	  ≥8	  points	  had	  a	  84%	  chance	  of	  progressing	  toward	  RA.	  Some	  criticism	  related	  
to	   methodological	   aspects	   of	   this	   model	   has	   been	   raised	   too.	   Firstly,	  
approximately	  20%	  of	  patients’	  scores	  fall	  between	  the	  cut-­‐off	  values	  of	  6	  and	  8,	  
so	  they	  cannot	  be	  classified.	  Secondly,	  a	  disadvantage	  of	  using	  positive	  predictive	  
value	   (PPV)	   and	   negative	   predictive	   values	   (NPV)	   is	   that	   these	   measures	   are	  
dependent	  on	  the	  disease	  prevalence	  that	  may	  vary	  across	  populations	  -­‐the	  higher	  
the	  incidence	  of	  RA,	  the	  higher	  the	  PPV	  and	  the	  lower	  the	  NPV.	  Nonetheless,	  the	  
diagnostic	   accuracy	   of	   the	   prediction	   rule	   was	   preserved	   in	   validation	   studies	  
performed	  across	  different	  cohorts.	  340	  Finally,	  as	  3	  of	  the	  9	  criteria	  that	  form	  the	  
prognostic	   algorithm	   are	   also	   part	   of	   the	   ACR	   1987	   criteria,	   Visser	   disputed	   the	  




suggesting	  this	  may	  have	  led	  to	   incorporation	  bias	  and	  circularity.	  He	  stated	  that	  
using	  a	  clinical	  outcome	  (such	  us	  persistence	  of	  arthritis)	  rather	  than	  fulfilment	  of	  
set	   criteria	   could	   have	   been	  more	   appropriate.	   342	   The	   authors	   replied	   that,	   as	  
there	  is	  not	  clear-­‐cut	  definition	  for	  ‘persistence	  of	  disease’,	  they	  preferred	  to	  avoid	  
such	  an	  indefinite	  outcome	  measure	  and	  rather	  use	  a	  validated	  one.	  
Since	   synovial	   inflammation	   is	   the	   pathological	   hallmark	   of	   arthritis,	   some	  
studies	  have	  aimed	  at	  exploring	  if	  the	  characteristics	  of	  the	  synovial	  tissue	  may	  be	  
able	   to	   facilitate	  a	  clinical	  diagnosis	  of	  RA	   in	  patients	  with	  new	  onset	  of	  arthritic	  
symptoms.	   van	   de	   Sande	   et	   al	   analysed	   69	   arthroscopic	   biopsy	   samples	   that	  
revealed	   no	   clear-­‐cut	   differences	   in	   the	   features	   of	   the	   synovium	   between	   RA	  
patients	   initially	  diagnosed	  as	  UA	  and	  subsequently	  re-­‐classified	  as	  RA	  and	  those	  
who	  originally	   fulfilled	   classification	   criteria	   for	   RA.	   343	   A	   further	   study	   analysing	  
arthroscopic	   biopsy	   samples	   from	   93	   early	   arthritis	   csDMARD	   naïve	   patients,	  
revealed	  no	  relationship	  between	  the	  presence	  of	  aggregates	  at	  baseline	  and	  the	  
fulfilment	   of	   a	   definitive	   diagnosis	   after	   2	   years	   follow-­‐up.	   In	   particular,	   the	  
presence	   of	   large	   aggregates	   at	   baseline	  was	   observed	   in	   about	   one-­‐third	   of	   all	  
diagnostic	   subgroups,	   with	   no	   clear-­‐cut	   differences	   between	   patients	   with	   self-­‐
limiting	   disease	   and	   those	  who	   developed	   persistent	   disease.	   314	   Conversely,	   an	  
analysis	   of	   synovial	   biopsies	   from	   95	   patients	   with	   early	   inflammatory	   arthritis	  
conducted	   by	   Kraan	   et	   al	   revealed	   that	   higher	   scores	   for	   plasma	   cells,	  
macrophages	  and	  CD22+	  B	  cells	  were	  sensitive	  markers	   to	  differentiate	  RA	   from	  





1.9.2	  	  	  Prediction	  models	  for	  the	  prognosis	  of	  rheumatoid	  arthritis	  
The	   clinical	   spectrum	  of	   RA	   ranges	   from	  a	  mild,	   non-­‐erosive	   to	   an	   aggressive	  
phenotype	  resulting	  in	  rapid	  joint	  destruction.	  Indeed,	  rather	  than	  a	  single	  disease,	  
RA	  could	  be	  defined	  as	  a	  clinical	  syndrome	  encompassing	  several	  disease	  subsets.	  
Predicting	  the	  outcome	  of	  RA	  at	  a	  group	  or	  even	  individual	  level	  would	  be	  most	  
relevant	  for	  therapeutic	  decision-­‐making,	  and	  especially	  identifying	  those	  patients	  
at	  risk	  of	  radiographic	  progression	  and	  poor	  response	  to	  treatment.	  345	  	  
A	   number	   of	   factors	   including	   presence	   of	   RF	   and	   ACPA,	   disease	   duration,	  
impaired	  functional	  status,	  presence	  of	  radiographic	  erosions,	  smoking	  status	  and	  
high	  inflammatory	  markers	  are	  associated	  with	  a	  more	  severe	  clinical	  course	  and	  
worst	  outcome.	  ACPA,	  in	  particular,	  have	  recently	  consolidated	  their	  role	  as	  strong	  
predictors	  of	  radiographic	  progression.	  207,346-­‐350	  However,	  the	  prediction	  accuracy	  
of	   each	   individual	   factor	   is	   low	   and	   a	   number	   of	   prediction	   models	   embracing	  
multiple	   parameters	   have	   been	   developed,	   with	   data	   demonstrating	   that	  
combining	  factors	  improves	  predictive	  power.	  For	  example,	  a	  model	  incorporating	  
anti-­‐CCP,	   IgM	  RF,	   female	   gender	   and	   ESR,	  was	   reported	   to	   have	   an	   accuracy	   of	  
73.6%	  to	  predict	   radiographic	  progression,	  with	  ACPA	  representing	  the	  strongest	  
contributor	  to	  the	  prediction	  rule.	   In	  addition,	  this	  work	  showed	  that	  the	  titre	  of	  
ACPA	  adds	  prognostic	  information,	  as	  patients	  with	  higher	  level	  of	  antibodies	  were	  
more	   prone	   to	   develop	   erosions	   compared	   to	   patients	   with	   low	   or	   moderate	  
levels.	   351	   A	   recent	   report	   has	   shown	   that	   two	   preliminary	   visual	  matrix	  models	  
including	   28	   swollen	   joint	   count,	   RF	   seropositivity	   and	   CRP	   or	   ESR	  were	   able	   to	  




Several	  studies	  have	  looked	  specifically	  at	  prognostic	  markers	  of	  erosive	  disease	  	  
in	   early	   RA,	   providing	   cumulative	   evidence	   for	   the	   role	   of	   autoantibodies,	   and	  
particularly	  ACPA,	  as	  predictors	  of	  radiographic	  changes	  in	  the	  long-­‐term.	  353-­‐356	  A	  
study	   from	   Sanmarti	   et	   al	   showed	   that	   the	   presence	   of	   ACPA	   was	   the	   most	  
important	   contributor	   to	   a	   multivariate	   model	   for	   radiological	   progression	   in	   a	  
cohort	  of	  early	  RA	  patients	  treated	  with	  csDMARD	  and	   low	  doses	  of	  steroids.	   357	  
Machold	  and	  colleagues	  observed	  that,	  in	  an	  inception	  cohort	  of	  55	  patients	  with	  
very	   early	   RA	   (≤3	   months	   onset),	   erosions	   appeared	   over	   3	   years	   in	   63%	   of	  
patients	  despite	  early	  treatment,	  with	  a	  vast	  majority	  already	  within	  the	  first	  year	  
(74%)	  and	  seropositivity	  for	  either	  RF	  or	  ACPA	  contributed	  to	  explain	  radiographic	  
progression.	  358	  
	  
1.9.3	  	  	  Contribute	  of	  imaging	  to	  a	  prognostic	  model	  for	  rheumatoid	  arthritis	  
The	  presence	  of	  erosions	  on	  plain	  radiographs	  of	  hands	  and	  feet	  at	  baseline	  is	  a	  
strong	   predictor	   of	   further	   deterioration.	   347	   However	   this	   is	   not	   particularly	  
helpful	  in	  early	  RA,	  as	  the	  presence	  of	  erosive	  changes	  indicates	  failure	  to	  identify	  
patients	   during	   the	   window	   of	   opportunity	   period,	   when	   the	   prevention	   of	  
structural	  damage	  should	  be	  a	  realistic	  target.	  Therefore,	  efforts	  have	  been	  made	  
to	   focus	  on	   imaging	   techniques	   that	  are	  able	   to	  provide	  valuable	  diagnostic	   and	  
prognostic	   information	   at	   early	   stage.	  MRI	   and	  US	   have	   both	   shown	   superiority	  
compared	   to	   plain	   XR	   in	   the	   early	   diagnosis	   of	   RA	   and	   monitoring	   of	   its	  
progression.	  	  
MRI	   has	   demonstrated	   to	   be	   able	   to	   identify	   bone	   erosions	   359	   as	   well	   as	  




by	  Navalho	  et	  al,	   showed	   that	  MRI-­‐detected	   synovitis	  of	   carpal	   joints	   and	   flexor	  
tendons	   was	   the	   most	   powerful	   predictor	   of	   progression	   toward	   RA	   in	   a	  
population	   with	   recent-­‐onset	   polyarthritis.	   361	   Machado	   et	   al	   reported	   that	  
MRI	  bone	   oedema	   along	   with	   combined	  MRI	   synovitis	   and	   erosive	   pattern	   was	  
helpful	  to	  predict	  progression	  of	  UA	  toward	  persistent	  RA,	  meanwhile	  the	  absence	  
of	  MRI	  synovitis	  was	  useful	  in	  excluding	  development	  of	  RA.	  362	  Duer-­‐Jensen	  et	  al	  
confirmed	   these	   findings.	   363	  Hetland	  et	  al	   reported	   that	  MRI	  bone	  oedema	  was	  
the	  strongest	  predictor	  of	  subsequent	  radiographic	  progression	  in	  early	  RA.	  364	  	  
Compared	  to	  MRI,	  US	  has	  the	  advantage	  of	  being	  cheaper,	  reproducible,	  with	  
virtually	   no	   contraindication	   and,	   of	   most	   importance,	   can	   be	   performed	   and	  
interpreted	   by	   rheumatologists	   in	   a	   standard	   clinic	   setting,	   allowing	   real	   time	  
clinical	  decisions	  guidance.	  
Ultrasonography	  has	  proved	  to	  be	  a	  powerful	  tool	  to	  estimate	  the	  presence	  and	  
the	   extent	   of	   inflammation	   within	   the	   synovium	   365,366	   US	   imaging	   of	   synovial	  
joints	   provides	   an	   objective	   assessment	   of	   synovial	   hypertrophy	   -­‐referred	   to	   as	  
synovial	   thickening	   ultrasound	   (STUS),	   and	   vascular	   flow	   within	   the	   synovium	   -­‐
referred	  to	  as	  power	  doppler	  ultrasound	  (PDUS).	  PDUS,	  in	  particular,	  has	  attracted	  
increasing	  attention	  in	  research	  and	  clinical	  practice,	  as	  it	  has	  been	  demonstrated	  
to	   correlate	   well	   with	   inflammatory	   markers,	   disease	   activity	   and	   outcome.	   367	  
Furthermore	   it	   is	   acknowledged	   that	   neo-­‐angiogenesis	   and	   hypervascularity	  
represent	  early,	   critical	   aspects	   to	   synovial	   inflammation	  and	   structural	  damage.	  
368	  Neo-­‐angiogenesis	  is	  defined	  as	  the	  development	  of	  new	  blood	  vessels	  from	  the	  




such	  as	  VEGF	  and	  pro-­‐inflammatory	  cytokines,	  such	  as	  TNFα,	  IL-­‐1	  and	  IL-­‐6,	  which	  
have	  a	  direct	  influence	  on	  neo-­‐angiogenesis	  via	  VEGF-­‐dependent	  pathways.	  	  
PDUS	   shows	   important	   prognostic	   implications.	   Naredo	   et	   al	   reported	   that	  
PDUS-­‐detected	   synovitis	   in	   early	   RA	   is	   predictive	   of	   disease	   activity	   and	  
radiological	   progression.	   367	   A	  milestone	   study	   by	   Brown	   at	   al	   showed	   that	   the	  
persistence	  of	  PDUS	  signal	   in	  asymptomatic	  MCP	   joints	  was	  predictive	  of	  12	  fold	  
higher	  risk	  of	  future	  joint	  damage	  in	  RA	  patients	  who	  were	  in	  clinical	  remission.	  226	  
Other	  studies	  have	  demonstrated	  the	  ability	  of	  persistent	  PDUS	  signal	   to	  predict	  
short-­‐term	   relapse	   in	   patients	   who	   fulfilled	   clinical	   remission	   criteria	   369,	  
reinforcing	  the	  concept	  of	   imaging	  remission	  beyond	  the	  classic	  notion	  of	  clinical	  
remission.	  	  Notably,	  Seymour	  at	  al	  reported	  that	  US	  of	  the	  MCP	  joints	  is	  a	  sensitive	  
and	  reliable	  indicator	  of	  response	  to	  therapy	  in	  early	  RA.	  370	  	  
The	   incorporation	   of	   US	   within	   current	   prognostic	   models	   seems	   to	   provide	  
additional	  predictive	  value.	  Freeston	  et	  al	  demonstrated	  the	  diagnostic	  benefit	  of	  
adding	  ultrasonographic	  examination	  of	  the	  MCP	  joints,	  wrists	  and	  flexor	  tendons	  
to	  conventional	  clinical	  tools	  (antibody	  status,	  ESR/CRP,	  radiographic	  damage)	  for	  
the	   diagnosis	   of	   very	   early	   inflammatory	   arthritis.	   The	   predictive	   algorithm	  
appeared	   particularly	   helpful	   in	   seronegative	   patients,	   with	   a	   probability	   of	  
diagnosis	   increasing	   from	   30%	   to	   94%.	   	   371	   A	   recent	   study	   by	   Filer	   et	   al	   on	   58	  
patients	  with	  very	  early	  arthritis	   (<	  3	  months),	   showed	   that	   the	   incorporation	  of	  
grey	  scale	  and	  power	  Doppler	  assessment	  of	  the	  MCP,	  wrist	  and	  MTP	   joints	   into	  
the	  van	  der	  Helm	  prediction	  rule	  resulted	  in	  an	  increase	  of	  the	  predictive	  value	  of	  




However	  several	  issues	  regarding	  the	  methodology	  of	  US	  assessment	  remain	  to	  
be	  addressed,	  such	  as	  the	  scoring	  method	  to	  be	  utilized	  and	  the	  minimum	  number	  
of	   joints	   to	   be	   included	   in	   the	   US	   examination.	   In	   theory,	   including	   the	   highest	  
number	  of	  joints	  should	  provide	  the	  most	  faithful	  picture	  of	  the	  overall	  synovitis;	  
however,	   if	  multiple	   joints	  need	   to	  be	  scanned	  repeatedly,	   the	  procedure	  would	  
result	   time	   consuming	   and	   unfeasible	   for	   use	   in	   daily	   practice.	   Therefore,	   a	  
reduced	   number	   of	   target	   joints	   should	   be	   ideally	   selected,	   or	   at	   least	   the	  
minimum	  possible	  number	  of	  joints	  allowing	  to	  get	  exhaustive	  information	  and	  at	  
the	   same	   time	   making	   the	   US	   assessment	   a	   practical	   tool	   in	   real	   life	   settings.	  
Despite	   significant	   efforts	   undertaken	   over	   the	   past	   few	   years	   at	   the	  OMERACT	  
level,	  a	  final	  validation	  has	  not	  been	  achieved	  yet.	  373	  Naredo	  et	  al	  proposed	  a	  4-­‐
point	   semi-­‐quantitative	   PDUS	   imaging	   of	   28	   joints,	   named	   the	   ‘overall	   US	   joint	  
index	   for	   power	   Doppler	   signal’.	   367	   Subsequently	   the	   same	   group	   proposed	   a	  
simplified	  12	   joint	   set	   (elbows,	  wrists,	   2nd	   and	  3rd	  MCP	   joints,	   knees	  and	  ankles)	  
showing	  an	  excellent	   correlation	  with	  a	  more	  extended	  60-­‐joint	   score	  as	  well	   as	  
with	  clinical	  and	  laboratory	  parameters.	  374	  Backhaus	  et	  al	  developed	  a	  composite	  
US	  score	  evaluating	  7	  joint	  regions	  (wrists,	  2nd	  and	  3rd	  MCP	  and	  PIP	  joints,	  2nd	  and	  
5th	  MTP	  joints)	  named	  the	  ‘German	  US7	  score’.	  375	  In	  another	  study	  Seymour	  et	  al	  
have	  shown	  the	  reproducibility	  and	  the	  capability	  to	  reflect	  synovial	  inflammation	  
and	   detect	   short-­‐term	   post-­‐treatment	   changes	   of	   a	   10	   joint	   set	   including	   1st-­‐5th	  
MCPs	   bilaterally.	   370	   Overlooking	   the	   literature,	   the	   number	   of	   joints	   assessed	  
ranged	  from	  5	  to	  44	  across	  studies,	  with	  the	  wrist	  and	  MCP	  joints	  of	  the	  dominant	  





1.9.4	  	  	  The	  synovial	  biopsy	  as	  a	  potential	  prognostic	  tool	  
RA	   is	   characterised,	   as	   well	   as	   by	   clinical	   variability,	   by	   a	   high	   degree	   of	  
biological	   heterogeneity	   at	   the	   tissue	   level.	   Whether	   distinct	   synovial	   features	  
translate	  into	  specific	  clinical	  phenotypes	  and	  predict	  diverse	  clinical	  outcomes	  is	  
still	  largely	  unknown.	  	  
So	   far,	   a	   limited	   number	   of	   studies	   have	   evaluated	   the	   potential	   impact	   of	  
synovial	  lymphocytic	  aggregates	  on	  predicting	  prognosis	  in	  inflammatory	  arthritis,	  
and	   the	  majority	  of	   them	  have	  been	  performed	   in	  patients	  with	  established	  RA.	  
Relatively	   few	   studies	   were	   performed	   in	   patients	   captured	   at	   an	   early	   phase.	  
Also,	  the	  interpretation	  of	  the	  existing	  data	  is	  complicated	  by	  a	  number	  of	  issues.	  
Firstly	  no	  specific	  criteria	  are	  consistently	  used	  between	  studies	  to	  define	  synovial	  
aggregates	  histologically	  and	  as	  such	  the	  definition	  of	  ELS	  has	  been	  variously	  used	  
to	   refer	   to	   aggregates	   of	   differing	   size	   and/or	   expressing	   different	   specific	  
immunological	  cells	  (e.g.	  FDC,	  T	  cells,	  B	  cells).	  Further	  comparing	  data	  from	  cross	  
sectional	   studies	   including	   patients	   with	   varying	   a)	   disease	   duration,	   b)	  
radiographic	   damage	   and	   c)	   treatment	   exposure	   has	   inherent	   methodological	  
discrepancies.	  Finally,	  excessive	  prevalence	  of	  synovial	  tissue	  from	  the	  knee,	  as	  is	  
the	   case	  with	   a	   number	   of	   studies,	  may	   introduce	   systematic	   bias,	   by	   including	  
those	   patients	   with	   the	   most	   aggressive	   disease.	   288	   Therefore,	   this	   concept	  
requires	   further	   examination	   in	   a	   large	   scale	   prospective	   study	   of	   early	   arthritis	  
patients	  naïve	  to	  therapy.	  	  
A	  key	  question	  to	  address	  is	  the	  utility	  of	  pathobiology	  in	  informing	  therapeutic	  
intervention/response.	   This	   is	   particularly	   relevant	   for	   bDMARD	   which,	   despite	  




range	  of	  inter-­‐individual	  variability	  in	  the	  response.	  In	  particular,	  TNFα	  antagonists	  
are	  the	  most	  widely	  used	  bDMARD	  and	  have	  been	  in	  routine	  use	  for	  the	  longest.	  
TNFα	   is	   an	   important	  mediator	   of	   the	   induction	   and	  maintenance	   of	   secondary	  
lymphoid	  organs	   377,378,	   so	   the	  capacity	   for	  modulation	  of	  synovial	  aggregates	  by	  
TNFα	  inhibitors	  has	  the	  potential	  to	  dissect	  the	  pathophysiology	  of	  the	  disease	  as	  
well	   as	   identification	   of	   biomarkers.	   Recent	   studies	   have	   produced	   somewhat	  
conflicting	   results.	   	   A	   first	   study	   from	   Canete	   et	   al	   investigated	   the	   relationship	  
between	  response	  to	  anti-­‐rheumatic	  treatment	  including	  TNFα	  inhibitors	  and	  the	  
identification	   of	   large	   B	   cell	   aggregates	   on	   pre-­‐treatment	   arthroscopic	   synovial	  
biopsy	   in	  86	  patients:	   data	   suggested	   that	   synovial	   lymphoid	  neogenesis	  was	  an	  
independent	  negative	  predictor	  of	  response	  to	  therapy,	  and	  response	  to	  anti-­‐TNFα	  
treatment	   was	   associated	   with	   the	   regression	   of	   lymphocytic	   aggregates.	   330	  
However,	   a	   subsequent	   report	   from	   Klaasen	   in	   which	   synovial	   biopsies	   were	  
performed	  on	  97	  patients	  prior	   to	  commencing	  treatment	  with	   Infliximab,	   found	  
that	   the	   presence	   of	   lymphocytic	   aggregates	   was	   rather	   a	   positive	   predictor	   of	  
response	  at	  16	  weeks.	   324	  There	  are	  a	  number	  of	   reasons	   for	   such	  discrepancies	  
between	  the	  two	  groups	  including	  patient	  cohorts	  differing	  in	  terms	  of	  past	  drug	  
exposure,	   disease	   duration	   and	   a	   non	   homogeneous	   definition	   of	   synovial	  
aggregates	  used	  within	  each	  study.	  
Another	   study	   identified	   pre-­‐treatment	   levels	   of	   synovial	   TNFα	   as	   a	   positive	  
predictor	   of	   response	   to	   treatment.	   379	   A	   subsequent	   study	   of	   143	   patients	  
supported	   these	   results	   showing	   that	   TNFα	   expression	   within	   the	   synovial	   sub-­‐
lining	  explained	  about	  10%	  of	  the	  variance	  in	  response	  to	  therapy;	  further	  when	  a	  




the	   synovial	   sub-­‐lining	  was	   formulated,	   17%	   of	   variance	   in	   response	   to	   therapy	  
could	  be	  explained.	  	  380	  
Finally,	  previous	  works	  suggested	  an	  association	  between	  the	  number	  of	   sub-­‐
lining	   synovial	   macrophages	   and	   joint	   damage	   in	   RA.	   The	   importance	   of	  
macrophages	   in	   disease	   pathogenesis	   is	   indirectly	   suggested	   by	   the	   beneficial	  
effect	  of	  strategies	  aimed	  at	  targeting	  macrophage-­‐derived	  cytokines	  like	  TNFα,	  IL-­‐
1,	   and	   IL-­‐6.	   As	   previously	   mentioned,	   it	   has	   been	   observed	   that	   sub-­‐lining	  
macrophages	   (CD68sl)	   are	   a	   sensitive	   biomarker	   for	   response	   to	   treatment	   in	  
patients	   with	   RA,	   specifically	   there	   was	   a	   significant	   correlation	   between	   the	  
change	   in	   the	   number	   of	  macrophages	   and	   the	   change	   in	   DAS28.	   64	   The	   results	  
suggest	  that	  synovial	  sublining	  macrophages	  might	  be	  used	  for	  the	  evaluation	  of	  
new	  anti-­‐rheumatic	  treatments.	  381	  
Thus	   although	   at	   present	   we	   remain	   some	   distance	   from	   personalised	  
healthcare,	  these	  studies	  demonstrate	  proof	  of	  concept	  that	  in	  the	  long	  term	  the	  
integration	  of	  synovial	  pathobiology	   into	  clinical	  prediction	  models	  may	  prove	  to	  
be	   a	   useful	   clinical	   tool.	   It	   seems	   likely	   that	   any	   robust	   prediction	  model	   in	   the	  
future	   will	   have	   to	   incorporate	   multiple	   pathobiological	   in	   addition	   to	   clinical,	  
serological	  and	  imaging	  tools.	  
	  
1.10	  	  	  SUMMARY	  AND	  HYPOTHESIS	  
Rheumatoid	   arthritis	   (RA)	   is	   a	   chronic	   autoimmune	   inflammatory	   disease	   of	  
unknown	   origin	   associated	   with	   considerable	   morbidity	   and	   early	   mortality.	   Its	  
clinical	  course	  is	  highly	  variable,	  ranging	  from	  self-­‐limiting	  to	  severe	  disease,	  which	  




Advances	   in	   recent	   years,	   such	   as	  early	   intervention,	   treat	   to	   target	   strategy	  
and	   introduction	  of	  biologic	  drugs	  have	   revolutionised	   the	  natural	  history	  of	   the	  
disease	  and	  improved	  outcome	  and	  quality	  of	  life	  of	  patients.	  1	  However	  treating	  
patients	   with	   RA	   remains	   challenging.	   To	   start	   an	   appropriate	   treatment	   at	   an	  
individual	   level,	   it	   is	   crucial	   to	   stratify	   patients	   into	   accurate	   diagnostic	   and	  
prognostic	  categories.	  Current	  prediction	  models	  have	  limited	  value	  in	  identifying	  
progressive	   disease	   in	   early	   arthritis.	   382	   This	   suggests	   there	   is	   a	   high	   need	   for	  
identification	  of	  new	  biomarkers	  of	  disease	  prognosis	  and	  response	  to	  therapy.	  	  
Importantly,	   as	   well	   as	   clinical	   variability,	   RA	   shows	   high	   biological	  
heterogeneity.	   In	   the	   past	   decades	   there	   has	   been	   increasing	   recognition	   that	  
synovial	   tissue	   is	   the	  primary	   site	  of	   inflammation.	  Nonetheless	   limited	  data	  has	  
evaluated	  synovial	  cellular	  biomarkers	  of	  disease	  prognosis	   including	  response	  to	  
therapy,	  with	  most	  studies	  of	  small	  cohorts	  in	  long	  standing	  disease.	  	  	  
The	  aim	  of	  this	  thesis	  is	  to	  examine	  the	  hypothesis	  that	  distinct	  pathotypes	  can	  
be	  identified	  in	  the	  rheumatoid	  synovium	  at	  both	  an	  early	  and	  longstanding	  stage,	  
which	   associate	   with	   specific	   clinical	   phenotypes	   and	   moreover	   can	   predict	  
response	  to	  therapy.	  	  	  
The	  specific	  aims	  are	  to	  identify	  whether:	  
1.	   in	  an	  early	  RA	  cohort,	  the	  synovial	  pathotype	  significantly	  associates	  with	  a	  
specific	  clinical	  phenotype;	  	  
2.	   in	   an	   early	   RA	   cohort,	   the	   synovial	   pathotype	   predicts	   clinical	   response	   to	  
csDMARD	  treatment;	  
3.	  in	  an	  established	  RA	  cohort,	  the	  synovial	  pathotype	  predicts	  clinical	  response	  



















2.1	  	  	  GENERAL	  PROTOCOLS	  
This	  thesis	  will	  focus	  on	  two	  separate	  cohorts	  of	  patients	  with	  RA:	  an	  early	  RA	  
cohort	   (experimental	   chapters	   3	   and	   4)	   and	   an	   established	   RA	   cohort	  
(experimental	  chapter	  5).	  
The	   first	   cohort	   is	   represented	   by	   63	   consecutive	   patients	   with	   early	   RA	  
(disease	  duration	  <12	  months)	  who	  were	  csDMARD	  and	  corticosteroid	  treatment	  
naïve	   recruited	   at	   Barts	   Health	  National	   Health	   Service	   (NHS)	   Trust	   as	   part	   of	   a	  
multicentric,	  Medical	  Research	  Council	   (MRC)-­‐funded	   study	  named	  Pathobiology	  
of	   Early	  Arthritis	   Cohort	   	   (PEAC),	   http://www.peac-­‐mrc.mds.qmul.ac.uk.	   The	   aim	  
of	   PEAC	   study	   was	   to	   generate	   an	   extensive	   cohort	   of	   patients	   with	   early	  
inflammatory	   arthritis	   with	   linked	   clinical,	   serological,	   radiological	   and	  
pathobiological	   data.	   This	   data	   includes	   gene	   expression	   profiling,	   proteomics,	  
metabonomics,	   serum	   and	   synovial	   fluid	   cytokine	   and	   chemokine	   analysis,	  
radiographic	  and	  ultrasound	  imaging,	  synovial	  tissue	  analysis,	  and	  detailed	  clinical	  
phenotyping.	   	   This	   to	   facilitate	   understanding	   the	   spectrum	   of	   molecular	   and	  
cellular	   pathways	   underlying	   disease	   heterogeneity	   and	   identifying	   potential	  
biomarkers	  of	  disease	  progression	  and	  treatment	  response.	  










Table	  2.1:	  PEAC	  study:	  inclusion/exclusion	  criteria	  














INCLUSION	  CRITERIA	   EXCLUSION	  CRITERIA	  
-­‐ ≥	  18	  and	  years	  of	  age	   -­‐ Biopsy	  contraindicated	  (e.g.	  
patients	  taking	  anticoagulants)	  
-­‐	  	  	  Evidence	  of	  active	  arthritis	  DAS28>2.6	   -­‐ Serious	  underlying	  medical	  
disorders	  (e.g.	  active	  infection,	  
cancer,	  end	  stage	  renal	  or	  hepatic	  
disease)	  
-­‐	  	  	  At	  least	  one	  swollen	  joint	  
	  
	  




The	  study	  received	  local	  ethical	  approval	  (REC	  05/Q0703/198)	  and	  all	  patients	  
gave	  written	  informed	  consent.	  	  
The	  second	  cohort	  includes	  28	  consecutive	  patients	  with	  established	  RA	  (mean	  
disease	   duration	   6.2	   years)	   fulfilling	   2010	   ACR/EULAR	   criteria,	   who	   had	   failed	   a	  
course	   of	   at	   least	   two	   csDMARD,	   of	  which	   one	   represented	   by	  MTX,	  who	  were	  
eligible	   for	   anti-­‐TNFα	   therapy	   according	   to	   NICE	   guidelines	  
[http://www.nice.org.uk/nicemedia/pdf/CG79NICEGuideline.pdf].	   These	   patients	  
were	   part	   of	   a	  monocentric	   observational	   cohort	   of	   a	   study	   conducted	   at	   Barts	  
Health	  NHS	  Trust	  sponsored	  by	  Queen	  Mary	  University	  of	  London	  (QMUL)	  named	  
“Clinical	   responsiveness	   to	   anti-­‐TNFα	   therapy	   and	   modulation	   of	   synovial	  
lymphoid	   structures	   and	   B	   cell	   function	   in	   RA-­‐	   An	   exploratory	   open	   label	  
prospective	  study	  in	  RA	  -­‐(CLIP-­‐Cert)”.	  The	  study	  received	  local	  ethic	  approval	  and	  
written	  informed	  consent	  was	  obtained	  by	  all	  patients.	  
	  
2.2	  	  	  CLINICAL	  ASSESSMENT	  
	  Clinical	  assessment	  included	  the	  following	  parameters:	  smoking	  status;	  disease	  
duration;	   number	   of	   swollen	   joints	   (SJ)	   and	   tender	   joints	   (TJ);	   a	   100-­‐	   cm	   scale	  
Visual	  Analogue	  Score	  for	  Global	  Health	  (VAS-­‐GH)	  assessed	  by	  patient;	  measure	  of	  
disease	   activity	   assessed	   by	   28	   joint	   count-­‐Disease	   Activity	   Score	   (DAS28),	   a	  
universally	  validated	  composite	  measure	  incorporating	  TJ,	  SJ,	  ESR	  and	  VAS-­‐GH	  383.	  
DAS28	  scores	  range	  from	  0	  to	  10	  scale,	  with	  DAS28	  <	  2.6	  representing	  remission,	  	  
≤	  3.2	  low	  disease	  activity,	  <	  3.2	  and	  ≤	  5.1	  moderate	  disease	  activity,	  and	  >	  5.1	  high	  




Response	  to	  treatment	  was	  evaluated	  according	  to	  EULAR	  response	  criteria,	  a	  
fully	   validated	   tool	   based	   on	  DAS28	   changes	   (Table	   2.2).	   385	   Three	   categories	   of	  
response	  were	  inferred:	  good	  response,	  moderate	  response	  and	  no	  response.	  For	  
the	  purpose	  of	  this	  thesis,	  clinical	  response	  was	  defined	  as	  achievement	  of	  either	  
good	   or	   moderate	   EULAR	   response.	   The	   impact	   of	   the	   disease	   on	   physical	  
performance	  was	  evaluated	  by	  using	  the	  Health	  Assessment	  Questionnaire	  (HAQ),	  

















	  	  	  	  	  	  	  	  Table	  2.2:	  The	  EULAR	  response	  criteria	  based	  on	  DAS28	  





































2.	  3	  LABORATORY	  ASSESSMENT	  
Laboratory	   assessment	   included	   routine	   biochemistry	   (full	   blood	   count,	   liver	  
function	  test,	  urea	  and	  electrolytes),	  ESR,	  CRP.	  Presence	  of	  IgM-­‐RF	  determined	  by	  
nephelometry	   (positive	  >	  20	  UI/ml)	  and	  ACPA	  antibodies	  determined	  by	  second-­‐
generation	   enzyme-­‐linked	   immunosorbment	   assay	   (positive	   >	   9	   UI/ml)	   was	  
assessed	   in	   all	   patients	   at	   baseline.	   These	   tests	   were	   performed	   by	   the	   NHS	  
laboratories	  at	  The	  Royal	  London	  Hospital,	  Barts	  and	  The	  London	  Trust.	  
	  
2.4	  	  	  RADIOGRAPHIC	  ASSESSMENT	  
Digital	  antero-­‐posterior	  radiographs	  (XR)	  of	  the	  hands	  and	  feet	  were	  obtained	  
at	  baseline.	  	  
For	   the	   early	   RA	   cohort	   only,	   XR	   were	   repeated	   at	   12	   months	   in	   order	   to	  
evaluate	  radiographic	  progression.	  Anonymised	   images	  were	  scored	  according	  to	  
the	   van	   der	   Heijde	  modified	   Sharp	   score	   (ShSS).	   387	   The	   total	   ShSS	   score	   is	   the	  
result	  of	  the	  sum	  of	  two	  parameters:	  joint	  erosions	  (JE)	  and	  joint	  space	  narrowing	  
(JSN)	  for	  hands	  and	  feet.	  The	  ShSS	  method	  includes,	  in	  each	  hand,	  16	  areas	  for	  JE	  
and	  15	   areas	   for	   JSN,	   and,	   in	   each	   foot,	   6	   areas	   for	   JE	   and	  6	   areas	   for	   JSN.	   The	  
erosion	  score	  per	  joint	  of	  the	  hands	  can	  range	  from	  0	  to	  5.	  The	  erosion	  score	  per	  
joint	  of	  the	  foot	  range	  from	  0	  to	  10.	  The	  Joint	  space	  narrowing	  score	   is	   identical	  
for	   hands	   and	   feet	   ranging	   from	   0	   to	   4.	  Erosions	   and	   joint	   space	   narrowing	   are	  
always	   scored	   and	   no	   judgment	   should	   be	   made	   on	   whether	   they	   are	   due	   to	  
rheumatoid	   process	   or	   to	   osteoarthritic	   lesions.	   The	   total	   replacement	   or	   the	  
chirurgical	  fusion	  of	  a	  joint	  automatically	  assigns	  a	  maximal	  erosion	  and	  narrowing	  




total	  erosion	  score	  of	  the	  feet	  is	  120.	  Maximal	  total	  erosion	  score	  (hands	  and	  feet)	  
is	  280.	  Maximal	  total	  narrowing	  score	  in	  the	  hands	  is	  120.	  Maximal	  total	  narrowing	  
score	   in	   the	   feet	   is	   48.	  Maximal	   total	   narrowing	   score	   (hands	   and	   feet)	   is	   168.	  
Maximal	  total	  Sharp/van	  der	  Heijde	  score	  is	  448.	  
Images	   have	   been	   acquired	   at	   Barts	   and	   The	   London	   Hospitals	   radiology	  
department,	  and	  scored	  by	  Dr	  Frances	  Humby,	  a	  trained	  reader	  who	  was	  blinded	  
for	   clinical	   and	   histopathological	   data.	   10%	   of	   images	  were	   scored	   by	   a	   second	  
independent	   observer,	  Dr	  Annette	   van	   der	  Helm-­‐van	  Mil,	   in	   order	   to	   determine	  
intra-­‐class	  correlation	  coefficients	  (ICC)	  for	  reliability.	  	  
Mean	   total	   ShSS,	  mean	   JSN	  and	  mean	   JE	  between	   synovial	   pathotype	  groups	  
were	  examined.	  In	  addition	  the	  mean	  changes	  between	  baseline	  and	  12	  months	  in	  
the	   three	   radiographic	  parameters	  were	  evaluated.	  Radiological	  progression	  was	  
defined	   as	   any	   increase	   (≥	   1	   point)	   in	   the	   ShSS	   or	   in	   any	   of	   its	   individual	  
component	  (JSN	  and	  SE).	  
For	   the	   established	   RA	   cohort,	   the	   ShSS	   scoring	   was	   not	   applicable,	   and	   the	  
erosive	   status	   was	   assessed	   according	   to	   the	   evaluation	   of	   an	   experienced	  
musculoskeletal	  radiologist	  at	  Barts	  and	  The	  London	  Hospitals.	  	  
	  
2.5	  	  	  ULTRASONOGRAPHIC	  ASSESSMENT	  
US	  images	  were	  acquired	  by	  myself	  using	  a	  GE	  Logic	  9	  ultrasound	  machine	  with	  
a	  two-­‐dimensional	  M12L	  transducer	  (14MHz).	  Standard	  longitudinal	  images	  of	  the	  
1st-­‐5th	  MCP	   (Figure	  2.1)	   and	  midline,	   radial	   and	  ulnar	   views	  of	   both	  wrists	   joints	  
(Figure	   2.2)	   were	   acquired	   as	   previously	   described.	   287	   	   The	   ultrasound	  




used	  minimal	  probe	  pressure	  after	  applying	  ultrasound	  gel	  on	  the	  surface	  of	   the	  
skin	  and	  maintaining	  a	  distance	  of	  at	  least	  1	  mm	  of	  gel	  between	  the	  probe	  and	  the	  
contact	  surface.	  The	  colour	  box	  was	  adjusted	  to	  cover	  the	  region	  of	  interest	  (ROI).	  
The	   colour	   priority,	   dynamic	   range	   and	   persistence	   were	   set	   high.	   The	   power	  
Doppler	   settings	   were	   adjusted	   to	   the	   lowest	   permissible	   pulse	   repetition	  
frequency	   to	  maximize	   sensitivity,	   and	  maximum	  colour	   gain	  was	   set	   just	   below	  
noise	  level.	  
In	  summary,	  the	  setting	  was	  as	  follows:	  Grey	  Scale-­‐	  Frequency	  14	  MHz;	  Power	  
Doppler	  -­‐	  Frequency	  7.5	  MHz,	  Gain	  41,	  PRF	  1.4	  kHz,	  Wall	  Filter	  127	  Hz.	  
Images	  were	   stored	   in	   DICOM	   format.	   The	   digitally	   stored	   images	  were	   then	  
transferred	   to	   a	   processing	   program	   (ImagePro)	   and	   subsequently	   underwent	  
semi-­‐quantitative	   (SQ)	   assessment	   for	   synovial	   thickening	   and	   power	   doppler	  
signal	  by	  two	  trained	  independent	  assessors-­‐	  Dr	  Nora	  Ng	  and	  Dr	  Ilias	  Lazarou-­‐	  who	  
were	  blinded	  to	  clinical	  and	  histopathological	  data.	  The	  scoring	  was	  performed	  in	  
compliance	  with	  the	  Outcome	  Measures	  in	  Rheumatology	  (OMERACT)	  US	  synovitis	  
scores.	  388	  An	  illustration	  and	  detailed	  description	  of	  the	  scoring	  system	  is	  shown	  
on	  Figure	  2.3.	  Briefly,	  a	  0-­‐3	  SQ	  scoring	  system	  was	  applied	  to	  quantify	  STUS	  and	  
PDUS	  at	  the	  single	  joint	   level	  (10	  MCP	  joints	  and	  midline	  view	  of	  both	  wrists)	  for	  
each	  patient,	  with	  ST-­‐G0	  and	  PD-­‐G0	   representing	  absence	  and	  ST-­‐G3	  and	  PD-­‐G3	  
representing	  maximum	  grade	  of	  ST/PD	  respectively.	  The	  total	  STUS	  and	  the	  total	  
PDUS	  scores	  were	  then	  calculated	  by	  summing	  up	  the	  respective	  scores	  for	  each	  
of	   the	   12	   joints	   examined,	   therefore	   ranging	   from	   a	   minimum	   value	   of	   0	   to	   a	  
maximum	  value	  of	  36.	   In	   this	   thesis,	  by	  STUS	  and	  PDUS	  scores	   I	  will	   refer	   to	   the	  




10%	   of	   images	   were	   scored	   by	   a	   second	   independent	   observer,	   Dr	   Stephen	  
Kelly,	  showing	  good	  to	  excellent	  ICC.	  
The	  variation	  of	  STUS	  and	  PDUS	  scores	  between	  baseline	  and	  6	  months	  were	  	  	  










































Figure	  2.1:	  Ultrasound	   scan	  of	   longitudinal	   view	  of	   the	  































Figure	  2.2:	  Ultrasound	   scan	  of	   longitudinal	   view	  of	   the	  















Figure	   2.3:	   Semi-­‐quantitative	   assessment	   for	   synovial	   thickening	   and	   power	   doppler	   activity	  
according	  to	  the	  OMERACT	  definition	  	  
Abbreviations:	  STUS=	  synovial	  thickening	  ultrasound;	  PDUS=	  power	  doppler	  ultrasound.	  
Score	  range	  from	  grade	  0	  (G0)	  to	  grade	  3	  (G3)	  for	  each	  parameter.	  
	  
Scoring	  for	  STUS	  
STUS-­‐G0=	  No	  hypoechoic	  synovial	  thickening.	  
STUS-­‐G1=	   Minimal	   hypoechoic	   synovial	   thickening	   (filling	   the	   angle	   between	   the	   periarticular	  
bones,	  without	  bulging	  over	  the	  line	  linking	  tops	  of	  the	  bones).	  
STUS-­‐G2=	   Hypoechoic	   synovial	   thickening	   bulging	   over	   the	   line	   linking	   tops	   of	   the	   periarticular	  
bones	  but	  without	  extension	  along	  the	  bone	  diaphysis.	  
STUS-­‐G3=	   Hypoechoic	   synovial	   thickening	   bulging	   over	   the	   line	   linking	   tops	   of	   the	   periarticular	  
bones	  and	  with	  extension	  to	  at	  least	  one	  of	  the	  bone	  diaphyses.	  
	  
Scoring	  for	  PDUS	  
PDUS-­‐G0=	  No	  flow	  in	  the	  synovium.	  
PDUS-­‐G1=	  Up	  to	  3	  single	  spots	  or	  up	  to	  2	  confluent	  spots	  or	  1	  confluent	  spot	  +	  up	  to	  2	  single	  spots.	  
PDUS-­‐G2=	  Vessel	  signals	  in	  less	  than	  half	  of	  the	  area	  of	  the	  synovium	  (<	  50%).	  
PDUS-­‐G3=	  Vessel	  signals	  in	  more	  than	  half	  of	  the	  area	  of	  the	  synovium	  (>	  50%).	  
	  








2.6	  	  	  ULTRASOUND-­‐GUIDED	  SYNOVIAL	  BIOPSY	  
All	   patients	   underwent	   an	   US-­‐guided	   synovial	   biopsy	   	   of	   a	   clinically	   inflamed	  
joint	  before	  starting	  treatment.	  In	  order	  to	  facilitate	  the	  joint	  selection	  for	  biopsy,	  
US	   assessment	   pre-­‐biopsy	   was	   utilized,	   and	   specifically	   the	   level	   of	   STUS.	   	   The	  
STUS	   scoring	   was	   done	   real	   time	   by	   mutual	   agreement	   between	   the	  
ultrasonographer	   and	   a	   second	   assessor	   (Dr	   Nora	   Ng	   or	   Dr	   Ilias	   Lazarou).	   The	  
subsequent	   decision	   tree	   was	   followed:	   medium	   or	   large	   joint	   with	   STUS=	   3;	  
small/medium/large	  joint	  with	  STUS	  ≥	  2;	  medium/large	  joint	  with	  STUS	  ≥	  1;	  small	  
joint	  of	  any	  ST	  grade.	  287	  
Biopsies	  were	  performed	  by	  trained	  Rheumatologists	  within	  the	  Rheumatology	  
Department	  at	  The	  Royal	  London	  Hospital:	  Dr	  Stephen	  Kelly,	  Dr	  Frances	  Humby,	  Dr	  
Nora	  Ng,	  Dr	  Arti	  Mahto,	  Dr	  Ilias	  Lazarou.	  	  
1-­‐3	  mls	   of	   local	   anaesthetic	  was	   injected	   into	   the	   soft	   tissues	   up	   to	   the	   joint	  
capsule,	  visualized	  under	  US	  guidance.	  A	  further	  2-­‐5	  mls	  of	   local	  anaesthetic	  (1%	  
lignocaine)	  was	  instilled	  into	  small	  joints,	  10-­‐15	  mls	  into	  large	  joints.	  
A	   16/14G	   Quick-­‐Core®	   Biopsy	   Needle	   (Cook	   medical,	   Limerick,	   Ireland)	   was	  
then	  placed	  within	   the	   joint	   capsule	  and	  a	   longitudinal	  US	   image	  used	   to	  detect	  
the	   needle	   and	   guide	   it	   to	   an	   appropriate	   pre-­‐determined	   site	   for	   biopsy.	   A	  
minimum	  of	  6	  biopsies	  were	  taken	  and	  immediately	  fixed	  in	  4%	  paraformaldehyde	  
for	  subsequent	  paraffin	  embedding.	  287	  
Examples	  of	  US	  guided	  synovial	  biopsy	  of	  the	  second	  MCP	  and	  wrist	  are	  shown	  

















Figure	  2.4:	  Ultrasound-­‐guided	  synovial	  biopsy	  of	  the	  second	  MCP	  joint	  
Abbreviations:	  MCP=	  metacarpophalangeal.	  
Courtesy	  of	  Dr	  Stephen	  Kelly	  
	  
	   	  
	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  Figure	  2.5	  :	  Ultrasound-­‐guided	  synovial	  biopsy	  of	  the	  wrist	  





2.7	  	  HISTOPATHOLOGICAL	  ANALYSIS	  
Histopathological	  analysis	  was	  performed	  by	  Dr	  Rebecca	  H.	  Hands,	  Mrs	  Vidalba	  
Rocher	   and	   Dr	   Alessandra	   Nerviani	   in	   the	   central	   laboratory	   at	   Experimental	  
Medicine	  and	  Rheumatology,	  William	  Harvey	  Institute,	  Queen	  Mary	  University	  of	  
London.	  	  
Following	   US-­‐guided	   biopsy,	   synovial	   tissue	   was	   immediately	   fixed	   in	   4%	  
paraformaldehyde	   for	   later	   paraffin	   embedding.	   A	  minimum	   of	   2	   samples	  were	  
embedded	   per	   block.	   After	   paraffin	   embedding,	   three	   5-­‐μm-­‐thick	   sections	   from	  
each	  biopsy	  specimen	  obtained	  50	  μm	  apart	  underwent	  routine	  haematoxylin	  and	  
eosin	   (H&E)	   staining	   and	   if	   intact	   lining	   layer	   identified	   graded	   as	   suitable	   for	  
further	  histopathological	  assessment.	  If	  no	  intact	  lining	  layer	  was	  visible,	  a	  further	  
three	   5-­‐μm-­‐thick	   sections	   at	   least	   50	   μm	   apart	   were	   cut	   and	   examined.	   If	   no	  
visible	  lining	  layer	  was	  seen,	  tissue	  was	  counted	  as	  ungraded.	  289	  	  
In	  order	  to	  define	  the	  predominant	  histological	  pattern	  within	  each	  sample	  the	  
presence	   and/or	   size	   of	   lymphocytic	   aggregates	   within	   each	   section	   was	  
determined	   and	   graded	   according	   to	   a	   modified,	   previously	   published	   grading	  
system	  319	  with	  grade	  1	  (G1)	  aggregates	  displaying	  a	  radial	  cell	  number	  between	  2	  
and	  5	  cells,	  grade	  2	  (G2)	  between	  6	  and	  10	  cells	  and	  grade	  3	  (G3)	  greater	  than	  10	  
cells,	  with	  G2	  and	  G3	  defining	  large	  sized	  lymphocytic	  aggregates.	  
Additionally	   in	   order	   to	   determine	   the	   degree	   of	   immune	   cell	   infiltration	  
sequentially	  formalin-­‐fixed	  paraffin-­‐embedded	  tissue	  sections	  were	  deparaffinised	  
and	   rehydrated	   through	   graded	   ethanol	   solutions	   and	   then	   stained	   for	   B	   cells	  
(CD20),	  T	  cells	  (CD3),	  macrophages	  (CD68)	  and	  plasma	  cells	  (CD138)	  as	  previously	  




Solution	  (DAKO).	  The	  following	  primary	  antibodies	  were	  used:	  mouse	  anti-­‐human	  
CD20	  (L26,	  DAKO),	  rabbit	  anti-­‐human	  CD3	  polyclonal	  (A0452,	  DAKO),	  mouse	  anti-­‐
human	   CD68	   (PGM1,	   DAKO),	   mouse	   anti-­‐human	   CD138	   (MI15,	   DAKO).	  
Appropriated	  biotinylated	  secondary	  antibodies	  were	  used.	  	  
Sections	   then	   underwent	   SQ	   (0-­‐4)	   for	   CD3,	   CD20,	   CD68	   lining	   (CD68l),	   CD68	  
sub-­‐lining	   (CD68sl)	   and	   CD138,	   with	   a	   score	   of	   0	   representing	   minimal	   cellular	  
expression	   and	   a	   score	   of	   4	   high	   cellular	   expression.	   Two	   trained	   readers	   –	   Dr	  
Rebecca	   E.	   Hands	   and	   Mrs	   Vidalba	   Rocher-­‐	   who	   were	   blinded	   with	   regard	   to	  
clinical	  details	  scored	  all	  sections.	  When	  scores	  between	  the	  two	  readers	  did	  not	  
match,	  the	  scoring	  was	  resolved	  by	  mutual	  agreement.	  
Samples	   were	   classified	   as:	   ‘Lymphoid’	   based	   on	   the	   presence	   of	   large	  
lymphocytic	   aggregates	   (G2/G3);	   ‘Myeloid’	   based	   on	   the	   absence	   of	   G2/G3	  
aggregates	   but	   abundant	   CD68sl	   (2-­‐4	   SQ);	   ‘Pauci-­‐immune’	   (PI)	   characterised	   by	  










2.8	  	  	  STATISTICAL	  ANALYSIS	  
Statistics	  will	  be	  described	  in	  each	  experimental	  chapter	  according	  to	  the	  type	  
of	  evaluations	  and	  analysis	  performed.	  In	  this	  paragraph	  I	  will	  briefly	  enounce	  the	  
general	  principles	  followed.	  	  
Continuous	  variables	  were	  expressed	  as	  mean	  (standard	  deviation,	  SD),	  ordinal	  
variables	  were	  expressed	  as	  median	  (interquartile	  range,	  IQR).	  
Demographics	   and	   clinical	   characteristics	   between	   groups	   were	   compared	  
using	   Chi-­‐Square	   test	   for	   qualitative	   variables	   or	   Kruskal	   Wallis	   test	   for	  
quantitative	  variables,	  as	  appropriate.	  	  
Spearman	   correlation	   coefficients	   were	   used	   for	   semi-­‐quantitative	   variables	  
and	  Pearson	  correlation	  coefficient	  for	  continuous	  variables.	  
Logistic	  regression	  analysis	  was	  performed	  to	  estimate	  if	  the	  synovial	  pathotype	  
was	  an	  independent	  predictor	  of	  response	  to	  therapy	  after	  6	  months	  in	  the	  PEAC	  
and	  after	  3	  months	  in	  the	  CLIP-­‐Cert	  cohort.	  The	  relevant	  adjusting	  variables	  were	  
sequentially	  selected	  in	  the	  modelling	  process.	  
Missing	   values	   in	   the	   dataset	  were	   imputed	   using	  multivariate	   imputation	   by	  
chained	  equations	  (MICE).	  390	  The	  multiple	  imputations	  were	  implemented	  using	  R	  
3.0.2	  package	  ‘mice’.	  Statistical	  analyses	  were	  performed	  using	  SPSS	  (IBM	  version	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3.1	  	  	  INTRODUCTION	  
The	  presence	  of	  distinct	  molecular	  and	  cellular	  phenotypes	  within	  the	  synovium	  
has	   attracted	   increased	   attention	   since	   its	   recognition	   as	   the	   primary	   site	   of	  
inflammation	  in	  RA.	  However	  whether	  specific	  synovial	  pathotypes	  are	  associated	  
with	   distinct	   disease	   subtypes	   (e.g.	   seronegative	   versus	   seropositive,	   erosive	  
versus	   non	   erosive,	   responding	   versus	   resistant	   pattern)	   remains	   unknown.	  
Furthermore	   there	   is	   a	   growing	   body	   of	   evidence	   to	   suggest	   that	   early	   RA	  may	  
represent	  a	  distinct	  phase	  of	  the	  pathobiological	  disease	  process,	  but	  the	  notion	  of	  
‘early	  disease’	  remains	  purely	  clinical	  and	  its	  temporal	  cut-­‐off	  arbitrary.	  	  
Synovial	   inflammation	   has	   been	   identified	   at	   a	  microscopic	   level	   prior	   to	   the	  
onset	   of	   clinically	   apparent	   synovitis	   in	   RA	   patients.93	   However	   whether	   the	  
cellular	   and/or	  molecular	   characteristics	   of	   the	   synovium	   are	   distinct	   at	   distinct	  
disease	  phases	   is	   currently	  unknown.	  Such	  a	  hypothesis	  has	  been	  examined	   in	  a	  
number	   of	   different	   cohorts	   with	   somewhat	   conflicting	   results.	   Some	   authors	  
postulated	   that,	   whenever	   differences	   in	   the	   features	   of	   the	   synovium	   are	  
observed,	   they	   do	   not	   appear	   to	   depend	   on	   disease	   duration	   but	   rather	   on	   the	  
level	   of	   disease	   activity	   at	   that	   specific	   time-­‐point,	   reflecting	   the	   status	   of	   local	  
inflammation	  rather	  than	  a	  specific	  chronological	  phase	  of	  the	  disease	  process.	  391	  
Examining	  synovial	  samples	  obtained	  within	  the	  first	  4	  weeks	  of	  symptoms	  onset,	  
Schumacher	  and	  Kitridou	  found	  no	  major	  differences	  compared	  to	  tissue	  samples	  
from	   patients	   with	   longer	   disease	   duration.	   392	   Similarly,	   Smeets	   et	   al	   reported	  
that	   the	   degree	   of	   cellular	   infiltration	   and	   T-­‐cell	   activation	  were	   similar	   in	   early	  
versus	   long-­‐standing	   RA.	   393	   A	   subsequent	   study	   comparing	   31	   samples	   from	  




to	  identify	  major	  differences	  with	  regard	  to	  lining	  layer	  hyperplasia,	  infiltration	  by	  
monocytes/macrophages,	   lymphocytes,	   polymorphonuclear	   cells	   and	  mast	   cells,	  
and	  expression	  of	  IL-­‐6	  and	  TNFα.	  394	  Conversely,	  Singh	  JA	  et	  al,	  analysing	  synovial	  
specimens	   from	   8	   patients	   with	   very	   early	   RA	   (<	   6	   weeks	   duration),	   detected	  
profound	  differences	  compared	  with	  an	  established	  disease	   infiltrate:	  specifically	  
they	  could	  not	  see	  any	  presence	  of	  lymphoid	  aggregates	  in	  early	  RA,	  and	  observed	  
a	  cellular	  infiltrate	  limited	  to	  the	  superficial	  area	  of	  the	  synovium	  only,	  consisting	  
mainly	  of	  perivascular	  T	  cells	  with	  a	  limited	  number	  of	  B	  cells,	  along	  with	  a	  scarce	  
expression	  of	  neo-­‐vascularity.	  395	  	  
More	   recently,	   gene	   expression	   profiling	   technologies	   have	   represented	   an	  
important	   step-­‐up	   in	   synovial	   tissue	   analysis,	   allowing	   further	   dissection	   of	   the	  
molecular	   heterogeneity	   of	   RA	   synovium	   at	   different	   time-­‐points.	   Genomics	  
studies	   were	   able	   to	   detect	   marked	   differences	   in	   synovial	   RNA	   expression	  
between	  patients	  with	  early	  and	  established	  RA.	  For	  example,	  a	  study	  comparing	  4	  
early	   versus	   4	   long-­‐standing	   RA	   identified	   specific	   gene	   clusters	   and	   molecular	  
signatures	   expressed	   differently	   in	   the	   early	   and	   long-­‐standing	   synovium,	  
suggesting	   the	   prevalence	   of	   distinct	   pathophysiological	   mechanisms	   during	  
different	  phases	  of	  the	  disease.	  396	  	  
To	   date,	   given	   such	   amount	   of	   controversial	   and	   often	   opposite	   results,	   it	   is	  
difficult	   to	   draw	   any	   reliable	   conclusion	   about	   distinct	   stages	   of	   synovial	  
inflammation	   and	   intrinsic	   pathobiological	   features.	   However,	   the	   majority	   of	  
these	  studies	  are	  affected	  by	  several	  methodological	  discrepancies	  where	  multiple	  
biases	   had	   been	   operating.	   Firstly,	   most	   studies	   are	   small	   in	   size	   and	   based	   on	  




of	  arthroplastically	  obtained	  synovial	   tissue	  and	   large	   joint	  arthroscopic	  biopsies,	  
which	  may	  have	   introduced	  bias	  by	   selecting	  more	  severe	  patients.	   288	  This	   is	  of	  
particular	  concern	  when	  evaluating	  early	  arthritis	  cohorts,	  where	  small	  rather	  than	  
large	  joints	  are	  most	  commonly	  involved.287	  It	  is	  also	  relevant	  to	  note	  that	  synovial	  
pathobiology	   can	   also	   be	   modulated	   by	   therapeutic	   intervention.	   Not	   less	  
importantly,	   there	   is	   a	   high	   variability	   in	   terms	   of	   synovial	   tissue	   extraction	  
techniques	   (e.g.,	   tissue	   obtained	   during	   joint	   replacement	   surgery,	   arthroscopy,	  
needle	   biopsies,	   US-­‐guided	  minimally	   invasive	   biopsy),	   as	  well	   as	   synovial	   tissue	  
analysis	  methods,	   histological	   classifications	   and	   scoring	   systems	   to	  quantify	   the	  
degree	   of	   cellular	   infiltrate.	   	   Collectively,	   these	   factors	   represent	   important	  
caveats	  of	   synovial	   tissue	   studies	   so	   far.	   Therefore	   further	  examination	  of	   large-­‐
scale,	  systematic	  prospective	  studies	  of	  synovial	  membrane	  are	  needed	  to	  better	  
understand	   the	   pathophysiological	   mechanisms	   involved	   in	   RA,	   particularly	   in	  
early	  RA	  patients	  who	  are	  naïve	  to	  any	  anti-­‐rheumatic	  treatment.	  	  
Moreover	   US	   has	   been	   long	   recognised	   as	   an	   accurate	   reflection	   of	   disease	  
activity	   in	   inflammatory	   arthritis,	   and	   actually	   PDUS	   has	   proved	   to	   be	   more	  
sensitive	  than	  clinical	  assessment	  in	  detecting	  joint	   inflammation.	  220,397	  However	  
little	   is	  known	  about	   the	  relationship	  between	  US	  and	  synovial	  pathology.	  A	   few	  
studies	   have	   shown	   that	   US	   measures	   of	   inflammation	   reflect	   features	   of	  
histological	  synovitis,	  but	  these	  were	  mostly	  performed	  examining	   large	   joints	  of	  
patients	   at	   end-­‐stage	   disease.	   398-­‐401	   Little	   work	   has	   been	   done	   to	   describe	   this	  
relationship	  in	  early	  RA	  populations.	  	  
Koski	   et	   al	   examined	   PDUS	   in	   relation	   to	   histopathological	   features	   of	   44	  




Biopsy	   samples	   were	   obtained	   by	   using	   US-­‐guided	   synovial	   biopsy.	   The	   authors	  
found	  no	  significant	  correlations	  between	  the	  extent	  of	  synovial	  inflammation	  and	  
the	  amount	  of	  power	  Doppler	   signal	  assessed	  on	  a	  SQ	  scale.	  An	  association	  was	  
found	  with	  the	  presence/absence	  of	  PD	  signal	  only.	  Conversely,	  in	  a	  recent	  study	  
by	   Andersen	   et	   al	   evaluating	   81	   needle	   arthroscopy	   samples	   from	   hands	   and	  
wrists	   of	   29	   RA	   patients,	   a	   significant	   association	   between	   the	   doppler	   colour	  
fraction	   and	   the	   extent	   of	   inflammation,	   including	   correlation	   with	   specific	   cell	  
subsets	  CD68	  and	  CD3,	  was	  found.	  403	  	  
A	   recent	   publication	   examined	   the	   relationship	   between	   US	   synovitis	   and	  
synovial	   vascularity	   including	   the	   expression	   of	   angiogenic	   factors,	  
lymphangiogenic	   factors	   and	   cellular	   mediators	   of	   inflammation	   in	   a	   cohort	   of	  
early	  RA	  patients	  prior	  to	  therapeutic	   intervention.	  An	  US-­‐guided	  synovial	  biopsy	  
of	   the	   supra-­‐patella	   pouch	  was	   performed	   in	   12	   patients.	   PDUS	   showed	   a	   good	  
correlation	  with	  angiogenic	   factors	   such	  as	  vascular	  endothelial	  growth	   factor-­‐	  A	  
(VEGF-­‐A),	   Angiopoietin	   2	   and	   Tie-­‐2.	   A	   significant	   correlation	   was	   also	   found	   for	  
both	   STUS	   and	   PDUS	   with	   the	   pro-­‐inflammatory	   cellular	   and	   cytokine	   profile	  
specifically	   TNFα,	   IL-­‐6,	   IL-­‐1β,	   podoplanin	   (a	   lymphatic	   endothelial	   marker)	   and	  
CD68,	  providing	  consistent	  validity	  in	  its	  use	  as	  an	  objective	  assessment	  of	  synovial	  
inflammation.	  404	  
	  
3.2	  	  	  AIMS	  AND	  OBJECTIVES	  	  
The	   aim	   of	   this	   chapter	   was	   to	   determine	   whether	   synovial	   pathotype	  
significantly	   associates	   with	   clinical	   phenotype	   in	   an	   early	   RA	   treatment	   naïve	  




1) describe	   the	   pathological	   characteristics	   of	   the	   synovial	  membrane	   in	   a	  
treatment	  naïve	  early	  RA	  cohort;	  
2) evaluate	   whether	   the	   pathological	   features	   of	   the	   synovium	   were	  
associated	   with	   distinct	   phenotypes	   with	   regard	   to	   clinical	   features,	  
antibody	  status,	  radiological	  and	  ultrasound	  findings.	  
	  
3.3	  	  	  MATERIALS	  AND	  METHODS	  	  
3.3.1	  	  	  Study	  population	  	  
63	  consecutive	  patients	  with	  early	  RA	   (disease	  duration	  <12	  months,	   fulfilling	  
2010	  ACR	  classification	  criteria)	  who	  were	  csDMARD	  and	  corticosteroid	  treatment	  
naïve	  were	  recruited	  at	  Barts	  Health	  NHS	  Trust	  as	  part	  of	  the	  multi-­‐centred	  MRC-­‐
funded	   Pathobiology	   of	   Early	   Arthritis	   Cohort	   	   (PEAC),	   http://www.peac-­‐
mrc.mds.qmul.ac.uk.	  The	  study	  has	  been	  described	   in	  details	   in	  the	  Material	  and	  
Methods	  section	  (Chapter	  3).	  
	  
3.3.2	  	  	  Patient	  assessment	  
Patients	   underwent	   baseline	   clinical	   and	   laboratory	   assessment,	   XR	   of	   hands	  
and	  feet,	  US	  of	  10	  MCPs	  and	  wrists	  and	  US-­‐guided	  synovial	  biopsy	  prior	  to	  starting	  
csDMARD	  treatment,	  as	  described	  in	  details	  in	  Chapter	  3.	  	  
	  
3.3.3	  	  	  Tissue	  sample	  collection	  and	  histopathological	  analysis	  	  
Detailed	   methods	   of	   biopsy	   procedure,	   tissue	   collection,	   histopathological	  




Synovial	   samples	   were	   then	   stratified	   in	   one	   of	   the	   three	   pathobiological	  
groups:	   ‘Lymphoid’,	   based	   on	   the	   presence	   of	   large	   lymphocytic	   aggregates	  
(G2/G3);	   ‘Myeloid’,	  based	  on	  the	  absence	  of	  G2/G3	  aggregates	  and	  predominant	  
expression	  of	  and	  CD68sl	  2-­‐4	  SQ;	  ‘Pauci-­‐immune’	  (PI)	  characterised	  by	  the	  absence	  
of	  G2/G3	  aggregates	  and	  scarce/absent	  CD68sl	  (0-­‐1	  SQ).	  
	  
3.3.4	  	  	  Statistical	  analysis	  
Continuous	   variables	   were	   expressed	   as	   mean	   (+/-­‐	   SD),	   ordinal	   variables	   as	  
median	  (+/-­‐	  IQR).	  
Demographics	  and	  characteristics	  of	  patients	  across	  the	  three	  histopathological	  
groups	  were	   compared	   using	   Chi-­‐Square	   test	   for	   qualitative	   variables	   or	   Kruskal	  
Wallis	  test	  for	  quantitative	  variables,	  as	  appropriate.	  	  
Spearman	  correlation	  coefficient	  was	  used	  for	  semi-­‐quantitative	  variables	  and	  
Pearson	  correlation	  coefficient	  for	  continuous	  variables.	  	  
A	   p-­‐value	   <	   0.05	   was	   considered	   statistically	   significant.	   Statistical	   analyses	  
were	  performed	  using	  SPSS	  (IBM	  version	  21.0	  for	  Mac).	  
	  
3.4	  	  	  RESULTS	  
3.4.1	  	  	  Characteristics	  of	  patients	  	  
The	  demographic	  and	  clinical	  characteristics	  of	  patients	  at	  baseline	  are	  shown	  
on	  Table	  3.1.	  
Among	   the	   63	   patients,	   73%	  were	   female.	  Mean	   age	  was	   50.4±17.5.	   24.6	   %	  
were	   current	   smokers.	   The	   mean	   duration	   of	   symptoms	   onset	   was	   5.4±3.1	  




seropositive	  for	  RF	  and	  68.2%	  for	  ACPA.	  Mean	  TJC	  was	  12.0±7.2	  and	  mean	  STJ	  was	  
8.0±5.3.	   The	   mean	   DAS28	   was	   5.8±1.2,	   falling	   in	   a	   high	   disease	   activity	   range.	  
Mean	  HAQ	  was	  1.63±0.67.	  	  
Of	  the	  63	  US-­‐guided	  synovial	  biopsy	  procedures,	  50	  (79.4%)	  were	  performed	  on	  
small	  joints	  (40	  wrists,	  8	  MCPs,	  2	  PIPs)	  and	  13	  (20.6%)	  on	  large	  joints	  (12	  knees,	  1	  
elbow).	  	  




	  	  	  	  	  	   	  	  	  
	  	  
	  	  	  	  	  	  	  	  	  	  	  	  Table	  3.1:	  Demographics	  and	  clinical	  characteristics	  of	  PEAC	  patients	  at	  baseline	  
Abbreviations:	  ACPA=	  anti-­‐cyclic	  citrullinated	  proteins	  antibodies;	  CRP=	  C-­‐reactive	  
protein;	   DAS28=	   28	   joint	   count-­‐Disease	   Activity	   Score;	   ESR=	   erythrocyte	  
sedimentation	   rate;	  HAQ=	  Health	  Assessment	  Questionnaire;	   JE=	   joint	  erosions;	  
JSN=	   joint	   space	   narrowing;	   RF=	   rheumatoid	   factor;	   ShSS=	   van	   der	   Heijde	  
modified	   Sharp	   score;	   SJ=	   swollen	   joints;	   TJ=	   tender	   joints;	   VAS-­‐GH=	   Visual	  









3.4.2	  	  	  A	  Lymphoid	  synovial	  pathotype	  significantly	  associates	  with	  higher	  levels	  
of	  ESR	  and	  seropositivity	  for	  RF	  and	  ACPA	  antibodies	  
A	  Lymphoid	  pattern	  was	  found	  in	  24	  patients	  (38.1%),	  a	  Myeloid	  pattern	  in	  19	  




















A.	  Pauci-­‐immune	  pattern	  (31.7%	  of	  patients)	  
	  
	  
B.	  Myeloid	  pattern	  (30.2%	  of	  patients)	  
	  
	  
C.	  Lymphoid	  pattern	  (38.1%	  of	  patients)	  
Figure	  3.1:	  Representative	  images	  of	  the	  three	  histopathotype	  patterns	  
Pauci-­‐immune	   (A),	   characterised	   by	   absence	   of	   lymphocytic	   aggregates	   and	   scarce/absent	  
sublining	  macrophages	   (SQ	  0-­‐1);	  Myeloid	   (B)	   characterised	   by	   absence	  of	   lymphocytic	   aggregate	  
and	  presence	  of	  sublining	  macrophages	   (SQ	  2-­‐4);	  and	  Lymphoid	   (C)	  characterised	  by	  presence	  of	  
large	  lymphocytic	  aggregates	  grade	  2-­‐3	  (black	  arrows)	  resembling	  ectopic	  lymphoid	  tissue.	  




In	   order	   to	   determine	   if	   there	   were	   significant	   differences	   in	   disease	  
characteristics	   between	   patients	   classified	   as	   Lymphoid,	   Myeloid	   or	   PI,	  
patients	  were	  segregated	  into	  each	  pathological	  group	  and	  mean	  differences	  
in	  demographics	  compared	  (Table	  3.2).	  





Table	  3.2:	  Characteristics	  of	  patients	  compared	  across	  the	  histopathotype	  groups	  
Kruskal	  Wallis	  test	  or	  Chi-­‐Square	  test,	  as	  appropriate.	  
Abbreviations:	  ACPA=	  anti-­‐cyclic	   citrullinated	  proteins	  antibodies;	  CRP=	  C-­‐reactive	  protein;	  
DAS28=	  28	   joint	   count-­‐Disease	  Activity	  Score;	  ESR=	  erythrocyte	   sedimentation	   rate;	  HAQ=	  
Health	   Assessment	   Questionnaire;	   JE=	   joint	   erosions;	   JSN=	   joint	   space	   narrowing;	   RF=	  
rheumatoid	   factor;	   ShSS=	   van	   der	   Heijde	   modified	   Sharp	   score;	   SJ=	   swollen	   joints;	   TJ=	  















Female,*n*(%)* 16*(80.0%)* 11*(57.9%)* 19*(79.2%)* 0.20*
Age*(years),*mean*±*SD* 45.3*±*15.7* 55.3*±*19.6* 50.8*±*16.7* 0.17*
Onset*(months),*mean*±*SD* 6.3*±*3.4* 4.5*±*2.0* 5.3*±*3.5* 0.23*
Smoking,*n*(%)* 5*(27.8%)* 6*(31.6%)* 4*(16.7%)* 0.49*
ESR*(mm/h),*mean*±*SD* 30.8*±*25.9* 35.9*±*24.9* 50.3*±*25.6* 0.01*
CRP*(mg/L),*mean*±*SD* 20.6*±*43.4* 14.4*±*16.1* 20.0*±*19.9* 0.08*
RF*+,*n*(%)* 11*(57.9%)* 10*(52.6%)* 21*(87.5%)* 0.02*
ACPA*+,*n*(%)** 12*(60%)* 10*(52.6%)* *21*(87.5%)* 0.03*
TJ*(28*joints),*mean*±*SD* 11.8*±*7.7* 11.4*±*6.9* 12.7*±*7.3* 0.74*
SJ*(28*joints),*mean*±*SD* 6.9*±*5.8* 8.1*±*5.4* 8.7*±*5.0* 0.25*
VAS&GH*(0&100*mm),*mean*±*SD* 59.1*±*30.9* 66.1*±*27.5** 71.6*±*18.9* 0.51*
DAS28,*mean*±*SD* 5.5*±*1.4* 5.7*±*1.2* 6.3*±*0.8* 0.10*
HAQ,*mean*±*SD* 1.65*±*0.75* 1.68*±*0.54* 1.57*±*0.73* 0.98*
ShSS,*mean*±*SD* 11.6*±*15.9* 17.2*±*21.6* 13.4*±*11.0* 0.45*
JSN,*mean*±*SD* 10.5*±*13.5* 14.0*±*15.9* 12.1*±*9.5* 0.46*




Although	   there	   were	   no	   significant	   differences	   in	   demographics	   including	  
gender,	  age,	  smoking	  status	  and	  clinical	  characteristics	  including	  disease	  duration,	  
TJ,	  SJ,	  VAS-­‐GH,	  DAS28,	  HAQ	  among	  groups,	  mean	  ESR	  was	  significantly	  higher	   in	  
the	  Lymphoid	  group	  (50.3	  ±	  25.6,	  compared	  with	  35.9	  ±	  24.9	   in	  the	  Myeloid	  and	  
30.8	  ±	  25.9	  in	  the	  PI,	  p=0.01).	  Additionally	  when	  patients	  were	  further	  segregated	  
into	  those	  who	  were	  RF+/-­‐	  and	  ACPA	  +/-­‐	  there	  was	  a	  significantly	  higher	  number	  
of	  RF+	  (PI=57.9%,	  Myeloid=52.6%,	  Lymphoid=87.5%,	  p=0.02)	  and	  ACPA	  +	  (PI=60%,	  
Myeloid=52.6%	  Lymphoid=87.5%,	  p=0.03)	  in	  patients	  categorised	  in	  the	  Lymphoid	  
group.	   Further	   a	   significant	   difference	   was	   observed	   on	   a	   direct	   pairwise	  
comparison	  of	   groups	  between	   Lymphoid	   and	  PI	   (p=	  0.03	   for	  RF	   and	  p=0.03	   for	  
ACPA)	  and	  between	  Lymphoid	  and	  Myeloid	  (p=0.01	  and	  p=0.01)	  however	  this	  was	  
not	  seen	  between	  Myeloid	  and	  PI	  (p=	  0.74	  and	  0.64).	  This	  data	  again	  supports	  the	  
significant	   relationship	   between	   a	   Lymphoid	   pathotype	   and	   circulating	   disease	  
specific	   autoantibodies.	   Testing	   for	  multiple	   comparisons	  was	   not	   performed	   as	  
the	  purpose	  of	  this	  work	  was	  looking	  at	  how	  specific	  variables	  affected	  the	  three	  
groups	  rather	  than	  proving	  that	  the	  three	  groups	  were	  generally	  different.	  	  
Given	  the	  significant	  association	  between	  tobacco	  smoking	  and	  ACPA	  positivity	  
we	   also	  went	   on	   to	   evaluate	  whether	   smoking	   habit	  was	   differently	   distributed	  
within	   the	   three	   histopathotype	   groups,	   but	   this	   was	   not	   the	   case	   (PI=27.8%,	  
Myeloid=31.6%	  and	  Lymphoid=16.7%,	  p=0.49).	  
In	  order	   to	  determine	  whether	   the	  presence	  of	   large	  synovial	  aggregates	  was	  
significantly	   associated	   with	   synovial	   infiltration	   of	   T	   cells,	   B	   cells	   and/or	  
macrophages,	  synovial	  samples	  were	  stratified	  into	  each	  synovial	  pathotype	  group	  




aggregates	   was	   significantly	   associated	   with	   a	   higher	   infiltration	   of	   CD3,	   CD20,	  





Table	  3.3:	  Synovial	  pathotype	  is	  associated	  to	  the	  extent	  of	  tissue	  cellularity	  
Values	  are	  expressed	  as	  median	  (interquartile	  range)	  of	  the	  semi-­‐quantitative	  	  (0-­‐4)	  score.	  	  
Kruskal	  Wallis	  test.	  
Abbreviations:	   CD3,	   T	   cells;	   CD20,	   B	   cells;	   CD68l,	   lining	  macrophages;	   CD68sl,	   sub-­‐lining	  


















CD3* 0*(0&0)* 1*(1&2)* *3*(2&4)* <0.01*
CD20* 0*(0&0)* 1*(0&1)* 3*(3&4)* <0.01*
CD68l* 1*(0&1)* 2*(1&2)* 3*(2&4)* <0.01*
CD68sl* 1*(0&1)* 2*(2&3)* 3*(3&4)* <0.01*




3.4.3	   	   	   Synovial	   pathotype	   does	   not	   discriminate	   between	   clinically	   assessed	  	  
levels	  of	  disease	  activity	  	  
No	  association	  was	  found	  between	  the	  synovial	  pathotype	  and	  clinical	  features	  
including	  TJ,	  SJ,	  VAS-­‐GH,	   level	  of	  disease	  activity	  expressed	  by	  DAS28.	  The	  mean	  
DAS28	   was	   5.8	   ±	   1.2,	   reflecting	   high	   disease	   activity	   status	   that	   was	   consistent	  
through	  all	  three	  histopathological	  groups	  in	  the	  cohort.	  
An	   association	   between	   the	   synovial	   pathotype	   and	   the	   functional	   status	  
measured	  by	  HAQ	  has	  not	  been	  detected	  either.	  	  
	  
3.4.4	  	  	  An	  aggregate	  synovial	  pathotype	  associates	  with	  significantly	  higher	  levels	  
of	  ultrasonographic	  disease	  activity	  
Next	  in	  order	  to	  determine	  if	  US-­‐synovitis	  scores	  correlated	  with	  laboratory	  and	  
clinical	  markers	  of	  disease	  activity,	  baseline	  STUS	  and	  PDUS	  scores	  were	  correlated	  
with	   clinical	   and	   laboratory	   parameters.	   Good	   quality	   US	   images	  were	   obtained	  
and	   scored	   for	   60	   patients.	   PDUS	   score	   significantly	   correlated	   with	   mean	   ESR	  
(r=0.31,	   p=0.01),	   CRP	   (r=	   0.45,	   p<0.01)	   and	   DAS28	   (r=0.30,	   	   p=0.01),	   whilst	   a	  
significant	   correlation	   with	   STUS	   score	   was	   only	   demonstrated	   for	   CRP	   (r=0.33,	  
p=0.01).	   This	   data	   indicates	   that	   in	   early	   RA	   synovial	   PDUS	   may	   be	   a	   better	  
indicator	   of	   disease	   severity	   than	   STUS,	   which	   as	   previously	   suggested	   may	  
associate	  more	  strongly	  with	  disease	  duration.	  405,406	  	  	  
Furthermore	  as	  clinical	  assessment	  has	  been	  demonstrated	  to	  be	   less	   reliable	  
than	  US	  assessment	  for	  the	  detection	  of	  synovitis	  226,366,	   in	  order	  to	  determine	   if	  
synovial	   pathotype	   associated	   with	   more	   severe	   disease	   assessed	  




Lymphoid,	  Myeloid	   and	   PI	   pathotypes	  were	   compared.	   There	  was	   no	   significant	  
difference	   in	   STUS	   scores	   between	   either	   pathotype	   but	   a	   significantly	   higher	  	  
PDUS	  score	  was	  demonstrated	  in	  patients	  with	  a	  Lymphoid	  (11.1	  ±	  9.5)	  compared	  
to	  Myeloid	  (7.3	  ±	  8.8)	  and	  PI	  (4.7	  ±	  7.9)	  pathotype	  (p=0.04),	  Table	  3.4	  supporting	  
the	   concept	   that	  an	  aggregate	  pathotype	  associates	  with	  more	  active	  disease	  at	  
the	  US	  level.	  
Finally	   in	  order	   to	  determine	  whether	  mean	  US	  scores	  significantly	  correlated	  
with	  degree	  of	  immune	  cell	  infiltration,	  SQ	  CD20,	  CD68l,	  CD68sl	  and	  CD138	  scores	  
were	   correlated	  with	   STUS	   and	   PDUS	   scores.	   I	   found	   no	   significant	   correlations	  
with	   STUS	   score,	   meanwhile	   a	   significant	   correlation	   with	   PDUS	   score	   was	  
observed	  (Table	  3.5)	  in	  line	  with	  previously	  reported	  data.	  403	  These	  observations	  









Table	  3.4:	  Ultrasound	  features	  at	  baseline	  compared	  across	  histopathotype	  groups	  
Values	  are	  expressed	  as	  mean	  ±	  SD.	  Kruskal	  Wallis	  test.	  




Table	   3.5:	   Power	   doppler	   ultrasound	   scores	   correlate	   significantly	  with	   the	   degree	   of	   synovial	  
immune	  cell	  infiltration	  
Values	  are	  expressed	  as	  Spearman	  Rho	  coefficient,	  *=	  significant	  at	  <0.05.	  **=	  significant	  at	  <0.01.	  
Abbreviations:	   CD3,	   T	   cells;	   CD20,	   B	   cells;	   CD68l,	   lining	   macrophages;	   CD68sl,	   sub-­‐lining	  

















STUS# 19.7#±#13.1# 19.2#±#11.0# 18.8#±#13.8# 20.8#±#14.7# 0.89#
PDUS# 8.0#±#9.1# 4.7#±#7.9# 7.3#±#8.8# 11.1#±#9.5# 0.04#
CD3$ CD20$ CD68l$ CD68sl$ CD138$
STUS$ /0.03$ 0.05$ /0.14$ 0.07$ 0.09$





3.4.5	  	  	  The	  synovial	  pathotype	  does	  not	  associate	  with	  a	  specific	  erosive	  pattern	  
at	  baseline	  	  
Finally,	   in	   order	   to	   determine	   whether	   synovial	   pathotype	   associated	   with	  
specific	   radiographic	  damage	  we	  stratified	  patients	   into	  each	   synovial	  pathotype	  
and	  evaluated	  whether	   there	  were	  significant	  differences	   in	   the	   total	  ShSS	  score	  
along	  with	  either	  JSN	  or	  erosions.	  Good	  quality	  XR	  images	  suitable	  for	  subsequent	  
scoring	   were	   obtained	   for	   54	   patients.	   No	   significant	   differences	   were	  
demonstrated	  in	  either	  the	  total	  ShSS	  or	  its	  individual	  components.	  
	  
3.5	  	  	  DISCUSSION	  
The	  existence	  of	  distinct	  histological	  patterns	  has	  been	  previously	  observed	  in	  
the	  RA	  synovium,	  however	  longitudinal	  data	  from	  patients	  with	  early	  RA	  naïve	  to	  
treatment	   are	   scarce.	  Within	   the	   early	   RA	   cohort	   described	   in	   this	   work,	   three	  
major	   pathotypes	   have	   been	   identified:	   Lymphoid	   (38%),	   characterised	   by	  
presence	   of	   large	   lymphocytic	   aggregates	   resembling	   ectopic	   lymphoid	   tissue;	  
Myeloid	   (30%),	   characterised	   by	   absence	   of	   lymphocytic	   aggregates	   however	  
presence	  of	  abundant	  inflammatory	  cells	  in	  a	  non-­‐aggregate	  distribution,	  including	  
sublining	   macrophages;	   and	   Pauci-­‐immune	   (32%)	   characterised	   by	   overall	  
scarce/absent	   immune	   cell	   infiltrate.	   Previous	   studies	   have	   suggested	   that	   the	  
presence	   of	   a	   distinct	   pathotype	  may	   confer	   specific	   phenotypic	   characteristics.	  
However,	  the	  role	  of	  the	  synovial	  pathotype	  in	  determining	  the	  clinical	  phenotype	  
including	  response	  to	  treatment	  is	  still	  controversial.	  	  
First	  of	  all,	   it	   is	  worth	  noting	   that	   the	  proportion	  of	  a	   Lymphoid	  pathotype	   in	  




biopsies	  from	  patients	  with	  established	  RA.	  323	  This	  suggests	  that	  the	  acquisition	  of	  
lymphocytic	   aggregates	   resembling	   ectopic	   lymphoid	   tissue	   represents	   an	   early	  
step	   of	   RA	   pathogenesis	   rather	   than	   a	   feature	   acquired	   at	   later	   stages	   as	   was	  
previously	   suggested	   407,	   supporting	   a	   potential	   role	   in	   an	   early	   local	   peripheral	  
breach	  of	   tolerance.	   	   	   In	  agreement	  with	   these	   findings,	  Cantaert	  at	  al	   reported	  
the	   presence	   of	   lymphoid	   aggregates	   in	   31%	   of	   RA	   patients,	   with	   no	   difference	  
between	  early	  and	  established	  disease.	  408	  
The	  results	  presented	  herein	  demonstrate	  a	  number	  of	  novel	   findings	  namely	  
that	  in	  early	  RA	  a	  Lymphoid	  synovial	  pathotype	  i)	  significantly	  associates	  with	  ESR	  
and	   seropositivity	   for	   both	   RF	   and	   ACPA;	   ii)	   significantly	   associates	   with	   mean	  
PDUS	  score	  which	  represents	  a	  reliable	  measure	  of	  synovitis.	  Collectively	  this	  data	  
suggests	   that	   a	   Lymphoid	   pathotype	   associates	   with	   a	   more	   aggressive	   clinical	  
phenotype.	  Furthermore	  the	  significant	  association	  between	  such	  pathotype	  and	  
seropositivity	   for	   RF	   and	   ACPA	   strongly	   supports	   the	   concept	   that	   synovial	  
aggregates	  are	   immunologically	   competent	  as	  demonstrated	  by	  previous	  ex	  vivo	  
data.	   325	   Since	   most	   studies	   failed	   to	   observe	   an	   association	   between	   antibody	  
status	   and	   presence	   of	   large	   aggregates	   in	   long-­‐standing	   RA	   323,408,	   our	   data	  
suggests	   that	   this	   could	   be	   a	   distinct	   characteristic	   of	   early	   RA.	   In	   addition	   the	  
significantly	   higher	   levels	   of	   CD138+	   plasma	   cells	   in	   tissue	   with	   lymphocytic	  
aggregates	  strongly	  suggests	  in	  situ	  B	  cell	  differentiation.	  	  
The	  results	  presented	  within	  this	  cohort	  are	  important	  and	  robust	  for	  a	  number	  
of	   key	   reasons.	   Firstly	   patients	   were	   treatment	   naïve	   early	   RA	   patients	   from	  
currently	  one	  of	  the	  largest	  reported	  pathobiological	  early	  RA	  series.	  This	  is	  critical	  




agents	  modulate	  synovial	  pathobiology	  324,330,	  a	  factor	  that	  was	  not	  controlled	  for	  
in	  previous	  studies.	  Secondly	   the	  application	  of	   the	  minimally	   invasive	  technique	  
of	  US-­‐guided	  synovial	  biopsy	   to	   this	  cohort	  ensured	  that	  patients	  were	  recruited	  
irrespective	   of	   the	   need	   for	   significant	   large	   joint	   involvement	   resulting	   in	   an	  
unbiased	   cohort.	   In	   former	   studies,	   biopsies	   have	   been	   mainly	   obtained	   from	  
arthroplasty	  knee	  joints	  with	  by	  definition	  end-­‐stage	  disease	  and	  may	  not	  be	  well	  
representative	  of	  typical	  histopatology	  changes	  characteristic	  of	  the	  early	  phase	  of	  
the	  disease.	  
In	   previous	   works,	   an	   association	   between	   the	   histological	   features	   of	   the	  
synovial	   membrane	   and	   the	   clinical	   measures	   of	   disease	   activity	   have	   been	  
reported.	   409,410	   I	   could	   not	   detect	   any	   significant	   association	   between	   synovial	  
pathotype	   and	   clinical	   features	   including	   TJ,	   SJ,	   VAS-­‐GH,	   DAS28	   and	   HAQ.	   This	  
suggests	  that,	  at	  least	  in	  the	  early	  phase	  of	  the	  disease,	  clinical	  features	  of	  patients	  
showing	  different	  pathotypes	  may	  be	  indistinguishable.	  Nonetheless,	  the	  failure	  to	  
detect	   differences	   could	   be	   due	   to	   low	   statistical	   power	   related	   to	   the	   small	  
sample	  size,	  which	  may	  have	  led	  to	  a	  classic	  type	  2	  statistical	  error.	  
Importantly	  herein	  I	  provide	  evidence	  that	  a	  Pauci-­‐immune	  synovial	  pathotype	  is	  
seen	   in	   over	   30%	   of	   patients.	   This	   pathotype,	   although	   characterised	   by	   a	   low	  
level/virtually	  absence	  of	  an	   immune	  cells	   infiltrate	  and	  despite	  being	  associated	  
to	  a	   lower	   level	  of	   autoantibodies	   and	  acute	  phase	   reactants,	   is	   associated	  with	  
clinically	   active	   disease.	   Recent	   evidence	   emerging	   from	   transcriptomic	   analysis	  
suggests	   that	   different	   pathotypes	   segregate	   with	   different	   cellular	   expression,	  
specifically	   the	   Lymphoid	   and	   Myeloid	   pattern	   are	   mostly	   represented	   by	  




segregates	   with	   a	   predominant	   fibroblast	   expression.	   411	   This	   is	   notable	  
particularly	   in	   view	   of	   recent	   advances	   in	   understanding	   the	   unique	   role	   of	  
synovial	   mesenchymal	   stromal	   cells,	   and	   especially	   synovial	   fibroblasts,	   as	  
powerful	   modulators	   of	   the	   immune	   response.	   76,81	   Indeed	   stromal	   cells,	  
traditionally	  considered	  as	  structural,	  homeostatic	  supportive	  and	   immunological	  
inert	   cells,	   are	   proved	   to	   be	   actively	   involved	   in	   innate	   and	   adaptive	   immune	  
response.	  Ultimately	  they	  can	  be	  viewed	  as	  tissue-­‐resident	  modifiers,	  functioning	  
through	  crosstalk	  with	  cells	  of	  hematopoietic	  origin.	  412	  
Townsend	   et	   al	   propose	   a	   schematic	   model	   summarizing	   different	   cellular	  
contribution	   to	   RA	   pathogenesis,	   highlighting	   the	   fact	   that,	   while	   biological	  
features	  such	  as	  the	  expression	  of	  inflammatory	  markers	  and	  autoantibodies	  may	  
fluctuate	   over	   different	   pathotype	   groups,	   the	   clinical	   features	   may	   be	   similar	  













Figure	   3.2	   :	   Differential	   cellular	   contributions	   to	   disease	   pathogenesis	   in	   the	   rheumatoid	  
synovium	  
This	  schematic	  representations	  shows	  that	  different	  predominant	  cell	  subsets	   (lymphocytes,	  
macrophages	   and	   fibroblasts)	  may	   characterise	   the	   heterogeneity	   of	   inflamed	   synovium	   in	  
rheumatoid	  arthritis,	  although	  these	  may	  represent	  continuous	  rather	  than	  discrete,	  mutually	  
exclusive	  subsets.	  	  These	  distinct	  synovial	  pathotypes	  may	  translate	  into	  different	  expression	  
of	  autoantibodies	  and	  acute	  phase	  reactants	  (higher	  in	  the	  lymphocyte-­‐predominant	  pattern	  
and	   minimal/virtually	   absent	   in	   the	   fibroblast-­‐predominant	   pattern)	   despite	   similar	   clinical	  
features	  expressed	  as	  number	  of	  swollen	  and	  tender	  joints.	  
Abbreviations:	  SJC=	  swollen	  joint	  count,	  TJC=	  tender	  joint	  count.	  	  














In	   this	   work	   a	   significant	   role	   for	   lymphocytic	   aggregates	   in	   disease	  
pathogenesis	  is	  also	  supported	  by	  the	  significant	  association	  with	  PDUS	  measures	  
of	  synovitis.	  Given	  that	  this	  is	  an	  early	  arthritis	  cohort,	  the	  lack	  of	  association	  with	  
STUS	  is	  not	  surprising,	  as	  PDUS	  has	  been	  demonstrated	  to	  be	  a	  more	  sensitive	  and	  
responsive	   measure	   of	   disease	   activity	   with	   the	   STUS/PDUS	   ratio	   generally	  
reduced	  in	  early	  RA	  compared	  to	  chronic	  disease.	  405,406	  These	  results	  reinforce	  the	  
general	  notion	  that	  the	  extent	  of	  STUS	  synovitis	  correlates	  with	  disease	  duration,	  
probably	   reflecting	   the	   level	   of	   persistent	   inflammation	   and	   subsequent	   fibrotic	  
changes;	   in	   contrast,	   the	   presence	   of	   PDUS	   signal	   seems	   to	   be	   independent	   of	  
disease	   duration	   and	   appears	   a	   specific	   indicator	   of	   active	   inflammation	   at	   any	  
given	  time-­‐point.	  Crucially	  as	  the	  US	  assessment	  was	  performed	  immediately	  prior	  
to	  synovial	  biopsy	  the	  confounding	  effect	  of	  daily	  variability	  in	  the	  synovial	  micro-­‐
flow	  was	  minimized.	  413	  
An	   important	   limitation	   of	   US-­‐based	   studies	   is	   the	   lack	   of	   agreement	   on	   the	  
standard	   joint	   set	   that	   should	   be	   adopted	   for	   assessing	   US	   synovitis	   in	   RA	  
patients.	  	  The	  12	  joint	  set	  applied	  to	  this	  cohort	  has	  been	  utilized	  in	  previous	  case	  
series,	   therefore	   is	   not	   without	   validation.	   414	   Notably,	   I	   have	   observed	   a	  
significant	   correlation	   between	   measures	   of	   US	   synovitis	   expressed	   as	   PDUS	  
activity	   and	  measures	   of	   global	   inflammation	   and	   disease	   activity	   including	   ESR,	  
CRP	  and	  DAS28,	  which	  strength	  the	  validity	  of	  the	  joint	  set	  selection.	  However	  in	  
addition	  to	  considering	  whether	  local	  synovial	  pathobiology	  reflects	  global	  disease	  
activity	  a	  crucial	   future	   research	  question	   is	  whether	   this	   relationship	  persists	  at	  




Despite	  demonstrating	  a	  significant	  association	  between	  a	  Lymphoid	  pathotype	  
and	  high	   levels	  of	  ESR,	  ACPA/RF	  positivity	  and	  PDUS	  synovitis	   suggesting	  a	  more	  
severe	   clinical	   phenotype	   this	   was	   not	   associated	   with	   worse	   radiological	   joint	  
damage	  at	  baseline.	  There	  are	  a	  number	  of	  reasons	  for	  this,	  firstly:	  by	  definition,	  
due	  to	  inclusion	  of	  patients	  with	  a	  short-­‐disease	  duration	  (mean	  disease	  duration	  
5.4	  months),	  only	  a	   few	  patients	  are	  expected	   to	  present	  with	  structural	   change	  
on	  plain	  XR.	  Indeed,	  disease	  duration	  may	  be	  too	  short	  for	  the	  XR	  to	  be	  sensitive	  
enough	   to	   detect	   erosive	   changes	   and	   other	   radiological	   features	   such	   as	  
periarticular	  osteoporosis	  have	  been	  suggested	  to	  be	  more	  sensitive	  indicators	  of	  
disease	  severity.	  415	  It	  could	  be	  speculated	  that	  more	  sensitive	  techniques	  such	  as	  
US	  and	  MRI	  may	  have	  been	  able	  to	  detect	  early	  structural	  changes,	  and	  possibly	  
differences	  among	  histopathological	  groups.	  Future	  studies	  integrating	  an	  imaging	  
modality	   such	   as	  MRI,	  with	   the	   capacity	   to	   correlate	   synovial	   pathobiology	  with	  
early	  markers	   of	   joint	   damage	   such	   as	   cartilage	   loss,	   bone	  marrow	  oedema	  and	  
erosions	  are	  likely	  to	  yield	  significant	  results.	  
Finally,	  in	  this	  study	  I	  have	  not	  specifically	  looked	  for	  fibroblasts	  expression	  on	  
the	  IHC	  analysis,	  and	  therefore	  it	  cannot	  be	  inferred	  that	  the	  PI	  pathotype	  equates	  
to	   a	   predominant	   fibroblastic	   group.	   However	   a	   detailed	   genome-­‐wide	  









Chapter	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  SYNOVIAL	  PATHOTYPE	  PREDICTS	  CLINICAL	  














4.1	  	  	  INTRODUCTION	  	  
Predicting	   the	   clinical	   course	   of	   RA	   is	   challenging	   as	   wide	   inter-­‐individual	  
variation	   in	   clinical	   outcome	   and	   response	   to	   treatment	   exists.	   It	   has	   been	  
estimated	  that	  major	  differences	  in	  the	  outcome	  range	  10-­‐12	  fold	  over	  10	  years.	  
416	  Treating	  patients	  early,	  intensively	  and	  to	  target	  is	  instrumental	  in	  maximizing	  
the	   clinical	   benefits	   of	   treatment	   as	   well	   as	   achieving	   effective	   prevention	   of	  
functional	   decline.	   237	   The	   introduction	   of	   new	   drugs	   and	   specifically	   biologic	  
agents	   has	   also	   represented	   a	   major	   therapeutic	   advance	   over	   the	   last	   two	  
decades,	  however	  high	  costs	  of	   these	  drugs	   limit	   their	  use	   to	  patients	  who	  have	  
already	  failed	  first-­‐line	  treatment	  with	  csDMARD	  therapy.	  This	  approach	  may	  lead	  
to	  treatment	  delay	  for	  patients	  with	  more	  aggressive	  disease.	  Indeed	  it	  has	  been	  
suggested	  that	  earlier	  intervention	  with	  biologic	  therapy	  in	  combination	  with	  MTX	  
could	   be	   indicated	   in	   a	   proportion	   of	   patients.	   417,418	   On	   the	   other	   hand,	   an	  
intensive	  approach	  is	  probably	  not	  necessary	  for	  all	  patients	  with	  a	  new	  diagnosis	  
of	   RA,	   and	   giving	   all	   patients	   maximal	   treatment	   would	   not	   only	   incur	   high	  
healthcare	  costs	  but	  also	  expose	  individuals	  to	  unnecessary	  risk	  of	  side	  effects.	  	  419	  	  
Unfortunately,	  it	  is	  difficult	  to	  predict	  which	  patients	  will	  respond	  adequately	  to	  
various	   treatment	   regimens,	   with	   current	   treatment	   algorithms	   based	   on	  
sequential	   therapies	   derived	   from	   trial	   and	   error	   rather	   than	   risk-­‐stratification	  
approach.	  	  
A	   number	   of	   clinical,	   laboratory,	   and	   genetic	   markers	   have	   been	   associated	  
with	   severe	   prognosis,	   particularly	   the	   presence	   of	   RF	   and	   ACPA.	   420	   However,	  




patients	   who	   will	   progress	   into	   worst	   outcome	   and	   able	   to	   inform	   treatment	  
decisions	  on	  individual	  basis.	  97,421	  	  
In	   the	   recent	   years,	   the	   recognition	   of	   the	   synovium	   as	   the	   primary	   site	   of	  
inflammation	  has	  led	  to	  its	  evaluation	  as	  a	  biomarker	  of	  prognosis	  and	  therapeutic	  
response	   in	   RA	   with	   the	   underlying	   premise	   that	   biological	   heterogeneity	  
observed	  at	  the	  tissue	  level	  may	  affect	  subsequent	  clinical	  outcome	  and	  response	  
to	   treatment.	   Such	   an	   approach	   offers	   the	   potential	   to	   dissect	   RA	   pathogenesis	  
and	   therefore	   may	   facilitate	   the	   discovery	   of	   new	   disease	   pathways	   and	  
therapeutic	   targets,	   and	   ultimately	   the	   development	   of	   new	   generation	   target-­‐
specific	  drugs.	  
Previous	   studies	   have	   suggested	   that	   the	   degree	   of	   sublining	   CD68+	  
macrophage	  infiltration	  at	  baseline	  is	  associated	  with	  progressive	  joint	  damage.	  422	  
Furthermore,	   sublining	   layer	   macrophages	   have	   been	   confirmed	   as	   a	   robust	  
biomarker	  of	  clinical	  response	  to	  both	  csDMARD	  and	  biologic	  agents.	  64,332	  Further	  
data	  have	  also	  suggested	  that	  clinical	  response	  to	  anti-­‐TNF	  therapy	  may	  be	  related	  
to	   synovial	   tissue	   inflammation	   levels	   prior	   to	   treatment,	   providing	   proof	   of	  
concept	   that	   synovial	   biomarkers	   may	   be	   used	   to	   predict	   the	   response	   to	  
treatment.	  324,330	  
However,	  little	  attention	  has	  been	  given	  to	  the	  potential	  prognostic	  role	  of	  the	  
synovium	  in	  early	  RA,	  where	  a	  limited	  number	  of	  confounding	  factors	  impacts	  on	  
the	  features	  of	  synovial	  infiltrate	  with	  the	  potential	  therefore	  to	  robustly	  evaluate	  
synovial	  pathobiological	  biomarkers.	  	  
	  According	   to	   the	   2016	   update	   of	   the	   EULAR	   recommendations	   for	   the	  




of	  RA	  is	  made.	  A	  trend	  towards	  a	  clinical	  improvement	  should	  be	  observed	  within	  
the	  first	  3	  months	  of	  therapy,	  and	  the	  achievement	  of	  the	  treatment	  target	  should	  
be	  attained	  within	  6	  months.	  However	  it	  is	  recognised	  that	  achievement	  of	  clinical	  
response,	  and	  even	  stable	  clinical	  remission,	  is	  not	  sufficient	  to	  ensure	  favourable	  
outcome	   over	   time.	   The	   first	   evidence	   of	   a	   significant	   disconnection	   between	  
clinical	  composite	  indices	  of	  remission	  and	  imaging	  findings	  was	  demonstrated	  by	  
Brown	   et	   al.	   220	   By	   performing	   US	   and	   MRI	   of	   2nd-­‐5th	   MCPs	   and	   wrist	   of	   the	  
dominant	   hand	   in	   107	   patients	   who	   were	   in	   stable	   clinical	   remission	   following	  
csDMARD	   treatment,	   they	   found	   that	   both	   US	   and	   MRI	   showed	   persistent	  
subclinical	   synovitis	   in	   a	   considerable	   proportion	   of	   patients:	  in	   particular,	   PDUS	  
signal	  was	  present	   in	  43%	  and	  MRI	   signal	   in	  96%	  of	  asymptomatic	  patients	  with	  
clinically	  normal	  joints.	  Of	  most	  importance,	  in	  a	  subsequent	  study	  of	  102	  patients,	  
the	  persistence	  of	  imaging-­‐detected	  synovitis	  correlated	  with	  long-­‐term	  structural	  
damage	   with	   an	   OR	   of	   12.	   226	   Similar	   findings	   have	   been	   confirmed	   by	   other	  
authors.	  221,424	  Further	  studies	  showed	  that	  the	  presence	  of	  PDUS	  activity	  was	  an	  
accurate	  predictor	  of	  flare/short	  term	  relapse.	  369,406,425	  	  
It	  has	  been	  estimated	  that	  up	  to	  50%	  of	  patients	  with	  RA	  will	  develop	  structural	  
damage	  over	  the	  first	  year	  147	  and	  more	  than	  80%	  within	  the	  second	  year	  148,	  and	  
that	   this	   is	   associated	   with	   decline	   in	   functional	   capacity	   and	   quality	   of	   life.	  
However,	  not	  all	  patients	  progress	  in	  the	  same	  way.	  Clinical	  heterogeneity	  of	  RA	  is	  
in	   fact	   further	   confirmed	   by	   discovery	   of	   coexisting	   “slowly”	   and	   “rapidly”	  
progressive	  phenotypes.	  426	  Several	  potential	  predictors	  of	  structural	  damage	  have	  
been	  identified,	   including	  both	  biological	   (genetic	  markers,	  autoantibodies,	  acute	  




clinical	  indicators	  (pre-­‐existing	  joint	  damage,	  number	  of	  swollen	  and	  tender	  joints,	  
measures	  of	  disease	  activity,	  body	  mass	  index).	  However	  none	  have	  been	  reliably	  
sensitive	   or	   specific	   to	   be	   used	   in	   routine	   clinical	   practice.	   The	   role	   of	   synovial	  
pathobiology	  in	  predicting	  joint	  damage	  progression	  in	  RA	  has	  also	  been	  examined	  
with	  generally	  discrepant	  results.	  Klimiuk	  and	  co-­‐workers	  observed	  more	  advance	  
joint	  destruction	  in	  patients	  with	  lymphoid	  aggregates	  compared	  to	  those	  without,	  
supporting	  a	  direct	   contribution	  of	   these	   structures	   in	   sustaining	   tissue	  damage.	  
329	   van	   de	   Sande,	   in	   a	   prospective	   analysis	   of	   93	   patients	   with	   early	   arthritis,	  
concluded	  that	  the	  presence	  of	  a	  lymphoid	  pattern	  at	  baseline	  was	  not	  predictive	  
of	  the	  development	  of	  persistent	  and	  erosive	  arthritis	  after	  2	  years	  of	   follow-­‐up.	  
314	   However	   to	   date	   there	   has	   been	   no	   examination	   of	   the	   role	   of	   synovial	  
pathobiology	  in	  predicting	  radiographic	  damage	  in	  therapy	  naïve	  early	  RA	  patients.	  
It	  was	  on	  this	  background	  that	  I	  aimed	  at	  exploring,	  in	  a	  treatment	  naïve	  early	  
RA	   cohort,	  whether	   the	   synovial	   pathotype	   at	   baseline	  would	  be	   able	   to	   inform	  
clinical	  outcome	  after	  6	  months	  of	  csDMARD	  therapy.	  The	  key	  question	  is	  whether	  
synovial	   heterogeneity	   translates	   into	   diverse	   clinical	   outcomes,	   and	   specifically	  
whether	  a	  synovial	  biopsy	  at	  onset	  could	  predict	  response	  to	  csDMARD	  therapy	  at	  
6	   months.	   Furthermore,	   given	   this	   dissociation	   between	   clinically-­‐detected	   and	  
imaging-­‐detected	  synovitis	  reported	  across	  studies,	  and	  provided	  that	  US	  seems	  to	  
reflect	   more	   faithfully	   the	   intrinsic	   pathobiological	   process	   of	   the	   disease	  
compared	   to	  clinical	   tools,	  an	   important	  additional	  aspect	  of	  my	  work	  will	  be	   to	  
evaluate	  STUS	  and	  PDUS	  scores	  change	  at	  6	  months,	  and	  especially	  the	  differences	  




the	   relationship	   between	   the	   baseline	   pathotype	   and	   the	   progression	   of	  
radiographic	  damage	  at	  12	  months	  will	  be	  evaluated.	  
	  
4.2	  	  	  AIMS	  AND	  OBJECTIVES	  
The	   aim	   of	   this	   work	   is	   to	   test	   the	   hypothesis	   that	   distinct	   histological	  
pathotypes	  within	   the	   synovial	  membrane	   in	   a	   treatment	   naïve	   early	   RA	   cohort	  
provide	   characteristic	   prognostic	   implications,	   and	   specifically	   to	   determine	  
whether	  the	  presence	  of	  a	  specific	  synovial	  pathotype	  at	  baseline:	  
1) can	   predict	   clinical	   response	   to	   treatment	   at	   6	  months	   as	   determined	   by	  
DAS28	  changes	  and	  achievement	  of	  EULAR	  response	  criteria;	  
2) it	   is	   associated	  with	   significant	  modulation	   of	   STUS	   and	   PDUS	   scores	   at	   6	  	  
months;	  	  
3) it	  is	  associated	  with	  radiographic	  joint	  damage	  progression	  at	  12	  months.	  
	  
4.3	  	  	  MATERIALS	  AND	  METHODS	  
4.3.1	  	  	  Study	  population	  
63	  consecutive	  early	  RA	  patients	   (disease	  duration	  <12	  months,	   fulfilling	  2010	  
ACR/EULAR	  classification	  criteria	  4,	  csDMARD	  and	  corticosteroids	  naïve)	  recruited	  
as	   part	   of	   the	   PEAC	   study	   at	   Barts	   Health	   NHS	   Trust	   were	   included	   within	   the	  
study.	  The	  baseline	  characteristics	  of	  the	  study	  population	  have	  been	  described	  in	  





4.3.2	  	  	  Clinical	  assessment	  	  
Patients	  were	  assessed	  at	  baseline	  and	  then	  3	  monthly	  for	  12	  months.	  At	  each	  
visit,	  clinical	  and	   laboratory	  assessment	  was	  performed	  as	  described	  in	  Materials	  
and	   Methods.	   The	   DAS28	   was	   utilized	   to	   assess	   disease	   activity	   and	   guide	  
therapeutic	  management	  based	  on	  a	  treat	  to	  target	  approach	  (set	  target	  DAS28	  <	  
2.6,	  defining	  clinical	  remission).	  	  
	  
4.3.3	  US	  guided	  synovial	  biopsy	  
At	  baseline,	  all	  patients	  underwent	  an	  US-­‐guided	  synovial	  biopsy	  of	  one	  actively	  
inflamed	  joint	  as	  previously	  described	  (Chapter	  2,	  paragraph	  2.6).	  	  At	  6	  months,	  a	  
second	  biopsy	  of	  the	  same	  joint	  was	  also	  obtained.	  	  
	  
4.3.4	  Histopathological	  analysis	  
According	   to	   the	   features	  of	   the	  synovium,	  patients	  were	  stratified	   into	   three	  
synovial	   pathotype	   groups:	   PI,	  Myeloid	   or	   Lymphoid	   and	   the	   degree	   of	   immune	  
cell	   infiltration	  with	  CD20,	  CD3,	  CD68	  and	  CD138	  determined	  semi-­‐quantitatively	  
(0-­‐4).	  
	  
4.3.5	  Ultrasonographic	  and	  radiographic	  assessment	  
Ultrasonographic	   assessment	   was	   performed	   at	   baseline	   and	   at	   6	   months	  
follow-­‐up.	  	  Radiographic	  assessment	  was	  performed	  at	  baseline	  and	  at	  12	  months	  
follow-­‐up.	   Please	   refer	   to	   Chapter	   2	   (paragraphs	   2.4	   and	   2.5)	   for	   detailed	  





4.3.6	  	  Treatment	  	  
Immediately	  following	  US-­‐guided	  synovial	  biopsy,	  patients	  were	  commenced	  on	  
combination	  with	  MTX	  (target	  dose	  20	  mg/weekly)	  plus	  SSZ	  (target	  dose	  2	  g/daily)	  
or	   HCQ	   (target	   dose	   400	  mg/daily).	   Patients	   on	  MTX	   also	   received	   ≥	   5	  mg	   Folic	  
acid/weekly	  according	  to	  standard	  guidelines.	  Oral	  PRED	  was	  started	  at	  physician	  
discretion	  at	  the	  dose	  of	  ≤	  7.5	  mg/daily.	  Concomitant	  treatment	  with	  NSAIDs	  and	  
intra-­‐articular	   injections	  of	  corticosteroids	  were	  allowed	  for	  all	   treatment	  groups	  
at	   physician	   discretion.	   Given	   that	   this	   was	   an	   observational	   rather	   than	  
interventional	   study	   alternative	   therapeutic	   regimens	   were	   also	   permitted	   e.g.	  
Leflunomide	  or	  csDMARD	  monotherapy.	  	  
Clinical	  assessments	  were	  subsequently	  performed	  at	  3	  month	  intervals	  with	  a	  
treat-­‐to-­‐target	  approach	  to	  treatment	  escalation	  with	  an	  aim	  for	  clinical	  remission	  
(DAS28	   <	   2.6).	   In	   case	   of	   side	   effects,	   treatment	   was	   continued	   at	   the	   lowest	  
tolerated	  dosage.	  
Patients	   failing	   csDMARD	   therapy	   at	   6	   months	   were	   considered	   for	   biologic	  
agent	  in	  accordance	  with	  NICE	  guidelines	  http://www.nice.org.uk,	  and	  managed	  in	  
line	  with	  best	  practice.	  	  
	  
4.3.7	  	  	  Outcome	  measures	  
Primary	  outcomes	  assessed	  after	  6	  months	  of	  therapy	  were:	  	  
1) mean	  change	  in	  disease	  activity	  based	  on	  DAS28;	  
2) proportion	  of	  patients	  achieving	  EULAR	  response	  at	  6	  months.	  
Secondary	  outcomes	  were:	  




2) mean	  change	  in	  mean	  ShSS,	  JSN	  and	  JE	  scores	  at	  12	  months.	  
	  
4.3.8	  	  Statistical	  analysis	  
Continuous	   variables	   were	   expressed	   as	   mean	   (+/-­‐	   SD),	   ordinal	   variables	   as	  
median	  (+/-­‐	  IQR).	  
Comparisons	  of	  characteristics	  between	  PI,	  Myeloid	  and	  Lymphoid	  groups	  were	  
made	   using	   Chi-­‐Square	   test	   for	   qualitative	   variables	   or	   Kruskal	   Wallis	   test	   for	  
quantitative	  variables,	  as	  appropriate.	  	  
Spearman	   correlation	   coefficients	   were	   used	   for	   semi-­‐quantitative	   variables	  
and	  Pearson	  correlation	  coefficients	  for	  continuous	  variables.	  
Logistic	  regression	  analysis	  was	  performed	  to	  estimate	  if	  the	  synovial	  pathotype	  
was	  an	  independent	  predictor	  of	  response	  to	  therapy	  after	  6	  months.	  The	  relevant	  
adjusting	   variables	   were	   sequentially	   selected	   in	   the	   modelling	   process.	   The	  
results	  were	  expressed	  as	  OR	  with	  95%	  confidence	  intervals	  (95%	  CI).	  
The	  statistical	  analysis	  for	  clinical	  outcomes	  (primary	  outcome)	  was	  performed	  
on	   all	   patients;	   the	   statistical	   analysis	   for	   US	   and	   XR	   scores	   change	   (secondary	  
outcomes)	  were	  performed	  on	  patients	  with	  a	  complete	  dataset	  only.	  	  
Missing	   values	   in	   the	   dataset	  were	   imputed	   using	  multivariate	   imputation	   by	  
chained	   equations	   (MICE).	   The	  multiple	   imputations	   were	   implemented	   using	   R	  
3.0.2	  package	   ‘mice’.	   390	  All	  other	  statistical	  analyses	  were	  performed	  using	  SPSS	  
(IBM	   version	   21.0	   for	   Mac).	   All	   tests	   were	   2-­‐sided	   and	   a	   p-­‐value	   <	   0.05	   was	  





4.4	  	  	  RESULTS	  
4.4.1	  	  	  The	  presence	  of	  a	  baseline	  Lymphoid	  pathotype	  predicts	  clinical	  response	  	  
to	  csDMARD	  therapy	  	  
55	  patients	   (87.3%)	   received	  csDMARD	  combination	   (42	  MTX+	  SSZ,	  13	  MTX	  +	  
HCQ)	  and	  7	   (11.1%)	   csDMARD	  monotherapy	   (2	  MTX,	  1	  SSZ,	  4	  HCQ).	   In	  one	  case	  
(1.6%)	  csDMARD	  were	  not	  started	  as	  clinically	  contraindicated.	  41	  subjects	  (65%)	  
received	  oral	  PRED	  at	  the	  dose	  of	  7.5	  mg	  or	  less	  daily.	  Triple	  therapy	  (MTX	  +	  SSZ	  +	  
HCQ)	  was	   started	  at	   3	  months	   in	   5	  patients	  who	  were	   still	   presenting	  with	  high	  
disease	  activity	  (DAS28	  >	  5.1)	  despite	  initial	  combination	  with	  MTX,	  SSZ	  and	  PRED.	  	  
4	  patients	  were	  started	  on	  biologics	  (3	  anti-­‐TNFα,	  1	  Rituximab)	  as	  presenting	  with	  
high	  persistent	  disease	  activity	  at	  6	  months.	  
In	  order	  to	  determine	  whether	  clinical	  response	  to	  treatment	  was	  influenced	  by	  
synovial	  pathotype,	  I	  first	  evaluated	  the	  difference	  in	  DAS28	  between	  6	  month	  and	  
baseline	  and	  compared	  across	  the	  three	  histopathological	  groups.	  	  
The	  mean	  DAS28	  at	  baseline	  was	  5.8	  ±	  1.2	  and	  at	  6	  months	  was	  3.8	  ±	  2.0,	  with	  a	  
lower	  DAS28	  in	  the	  Lymphoid	  compared	  to	  the	  Myeloid	  and	  PI,	  although	  this	  did	  
not	   reach	   statistical	   significance	   (PI=4.3	   ±	   2.2,	  Myeloid=3.6	   ±	   1.9	   and	   Lymphoid	  
=3.4	  ±	  1.8,	  p=0.38).	  The	  mean	  change	  (∆)	   in	  DAS28	  between	  the	  two	  time-­‐points	  
was	   -­‐2.0	  ±	  2.0,	  with	  a	   larger	   fall	   in	  DAS28	   in	  patients	   characterised	  as	   Lymphoid	  
(PI=-­‐1.1	  ±	  1.9,	  Myeloid=-­‐2.1	  ±	  2.1,	  Lymphoid=-­‐2.8	  ±	  1.6,	  p=0.01)	  Figure	  4.1.	  	  





Figure	  4.1:	  The	  Lymphoid	  histopathotype	  is	  associated	  with	  a	  higher	  fall	  
in	  DAS28	  at	  6	  months 
Abbreviations:	   ∆DAS28=	   mean	   change	   in	   28	   joint	   count-­‐Disease	   Activity	  
Score;	  SD=	  standard	  deviation. 




















Kruskal Wallis test 




Importantly,	   when	   Student’s	   test	   was	   applied	   it	   resulted	   that	   the	   change	   in	  
DAS28	  was	  not	  significantly	  affected	  by	  its	  baseline	  values	  (t=	  1.61,	  p=0.11).	  	  
There	   was	   a	   significant	   correlation	   between	   the	   ∆DAS28	   and	   baseline	  
expression	  of	  CD3	   (r=-­‐0.32,	  p=0.01),	  CD20	   (r=-­‐0.36,	  p<0.01)	   and	  CD68sl	   (r=-­‐0.34,	  
p=0.01),	  indicating	  that	  the	  higher	  the	  cellular	  infiltrate	  at	  baseline,	  the	  higher	  the	  
magnitude	  of	  the	  change	  in	  disease	  activity.	  
In	   addition	   the	   rate	   of	   patients	   that	   were	   EULAR	   responders	   was	   calculated,	  
and	  the	  proportion	  of	  responders	  in	  each	  pathotype	  group	  determined.	  A	  total	  of	  
43/63	   patients	   (68.3%)	   were	   good/moderate	   responders,	   with	   a	   significantly	  
higher	   number	   of	   patients	   responding	   within	   the	   Lymphoid	   group	   (PI:	  Myeloid:	  











Figure	   4.2:	   A	   significantly	   higher	   number	   of	   patients	   with	   a	   Lymphoid	   pathotype	  
achieved	  a	  EULAR	  response	  at	  6	  months	  vs	  Myeloid	  or	  Pauci-­‐immune	  











	   	  































Chi square test 




Furthermore	  when	  determining	  whether	   there	  were	   significant	   differences	   in	  
numbers	   of	   patients	   achieving	   EULAR	   good	   response	   within	   each	   pathotype	   I	  
found	   that	   it	   was	   significantly	   lowest	   in	   the	   PI	   group	   (PI:	   Myeloid:	   Lymphoid	   =	  
35.0%:	   55.6%:	   54.2%,	   p=0.06).	   However	   the	   numbers	   of	   patients	   reaching	   low	  
disease	   activity	   (DAS28	   ≤	   3.2)	   and	   remission	   (DAS28	   <	   2.6)	  was	   not	   significantly	  
different	  across	  the	  three	  groups	  (p=0.19	  and	  p=0.93,	  respectively).	  
I	   also	   found	   that	   baseline	   expression	   of	   CD3,	   CD20	   and	   CD68sl	   within	   the	  
synovium	   was	   significantly	   higher	   in	   patients	   who	   achieved	   EULAR	   response	  
compared	   to	  non	   responders:	   CD3=	  2.0	   (1.0-­‐3.0)	  vs	   1.0	   (0.0-­‐2.1),	   p=0.04;	   CD20=	  
1.7	   (0.0-­‐3.0)	   vs	   0.2	   (0.0-­‐1.7),	   p=	   0.049;	   CD68sl=	   3.0	   (2.0-­‐4.0)	   vs	   1.0	   (1.0-­‐3.0),	  
p=0.01.	  	  
I	   then	  performed	  a	   logistic	  regression	  analysis	  to	  assess	  the	  factors/covariates	  
predicting	  EULAR	  response.	  Variables	   included	   in	   the	  analysis	  were:	  gender,	  age,	  
ESR,	  CRP,	  DAS28,	  ACPA	  and	  RF	   status,	  use	  of	  oral	   steroids,	  PDUS,	   ShSS,	   synovial	  
pathotype.	  Each	  variable	  was	  tested	  for	  the	  association	  with	  EULAR	  response	  using	  
univariate	  logistic	  regression	  analysis,	  then	  multivariate	  logistic	  regression	  analysis	  
was	   performed	   using	   a	   backward	   stepwise	   method	   to	   select	   independent	  
predictors.	   Results	   are	   showed	   in	   Table	   4.1.	   Age	   and	   synovial	   pathotype	   were	  
identified	  as	  significant	  predictors	  of	  EULAR	  response,	  however	  synovial	  pathotype	  







 Univariate model Multivariate model 
 OR CI 95% p value OR CI 95% p value 
 Gender 1.733 0.485-6.199 0.39    
Age 0.981 0.951-1.012 0.22 0.900 0.835-0.970 <0.01 
ESR 1.004 0.984-1.025 0.68    
CRP 0.999 0.980-1.019 0.94    
DAS28 0.901 0.576-1.409 0.64    
ACPA+ 0.455 0.145-1.422 0.17    
RF+ 0.600 0.196-1.834 0.37    
Oral steroids 0.724 0.241-2.173 0.56    
PDUS 1.050 0.978-1.128 0.17    
ShSS 1.011 0.973-1.050 0.57    
Synovial pathotype 2.531 1.250-5.125 0.01 7.714 2.046-29.085 <0.01 
 
	  
Table	  4.1:	   	  Association	  between	  baseline	  characteristics	  and	  EULAR	  response	  at	  6	  months	  using	  
univariate	  logistic	  regression	  analysis	  and	  multivariate	  logistic	  regression	  analysis	  
Abbreviations:	  ACPA=	  anti-­‐cyclic	  citrullinated	  proteins	  antibodies;	  CI=	  confidence	  interval;	  CRP=	  C-­‐
reactive	   protein;	   DAS28=	   28	   joint	   count-­‐Disease	   Activity	   Score;	   ESR=	   erythrocyte	   sedimentation	  
rate;	   OR=	   odds	   ratio;	   PDUS=	   power	   doppler	   ultrasound;	   RF=	   rheumatoid	   factor;	   ShSS=	   van	   der	  

















4.4.2	   	   	   Fall	   in	   sublining	  macrophage	  number	   significantly	   correlates	  with	   fall	   in	  
DAS28	  at	  6	  months.	  	  
A	  second	  biopsy	  of	  the	  same	  joints	  was	  obtained	  for	  49	  patients	  at	  6	  months.	  
Pre-­‐	  and	  post-­‐treatment	  paired	  biopsy	  data	  were	  available	  for	  44	  patients.	  	  
I	  went	  onto	  to	  examine	  whether	  changes	  in	  SQ	  sublining	  macrophage	  number	  
between	   baseline	   and	   6	  months	   correlated	   significantly	  with	   changes	   in	   DAS28.	  	  
Paired	  synovial	  samples	  and	  clinical	  outcome	  data	  were	  available	  for	  44	  patients.	  
In	   line	   with	   previously	   reported	   data	   a	   significant	   correlation	   was	   observed	  





















	  	  	  	  
Figure	  4.3:	  Correlation	  between	  change	  in	  clinical	  disease	  activity	  and	  change	  
in	  semi-­‐quantitative	  sublining	  macrophages	  between	  baseline	  and	  6	  months	  
Abbreviations:	   ΔCD68sl=	   mean	   change	   in	   semi-­‐quantitative	   sublining	  	  	  	  	  	  














    p= 0.01 





4.4.3	   	   	   A	   numerically	   larger	   decrease	   in	   power	   doppler	   ultrasound	   synovitis	  
scores	  was	  seen	  in	  patients	  with	  a	  baseline	  Lymphoid	  	  pathotype	  	  
Next	   US	   response	   was	   examined.	   STUS	   and	   PDUS	   scores	   at	   6	   months	   were	  
correlated	  with	  laboratory	  and	  clinical	  markers	  of	  disease	  activity.	  	  
	  Paralleling	  results	  from	  baseline	  scores,	  PDUS	  at	  6	  months	  correlated	  with	  ESR	  
(r=0.40,	   p<0.01),	   CRP	   (r=0.72,	   p<0.01)	   and	   DAS28	   (r=0.29,	   p=0.04),	   meanwhile	  
STUS	  correlated	  with	  CRP	  only	  (r=0.39,	  p<0.01).	  	  
In	   order	   to	   determine	   whether	   STUS	   and	   PDUS	   scores	   changed	   in	   line	   with	  
clinical	  response,	  the	  variation	  of	  STUS	  and	  PDUS	  scores	  between	  baseline	  and	  6	  
months	  were	  correlated	  with	  the	  variation	  of	  DAS28	  in	  the	  cohort	  of	  47	  patients	  in	  
which	   paired	   US	   data	   was	   available:	   there	   was	   no	   significant	   association	   with	  
mean	   change	   in	   DAS28	   and	   mean	   change	   in	   STUS	   score	   (r=0.16,	   p=0.28)	  
meanwhile	   a	   significant	   correlation	   with	   mean	   change	   in	   PDUS	   score	   was	  
















Figure	  4.4:	  Fall	  in	  PDUS	  parallels	  fall	  in	  DAS28	  after	  6	  months	  	  
Abbreviations:	  ΔDAS28=	  mean	  change	  in	  28	  joint	  count-­‐Disease	  Activity	  Score;	  	  
ΔPDUS=	  mean	  change	  in	  power	  doppler	  ultrasound	  score.	   	  
p < 0.01 






	  	  	  Next	   given	   the	   importance	   of	   the	   modulation	   of	   US	   synovitis	   in	   determining	  
outcome	   for	   patients	   with	   RA	   427,	   the	   mean	   change	   in	   STUS	   and	   PDUS	   scores	  
between	  baseline	  and	  6	  month	  follow-­‐up	  was	  compared	  across	  the	  three	  synovial	  
pathotype	  groups.	  There	  was	  a	  trend	  toward	  larger	  mean	  fall	  in	  PDUS	  score	  in	  the	  
Lymphoid	  	  	  group	  	  compared	  	  to	  	  the	  	  other	  	  two	  	  groups	  	  (PI:	  Myeloid:	  Lymphoid	  =	  















	  	  	  
	  	  	  	  
	  	  	  Figure	  4.5:	  The	  presence	  of	  a	  Lymphoid	  histopathotype	  is	  associated	  with	  a	  trend	  in	  
higher	  fall	  in	  PDUS	  
	  	  	  Abbreviations:	  ΔPDUS=	  mean	  change	  in	  power	  doppler	  ultrasound	  score.	  
	  
	   	  
p= 0.08 
Kruskal Wallis test 




I	  also	  observed	  a	  significantly	  larger	  mean	  fall	  in	  the	  Lymphoid	  vs	  PI	  group	  in	  PDUS	  
score	   (p=0.02)	  but	  not	   in	  STUS	  score	   (p=0.91).	  Given	   the	   reverse	   ratios	  between	  
STUS	  and	  PDUS	  in	  early	  versus	  late	  disease	  405,406	  and	  previous	  data	  supporting	  a	  
critical	  role	  for	  PDUS	  but	  not	  for	  STUS	  in	  predicting	  disease	  progression	  226	  such	  a	  
result	   is	   not	   surprising	   and	   provides	   further	   support	   for	   the	   concept	   that	   a	  
Lymphoid	  pathotype	  is	  associated	  with	  more	  robust	  response	  to	  csDMARD	  in	  early	  
RA.	  
Finally	  I	  also	  went	  on	  to	  stratify	  patients	  into	  patients	  with	  a	  PDUS	  score	  ≤1	  and	  
>1	  and	  examined	  whether	  there	  were	  differences	  in	  numbers	  between	  the	  three	  
pathotypes.	  Overall	  53.2%	  of	  patients	  showed	  PDUS	  score	  ≤	  1	  and	  no	  significant	  
difference	  across	  the	  three	  pathotype	  groups	  was	  observed	  (p=0.49).	  
	  
4.4.4	   	   	   The	   synovial	   pathotype	   at	   baseline	   is	   not	   associated	   with	   significant	  
radiographic	  progression	  at	  12	  months	  
Finally	  in	  the	  group	  of	  42	  patients	  with	  a	  paired	  set	  of	  radiographic	  films	  at	  both	  
baseline	  and	  12	  months,	  the	  relationship	  between	  synovial	  pathotype	  at	  baseline	  
and	   joint	   damage	   progression	   was	   examined.	   Importantly	   the	   characteristics	   of	  
patients	  without	  paired	  data	  did	  not	  differ	  from	  the	  whole	  group.	  
Mean	   total	   ShSS,	  mean	   JSN	  and	  mean	   JE	  between	   synovial	   pathotype	  groups	  
were	  examined.	  In	  addition	  the	  mean	  change	  (∆)	  between	  baseline	  and	  12	  months	  
in	   the	   three	   radiographic	   parameters	   was	   evaluated	   and	   compared	   across	   the	  
three	   histopathotypes.	   No	   association	   between	   the	   histopathotype	   and	   the	  
erosive	   status	   at	   12	   months	   (mean	   ShSS,	   JSN	   and	   JE	   scores)	   as	   well	   as	   the	  




12	  months	  and	  baseline)	  was	  observed.	  The	  proportion	  of	  patients	  who	  showed	  a	  
progression	   in	   the	   ShSS	  was	  numerically	   higher	   in	   the	   Lymphoid	   group	   (35%)	   vs	  
the	  Myeloid	   group	   (20%)	   vs	   the	   PI	   group	   (10%),	   although	   these	   results	   did	   not	  
reach	   statistical	   significance	   (p=0.30).	   This	   is	   likely	   due	   to	   a	   number	   of	   factors	  
including	  the	  small	  number	  of	  patients	  with	  paired	  radiographic	  data.	  
A	  significant	  correlation	  between	  serum	  levels	  of	  RF	  at	  baseline	  with	  JE	  score	  at	  
12	  months	  (r=0.46,	  p<0.01)	  and	  ∆JE	  	  (r=0.43,	  p<0.01)	  was	  found,	  confirming	  wide	  
reports	  of	  RF	  as	  a	  strong	  predictor	  of	   radiological	  progression.	   354,420,428-­‐430	  These	  
results	  may	   reinforce	   the	   importance	   of	   the	   relationship	   between	   the	   antibody	  
titre	   at	   baseline	   and	   the	   joint	   damage	   during	   the	   course	   of	   RA,	   as	   reported	   by	  
other	   authors	   431,432	   and	   also	   highlighted	   by	   2010	   ACR/EULAR	   criteria.	   4	  
Intriguingly,	  a	  significant	  correlation	  between	  the	  number	  of	  synovial	  CD138	  and	  
the	  delta	  JE	  score	  was	  observed	  (r=0.35,	  p=0.02),	  suggesting	  that	  the	  plasma	  cells	  
in	   the	   synovium	   could	   be	   a	   direct	   source	   of	   pathogenetic	   antibodies.	   Although	  
significant	   correlations	   between	   structural	   progression	   and	   the	   ACPA	   levels	   at	  
baseline	  have	  been	  widely	  reported	  in	  the	  literature	  353,356,433,434,	  I	  was	  not	  able	  to	  
confirm	  similar	  results	  herein.	  	  
Notably	  in	  the	  patients	  that	  achieved	  US	  remission	  (PDUS	  score	  ≤1)	  at	  6	  months	  
versus	  those	  that	  did	  not,	  the	  JE	  score	  was	  significantly	  lower	  at	  12	  months	  (1.2	  ±	  
2.8	  vs	  3.5	  ±	  6.2,	  p=0.01)	  in	  addition	  to	  a	  significantly	  lower	  increase	  in	  JE	  between	  
baseline	  and	  12	  months	  (0.0	  ±	  0.2	  vs	  0.3	  ±	  0.4,	  p=0.04).	  	  This	  result	  is	  in	  line	  with	  
previous	   data	   demonstrating	   that	   persistent	   US	   synovitis	   associates	   with	   worse	  





4.5	  	  	  DISCUSSION	  
RA	   is	   characterised	   by	   biological	   and	   clinical	   variability,	   including	  
heterogeneous	  response	  to	  treatment.	  The	  extent	  and	  the	  features	  of	  the	  immune	  
cell	  infiltrate	  within	  the	  synovium	  are	  variable	  among	  individuals	  with	  RA	  since	  the	  
early	   stage	   of	   the	   disease.	   In	   some	   patients,	   a	   scarce/absent	   infiltration	   is	  
observed;	   in	   others	   the	   cellular	   infiltrate	   is	   randomly	   diffused	   within	   the	   joint	  
tissue;	  in	  a	  few	  more,	  B	  and	  T	  cells	  are	  organised	  into	  lymphocyte	  aggregates	  that	  
may	  exhibit	  germinal	  centre–like	  features.	  At	  present,	  it	  is	  unknown	  whether	  there	  
is	  a	  differential	  response	  to	  specific	  treatments	  between	  patients	  exhibiting	  these	  
distinct	  pathogenic	  subsets.	  	  
Herein	  I	  have	  investigated	  the	  relationship	  between	  the	  pre-­‐treatment	  synovial	  
pathotype	  and	  the	  clinical	  response	  to	  first	   line	  csDMARD	  in	  a	  cohort	  of	  63	  early	  
RA	  patients	  after	  6	  months	  of	  therapy.	  
The	  results	  revealed	  a	  highly	  significant	  relationship	  between	  the	  presence	  of	  a	  
specific	   synovial	   pathotype	   at	   baseline	   and	   the	   primary	   clinical	   response	   to	  
csDMARD.	  When	  the	  synovial	  pathotype	  was	  added	  into	  a	  prediction	  model	  along	  
with	   demographics,	   clinical	   and	   serological	   parameters,	   and	   after	   adjusting	   for	  
potentially	   confounding	   variables	   by	   multivariate	   analysis,	   the	   presence	   of	   a	  
Lymphoid	   pathotype	   resulted	   as	   a	   strong	   independent	   predictor	   of	   response	   to	  
therapy.	  Conversely,	  the	  predominance	  of	  a	  Pauci-­‐immune	  histological	  pattern	  in	  
the	   non-­‐responder	   group	   suggests	   that	   this	   subset	   may	   be	   associated	   with	  
treatment	   resistant	   early	   RA.	   Because	   the	   patients	   with	   a	   Lymphoid	   pathotype	  
were	  presenting	  with	  features	  of	  more	  severe	  disease	  such	  as	  higher	  level	  of	  ESR	  




postulated	   that	   these	   patients	   were	   likely	   to	   have	   received	   more	   intensive	  
treatment.	  That	  was	  not	  the	  case	  in	  the	  present	  cohort,	  as	  the	  treatment	  was	  not	  
different	  across	  categories.	  This	  because	  all	  patients	  had	  similar	  degree	  of	  disease	  
activity	   expressed	   by	   DAS28	   score	   and	   were	   therefore	   managed	   intensively.	  
Moreover,	  the	  use	  of	  steroids	  was	  similar	  across	  the	  3	  histopathotype	  categories	  
and	   has	   not	   been	   selected	   as	   a	   potential	   predictor	   of	   response	   in	   the	   logistic	  
regression	  model.	  	  
Previous	  data	  has	  suggested	   that	  a	  Lymphoid	  pathotype	  can	  predict	   response	  
to	  Infliximab	  in	  csDMARD	  resistant	  RA	  patients.	  324	  However	  this	  is	  the	  first	  report	  
in	   a	   treatment	   naïve	   early	   RA	   cohort	   examining	   response	   to	   csDMARD.	   The	  
majority	   of	   patients	  were	   treated	  with	  MTX	   (90%),	   with	   68.3%	   (43/63)	   patients	  
achieving	  a	  moderate/good	  EULAR	  response	  at	  6	  months.	  Given	  that	  MTX	  remains	  
the	   gold	   standard	   first-­‐line	   treatment	   for	   patients	   with	   RA	   253	   despite	   a	   poorly	  
understood	  mechanism	  of	  action	  435,	  elucidating	  the	  heterogeneous	  responses	  to	  
treatment	   and	   moreover	   identification	   of	   a	   robust	   prognostic	   biomarker	   of	  
response	   would	   prove	   invaluable.	   	   Clinical	   response	   to	   MTX	   therapy	   is	  
multifactorial,	   and	   several	   key	   elements	   such	   as	   pharmacogenetics,	  
pharmacokinetics	   and	   pharmacodynamics	   are	   involved,	   which	   have	   not	   been	  
explored	   in	   the	   present	   work.	   In	   particular,	   it	   has	   been	   reported	   that	   several	  
genetic	  variants	  have	  been	  associated	  to	  MTX	  response,	  such	  as	  polymorphisms	  in	  
genes	   coding	   for	   methylenetetrahydrofolate	   reductase	   (MTHFR),	   adenosine	  
monophosphate	  deaminase	  1	  (AMPD1),	  and	  several	  others.	  436-­‐440	  Interpreting	  our	  
data	  is	  complicated	  by	  the	  fact	  that	  the	  majority	  of	  patients	  (87.3%)	  were	  treated	  




current	   evidence	   supporting	   either	   initial	   combination	   or	   a	   subsequent	   step	   up	  
approach	  232,266,441,	  however	  the	  superiority	  of	  initial	  csDMARD	  combination	  versus	  
MTX	   monotherapy	   remains	   controversial	   442.	   	   In	   future	   dissecting	   key	  
inflammatory/immune	  pathways	  at	  the	  molecular	  level	  are	  likely	  to	  elucidate	  such	  
heterogeneous	   responses,	   including	   whether	   differential	   expression	   of	  
lymphocytic	  versus	  myeloid/fibroblast	  pathways	  mediate	   short	  and/or	   long	   term	  
outcome	  as	  previously	  postulated.	  297	  
A	   further	  element	   that	   is	  worth	  of	  note	   is	   the	  significant	  correlation	  between	  
the	   post-­‐treatment	   reduction	   in	   DAS28	   and	   CD68sl.	   The	   change	   in	   CD68sl	   is	   an	  
established	   biomarker	   for	   evaluating	   response	   to	   treatment	   in	   established	   RA	  
64,332,443.	  However	  this	  relationship	  has	  not	  been	  extensively	  reported	   in	  early	  RA	  
yet,	   therefore	   this	   data	   is	   relevant.	   This	   suggests	   that	   the	   changes	   seen	   in	   the	  
synovial	  tissue	  truly	  reflect	  the	  inflammatory	  process	  and	  the	  clinical	  features	  over	  
time.	  	  	  
Then	  when	  analysing	  US	  data,	  I	  observed	  a	  significant	  correlation	  between	  the	  
mean	  change	  in	  DAS28	  and	  the	  mean	  change	  in	  the	  PDUS	  scores,	  but	  not	  between	  
DAS28	   and	   STUS	   scores.	   When	   comparing	   the	   mean	   changes	   across	   the	   three	  
pathotypes,	   there	  was	  a	   trend	   toward	   larger	  mean	   fall	   in	  PDUS	   in	   the	  Lymphoid	  
group,	  however	   this	  did	  not	   reach	   statistical	   significance	   (p=0.08).	  Anyway	   there	  
are	   some	   important	   considerations	  when	   interpreting	   this	  data.	   Firstly	  only	  74%	  
(47/63)	  patients	  had	  paired	  STUS	  and	  PDUS	  scores.	  Secondly	  a	  limited	  set	  of	  joints	  
has	   been	   examined	   that	   could	   not	   have	   reflected	   with	   sufficient	   accuracy	   the	  
synovial	   inflammatory	  process.	  The	   incorporation	  of	  other	   joints	  particularly	   feet	  




realistic	  picture	  of	  the	  global	  synovitis	  (personal	  communication).	  However,	  from	  a	  
practical	  perspective,	  several	  studies	  have	  highlighted	  the	  utility	  of	  PDUS	  score	  of	  
the	  hand	  and	  wrist	   joints	   for	   the	  monitoring	  of	  synovitis,	  which	  mostly	   influence	  
clinicians'	   decisions	   in	   the	  daily	   rheumatology	  practice.	   414	  Another	   aspect	   to	  be	  
considered	  is	  that	  the	  sensitivity	  to	  change	  for	  the	  US	  could	  be	  lower	  compared	  to	  
the	   clinical	   composite	   indices	   such	   as	   DAS28.	   These	   findings	   are	   in	   accordance	  
with	   several	   studies	   that,	   although	   demonstrating	   the	   superiority	   of	   STUS	   and	  
PDUS	  over	  clinical	  examination	  with	  regard	  to	  reliability	  in	  reflecting	  synovitis,	  did	  
not	   show	   enhanced	   sensitivity	   to	   change	   for	   the	   US	   parameters	   compared	   to	  
clinical	  parameters.	  444,445	  
Finally	   I	   examined	   whether	   baseline	   synovial	   pathotype	   associated	   with	  
radiographic	   outcome	   at	   12	   months.	   Again	   this	   data	   should	   be	   interpreted	  
cautiously,	   as	   only	   66%	   (42/63)	   patients	   had	   paired	   radiographs	   available	   for	  
analysis.	  Secondly	  the	  commencement	  of	  biologic	  therapy	  in	  4	  patients	  within	  the	  
12	   month	   follow-­‐up	   period	   are	   likely	   to	   have	   significant	   impact	   on	   the	   results	  
257,276.	  Future	  studies	  integrating	  an	  imaging	  modality	  like	  MRI,	  with	  the	  capacity	  to	  
correlate	   synovial	   pathobiology	   with	   early	   markers	   of	   joint	   damage	   such	   as	  
cartilage	  loss,	  bone	  marrow	  oedema	  and	  erosions	  are	  warranted.	  
55%	  of	  patients	  in	  clinical	  remission	  at	  6	  months	  had	  persistent	  PDUS,	  and	  this	  
associated	  with	  a	   significantly	  higher	   joint	  erosion	   score	  at	  12	  months.	  This	   is	   in	  
line	   with	   previous	   data	   demonstrating	   that	   persistent	   synovial	   neo-­‐vascularity	  
equates	   to	   higher	   levels	   of	   radiological	   damage	   and	   reinforces	   recent	   initiatives	  
such	   as	   US	   treat	   to	   target	   227.	   A	   shortfall	   of	   this	   analysis	   is	   that	   I	   have	   used	   an	  




adopted	   by	   other	   groups	   222,	   although	   most	   studies	   have	   opted	   for	   a	   more	  
stringent	  one,	  namely	  absence	  of	  PDUS	  signal	  405,406,446-­‐448.	  Indeed	  the	  definition	  of	  
US	  remission	  is	  still	  vague	  and	  remission	  criteria	  vary	  from	  one	  group	  to	  another,	  
as	  the	  minimal	  accepted	  level	  of	  US	  remains	  unknown.	  227,376	  	  
In	  conclusion,	  this	  data	  highlights	  the	  potential	  role	  of	  synovial	  pathotype	  as	  a	  
biomarker	   of	   response	   to	   csDMARD	   therapy	   in	   patients	   with	   early	   RA.	   This	   is	  
relevant	   particularly	   because	  none	  of	   the	   laboratory,	   clinical	   or	   imaging	   findings	  
were	   predictive	   of	   clinical	   response.	   Once	   assessed	   that	   the	   probability	   of	  
response	   to	   early	   csDMARD	   treatment	   is	   low	   in	   specific	   groups	   of	   patients,	  
therapeutic	  alternatives	  should	  be	  explored.	  	  
The	   present	   findings	   support	   a	   role	   for	   synovial	   biopsy	   studies	   in	   the	  
stratification	   of	   early	   RA	   patients.	   Additional	   and	   implemented	   studies	   in	   larger	  
cohorts	   are	   needed	   to	   replicate	   these	   results	   and	   provide	   further	   insight	   in	   the	  














Chapter	  5 :	   SYNOVIAL	   PATHOTYPE	   PREDICTS	  
RESPONSE	   TO	   CERTOLIZUMAB	   PEGOL	   IN	   PATIENTS	  











5.1	  	  	  INTRODUCTION	  
Despite	   major	   therapeutic	   advances	   over	   the	   last	   two	   decades,	   the	  
management	  of	  RA	   remains	  problematic.	   	  Approximately	  30–40%	  of	  patients	  do	  
not	   respond	  to	   initial	   treatment	  with	  MTX	  alone	  or	   in	  combination	  with	  steroids	  
and/or	   other	   csDMARD.	   269	   After	   failure	   of	   csDMARD	   therapy,	   second	   line	  
treatment	  with	  biologic	  drugs	  is	  commenced,	  in	  most	  cases	  TNF	  inhibitors	  (TNFi).	  
Nonetheless	   only	   70%	   of	   patients	   respond	   to	   first	   line	   biologic,	   and	   only	   30%	  
achieve	   a	   state	   of	   low	   disease	   activity	   or	   remission	   449,450	  Moreover,	   30-­‐40%	   of	  
initial	  responders	  subsequently	  develop	  an	  inadequate	  response.	  451	  
Unfortunately,	  predictors	  of	  response	  to	  anti-­‐rheumatic	  therapy	  including	  TNFi	  
are	  scarce.	   350,452,453	  Mechanisms	  of	   response/non	  response	  are	   largely	  unknown	  
and	  treatment	  strategies	  are	  still	  based	  on	  a	  ‘trial	  and	  error’	  approach	  rather	  than	  
on	  prognostic	  stratification	  of	  patients.	  382	  Given	  the	  clinical	  heterogeneity	  of	  RA	  in	  
addition	  to	  variable	  therapeutic	  response,	  factors	  such	  as	  prognostic	  outcome	  may	  
need	   to	   be	   incorporated	   into	   therapeutic	   algorithms	   given	   the	   potential	   toxicity	  
and	  high	  cost	  of	  biologic	  drugs.	  454	  
Currently	  five	  TNFi	  are	  approved	  for	  the	  treatment	  of	  RA	  in	  Europe	  and	  the	  US:	  
Infliximab,	   Etanercept,	   Adalimumab,	   Certolizumab	   pegol	   and	   Golimumab.	  
Numerous	  studies	  have	  shown	  that	  these	  agents	  display	  similar	  effects	  in	  terms	  of	  
efficacy	   and	   safety	   profile.	   450	   However	   they	   have	   distinct	   pharmacokinetic	   and	  
pharmacodynamic	   properties	   that	   may	   affect	   their	   biological	   and	   clinical	  
properties.	  Certolizumab	  pegol	  (CZP)	  -­‐the	  agent	  utilized	  in	  this	  research	  project-­‐	  
has	  a	  unique	  biochemical	  structure,	  as	  it	  is	  the	  only	  pegylated	  compound	  among	  




proteins	  with	  polyethylene	  glycol	  (PEG),	  leads	  to	  a	  number	  of	  biopharmaceutical	  
improvements,	   including	   increased	   half-­‐life,	   increased	   solubility	   and	   reduced	  
immunogenicity.	   455	   In	   contrast	   to	   the	   other	   TNFi,	   CZP	   does	   not	   cause	  
complement-­‐dependent	   cytotoxicity	   (CDC)	   and	   antibody-­‐dependent	   cell-­‐
mediated	   cytotoxicity	   (ADCC),	   because	   of	   the	   lack	   of	   a	   Fc	   region.456	   Animal	  
studies	   have	   demonstrated	   that	   CZP	  may	   also	   penetrate	  more	   effectively	   into	  
inflamed	  arthritic	  tissue	  than	  other	  TNFi.	  457	  	  
Anti-­‐TNFα	   agents	   interfere	  with	   a	   number	   of	   significant	   pathways	   driving	   RA	  
pathogenesis	  within	  the	  synovium:	  these	   include	   local	  production	  of	  chemokines	  
and	   cytokines	   458,459,	   endothelial	   expression	   of	   adhesion	   molecules	   460,461,	  
regulation	   of	   cellular	   infiltrate	   462,	   production	   of	   matrix	   metalloproteinases	   463.	  
Within	   this	   thesis	   I	   have	   demonstrated	   that	   both	   the	   extent	   and	   the	   pattern	   of	  
synovial	   immune	   infiltration	   are	   remarkably	   variable	   among	   different	   individual	  
with	  early	  RA,	  associate	  with	  specific	  clinical	  phenotypes	  and	  predict	  response	  to	  
csDMARD.	   However	   whether	   the	   synovial	   pathotypes	   may	   be	   used	   to	   stratify	  
patients	   response	   to	   anti-­‐TNFα	   therapy	   remains	   poorly	   understood.	  
Transcriptome	   analysis	   of	   synovial	   biopsies	   prior	   commencement	   of	   treatment	  
showed	  that	  different	   levels	  of	   tissue	   inflammation	  are	  associated	  with	  different	  
degree	   of	   response	   to	   TNFα	   blockade,	   providing	   proof	   of	   concept	   that	   synovial	  
biomarkers	   can	   be	   helpful	   to	   discriminate	   between	   responders	   and	   non-­‐
responders.	   464	   Badot	   et	   al	   performed	   microarray	   and	   himmunoistochemistry	  
analysis	   on	   25	   arthroscopic	   synovial	   tissue	   from	   csDMARD-­‐resistant	   RA	   patients	  
prior	  initiation	  of	  Adalimumab	  and	  evaluated	  response	  at	  3	  months,	  founding	  that	  




genes	   involved	   in	   the	   regulation	   of	   immune	   responses.	   465	   Wijbrandts	   and	  
colleagues	  observed	  that	  the	  clinical	  response	  to	  Infliximab	  was	  in	  part	  dependent	  
on	   pre-­‐treatment	   TNFα	   level	   in	   the	   synovium;	   the	   synovial	   expression	   of	  
macrophages	  and	  T	  cells,	  both	  representing	  an	  important	  source	  of	  TNFα,	  was	  also	  
significantly	  higher	  in	  responders	  than	  in	  non-­‐responders.	  380	  
Given	   the	   controversial	   role	   of	   synovial	   lymphocytic	   aggregates	   in	   RA	  
pathogenesis,	  some	  studies	  have	  specifically	  focused	  on	  the	  relationship	  between	  
the	  presence	  of	  such	  structures	  and	  the	  response	  to	  anti-­‐TNFα	  treatment.	  Several	  
evidences	  have	  indicated	  that	  cytokines	  of	  the	  TNF	  family	   including	  LTβ,	  LTα	  and	  
TNFα	   play	   a	   key	   role	   in	   the	   pathways	   that	   control	   the	   lymphoid	   tissue	  
development.	  Pasparakis	  et	  al	  reported	  lack	  development	  of	  splenic	  primary	  B	  cell	  
follicles,	   follicular	  dendritic	  cells	  and	  germinal	  centres	   in	  TNFα-­‐deficient	  mice.	   466	  	  
In	   a	   following	   report,	   these	   observations	   were	   extended	   to	   other	   secondary	  
lymphoid	   organs	   including	   Peyer’s	   patches	   and	   peripheral	   lymphonodes,	  
demonstrating	   the	   strategic	   role	   of	   TNFα	   in	   secondary	   lymphoid	   tissue	  
organisation	   independently	  of	   the	  anatomical	  or	  embryological	  determinants.	   467	  
Although	   the	   exact	   role	   of	   TNFα	   in	   the	   organisation	   of	   B	   cell	   follicles	   remains	  
poorly	  characterised,	   it	  has	  been	  proposed	  that	  in	  TNFα	  knockout	  animal	  models	  
the	   primary	   defect	   may	   be	   the	   failure	   of	   follicular	   dendritic	   cell	   precursors	   to	  
migrate	   to	   the	   follicular	   area.	   468	   In	   addition,	  Ngo	   et	   al	   have	   demonstrated	   that	  
TNFα	  is	  required	  for	  normal	  expression	  of	  CXCL13	  and	  CCL21,	  critical	  chemokines	  
involved	  in	  the	  lymphoid	  organisation.	  469	  Klimiuk	  et	  al	  have	  recently	  reported	  that	  
synovial	   tissues	   containing	   follicular	   aggregates	   show	   increased	   transcriptional	  




concentrations	  of	  TNFα	  and	  soluble	  TNFα	  receptors	  in	  the	  serum	  of	  patients	  with	  
synovial	  aggregates,	  and	  these	   levels	  correlated	  with	  markers	  of	  disease	  activity.	  
Further	   evidence	   reinforcing	   these	   concepts	   has	   been	   recently	   provided	   by	  
Thurlings	  et	  al,	  who	  reported	  a	  significant	  increase	  of	  TNFα	  producing	  cells	  in	  the	  
sublining	  of	  synovium	  containing	  lymphoid	  aggregates	  along	  with	  increased	  levels	  
of	  biomarkers	  of	  systemic	  inflammation.	  323	  
It	   has	   been	   mentioned	   that,	   because	   of	   its	   peculiar	   structure	   and	  
pharmacodynamic	   properties	   among	   all	   the	   TNFi,	   CZP	   may	   have	   a	   different	  
mechanism	   of	   action	   compared	   to	   the	   other	   agents	   of	   the	   same	   class. For	  
example,	   the	   ability	   of	   CZP	   to	   penetrate	  more	   effectively	   into	   inflamed	   arthritic	  
tissue	  has	  been	  observed	  on	  biofluorescence	  imaging	  in	  animal	  studies.	  457	  Canete	  
demonstrated	  the	  ability	  of	  TNFi	  to	  revert/disrupt	  lymphoid	  structures:	  of	  the	  16	  
patients	   who	   had	   a	   lymphoid	   pattern	   in	   the	   first	   biopsy,	   9	   turned	   lymphoid	  
negative	  (5	  received	  Adalimumab,	  2	  Infliximab	  and	  2	  Etanercept)	  and	  7	  remained	  
positive	   at	   second	   biopsy	   after	   therapy.	   330	   Whether	   the	   superior	   tissue	  
penetration	   of	   CZP	   could	   translate	   into	   a	   better	   ability	   to	   penetrate	   and	  
theoretically	  disrupt	  lymphoid	  structures	  is	  unknown	  and	  represents	  an	  intriguing	  
hypothesis	  to	  be	  explored	  in	  further	  studies.	  	  
When	  looking	  at	  the	  prognostic	  role	  of	  synovial	  aggregates	  to	  predict	  response	  
to	  anti-­‐TNFα	  treatment,	  the	  results	  of	  current	  studies	  are	  conflicting.	  Lindberg	  et	  
al	   analysed	   62	   arthroscopic	   biopsies	   of	   RA	  patients	   prior	   initiation	   of	   Infliximab.	  
They	   found	  an	  overexpression	  of	   synovial	  aggregates	   (both	  small	  and	   large-­‐sized	  
aggregates)	  in	  patients	  who	  were	  good	  responders	  according	  to	  EULAR	  criteria	  at	  




model.	   470	   Canete	   et	   al	   showed	   that	   presence	   of	   pre-­‐treatment	   synovial	  
aggregates	  was	  an	  independent	  negative	  predictor	  of	  response	  to	  treatment	  in	  86	  
patients	  with	  RA	  (of	  whom	  24	  to	  anti-­‐TNFα	  therapy).	   330	  These	  results	  are	   in	  net	  
contrast	  with	  those	  from	  Klaasen	  et	  al	  who	  reported	  that	  the	  presence	  of	  synovial	  
aggregates	  was	  a	  positive	  predictor	  of	  response	  to	  Infliximab	  in	  97	  RA	  patients.	  324	  
However	  these	  two	  studies	  show	  profound	  methodological	  differences.	  Firstly,	  the	  
definition	   of	   synovial	   aggregates	   was	   different:	   Canete	   considered	   only	   highly	  
organised	  B	  and	  T	  cell	  aggregates	  (grade	  2	  or	  3	  with	  specific	  features	  of	  lymphoid	  
structures	   including	   T	   cell/B	   cell	   compartmentalization	   and	   PNAd	   positive	  
immunostaining)	  meanwhile	  Klaasen	  included	  aggregates	  of	  any	  size.	  As	  discussed	  
in	  Chapter	  1,	   this	  difference	   is	   relevant	  as	  only	  B-­‐cell	   rich	   large-­‐sized	  aggregates	  
show	   the	   potential	   to	   acquire	   characteristics	   of	   ectopic	   lymphoid	   structures,	  
meanwhile	  the	  biologic	  significance	  of	  small	  aggregates	  is	  uncertain.	  322	  Moreover,	  
in	  the	  Canete’s	  study	  the	  cohort	  was	   largely	  heterogeneous	   including	  patients	  at	  
different	  stages	  of	  disease	  (from	  early	  untreated	  RA	  to	  anti-­‐TNFα	  failure	  patients,	  
the	   latter	   clearly	   representing	  a	   treatment-­‐resistant	   subgroup)	  and	   the	  outcome	  
was	  evaluated	  at	  different	  end-­‐points,	  meanwhile	  in	  the	  Klaasen	  study	  all	  patients	  
were	   evaluated	   at	   a	   fixed	   end-­‐point	   (after	   16	   weeks	   of	   Infliximab	   therapy)	   and	  
previous	  use	  of	  TNFα	  inhibitors	  was	  an	  exclusion	  criterion.	  
Herein	  I	  would	  like	  to	  assess	  whether	  synovial	  tissue	  analysis	  might	  be	  helpful	  
to	  predict	  the	  clinical	  response	  to	  anti-­‐TNFα	  therapy	  in	  a	  cohort	  of	  biologic	  naïve	  
csDMARD-­‐failure	   RA	   patients	   who	   qualified	   for	   anti-­‐TNFα	   according	   to	   NICE	  
guidelines.	  In	  the	  first	  instance	  the	  relationship	  between	  the	  clinical	  features	  and	  




CZP	  will	   be	   explored.	   Then	   I	   will	   investigate	  whether	   the	   presence	   of	   a	   specific	  
synovial	  pathotype	  at	  baseline	  is	  a	  potential	  predictor	  of	  the	  clinical	  response	  at	  3	  
months.	  
A	   further	   aspect	   that	   will	   be	   explored	   is	   the	   association	   of	   synovial	   features	  
with	   level	  of	   synovitis	  assessed	  by	  US	   imaging	  prior	  and	  post	  anti-­‐TNFα	   therapy.	  
Over	  the	  past	  few	  years,	  US	  and	  particularly	  the	  presence	  of	  PDUS	  signal	  reflecting	  
synovial	  vascularization	  has	  proved	  to	  be	  a	  sensitive	  tool	  for	  detecting	  persistence	  
of	  active	  synovitis	  which	   is	  often	  underestimated	  by	  clinical	  measures.	   Indeed,	   it	  
has	  long	  been	  appreciated	  that	  joint	  destruction	  continues	  to	  progress	  despite	  the	  
apparent	   suppression	  of	   synovitis	  as	  assessed	  by	  clinical	  examination	   in	  patients	  
on	  anti-­‐TNFα.	  Indeed	  hypervascularization	  and	  overexpression	  of	  pro-­‐angiogenetic	  
factors	  within	  the	  synovial	  tissue	  are	  essential	  pathogenic	  mechanisms	  leading	  to	  
joint	   inflammation	   and	   subsequent	   damage,	   and	   TNFα	   participates	   in	   several	  
mechanisms	   of	   neo-­‐angiogenesis	   and	   vasodilatation	   such	   as	   local	   activation	   of	  
endothelial	   cells,	   release	   of	   nitric	   oxide,	   production	   of	   pro-­‐angiogenetic	   factors	  
and	   increased	  vascular	  permeability.	   471-­‐473	  Agents	   that	  antagonize	   the	  effects	  of	  
this	   cytokine	   would	   be	   expected	   to	   decrease	   synovial	   vascularity,	   reflecting	   a	  
regression	   in	   the	   inflammatory	   activity,	   which	   is	   in	   line	   with	   previous	   findings.	  
118,474	   The	   potential	   value	   of	   US	   in	   monitoring	   anti-­‐TNFα	   treatment	   has	   been	  
evaluated	  only	  in	  a	  limited	  number	  of	  studies	  so	  far.	  388,475-­‐482	  	  
	  
5.2	  	  	  AIMS	  AND	  OBJECTIVES	  
The	   hypothesis	   of	   this	   experimental	   chapter	   was	   that	   in	   a	   biologic	   naive	   RA	  




The	   specific	   aims	   were	   to	   assess	   whether	   baseline	   synovial	   pathotype	  
significantly	   associated	   with	   the	   following	   clinical	   outcomes	   after	   3	   months	   of	  
treatment:	  
1) change	  in	  DAS28;	  
2) achievement	  of	  EULAR	  response;	  
3)	  	  	  	  	  	  	  change	  in	  STUS	  and	  PDUS	  scores.	  
	  
5.3	  	  	  MATERIALS	  AND	  METHODS	  
5.3.1	  	  	  Study	  population	  
28	  consecutive	  patients	  recruited	  as	  part	  of	  the	  CLIP-­‐cert	  study	  at	  Barts	  Health	  
NHS	  Trust.	  All	  patients	  fulfilled	  2010	  ACR/EULAR	  criteria	  for	  RA4	  and	  were	  eligible	  
for	   anti-­‐TNFα	   therapy	   according	   to	   NICE	   guidelines	  
[http://www.nice.org.uk/nicemedia/pdf/CG79NICEGuideline.pdf].	   Inclusion	   and	  
exclusion	  criteria	  for	  study	  enrolment	  are	  summarised	  in	  Table	  5.1.	  
	  
5.3.2	  	  	  Study	  design	  













Table	  5.1:	  CLIP-­‐Cert	  study:	  inclusion/exclusion	  criteria	  	  
	  
INCLUSION	  CRITERIA	   EXCLUSION	  CRITERIA	  
-­‐ ≥	  18	  and	  years	  of	  age	   -­‐ Women	  pregnant	  or	  breast	  feeding	  
-­‐ On	  MTX	  for	  at	  least	  4	  months,	  with	  a	  
stable	  dose	  of	  7.5-­‐25	  mg/week	  for	  a	  
minimum	  of	  4	  weeks	  
-­‐ Use	  of	  any	  investigational	  drug	  
within	  1	  month	  prior	  to	  screening	  
or	  within	  5	  half-­‐lives	  of	  the	  
investigational	  agent,	  whichever	  
longer	  
-­‐ Capable	  and	  willing	  to	  provide	  written	  
informed	  consent	  
-­‐ Serious	  active	  infections	  
	   -­‐ Active	   TB	   or	   evidence	   of	   latent	   TB	  
without	   documented	   adequate	  
prophylactic	  therapy	  
	   -­‐ Presence	   of	   a	   transplanted	   organ	  
(with	   the	   exception	   of	   a	   corneal	  
transplant	   >	   3	   months	   prior	   to	  
screening)	  
	   -­‐ History	   of	   malignancy	   within	   the	  
past	   5	   years	   (except	   for	   squamous	  
or	   basal	   cell	   carcinoma	   of	   the	   skin	  
that	   had	   been	   treated	   with	   no	  
evidence	  of	  recurrence)	  
	   -­‐ History	   of	   lymphoproliferative	  
disease,	   or	   signs	   and	   symptoms	  





5.3.3	  	  	  Patients	  assessment	  	  
Before	   study	   enrolment,	   all	   patients	   were	   assessed	   for	   anti-­‐TNFα	   eligibility	  
according	  to	  NICE	  criteria	  and	  underwent	  a	  safety	  screen	  prior	  commencement	  of	  
therapy	  as	  per	  local	  guidelines,	  including:	  pregnancy	  test	  in	  child-­‐bearing	  women,	  
Human	   Immunodeficiency	   Virus	   (HIV)	   screen,	   HBV	   and	   HCV	   screen,	   Interferon-­‐
Gamma	  Release	  Assay	  (IGRA)	  test	  for	  TB	  and	  chest	  XR.	  
Patients	  were	  assessed	  before	  and	  after	  3	  months	  of	  anti-­‐TNFα	  therapy.	  
At	   baseline	   demographic	   data	   were	   collected	   and	   clinical	   and	   laboratory	  
assessment	   (including	   RF	   and	   ACPA	   status)	   completed.	   US	   assessment	   and	   US-­‐
guided	   synovial	   biopsy	   of	   a	   swollen	   joint	  with	   relative	   histopathological	   analysis	  
were	   also	   performed,	   according	   to	   the	  methodology	   illustrated	   in	  Material	   and	  
Methods	   (Chapter	   2).	   A	   second	   biopsy	   of	   the	   same	   joint	   was	   performed	   in	   18	  
patients,	   and	  paired	  histology	  data	  were	   available	   for	   14	  patients.	  As	   previously	  
described,	  samples	  were	  classified	  as:	  ‘Lymphoid’	  based	  on	  the	  presence	  of	  large	  
lymphocytic	   aggregates	   (G2/G3);	   ‘Myeloid’	   based	   on	   the	   absence	   of	   G2/G3	  
aggregates	  and	  presence	  of	  CD68sl	  (2-­‐4	  SQ);	  ‘Pauci-­‐immune’	  (PI)	  characterised	  by	  
absence	  of	  G2/G3	  aggregates	  and	  scarce/absent	  CD68sl	  (0-­‐1	  SQ).	  
Standard	  AP	  radiographs	  of	   the	  XR	  of	  hands	  and	   feet	  were	  also	  performed	  at	  
baseline.	   The	   presence	   of	   erosions	   as	   assessed	   during	   routine	   reporting	   of	  
radiographs	  by	  a	  musculoskeletal	  radiologist	  was	  also	  determined.	  	  
After	   3	   months	   of	   therapy	   with	   CZP,	   clinical,	   laboratory	   and	   US	   assessment	  
were	  re-­‐evaluated;	  at	  this	  time	  point,	  clinical	  and	  PDUS	  and	  STUS	  outcomes	  were	  





5.3.4	  	  	  Therapeutic	  protocol	  
After	   undergoing	   synovial	   biopsy,	   patients	   were	   commenced	   on	   CZP	  
subcutaneous	   injections	   fortnightly	   (two	   induction	   doses	   of	   400	  mg	   followed	  by	  
maintenance	   dose	   of	   200	  mg).	   All	   patients	  were	   on	  MTX	   therapy	   for	   at	   least	   4	  
months,	  with	   a	   stable	   dose	   of	   7.5-­‐25	  mg/week	   for	   a	  minimum	  of	   4	  weeks,	   plus	  
Folic	   Acid	   ≥	   5	   mg/week.	   Other	   concomitant	   csDMARD	   were	   permitted.	   Oral	  
steroids	   (PRED	   ≤10	  mg/day,	   or	   equivalent	   corticosteroids	   dose)	   were	   allowed	   if	  
stable	  for	  at	  least	  one	  month	  prior	  to	  study	  enrolment.	  Use	  of	  NSAIDs	  was	  allowed	  
during	  the	  entire	  duration	  of	  the	  study.	  	  
	  
5.3.5	  	  	  Outcome	  measures	  
Outcome	  measures	  were	  assessed	  at	  baseline	  and	   following	  3	  months	  of	  CZP	  
therapy.	  
Primary	  outcomes	  were:	  
1) change	  in	  disease	  activity	  based	  on	  DAS28;	  
2) achievement	  of	  EULAR	  response.	  
	  	  	  	  	  Secondary	  outcome	  was:	  
	  	  	  	  	  	  	  -­‐	  	  	  	  changes	  in	  STUS	  and	  PDUS	  scores.	  
	  
5.3.6	  	  	  Statistical	  analysis	  
Continuous	  variables	  were	  expressed	  as	  mean	  (+/-­‐SD)	  and	  ordinal	  variables	  as	  
median	  (+/-­‐	  IQR).	  Chi-­‐Square	  test	  was	  used	  for	  comparison	  of	  qualitative	  variables	  
between	  PI,	  Myeloid	  and	  Lymphoid	  groups	  and	  Kruskal	  Wallis	  test	  for	  comparison	  




Spearman	   correlation	   coefficients	   were	   used	   for	   semi-­‐quantitative	   variables	  
and	  Pearson	  correlation	  coefficients	  for	  continuous	  variables.	  
To	  estimate	  whether	  the	  presence	  of	  a	  specific	  synovial	  pathotype	  at	  baseline	  
could	   serve	   as	   a	   predictor	   of	   response	   to	   TNFα	   blockade	   after	   3	   months	   of	  
treatment,	  multivariate	   logistic	   regression	   analysis	  was	   performed.	   The	   relevant	  
adjusting	   variables	  were	   sequentially	   selected	   in	   the	  modelling	   process	   and	   the	  
results	  were	  expressed	  as	  odds	  ratios	  (OR)	  with	  95%	  confidence	  intervals	  (95%	  CI).	  	  
The	   analysis	   was	   performed	   using	   SPSS	   (IBM	   version	   21.0	   for	  Mac).	   All	   tests	  
were	  2-­‐sided	  and	  the	  significance	  level	  was	  set	  at	  p	  <	  0.05.	  
	  
5.4	  	  	  RESULTS	  
5.4.1	  Patient	  demographics	  
Baseline	  demographics	  and	  clinical	  features	  of	  patients	  prior	  starting	  anti-­‐TNFα	  
treatment	  are	  shown	  on	  Table	  5.2.	  	  
Mean	  disease	  duration	  was	  6.2±5.7	  years.	  53.6%	  patients	  were	  seropositive	  for	  RF	  
and	  64.3%	  for	  ACPA.	  	  42.9%	  were	  erosive	  in	  either	  hands	  or	  feet.	  	  
35.7%	   were	   on	   a	   stable	   dose	   of	   oral	   steroids.	   Patients	   had	   been	   treated	  
unsuccessfully	  with	  an	  average	  of	  1.8±0.8	   csDMARD	   that	  had	  been	  discontinued	  









Table	  5.2:	  Demographics	  and	  clinical	  characteristics	  of	  CLIP-­‐Cert	  patients	  at	  baseline	  
Abbreviations:	  anti-­‐CCP=	  anti-­‐cyclic	  citrullinated	  proteins	  antibodies;	  CRP=	  C-­‐reactive	  
protein;	   csDMARD=	   conventional	   synthetic	   disease	  modifying	   antirheumatic	   drugs;	  
DAS28=	  28	   joint	  count-­‐Disease	  Activity	  Score;	  ESR=	  erythrocyte	  sedimentation	  rate;	  
HAQ=	  Health	   Assessment	  Questionnaire;	   RF=rheumatoid	   factor;	   SJ=	   swollen	   joints;	  




























5.4.2	  	  	  Baseline	  synovial	  pathotype	  does	  not	  define	  a	  specific	  clinical	  phenotype	  	  
The	  presence	  of	  a	  Lymphoid	  pattern	  was	  found	  in	  11	  (39.3%)	  patients,	  Myeloid	  
pattern	   in	   4	   (14.3%)	   and	  PI	   pattern	   in	   13	   (46.4%)	   (Table	   5.3).	   The	  proportion	  of	  
patients	   displaying	   large	   aggregates	   was	   in	   line	   with	   other	   reports	   cohorts	   of	  
csDMARD	  inadequate	  responder	  RA	  patients.	  323,324	  	  
I	  went	  on	   to	  determine	  whether	  significant	  differences	   in	  demographics	  were	  
seen	   between	   patients	   classified	   according	   to	   each	   synovial	   pathotype	   group.	   I	  
could	   find	   no	   differences	   in	   demographic	   factors	   including	   sex,	   age,	   disease	  
duration	   and	   potentially	   confounding	   factor	   such	   as	   smoking.	   Importantly,	   no	  
difference	  with	  regard	  to	  clinical	  or	  laboratory	  features	  including	  disease	  activity,	  
HAQ,	   erosive	   status,	   inflammatory	   markers	   and	   antibody	   status	   was	   detected	  
(Table	   5.3).	   Number	   of	   csDMARD	   previously	   taken	   was	   also	   similar	   across	   the	  
three	   groups.	   I	   did	   however	   find	   that	   a	   significantly	   higher	   number	   of	   patients	  
within	  the	  PI	  group	  were	  treated	  with	  oral	  steroids:	  PI=7	  (53.8%),	  Myeloid=3	  (75%)	  
and	  Lymphoid=0	  (0%),	  p<0.01	  (Table	  5.3).	  
I	   also	   went	   onto	   evaluate	   whether	   the	   degree	   of	   immune	   cell	   infiltration	  
assessed	  using	  SQ	  analysis	  differed	  across	  pathotypes.	  I	  found	  that	  the	  presence	  of	  
a	   Lymphoid	  pattern	  was	   significantly	   associated	  with	   a	   higher	   degree	  of	   CD3+	   T	  
cells,	   CD20+	   B	   cells,	   CD138+plasma	   cells	   and	   CD68+	   lining	   and	   sublining	   layer	  
macrophages	  (Table	  5.4).	  These	  observations	  confirm	  previous	  data	  323,	   including	  
data	   from	   the	   PEAC	   study,	   demonstrating	   a	   significant	   association	   between	   a	  





Table	   5.3:	   Baseline	   characteristics	   of	   CLIP-­‐Cert	   patients:	   comparison	   across	   synovial	   pathotype	  
groups	  
Values	  are	  expressed	  as	  mean	  ±	  SD	  or	  number	  (percentage).	  Kruskal	  Wallis	  test	  or	  Chi-­‐Square	  test,	  
as	  appropriate.	  	  
Abbreviations:	   anti-­‐CCP=	   anti-­‐cyclic	   citrullinated	   proteins	   antibodies;	   CRP=	   C-­‐reactive	   protein;	  
csDMARD=	  conventional	  synthetic	  disease	  modifying	  antirheumatic	  drugs;	  DAS28=	  28	  joint	  count-­‐
Disease	   Activity	   Score;	   ESR=	   erythrocyte	   sedimentation	   rate;	   HAQ=	   Health	   Assessment	  
Questionnaire;	   RF=rheumatoid	   factor;	   SJ=	   swollen	   joints;	   TJ=	   tender	   joints;	   VAS-­‐GH=	   Visual	  















Female,*n*(%)* 10*(76.9%)* 3*(75%)* 8*(72.7%)* 0.97*
Age*(years),*mean*±*SD* 54.6*±*10.2* 40.5*±*13.7* 52.3*±*12.7* 0.16*
Onset*(years),*mean*±*SD* 7.2*±*7.1* 8.0*±*5.7* 4.3*±*3.2* 0.52*
Smoking,*n*(%)* 6*(46.2%)* 2*(50%)* 4*(36.4%)* 0.84*
ESR*(mm/h),*mean*±*SD* 27.1*±*18.9* 32.7*±*26.2* 25.1*±*16.1* 0.93*
CRP*(mg/L),*mean*±*SD* 5.3*±*4.3* 35.0*±*59.5* 7.5*±*5.6* 0.43*
RF*+,*n*(%)* 7*(53.8%)* 2*(50%)* 6*(54.5%)* 0.98*
ACPA*+,*n*(%)* 9*(69.2%)* 2*(50%)* 7*(63.6%)* 0.78*
TJ*(28*joints),*mean*±*SD* 18*±*7* 16*±*5* 14*±*8* 0.45*
SJ*(28*joints),*mean*±*SD* 9*±*3* 10*±*3* 10*±*5* 0.61*
DAS28,*mean*±*SD* 6.5*±*0.8* 6.5*±*0.7* 6.1*±*0.7* 0.40*
HAQ,*mean*±*SD* 1.80*±*0.69* 1.12*±*1.06* 1.47*±*0.63* 0.27*
Erosive,*n*(%)* 5*(38.5%)** 3*(75%)** 4*(36.4%)* 0.37*
Oral*steroids,*n*(%)* 7*(53.8%)* 3*(75%)* 0*(0%)* <0.01*





Table	  5.4:	  Synovial	  pathotype	  is	  associated	  with	  degree	  of	  immune	  cell	  infiltration	  
Values	  are	  expressed	  as	  median	  (interquartile	  range)	  of	  the	  semi-­‐quantitative	  (0-­‐4)	  scores.	  	  
Kruskal	  Wallis	  test.	  
Abbreviations:	   CD3,	   T	   cells;	   CD20,	   B	   cells;	   CD68l,	   lining	  macrophages;	   CD68sl,	   sub-­‐lining	  






















CD3* 0.5*(0&1)* 1.5*(1&2)* *3*(3&4)* 0.01*
CD20* 0*(0&0.25)* 0.5*(0&1)* 3*(3&4)* <0.01*
CD68l* 1*(0.75&1.25)* 1*(0.25&1.75)* 3*(3&3)* <0.01*
CD68sl* 1*(1&1)* 2*(2&2)* 4*(3&4)* 0.02*




5.4.3	  Ultrasonographic	  power	  Doppler	  scores	  are	  significantly	  higher	  in	  patients	  
with	  a	  Lymphoid	  pathotype.	  
Baseline	  STUS	  and	  PDUS	  scores	  were	  available	  for	  20	  patients.	  I	  could	  not	  find	  
any	   significant	   correlation	   between	   STUS	   and	   PDUS	   scores	   and	   clinical	   and	  
laboratory	  parameters.	  However,	   in	   line	  with	   the	   findings	  observed	   in	   the	  PEAC,	  
the	  relationship	  between	  PDUS	  and	  level	  of	  CD3,	  CD20,	  CD68	  and	  CD138	  synovial	  
infiltration	   was	   relevant.	   	   In	   fact,	   meanwhile	   STUS	   was	   comparable	   among	   the	  
three	  synovial	  pathotype	  groups	   (p=0.15),	  PDUS	  was	   significantly	   lower	   in	   the	  PI	  
group	   (2.5±2.2),	   compared	   to	   the	   Myeloid	   (11.6±4.7)	   and	   Lymphoid	   (9.0+6.0)	  
group,	   p=0.01.	   Similarly,	   meanwhile	   STUS	   did	   not	   correlate	   with	   any	   of	   the	  
synovial	  cell	  subtypes,	  PDUS	  significantly	  correlated	  with	  CD3	  (r=0.54,	  p=0.01)	  and	  
CD20	  (r=0.54,	  p=0.01).	  Overall	  these	  results	  suggest	  that	  PDUS	  maybe	  a	  sensitive	  























5.4.4	  	  Baseline	  Lymphoid	  	  pathotype	  predicts	  clinical	  response	  to	  Certolizumab-­‐
pegol	  at	  3	  months	  
After	   3	   months	   of	   treatment	   with	   CZP,	   clinical	   response	   was	   evaluated	   by	  
assessment	   of	   DAS28	   score.	   Overall	   the	  mean	   fall	   in	   DAS28	   from	   baseline	   to	   3	  
months	  was	  -­‐2.3±1.3,	  with	  a	   lower	  fall	   in	  the	  PI	   -­‐1.7±1.4	  compared	  to	  Myeloid	  (-­‐
2.8±1.6)	  and	  Lymphoid	  (-­‐2.8±0.7)	  group,	  p=0.03	  (Figure	  5.1)	  
I	  then	  classified	  patients	  as	  EULAR	  responders/non	  responders	  and	  found	  that	  
20	   patients	   (71.4%)	   were	   classified	   as	   responders	   and	   8	   (28.6%)	   as	   non	  
responders.	  These	  results	  are	   in	   line	  with	  previously	   reported	  response	  rates	   for	  
other	  anti-­‐TNFα.	  449,450	  	  
I	   next	   went	   onto	   evaluate	   whether	   baseline	   synovial	   pathotype	   predicted	  
EULAR	  response	  at	  3	  months.	  The	  results	  demonstrated	  that	  a	  significantly	  higher	  
proportion	   of	   patients	  within	   the	   lymphoid	   group	   at	   baseline	  was	   associated	   to	  
the	  chance	  of	  achieving	  better	  outcome	  (p=0.01):	  in	  particular,	  the	  PI	  pattern	  was	  
associated	   with	   the	   lowest	   proportion	   of	   patients	   achieving	   EULAR	   response	  
(46%),	  meanwhile	  all	  patients	  who	  exhibited	  a	  Lymphoid	  pattern	  were	  classified	  as	  





	  	  	  	  	  	  	  	  	  	  	  Figure	  5.1:	  Mean	  fall	  in	  DAS28	  across	  the	  three	  histopathotype	  groups	  










	   	  
p=0.03 
Kruskal Wallis test 





Figure	  5.2:	  Achievement	  of	  EULAR	  response	  across	  the	  three	  histopathotype	  groups	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To	   assess	   whether	   the	   relationship	   between	   the	   synovial	   pathotype	   and	   the	  
clinical	  response	  was	  independent	  of	  other	  potential	  factors,	  a	  multivariate	  logistic	  
regression	  analysis	  was	  performed.	  Relevant	  study	  variables	  entered	  in	  the	  model	  
were:	  gender,	  age,	  disease	  duration,	  ESR,	  CRP,	  DAS28,	  HAQ,	  antibody	  status,	  use	  
of	  oral	   steroids,	  erosive	  status	  and	   the	  synovial	  pathotype.	  These	  variables	  were	  
firstly	   individually	   tested	   for	   their	   association	  with	   EULAR	   response	   at	   3	  months	  
using	   univariate	   logistic	   regression	   analysis.	   Subsequently	   multivariate	   logistic	  
regression	   analysis	   was	   performed	   using	   a	   backward	   stepwise	   method.	   The	  
synovial	   pathotype	   was	   identified	   as	   the	   only	   potential	   predictor	   of	   response	  











 Univariate model Multivariate model 
 OR CI 95% p value OR CI 95% p value 
 Gender 0.333 0.033-3.335 0.35    
Age 0.904 0.813-1.006 0.06    
Disease duration 0.948 0.825-1.090 0.45    
ESR 0.981 0.938-1.027 0.41    
CRP 1.068 0.889-1.282 0.48    
DAS28 0.494 0.168-1.450 0.19    
HAQ 0.224 0.046-1.093 0.06    
ACPA+ 0.500 0.080-4.000 0.45    
RF+ 0.962 0.995-1.005 1.00    
Oral steroids 1.114 0.203-6.105 0.90    
Erosive  0.667 0.128-3.470 0.63    
Synovial pathotype 7.775 1.237-48.859 0.02 9.885 1.352-72.277 0.02 
 
	  
Table	  5.5:	  Association	  between	  baseline	  characteristics	  and	  EULAR	  response	  at	  3	  months	  using	  
univariate	  logistic	  regression	  analysis	  and	  multivariate	  logistic	  regression	  analysis	  
Abbreviations:	  ACPA=	  anti-­‐cyclic	  citrullinated	  proteins	  antibodies;	  CI=	  confidence	  interval;	  CRP=	  C-­‐
reactive	   protein;	   DAS28=	   28	   joint	   count-­‐Disease	   Activity	   Score;	   ESR=	   erythrocyte	   sedimentation	  














5.4.5	   The	   change	   in	   clinical	   disease	   activity	   correlates	   with	   the	   change	   in	   the	  
synovial	  sublining	  macrophages	  	  
In	   addition	   to	   further	   evaluate	   whether	   synovial	   pathotype	   associated	   with	  
treatment	  response,	  the	  correlation	  between	  change	   in	  DAS28	  and	  change	   in	  SQ	  
CD68sl	  number	  between	  baseline	  and	  3	  months	  was	  determined	   for	  all	  patients	  
with	   paired	   histology	   data	   (n=14).	   The	   results	   demonstrated	   a	   significant	  
correlation	   between	   fall	   in	   DAS28	   and	   fall	   in	   sublining	   macrophage	   number	  



















Figure	  5.3:	  Significant	  correlation	  between	  change	  in	  DAS28	  and	  change	  in	  
semi-­‐quantitative	  sublining	  macrophages	  between	  baseline	  and	  3	  months	  
Abbreviations:	   ΔCD68sl=	   mean	   change	   in	   semi-­‐quantitative	   sublining	  	  	  	  	  	  	  	  
macrophages;	  ΔDAS28=	  mean	  change	  in	  28	  joint	  count-­‐Disease	  Activity	  Score.	  
	  	  
	  






5.4.6	   	   	   A	   baseline	   Pauci-­‐immune	   pathotype	   is	   associated	   with	   a	   significantly	  
lower	  fall	  in	  synovial	  thickening	  and	  power	  Doppler	  ultrasound	  scores	  	  
Next	  in	  order	  to	  determine	  whether	  STUS	  and	  PDUS	  scores	  matched	  changes	  in	  
disease	  activity	  after	  treatment,	  change	  in	  STUS	  and	  PDUS	  scores	  were	  correlated	  
with	   change	   in	   DAS28.	   In	   the	   patients	   with	   available	   paired	   US	   data	   available	  
(n=19)	   the	   results	   demonstrated	   a	   significant	   association	   with	   mean	   change	   in	  
DAS28	  and	  both	  mean	  change	  in	  STUS	  (r=0.50,	  p=0.02)	  and	  PDUS	  (r=0.69,	  p<0.01)	  
demonstrating	   that	  US	   synovitis	   scores	   fell	   in	   line	  with	   clinical	   response	   to	   CZP.	  
The	  total	  percentage	  of	  patients	  in	  US	  remission	  (mean	  PDUS	  ≤	  1)	  was	  31.6%.	  
	  I	   then	   went	   on	   to	   evaluate	   whether	   US	   outcome	  measures	   at	   3	   months	   were	  
influenced	   by	   baseline	   synovial	   pathotype.	  Mean	   differences	   in	   STUS	   and	   PDUS	  
between	   baseline	   and	   3	   months	   follow-­‐up	   were	   compared	   across	   the	   three	  
synovial	   pathotype	   groups.	   A	   significant	   difference	   in	   STUS	   (mean	   -­‐2.89±4.78	  
p=0.03)	  and	  PDUS	  change	   (mean	  -­‐3.63±5.9,	  p=0.04)	  across	   the	  three	  groups	  was	  
demonstrated	   (Figure	   5.4	   and	   Figure	   5.5).	   Of	   particular	   interest	   was	   the	  
significantly	   lower	   mean	   change	   observed	   within	   the	   PI	   pathotype	   group	  
suggesting	  a	  particularly	  treatment	  resistant	  pathotype.	  
In	   terms	   of	   achievement	   of	   US	   remission	   I	   could	   not	   observe	   any	   significant	  









Figure	  5.4:	  Mean	  fall	  in	  STUS	  in	  the	  three	  histopathotype	  groups	  
	  Abbreviations:	  ΔSTUS=	  change	  in	  synovial	  thickening	  ultrasound.	  
	  
	  
	   	  
p= 0.03 
Kruskal Wallis test 








	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  5.5:	  Mean	  fall	  in	  PDUS	  in	  the	  three	  histopathotype	  groups	  
	  	  	  	  	  	  	  	  	  Abbreviations:	  ΔPDUS=	  change	  in	  power	  doppler	  ultrasound.	  
	  
	   	  
p= 0.04 
Kruskal Wallis test 




5.5	  	  	  DISCUSSION	  
The	  aim	  of	  this	  work	  was	  to	  investigate	  the	  relationship	  between	  pre-­‐treatment	  
synovial	  pathotype	  and	  primary	  response	  to	  the	  anti-­‐TNFα	  agent	  CZP	   in	  a	  cohort	  
of	  csDMARD	  inadequate	  responder	  RA	  patients.	  
The	   results	   presented	   herein	   demonstrate	   a	   number	   of	   significant	   findings.	  
Firstly	  that	  the	  proportion	  of	  patients	  with	  a	  synovial	  Lymphoid	  pathotype	  within	  
the	  CLIP-­‐Cert	  cohort	  was	  consistent	  with	  that	  identified	  within	  the	  PEAC.	  Although	  
the	   two	   cohorts	   are	   not	   prospective,	   this	   suggests	   that	   the	   formation	   of	  
lymphocytic	  aggregates	  represents	  an	  early	  feature	  of	  RA	  and	  is	  not	  dependent	  on	  
disease	  duration.	  	  
Secondly,	   I	   could	   not	   demonstrate	   any	   significant	   association	   between	   the	  
presence	  of	   a	   specific	   histopathotype	   and	   indices	   of	   disease	   activity,	  markers	   of	  
inflammation	   and	   presence	   of	   autoantibodies.	   Similarly	   to	   data	   shown	   herein,	  
Klaasen	   et	   al	   324	   found	   no	   association	   between	   presence	   of	   large	   lymphocytic	  
aggregates	   and	   circulating	   autoantibodies,	   serological	   level	   of	   inflammatory	  
markers	  and	  clinical	  features.	  Thurlings	  et	  al	  323	  found	  that	  large	  aggregates	  were	  
associated	  with	  higher	  levels	  of	  ESR	  and	  CRP,	  but	  not	  with	  RF	  positivity,	  meanwhile	  
ACPA	  positivity	  was	  surprisingly	  more	  frequent	  in	  patients	  with	  diffuse	  synovitis.	  In	  
the	   cohort	   described	   by	   Canete	   et	   al	   330,	   patients	   with	   aggregates	   had	   higher	  
disease	   duration	   at	   baseline,	   but	   no	   association	   with	   antibody	   status,	  
inflammatory	  markers,	  disease	  activity	  and	  erosive	  status	  was	  detected.	  	  The	  lack	  
of	  association	  with	  clinical	  and	  serological	   features	   in	   the	  CLIP-­‐cert	  cohort	  are	   in	  
contrast	  with	  what	   observed	   in	   PEAC.	   This	  may	   suggest	   that	   the	   immunological	  




treatment	  naïve	  phase	  may	  be	  lost	  after	  the	  use	  of	  concomitant	  treatment	  such	  as	  
csDMARD	  and	  steroids.	  However,	  the	  smaller	  sample	  size	  could	  be	  accounted	  for	  a	  
low	  chance	  to	  detect	  statistically	  significant	  results.	  	  
Thirdly	   and	   of	   particular	   importance	   was	   the	   observation	   that	   synovial	  
pathotype	   predicted	   response	   to	   CZP	   at	   3	   months.	   This	   represents	   a	   critical	  
decision	   making	   point	   for	   clinicians	   as	   the	   clinical	   response	   to	   bDMARD	   is	  
expected	  to	  occur	  within	  the	  first	  3	  months	  of	  therapy.	  Only	  a	  minority	  of	  patients	  
will	  show	  response	  later,	  between	  3	  and	  6	  months.	  The	  response	  at	  3	  months	  has	  
been	   shown	   to	   be	   a	   good	   indicator	   of	   achievement	   of	   clinical	   remission	   at	   12	  
months.	   Therefore,	   patients	   who	   did	   not	   improve	   or	   improved	   only	   to	   a	  minor	  
extent	   are	   much	   less	   likely	   to	   miss	   treatment	   target	   at	   a	   later	   time	   point	   and	  
would	  benefit	  from	  a	  treatment	  switch.	  483	  Moreover,	  the	  response	  at	  later	  time-­‐
points	   could	   be	   more	   likely	   affected	   by	   confounding	   mechanisms	   including	   the	  
development	  of	  human	  anti-­‐drug	  antibodies.	  	  	  
Notably	   when	   the	   synovial	   pathotype	   was	   included	   into	   a	   logistic	   regression	  
model	   to	   predict	   response	   to	   therapy,	   the	   presence	   of	   a	   Lymphoid	   pathotype	  
resulted	   as	   a	   strong	   independent	   predictor	   of	   response.	   Meanwhile	   the	  
observation	   that	   a	   PI	   pathotype	   associated	   with	   a	   lower	   chance	   to	   achieve	  
response	   strongly	   suggests	   that	   patients	   characterised	   with	   this	   pathotype	   are	  
particularly	   resistant	   to	   treatment	   with	   CZP.	   These	   observations	   confirm	   the	  
original	   hypothesis	   that	   the	   histopathotype	  may	   translate	   into	   a	   specific	   clinical	  
phenotype	  with	  relevant	  prognostic	  implications.	  	  
Furthermore,	   as	   previously	   reported	   in	   various	   studies	   64,332,443,	   this	   data	  




changes	   in	   CD68sl,	   suggesting	   that	   synovial	  macrophages	   represent	   a	   candidate	  
biomarker	  to	  predict	  efficacy	  of	  anti-­‐rheumatic	  treatment.	  	  
Of	   note,	   because	   CZP	   is	   the	   only	   pegylated	   drug	   among	   TNFα	   inhibitors	   and	  
pegylation	   confers	   specific	   pharmacological	   properties,	   including	   more	   effective	  
distribution	   and	   retention	  within	   the	   inflamed	   joint	   tissue,	   it	   cannot	   be	   inferred	  
that	  the	  results	  obtained	  herein	  could	  be	  extended	  to	  other	  anti-­‐TNFα,	  and	  further	  
studies	  are	  necessary	   in	  that	  respect.	  A	  study	  conceptually	  and	  methodologically	  
similar	  to	  CLIP-­‐cert	  but	  based	  on	  the	  use	  of	  an	  alternative	  TNFi	  (Enbrel)	  is	  currently	  
ongoing	  in	  our	  department.	  It	  will	  be	  important	  to	  compare	  the	  findings	  of	  these	  
two	  works,	  however	  further	  and	  larger	  studies	  would	  be	  required.	  
When	   looking	   at	   the	   association	   between	   the	   synovial	   pathotype	   at	   baseline	  
and	   the	   change	   in	   STUS	   and	   PDUS	   after	   therapy,	   I	   observed	   that	   PI	   was	   a	  
particularly	   resistant	   pattern	   to	   change.	   Again	   this	   group	   appears	   to	   have	   a	  
pathological	   status	  whereby	   the	   control	  of	  mechanisms	   that	  drives	   synovitis	  has	  
not	  been	  achieved	  by	  therapy,	  and,	  on	  the	  opposite,	  that	  the	  other	  two	  groups	  are	  
more	   responsive	   to	   the	   immunomodulatory	   effect	   of	   anti-­‐TNFα	   treatment.	  	  
However,	  data	  should	  be	  evaluated	  with	  caution	  as	  the	  baseline	  levels	  of	  STUS	  and	  
PDUS	   in	   the	   PI	   group	  were	   lower	   compared	   to	   the	   other	   2	   groups	   (p=0.15	   and	  
p=0.01,	  respectively)	  and	  this	  could	  explain	  a	  less	  sensitivity	  to	  detect	  changes	  in	  
this	  specific	  group.	  Also,	  the	  small	  number	  of	  patients	  within	  this	  study	  is	  likely	  to	  
be	   underpowered	   to	   detect	   a	   real	   difference.	   Therefore	   these	   findings	   are	   only	  
exploratory	  and	  require	  further	  confirmation.	  	  	  
The	   final	   observations	   reported	   regarding	   clinical,	   pathological	   and	   US	  




and	   PDUS	   and	   STUS	   correlations	   were	   significantly	   associated	   provides	   an	  
objective	  measure	  of	  disease	  outcome	  in	  this	  observational	  study.	  Previous	  studies	  
reported	   that	   synovial	   tissue	   tends	   to	   become	   chronically	   thickened	   and	   less	  
reversible	  in	  long-­‐standing	  RA.	  406	  There	  are	  few	  reports	  of	  sustained	  regression	  of	  
ultrasonographic	  synovial	  thickening	  after	  TNFα	  blockade.	  For	  example,	   in	  a	  pilot	  
study	  assessing	  11	  patients	  with	  active	  RA	  prior	  and	  after	  six	  weeks	  of	   Infliximab	  
therapy,	  a	  significant	  decrease	  in	  both	  STUS	  and	  PDUS	  was	  observed	  (wrists,	  MCPs	  
and	  PIPs).	  477	  In	  line	  with	  these	  data,	  the	  results	  I	  have	  shown	  herein	  demonstrate	  
that	   chronic	   synovitis	   measured	   by	   STUS	   is	   capable	   of	   being	   modulated	   by	  
effective	  treatment.	  	  
Although	   the	   expression	   of	   angiogenic	   factors	   was	   not	   evaluated	   within	   this	  
study,	   previous	  observation	   that	  ultrasonographic	   features	  of	   synovitis	   associate	  
significantly	  with	  the	  expression	  of	  factors	  such	  as	  VEGF,	  Angiopoietin	  2	  and	  Tie-­‐2	  
is	   of	   relevance.404	   These	   factors	   are	   critical	   mediators	   of	   angiogenic	  
development/maintenance.	  As	  synovial	   lymphocytic	  aggregates	  have	  been	  noted	  
to	  be	  a	  significant	  source	  of	  angiogenic	  promoters	  316	  this	  maybe	  the	  mechanism	  
by	  which	   the	   significantly	  higher	  baseline	   levels	  of	   STUS	  and	  PDUS	  are	  observed	  
within	  the	  Lymphoid	  group.	  
A	   particular	   strength	   of	   this	  work	   is	   the	   homogeneous	   cohort	   of	   RA	   patients	  
with	   participants	   presenting	   similar	   clinical	   indices	   including	   disease	   duration,	  
number	   of	   previous	   csDMARD,	   concomitant	  MTX	   and	   clinical	   features	   including	  
presence	  of	  autoantibodies	  and	  level	  of	  disease	  activity.	  Also,	  we	  have	  been	  using	  




a	   fairly	   representative	   cohort	   of	   small	   joints	   and	   large	   joints,	   and	   a	   validated	  
scoring	  system	  for	  histopathological	  analysis	  and	  US	  data	  analysis.	  
This	   work	   has	   some	   limitations	   though.	   Firstly,	   the	   observational	   nature	   of	   the	  
study.	   Secondly,	   findings	   are	   preliminary	   because	   of	   the	   small	   sample	   size.	   The	  
clinical	   relevance	   of	   this	   data	   has	   to	   be	   proven	   in	   further	   larger	   studies.	   The	  
present	  study	  was	  aiming	  to	  represent	  the	  platform	  for	   larger	  and	  more	  detailed	  
works	   currently	   ongoing	   in	   our	   department,	   including	   a	   new	   study	   called	   STRAP	  
(Stratification	   of	   Biologic	  Therapies	   for	  RA	  by	  Pathobiology)	   where	   csDMARD	  
failure	  patients	  are	  stratified	  to	  Etanercept,	  Rituximab	  and	  Tocilizumab	  aiming	  to	  
identify	   synovial	   predictors	   of	   response/resistance	   to	   different	   first	   line	   biologic	  
strategies	   (http://www.matura-­‐mrc.whri.qmul.ac.uk/).	   Thirdly,	   I	   have	   used	   a	  
limited	  joint	  set	  for	  US	  evaluation	  that	  could	  not	  be	  faithfully	  representative	  of	  the	  
disease	   in	   its	   entirety.	   However	   there	   is	   still	   lack	   of	   knowledge	   in	   the	   scientific	  
community	  on	  how	  to	  best	  use	  US	  imaging	  in	  the	  context	  of	  clinical	  and	  research	  
studies,	   including	   the	  minimum	   joint	   set	   to	  be	  examined.	  Our	   joint	   set	  has	  been	  
used	  in	  previous	  studies	  so	  it	  is	  not	  without	  validation.	  370	  
In	   conclusion,	   these	   findings	   highlight	   the	   pathophysiological	   and	   clinical	  
significance	  of	  synovial	  pathotype	  as	  a	  potential	  biomarker	  of	  response	  to	  CZP	  in	  
patients	  with	  RA.	  	  Future	  work	  should	  expand	  the	  search	  for	  other	  biomarkers	  and	  
molecular	  networks,	   including	  genetics,	  epigenetics	  and	  proteomics	  analysis	  on	  a	  
larger	   scale	   of	   patients	   and	   using	   randomised	   control	   trials.	   To	   assess	   changes	  
within	   the	   synovial	   membrane	   over	   time,	   it	   would	   be	   critical	   to	   extend	   the	  
histopathological	  analysis	  of	  the	  post-­‐treatment	  biopsy.	   In	  particular,	   it	  would	  be	  




if	  such	  reversal	  is	  a	  good	  marker	  of	  persistence	  of	  the	  clinical	  response	  over	  time.	  
The	   post-­‐treatment	   biopsy	   may	   also	   represent	   an	   ideal	   platform	   to	   investigate	  
synovial	  biomarkers	  of	  response/resistance	  in	  patients	  who	  are	  due	  to	  commence	  
a	   second	   line	   biologic	   after	   the	   failure	   of	   the	   first	   line.	   The	   ultimate	   aim	   is	   to	  
provide	  a	  tailored	  approach	  to	  treatment	  decisions	  at	  each	  stage	  of	  the	  disease,	  in	  
order	  to	  maximise	  the	  potential	  response	  to	  therapy	  and	  provide	  the	  right	  drug	  to	  































Considerable	   patient-­‐to-­‐patient	   variation	   exists	   at	   the	   clinical	   and	   biological	  
level	   in	  RA.	  However	  whether	  the	  underlying	  tissue	  differences	  could	   impact	  the	  
clinical	  phenotype	  and	  define	  prognostic	  categories	  is	  not	  known.	  The	  main	  focus	  
of	   this	   thesis	   was	   to	   evaluate	   how	   the	   heterogeneity	   of	   synovial	   pathotypes	  
integrates	   with	   the	   heterogeneity	   of	   clinical	   phenotypes	   including	   the	  
heterogeneous	  response	  to	  treatment.	  	  
Personalised	  medicine	  based	  on	  targeted	  strategies	  for	  the	  individual	  patient	  is	  
one	  of	  the	  goals	  set	  for	  future	  healthcare.	  Current	  prognostic	  markers	  for	  RA	  are	  
unable	  to	  reliably	  predict	  those	  patients	  who	  would	  be	  most	   likely	  to	  respond	  to	  
individual	  therapeutic	  interventions,	  so	  additional	  prognostic	  markers	  are	  needed	  
in	   order	   to	   select	   the	   most	   effective	   therapy	   for	   that	   specific	   patient	   avoiding	  
treatments	   that	   could	   be	   ineffective	   or	   harmful.	   Since	   synovial	   tissue	   is	   the	  
epicentre	   of	   arthritis	   pathology,	   a	   deeper	   understanding	   of	   the	   pathobiological	  
processes	  that	  initiate	  and	  perpetuate	  joint	  inflammation	  is	  crucial	  to	  achieve	  this	  
goal	  in	  RA.	  The	  pathobiological	  processes	  may	  differ	  between	  patient	  subgroups	  or	  
even	  between	  different	  stages	  of	  the	  disease	  in	  the	  single	  patient.	  There	  is	  in	  fact	  
accumulating	   evidence	   that	   RA	   behaves	   differently	   in	   different	   phases	   of	   the	  
disease,	   and	   particularly	   that	   early	   RA	   represents	   a	   clinically	   and	   biologically	  
distinct	  phase.	  	  
I	   have	   examined	   a	   cohort	   of	   63	   early	   RA	   (PEAC)	   patients	  who	  were	   naïve	   to	  
treatment	  prior	   starting	   csDMARD,	   and	  a	   cohort	   of	   28	  patients	  with	   established	  
disease	  (CLIP-­‐Cert)	  who	  failed	  csDMARD	  and	  were	  eligible	  to	  start	  anti-­‐TNFα.	  The	  
first	  major	   component	  of	   this	   thesis	  was	   to	   examine	  whether	   the	  presence	  of	   a	  




and	  was	  able	  to	  predict	  response	  to	  csDMARD	  treatment	  at	  6	  months	  in	  the	  PEAC	  
and	  to	  anti-­‐TNFα	  at	  3	  months	   in	  the	  CLIP-­‐Cert.	   	   I	  am	  able	  to	  report	  a	  number	  of	  
observations:	  	  
• Firstly	   that	  RA	  exhibits	  similar	  histopathological	   findings	   in	  both	   the	  early	  and	  
long-­‐standing	   phase,	   with	   three	   histological	   subsets	   identified:	   Lymphoid,	  
characterised	   by	   the	   presence	   of	   large	   lymphocytic	   aggregates;	   Myeloid,	  
characterised	  by	   the	   absence	  of	   aggregates	   but	   significant	   expression	  of	   sub-­‐
lining	   macrophages	   (CD68sl);	   and	   Pauci-­‐immune	   (PI),	   characterised	   by	  
scarce/absent	  lymphocytic	  and	  macrophage	  infiltration.	  	  
• Secondly	   that	   the	   presence	   of	   a	   specific	   synovial	   pattern	   correlates	   with	  
markers	  of	  systemic	  inflammation	  and	  expression	  of	  autoantibodies	  in	  the	  PEAC	  
but	  not	  in	  the	  CLIP-­‐Cert.	  
• Thirdly	  that	  the	  presence	  of	  a	  Lymphoid	  pattern	  is	  a	  robust	  prognostic	  marker	  
of	  response	  to	  treatment	  in	  both	  the	  PEAC	  and	  CLIP-­‐Cert,	  meanwhile	  the	  Pauci-­‐	  
immune	  group	  represents	  a	  particularly	  resistant	  to	  treatment	  subset.	  
• Fourthly,	   the	   change	   in	   post-­‐treatment	   synovial	   CD68sl	   correlates	   with	   the	  
change	  in	  clinical	  disease	  activity	  in	  both	  cohorts.	  
• Finally,	   the	   synovial	   pathotype	   correlates	  with	  ultrasonographic	   expression	  of	  
active	  synovitis	  at	  baseline,	  confirming	  that	  US	  is	  a	  faithful	  measure	  of	  synovial	  
pathology.	   Moreover,	   change	   in	   US	   measures	   of	   synovitis	   after	   therapy	   is	  
lower/	  virtually	  absent	  in	  the	  Pauci-­‐immune	  group	  compared	  to	  the	  Lymphoid	  





There	   is	   pre-­‐existing	   evidence	   suggesting	   that	   histological	   classification	   of	  
synovial	  tissue	  ranging	  from	  a	  diffuse	  to	  aggregate	  infiltrate	  associates	  with	  clinical	  
phenotype.	  However	  several	  studies	  so	  far	  have	  led	  to	  conflicting	  or	  inconclusive	  
results.	   324,330	   Interpretation	  of	   such	  data	   is	   complicated	   though	  by	   a	  number	  of	  
inherent	  methodological	  discrepancies	   related	   to	   the	  uncontrolled	  nature	  of	   the	  
studies	   and	   the	   heterogeneity	   of	   the	   cohorts.	   Most	   of	   these	   works	   were	  
conducted	   on	   patients	   at	   end-­‐stage	   disease	   and	   previous	   exposure	   to	  
heterogeneous	   therapies,	   with	   a	   significant	   number	   of	   biases	   introduced.	   Few	  
findings	   have	   been	   validated	   with	   subsequent	   cohorts	   in	   early	   treatment	   naïve	  
patients.	  I	  have	  analysed	  a	  cohort	  of	  early	  RA	  patients	  naïve	  to	  treatment	  and,	  as	  
comparison,	   a	   non	   longitudinal	   cohort	   of	   long	   standing	   RA	   patients	  which	  were	  
similar	   for	   clinical	   characteristics,	   disease	   duration	   and	   exposure	   to	   previous	  
csDMARD.	  A	  minimally	   invasive	  US-­‐guided	  biopsy	   technique	  has	  been	  utilised	   to	  
extract	   synovial	   tissue	   from	   inflamed	   joints.	   This	   technique	   confirmed	   a	   reliable	  
method	  of	  acquiring	  synovial	  tissue	  from	  both	  large	  and	  small	  joints	  287	  	  proving	  to	  
be	   safe	   and	   well	   tolerated	   by	   patients	   with	   yield	   of	   good	   quantitative	   and	  
qualitative	  synovial	  tissue.	  US	  can	  also	  facilitate	  the	  selection	  of	  sampling	  sites	  in	  
order	  to	  allow	  extraction	  of	  sufficient	  quantity	  and	  good	  quality	  tissue.	  Specifically,	  
the	  presence	  of	  higher	  synovial	  thickening	  scores	   is	  associated	  with	  better	  tissue	  
yield.	  We	  have	   followed	   this	   rule	   empirically	   in	   the	   present	   study,	   however	   this	  
has	  been	  formally	  demonstrated	   in	  our	   further	  work	  recently.	   300	  The	  use	  of	  US-­‐
guided	   synovial	   biopsy	   has	   now	   been	   validated	   in	   several	   cohorts,	   but	   the	   gold	  
standard	   for	   joint	   tissue	   extraction	   remains	   synovial	   arthroscopy.	   289	   It	   will	   be	  




standard	  technique	  before	  adoption	  on	  large	  scale	  is	  recommended.	  Such	  studies	  
are	   planned	   as	   part	   of	   the	   EULAR	   synovitis	   study	   group	   and	  OMERACT	   research	  
agenda.	  	  
The	   tissue	   sampling	   and	   the	   histology	   analysis	   method	   utilized	   herein	   were	  
rigorous.	   The	   histological	   classification	   adopted	   is	   arbitrary	   however	   based	   on	  
recent	   new	   learning	   on	   synovial	   tissue	   pathology,	   to	   which	   our	   group	   has	  
contributed	  greatly.	  297	  Historically	  studies	  based	  on	  synovial	  tissue	  analysis	  have	  
focused	   on	   the	   classic	   paradigm	  of	  mutual	   distinction	   between	   two	  pathotypes:	  
diffuse	   (inflammatory	   cells	   randomly	   distributed	   within	   the	   synovium)	   and	  
aggregate	  (lymphocytes	  clustering	  in	  discrete	  entities	  resembling	  ectopic	  lymphoid	  
structures).	  We	  have	  observed	  that	  the	  diffuse	  group	  -­‐intrinsically	  characterised	  by	  
the	  absence	  of	   lymphocytic	   aggregates-­‐	   could	  be	   split	   up	   in	   at	   least	   two	   further	  
groups	  according	   to	   the	  presence/absence	  of	  macrophages	   in	   the	  sublining.	  This	  
supports	  the	  concept	  that	  synovial	  heterogeneity	  exists	  as	  a	  continuous	  spectrum	  
rather	  than	  discrete	  subsets	  of	  biological	  processes.	  I	  have	  therefore	  presented	  a	  
novel	   histological	   classification	   of	   the	   RA	   synovium,	   based	   on	   the	  
presence/absence	   of	   lymphocytic	   aggregates	   and	   further	   on	   the	  
presence/absence	  of	   sublining	  macrophages	   (CD68sl)	   resulting	   in	  a	  more	  precise	  
evaluation	   of	   the	   synovial	   pathology	   compared	   to	   the	   classic	   distinction	   in	  
aggregate/diffuse	  synovium.	   Indeed	  there	   is	  accumulating	  evidence	  of	  a	  key	  role	  
of	  macrophages	  in	  RA.	  These	  cells	  play	  a	  pivotal	  role	  in	  the	  innate	  response	  as	  well	  
as	   in	   the	  adaptive	   response,	  by	  acting	  as	  effective	  antigen	  presenting	  cells.	  They	  
are	  key	   in	   triggering	  and	  perpetuating	   the	  NF-­‐kB	   response	  and	   related	  cytokines	  




synovial	   macrophages	   and	   TNFα	   gene	   expression	   are	   correlated	   with	   clinical	  
outcome.	  324,380	  Further	  studies	  have	  demonstrated	  that	  the	  change	  in	  the	  number	  
of	   synovial	   CD68sl	   is	   a	   potential	   biomarker	   to	   predict	   response.	   64	  However	   this	  
relationship	   has	   not	   been	   extensively	   reported	   in	   early	   RA	   cohorts	   as	   yet.	   The	  
results	   presented	  herein	   show	   that	   changes	   in	   the	   number	   of	   synovial	   sublining	  
macrophages	  correlate	  with	  clinical	   improvement	  both	  in	  the	  PEAC	  and	  the	  CLIP-­‐
Cert,	  so	  it	  appears	  independent	  of	  therapeutic	  exposure	  and	  disease	  stage.	  	  
The	  frequency	  of	  the	  three	  synovial	  pathotypes	  described	  is	  similar	  in	  the	  PEAC	  
and	  CLIP-­‐Cert.	  	  Therefore	  I	  provide	  evidence	  that	  synovial	  aggregates	  are	  present	  
during	   the	  early	  phase	  of	   the	  disease	  and	  can	  persist	  after	  csDMARD	  treatment.	  
However,	   despite	   several	   studies	   including	   our	   own	  work	   using	   the	   SCID	  mouse	  
model325	   having	   suggested	   a	   role	   for	   synovial	   aggregates	   in	   the	   promotion	   of	  
autoimmunity	  at	  the	  tissue	   level,	   the	  functionality	  of	   these	  structures	   is	  debated	  
and	   their	   role	   in	   the	   initiation	   and	   perpetuation	   of	   the	   disease	   is	   not	   entirely	  
defined.	   Findings	   from	   the	   PEAC	   support	   a	   direct	   pathogenetic	   role,	   since	   a	  
significant	  association	  between	  the	  synovial	  pathotype	  and	  biomarkers	  of	  systemic	  
inflammation	  and	  autoantibodies	  has	  been	  observed.	  Conversely,	   I	  could	   find	  no	  
association	   between	   histopathology	   and	   biochemical	   features	   in	   the	   CLIP-­‐Cert.	  
These	  discrepancies	  may	  be	  explained	  by	  disease	  stage	  differences	  supporting	  the	  
notion	   that	   synovial	   aggregates	   might	   play	   different	   roles	   in	   early	   versus	   late	  
disease.	  This	  may	  reinforce	  the	  concept	  that	  indeed	  early	  RA	  represents	  a	  distinct	  
phase.	   However	   addressing	   the	   correlations	   between	   histological	   features	   and	  
clinical	   and	   biochemical	   markers	   on	   a	   historical	   cohort	   of	   patients	   with	   varying	  




Notably	   though	   despite	   a	   lack	   of	   association	  with	   inflammatory	  markers	   and	  
autoantibodies	  at	  baseline	  in	  the	  CLIP-­‐Cert,	  the	  histological	  features	  do	  not	  remain	  
uncoupled	  from	  clinical	  behaviour.	  	  Indeed	  in	  both	  the	  PEAC	  and	  the	  CLIP-­‐Cert	  the	  
synovial	   pathotype	   is	   significantly	   associated	   with	   change	   in	   disease	   activity	  
expressed	   by	   DAS28.	   Importantly,	   when	   several	   variables	   including	   clinical,	  
serological,	  radiological	  and	  ultrasonographic	  measures	  are	  put	  into	  a	  multivariate	  
logistic	  prognostic	  model,	  synovial	  pathotype	  represents	  the	  strongest	  predictor	  of	  
clinical	  response	  in	  both	  cohorts.	  Specifically,	  the	  presence	  of	  a	  Lymphoid	  pattern	  
at	  baseline	  is	  associated	  with	  the	  highest	  chance	  of	  achieving	  a	  primary	  response	  
to	  both	  csDMARD	  and	  anti-­‐TNFα.	  Dennis	  et	  al	  recently	  reported	  a	  classification	  of	  
the	  RA	  synovium	  based	  on	  four	  synovial	  categories	  designated	  as	  lymphoid	  (B	  cell	  
dominated	   and	   associated	   with	   presence	   of	   lymphocytic	   aggregates),	   myeloid	  
(macrophage	   and	   NF-­‐κ	   B	   process	   dominated)	   low	   inflammation	   (intermediate	  
characteristics	   of	   the	   previous	   two	   subsets)	   and	   fibroid	   (comprising	   hyperplastic	  
but	   scarcely	   infiltrated	   tissue),	   observing	   that	   the	  myeloid	  but	  not	   the	   lymphoid	  
group	   was	   significantly	   associated	   with	   good	   clinical	   response	   to	   anti-­‐TNFα	  
therapy.	   312	  At	  a	   first	  glance	  this	  seems	  conflicting	  with	  our	  results,	  however	   the	  
above	  classification	  was	  based	  on	  gene	  signature	  expression,	  which	  is	  profoundly	  
different	   from	   a	   purely	   histological	   classification.	   Particularly	   the	   definition	   of	  
lymphoid	   and	   myeloid	   in	   the	   above	   mentioned	   study	   was	   derived	   by	   gene	  
expression	   profiles	   marking	   clear-­‐cut	   distinction	   between	   the	   lymphoid	   and	  
myeloid	  immune	  axis.	  The	  classification	  that	  I	  have	  adopted	  herein	  is	  not	  based	  on	  
gene	   signature	   expression.	   The	   difference	   between	   Lymphoid	   and	   Myeloid	  




aggregates	   rather	   than	   on	   the	   expression	   of	   cells/pathways	   derived	   from	   the	  
lymphoid	   or	   myeloid	   lineage.	   Macrophages	   are	   abundantly	   expressed	   in	   the	  
Lymphoid	   subset	   as	   well	   leading	   to	   a	   significantly	   overlap	   in	   terms	   of	   myeloid	  
axis/pathway	   expression	   across	   the	   two	   groups.	   	   Ideally	   histological	   analysis	  
should	  be	   implemented	  with	  more	  sophisticated	  analysis	   including	  genomics	  and	  
proteomics.	  The	  present	  study	   is	  aiming	  at	   representing	   the	  platform	  for	   further	  
detailed	  analysis	  that	  is	  currently	  ongoing	  in	  our	  department.	  	  
From	  the	  present	  work	  it	  emerges	  clearly	  that	  the	  presence	  of	  a	  Pauci-­‐immune	  
pattern	   is	   associated	  with	   a	   lower	   chance	  of	   responding	   to	   treatment.	   It	   indeed	  
makes	  	  sense	  that	  patients	  with	  lower	  levels	  of	  synovial	  infiltrate	  may	  present	  with	  
lower	  degree	  of	  response	  to	  both	  csDMARD	  and	  anti-­‐TNFα	  therapy.	  This	  suggests	  
that	   other	   factors	   contribute	   to	   determining	   synovitis	   namely	   activation	   of	  
alternative	   immunological	   pathways	   and	   release	   of	   different	   inflammatory	  
mediators.	   	  A	  number	  of	  other	  biologic	  agents	  are	  currently	  available	  other	  than	  
TNFα.	  Thus,	  it	  is	  conceivable	  that	  this	  subset	  of	  patients	  could	  responder	  better	  to	  
alternative	  treatment	  e.g.	  targeting	  the	  IL-­‐6	  or	  IL-­‐17	  axis	  which	  are	  activated	  at	  the	  
stromal	  level,	  or	  even	  novel	  pathways	  that	  synovial	  tissue	  analysis	  may	  contribute	  
to	   the	  discovery	  of.	  Further	  work	   is	  necessary	   to	  explore	   the	  main	   inflammatory	  
pathways	  driven	   in	   this	  group	  of	  patients	  other	   than,	   for	  example,	   the	  canonical	  
NF-­‐κB	  signalling	  which	  is	  predominantly	  targeted	  by	  csDMARD	  and	  anti-­‐TNFα.	  	  
However,	   the	   prediction	   value	   of	   the	   synovial	   pathotype	   presents	   some	  
limitations.	   For	   example,	   the	   synovial	   pathotype	   did	   not	   predict	   damage	  
progression	   over	   a	   12	  months	   period	   in	   the	   PEAC.	   A	   significant	   association	  was	  




burden329	  but	  the	  same	  authors	  and	  others	  in	  larger	  cross	  sectional	  cohorts	  found	  
no	   association	   between	   synovial	   aggregates	   and	   radiological	   damage.	   323	   We	  
recently	  reported	  an	  association	  between	  the	  presence	  of	  synovial	  aggregates	  and	  
the	   erosive	   burden	   in	   a	   larger	   early	   RA	   cohort	   that	   was	   also	   part	   of	   the	   PEAC	  
platform.	   381	   Potentially,	   a	   larger	   sample	   size	   and	   an	   extended	   follow	  up	   period	  
could	  have	  led	  to	  similar	  conclusions	  herein.	  
Finally,	   the	   PDUS	   scores	   were	   associated	   with	   the	   overall	   pathology	   in	   the	  
synovium.	  PDUS	  was	  highly	  significantly	  related	  to	  the	  degree	  of	  change	  in	  clinical	  
disease	   activity	   after	   treatment	   in	   both	   the	   PEAC	   and	   CLIP-­‐Cert	   cohorts,	   as	  
previously	  reported	  by	  other	  authors.	  STUS	  scores	  changed	  in	  parallel	  with	  disease	  
activity	   in	   the	   CLIP-­‐Cert	   cohort	   only.	   One	   could	   have	   expected	   to	   observe	   this	  
correlation	   rather	   in	   the	   PEAC,	   where	   collagenous	   thickness,	   fibrosis	   and	   other	  
changes	  typical	  of	  long-­‐standing	  disease	  are	  less	  pronounced.	  A	  number	  of	  reports	  
have	   indeed	  shown	  a	  disparity	  of	  US	  remission	  rate	   in	  early	  versus	   long	  standing	  
disease,	  as	   synovial	   tissue	  become	  chronically	   thickened	  and	   less	   reversible	  with	  
disease	   progression.	   406	   However,	   synovial	   thickening	   is	   also	   the	   result	   of	  
neoangiogenesis	   and	   cellular	   infiltration	   that	   can	   revert	   dramatically	   after	  
effective	   anti-­‐TNFα	   therapy.	   These	   results	   should	   be	   interpreted	   cautiously,	  
primarily	   because	   of	   the	   limited	   sample	   size.	   	   Secondly,	   although	   US	   has	   been	  
performed	   by	   expert	   ultrasonographers	   and	   the	   process	   of	   imaging	   and	   scoring	  
acquisition	  was	  rigorous,	  these	  results	  are	  based	  on	  arbitrarily	  selected	  number	  of	  
joints	  (bilateral	  wrist	  and	  MCP	  joints)	  which	   lacks	  validation.	  The	  performance	  of	  
the	   limited	   joint	   set	   has	   not	   been	   compared	  with	   an	   extended	   joint	   set,	   which	  




372	  Correlating	   the	  histology	  and	   the	  US	  data	  at	   the	   single	   joint	   level	   could	  have	  
also	  added	  further	  relevant	  information,	  but	  this	  aspect	  has	  not	  been	  included	  in	  
the	  present	  analysis.	  	  
In	   the	   work	   I	   have	   presented,	   synovial	   pathobiology	   added	   significant	  
prognostic	  information	  to	  clinical,	  serological	  and	  imaging	  parameters,	  resulting	  as	  
the	  strongest	  prognostic	  factor	  of	  response	  to	  treatment	  at	  6	  months	  in	  the	  PEAC	  
and	   at	   3	   months	   in	   the	   CLIP-­‐Cert,	   which	   represent	   crucial	   time-­‐points	   to	   make	  
clinical	   decision	   including	   switching	   to	   alternative	   treatment.	   Predicting	   which	  
patients	  are	   likely	   to	  respond	  according	  to	  the	  pre-­‐treatment	  synovial	  pathotype	  
would	  be	  of	   invaluable	  utility.	   It	  seems	  realistic	  to	  suggest	  that	   in	  future	  synovial	  
pathobiology	  will	  be	   integrated	   into	  current	  clinical	  prediction	  models	  with	  great	  
benefits	   for	   patient	   care	   and	   health	   economics.	   The	   next	   step	   would	   be	   the	  
integration	   within	   more	   sophisticated	   clinical	   prognostic	   model	   incorporating	  
more	  detailed	  molecular	  and	  genetic	  data	  and	  validation	  in	  large	  patient	  cohorts.	  
Especially	  further	  examination	  on	  large	  scale	  prospective	  studies	  of	  early	  arthritis,	  
treatment	   naive	   patients	   are	   needed.	   Also,	   I	   have	   reported	   a	   single-­‐centre	  
experience,	  and	  further	  work	  is	  needed	  to	  confirm	  these	  findings	  across	  multiple	  
centres.	  	  
In	   conclusion,	   the	   present	   thesis	   provides	   evidence	   to	   support	   that	   synovial	  
pathobiology	   could	   represent	   the	   key	   to	   personalised	   healthcare	   in	   RA	   thus	  
suggesting	   potential	   application	   in	   future	   studies.	   At	   the	   present	   time,	  
stratification	   of	   RA	   patients	   in	   clinical	   trials	   is	   based	   on	   parameters	   (disease	  
activity,	  autoantibodies,	  radiographic	  evidence	  of	  erosions,	  acute	  phase	  reactants)	  




individual	   basis.	   This	   data	   provides	   a	   strong	   rationale	   for	   including	   synovial	  
analysis	   in	   the	   stratification	   of	   patients	   according	   to	   prognostic	   and	   therapeutic	  
response	  categories,	  in	  view	  of	  the	  ability	  to	  identify	  patients	  with	  a	  higher/lower	  
chance	   to	   respond	   to	   treatment.	   Histological	   assessment	   has	   become	   part	   of	  
standard	  clinical	  care	  in	  several	  chronic	  autoimmune	  diseases	  (e.g.	  lupus	  nephritis	  
and	  vasculitis)	  or	  cancer	  medicine,	  with	  management	  decisions	  resulting	  from	  the	  
integration	   of	   pathobiology	   into	   clinical,	   biochemical	   and	   imaging	   features.	   In	   a	  
similar	  way,	   incorporating	   synovial	   analysis	   in	   the	   decision	  making	   strategy	  may	  
revolutionise	   the	  management	   of	   RA	   patients	   in	   the	   near	   future	   optimising	   the	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